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The burden of non-communicable diseases (NCDs), which cannot be transferred from one 
person to another, is rapidly increasing globally. Africa is particularly worst hit owing to 
rapid urbanization, population growth and ageing, and increased uptake of lifestyles 
associated with many NCDs, including tobacco smoking, alcohol consumption, sedentary 
lifestyles and increased consumption of food substances with high cholesterol and salts 
content. There is also poor data management and low level of research on many NCDs in 
Africa, and consequently, public health response has been suboptimal. This thesis focusses 
on understanding and estimating the prevalence, and/or where there are available data, the 
incidence, of major NCDs in Africa.  
In 2010, about 130 million cases of hypertension were estimated in Africa, 58 million cases 
of asthma, 26 million cases of COPD, 25 million cases of diabetes, and 2 million cases of 
stroke. There were also about 496 thousand new cases of stroke. Among women, there were 
about 129 thousand new cases of cervical cancer and 81 thousand new cases of breast 
cancer. Among men, there were about 75 thousand and 74 thousand new cases of prostate 
cancer and Kaposi’s sarcoma, respectively. These are relatively high estimates, which 
suggest that the burden of NCDs is growing in Africa. It is still not possible to state with all 
certainty how representative these estimates are, with regards to the entire African 
population. Without the availability of good data, research output my still be low and Africa 
may find it difficult to address this growing burden of NCDs. It is hoped that this research 
will prompt appropriate policy response across many countries in Africa. 
 





The burden of non-communicable diseases (NCDs) is rapidly increasing globally, and 
particularly in Africa, where the health focus, until recently, has been on infectious diseases. The 
response to this growing burden of NCDs in Africa has been affected owing to a poor 
understanding of the burden of NCDs, and the relative lack of data and low level of research on 
NCDs in the continent. Recent estimates on the burden of NCDs in Africa have been mostly 
derived from modelling based on data from other countries imputed into African countries, and 
not usually based on data originating from Africa itself. In instances where few data were 
available, estimates have been characterized by extrapolation and over-modelling of the scarce 
data. It is therefore believed that underestimation of NCDs burden in many parts of Africa cannot 
be unexpected.  With a gradual increase in average life expectancy across Africa, the region now 
experiencing the fastest rate of urbanization globally, and an increase adoption of unhealthy 
lifestyles, the burden of NCDs is expected to rise. This thesis will, therefore, be focussing on 
understanding the prevalence, and/or where there are available data, the incidence, of four major 
NCDs in Africa, which have contributed highly to the burden of NCDs, not only in Africa, but 
also globally.  
Methods 
I conducted a systematic search of the literature on three main databases (Medline, EMBASE and 
Global Health) for epidemiological studies on NCDs conducted in Africa. I retained and 
extracted data from original population-based (cohort or cross sectional), and/or health service 
records (hospital or registry-based studies) on prevalence and/or incidence rates of four major 
NCDs in Africa. These include: cardiovascular diseases (hypertension and stroke), diabetes, 
major cancer types (cervical, breast, prostate, ovary, oesophagus, bladder, Kaposi, liver, stomach, 
colorectal, lung and non-Hodgkin lymphoma), and chronic respiratory diseases (chronic 
obstructive pulmonary disease (COPD) and asthma). From extracted crude prevalence and 
incidence rates, a random effect meta-analysis was conducted and reported for each NCD. An 
epidemiological model was applied on all extracted data points. The fitted curve explaining the 
largest proportion of variance (best fit) from the model was further applied. The equation 
generated from the fitted curve was used to determine the prevalence and cases of the specific 
NCD in Africa at midpoints of the United Nations (UN) population 5-year age-group population 
estimates for Africa. 




From the literature search, studies on hypertension had the highest publication output at 7680, 92 
of which were selected, spreading across 31 African countries. Cancer had 9762 publications and 
39 were selected across 20 countries; diabetes had 3701 publications and 48 were selected across 
28 countries; stroke had 1227 publications and 19 were selected across 10 countries; asthma had 
790 publications and 45 were selected across 24 countries; and COPD had the lowest output with 
243 publications and 13 were selected across 8 countries. From studies reporting prevalence 
rates, hypertension, with a total sample size of 197734, accounted for 130.2 million cases and a 
prevalence of 25.9% (23.5, 34.0) in Africa in 2010. This is followed by asthma, with a sample 
size of 187904, accounting for 58.2 million cases and a prevalence of 6.6% (2.4, 7.9); COPD, 
with a sample size of 24747, accounting for 26.3 million cases and a prevalence of 13.4% (9.4, 
22.1); diabetes, with a sample size of 102517, accounting for 24.5 million cases and a prevalence 
of 4.0% (2.7, 6.4); and stroke, with a sample size of about 6.3 million, accounting for 1.94 
million cases and a prevalence of 317.3 per 100000 population (314.0, 748.2). From studies 
reporting incidence rates, stroke accounted for 496 thousand new cases in Africa in 2010, with a 
prevalence of 81.3 per 100000 person years (13.2, 94.9). For the 12 cancer types reviewed, a total 
of 775 thousand new cases were estimated in Africa in 2010 from registry-based data covering a 
total population of about 33 million. Among women, cervical cancer and breast cancer had 129 
thousand and 81 thousand new cases, with incidence rates of 28.2 (22.1, 34.3) and 17.7 (13.0, 
22.4) per 100000 person years, respectively. Among men, prostate cancer and Kaposi sarcoma 
closely follows with 75 thousand and 74 thousand new cases, with incidence rates of  14.5 (10.9, 
18.0) and 14.3 (11.9, 16.7) per 100000 person years, respectively. 
Conclusion 
This study suggests the prevalence rates of the four major NCDs reviewed (cardiovascular 
diseases (hypertension and stroke), diabetes, major cancer types, and chronic respiratory diseases 
(COPD and asthma) in Africa are high relative to global estimates. Due to the lack of data on 
many NCDs across the continent, there are still doubts on the true prevalence of these diseases 
relative to the current African population. There is need for improvement in health information 
system and overall data management, especially at country level in Africa. Governments of 
African nations, international organizations, experts and other stakeholders need to invest more 
on NCDs research, particularly mortality, risk factors,  and health determinants to have 
evidenced-based facts on the drivers of this epidemic in the continent, and prompt better, 
effective and overall public health response to NCDs in Africa. 
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1.1 OVERVIEW 
In the last two decades, the burden of diseases in Africa has been tagged ‘double 
burden’. This term refers to the burden of diseases in Africa due to the dual effects of 
the already present high burden of communicable (infectious) diseases and a growing 
burden of non-communicable diseases (NCDs) (Boutayeb, 2006). The health focus in 
Africa, until recently, has been on communicable diseases, notably HIV/AIDS, 
malaria and tuberculosis, with minimal attention on NCDs (Dalal et al., 2011). The 
burden of NCDs in Africa, having presumably gone unnoticed over the years, has 
gradually become a major public health concern (Boutayeb, 2006, Amuyunzu-
Nyamongo, 2010). The World Health Organization (WHO) news release explained 
that NCDs are on the increase, that they became the leading killer diseases today and 
have caused a two-punch blow to global development (World Health Organization, 
2011b).  
The burden of non-communicable diseases (NCDs) is rapidly increasing globally 
(World Health Organization, 2008). The 2011 United Nations (UN) high level 
political meeting on NCDs affirmed that NCDs jointly became the leading cause of 
deaths globally, and are expected to account for about 52 million deaths by the year 
2030 (United Nations, 2011, Beaglehole et al., 2011). Evidence suggests that this 
global increase in NCDs burden over the last two to three decades may be due to the 
fact that awareness and health response at global levels have been weighted towards 
infectious disease than NCDs (Beaglehole et al., 2011). For example, a review of 
World Health Assembly (WHA) resolution from 1948 to 2013 revealed that of the 
total 484 resolutions made by WHA, 368 (76.0%) were on infectious diseases, 99 
(20.5%) on NCDs and 17 (3.5%) on both (World Health Organization, 2014e, World 
Health Organization, 2014d). Meanwhile, the WHO and many stakeholders have in 
recent times turned towards addressing NCDs burden more keenly, especially in 
Africa and many low- and middle-income countries (LMIC), where infectious 
diseases still remain a large public health issue (World Health Organization, 2008). 
In 2012, the World Health Assembly endorsed a new health goal (the “25 by 25 
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goal”), mainly focussing on reduction of avoidable deaths from non-communicable 
diseases (NCDs) by 25% by the year 2025 (Horton, 2013). Experts have again lauded 
this as a step in the right direction, especially after the 2011 UN political declaration 
on control and prevention of NCDs (Bonita et al., 2013). However, according to 
Horton,  there are lots of obstacles (local, regional and global) that have prevented 
this goal and many other initiatives on NCDs from being achieved, which has thus 
constrained the ability of many stakeholders to transform their understandings of the 
NCDs burden into political action (Horton, 2013). 
Records show that Africa is currently experiencing the fastest rate of urban 
development and industrialization worldwide (Mufunda et al., 2006b). Consequently, 
with increasing living standards and better healthcare seeking across many African 
countries, life expectancy will continue to rise (Ezzati et al., 2003). Therefore, the 
fast rising burden of NCDs in Africa could be partly due to demographic changes or 
population dynamics, including migration and ageing of the population, and partly to 
rapid industrialization and adoption of urban lifestyles (Lim et al., 2012). These two 
are jointly the main drivers of the pandemics of NCDs in Africa. In the absence of 
effective interventions and control measures, they are likely to increase both the 
prevalence and the total number of cases for many NCDs across Africa in the near 
future (Beaglehole, 2011). 
What does the term “burden” imply in this context? 
Generally, burden of disease can be described as a measure employed in assessing 
the health impact of different diseases (including injuries) on a defined population 
(Bloom et al., 2011). Assessing the burden of disease may involve the following: 
i. Measuring the occurrence of a disease in a population: This involves 
estimating the number of people with a disease in a population. It is usually 
expressed as incidence or prevalence. These are further explained below.  
ii. Measuring deaths from a disease in a population: The number of deaths 
resulting from a particular disease is another measure of disease burden. This 
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may be expressed as mortality rate, case fatality rate, among others. These 
are also explained further below. 
iii. Measuring risk factors associated with a disease in a population: A risk 
represents the probability of the occurrence of a health outcome or an event 
(e.g. risk of having a disease or risk of dying from a disease) in a defined 
population (Alwan et al., 2010). In other words, a risk may be described as an 
aspect of an individual’s characteristics, inherited feature, lifestyle, and/or 
environmental exposure that is associated with an increased probability of 
occurrence of a disease (Kamadjeu et al., 2006). Some risk factors may be 
modifiable, and intervening to alter these risk factors may reduce the 
occurrence of disease/s they are associated with. Specifically for NCDs, 
tobacco smoking, harmful use of alcohol, unhealthy diet and physical 
inactivity have been described as the four major risk factors (Boutayeb, 
2006). This is explained further under section 1.1.5- risk factors. 
iv. Measuring the socio-economic impact or financial cost of a disease in a 
population: This is another measure of disease burden that describes the 
social, economic, and financial impact of disease in a population (Schneider 
et al., 2009). In some instances, an assessment of the socio-economic burden 
has been applied by governments to make vital policy decisions on a disease 
(Boutayeb, 2006, Bloom et al., 2011). This is further explained under section 
1.1.4- socio-economic burden. 
Meanwhile, in the last two decades, burden of disease has been described in terms of 
years of healthy lives lost due to a particular disease, and years lived with disability 
as a result of the disease (Murray and Lopez, 1996). The above are all measures of 
different elements of the overall burden of disease. The use of each (i.e. incidence, 
prevalence, mortality rate, CFR, risk factors or assessment of socio-economic burden 
of a disease) may depend, among many others, on what has already been measured 
on the disease, feasibility and cost effectiveness of embarking on such measures of 
disease burden, what interventions are being targeted and how such measures of 
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disease burden (when reported) may positively influence healthy public decisions 
and policies. 
In estimating the burden of disease, one fundamental step is to appropriately define 
the disease following agreed or standard case definitions. This generally requires 
standard clinical criteria to be met (which may include the use of standard tests) to 
meet internationally agreed case definitions (Burney et al., 1989). Thus, during 
epidemiological surveys, it may not be sufficient  to count the number of locally 
recorded disease cases, rather, counting the number of people that meet 
internationally agreed case definitions is required (Trepka et al., 2009). A major 
limitation, which was observed in this thesis, is that case definitions are often 
imperfect and not applied consistently in all studies. 
As noted above, measuring the occurrence of a disease in a population may involve 
measurement of prevalence and/or incidence rates of the disease. In simple 
quantitative terms, prevalence is defined as the number of persons with a disease 
divided by the total number of people assessed for the presence of disease (Kamadjeu 
et al., 2006). While this has been described as a useful epidemiological measure to 
inform policy decisions (in that, it is a simple straightforward measure of the number 
of people living with a disease (Alwan et al., 2010)), it has a number of important 
limitations. These include problems with case definitions, variable degrees of proper 
application of standard protocols, sampling errors, problems of incomplete data due 
to low levels of voluntary participation in the prevalence survey, challenges arising 
from those with positive history of the disease but who do not have identifiable 
disease at the time of survey, and problems arising due to imperfect sensitivity and 
specificity of survey methods, leading to over- or under-estimation of the disease 
(Alwan et al., 2010). Point-prevalence is simply the number of people with 
identifiable disease at a particular point in time; period-prevalence is the number of 
people with identifiable disease over a period of time; and lifetime-prevalence is the 
number of people who have or have had the disease at any point in their life. One of 
the major challenges encountered in conducting systematic reviews of prevalence 
Estimating the Prevalence of NCDs in Africa 
 
Introduction  6 
studies is that studies use different prevalence measures and sometimes do not make 
it clear which measure they are reporting. 
Incidence introduces the concept of time into disease measurement (Chokunonga et 
al., 2000). It is usually measured in prospective longitudinal studies, where all people 
in the study are assumed to be healthy at the start of the survey (with attempts made 
to exclude people with prevalent disease) and are followed up over a period of time 
to detect new cases of the disease (Arbyn et al., 2011). It is calculated as the number 
of new cases of a disease divided by total number of persons at risk over the follow-
up period (Chokunonga et al., 2000). It is, however, important to have an appropriate 
understanding of the study population and its age and gender distribution to allow for 
appropriate comparisons with other population groups. This is particularly important 
when seeking to make summary estimates in systematic reviews.  
Deaths from diseases are measures of disease burden that are commonly expressed as 
mortality or case fatality rates (Walker et al., 2013).  Mortality can be defined just 
like incidence but with the numerator having deaths in place of new cases of the 
disease (Danesi et al., 2013). Mortality rate is calculated as the number of deaths 
from a disease occurring in a population over a particular period divided by the total 
number of persons at risk of dying during this period (Walker et al., 2013). Crude 
mortality rate describes deaths from all causes, while disease-specific mortality rate 
only covers deaths due to one disease (Walker et al., 2013, Danesi et al., 2013). 
Meanwhile, case fatality rate (CFR) is based on numbers of deaths and total incident 
cases. It is defined as the proportion of incident cases that die within a specific time 
period, or the proportion of deaths within a defined population of incident cases 
measured over the course of the disease (Danesi et al., 2013, Murray and Lopez, 
1996). CFR is commonly applied to a specific outbreak of acute disease in a 
population in which all affected cases have been followed for an adequate period of 
time to include all deaths due to the disease (Danesi et al., 2013). Again, many of the 
challenges highlighted under prevalence studies may also be encountered here. 
As noted above, in recent times, the Institute of Health Metrics Evaluation (IHME) 
has developed alternative measures to estimate the burden of disease (Lozano et al., 
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2012, Murray et al., 2012). This is mainly expressed in the form of disability 
adjusted life years (DALYs). DALY is defined as the sum of years lived with 
disability (morbidity) and years of healthy life lost due to premature mortality 
(Murray and Lopez, 1996). This is discussed further in the next section.  
Understanding the concept of DALYs and YLL in the estimation of disease burden 
In the early 1990s, the concept of DALYs gradually became a widely accepted 
metric in the measure of disease burden (Murray and Lopez, 1996). According to 
Murray and Lopez, the DALYs philosophy was to provide a summary measure of 
disease burden for public health use by combining morbidity, mortality, disease 
occurrence and severity in an estimation model (Murray and Lopez, 2013). Murray 
and Lopez further stated that this approach was necessary to inform health priority 
setting, health research priority setting, and identification of disadvantaged groups to 
be targeted with health interventions. It also provided a metric for use in evaluations 
of interventions and health programmes and in planning exercises (Murray and 
Lopez, 2013). The first study of the global burden of disease using DALYs was 
conducted in 1990. This study quantified the health effects of over a hundred 
diseases and injuries for eight regions of the world. As noted in the preceding 
section, a DALY is expressed mathematically as: 
1 DALY = YLD + YLL  
where YLD = Years Lived with Disability (morbidity)  
1 YLD = Number of cases * Duration * Disability Weight  
 and YLL = Years of Life Lost due to premature mortality  (mortality)  
1 YLL = Number of deaths * Life Expectancy at Age of death  
(Murray and Lopez, 2013, Murray and Lopez, 1996). 
Concerns have been raised by some health experts over how equitable these 
disability weights (and/or age weightings) are, and whether they also take into 
consideration comparability between countries and regions (Anand and Hanson, 
1998, Anand and Hanson, 1997). These weightings may reflect more the 
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understanding of researchers and the baseline estimation methods may not be 
applicable to all countries. Another issue which has been raised is the extent to which 
a “true” life expectancy table has been developed and to what extent age and gender 
have been equally considered in this approach (Anand and Hanson, 1997).  
Aside from these methodological issues, DALYs have been described as a complex 
simplification of reality, and may only give a crude indication of disease burden. 
DALYs have been thought not to capture other aspects of disease pathways, 
including pain, depreciating quality of life, and emotional, physical and 
psychological trauma (World Health Organization, 1996). Additionally, with a 
widely accepted use of DALYs in the estimation of disease burden, it is possible that 
donors may have directed their funds (on a very large scale) at diseases with high 
DALYs in a particular region, while ignoring the fact some diseases with lower 
DALYs in this region may still be a major cause of disease burden in some other 
world regions (Steenland and Armstrong, 2006). 
Notwithstanding these criticisms, it is important to state that the recent IHME GBD 
estimates (the Global Burden of Disease 2010 (GBD-2010)) are still regarded as one 
of the largest epidemiological assessments of global data on health ever conducted 
(Lim et al., 2012, Lozano et al., 2012, Murray et al., 2012). Some of the major 
limitations (some of which were first identified in the 1990s when DALYs was 
introduced (World Health Organization, 1996)) are briefly discussed in the next 
section. 
Limitations of IHME methods and estimation 
Experts have described DALYs mainly as an aggregate measure of health status, and 
may not be closely (and/or truly) representative of country or regional estimates 
(World Health Organization, 1996). The estimates attempt to characterize loss of 
health from diseases and injuries, while also assessing the role of major risk factors 
across many world regions (Murray and Lopez, 2013). This approach has tended to 
give insufficient attention to obvious country and regional heterogeneities and so 
much useful information may actually be hidden. Byass and colleagues critically 
appraised the GBD 2010 study and reported that estimates should be clearly regarded 
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as estimates, and by no means described as actual measurements (Byass et al., 
2013b). 
Concerns have been raised among experts on the source/s of data from which these 
estimates are derived, especially for the GBD 2010 study (Byass et al., 2014, World 
Health Organization, 1996). IHME did report that data were derived from a mixture 
of vital registration, sample registration and survey data (Murray and Lopez, 2013). 
The question is where exactly were these data sourced from and why were they not 
made publicly available? In this thesis, access to these data sources could have 
allowed direct comparisons and possible corroborates to be made with the reported 
estimates. 
Another limitation of the IHME approach is that available data are not sufficient to 
support valid and precise large estimates on all diseases, injuries and risk factors 
across all world regions (World Health Organization, 1996). In the view of many 
commentators, these estimates are a product of sophisticated modelling of sparse and 
inconsistent data (Byass et al., 2014, World Health Organization, 1996). Vital 
registration currently covers about 40% of global deaths, with many of these coming 
from regions with incomplete, passive and irregular vital registration (Byass et al., 
2014, Murray and Lopez, 2013). In addition, many diseases and deaths occur in rural 
areas worldwide, especially in Africa, with most of these occurring without any 
record (Byass et al., 2014). This raises concerns about the level of coverage and 
completeness of underlying mortality data, especially from low income countries. 
This also affects the uncertainty intervals of the estimates reported. Byass and 
colleagues reported that the IHME 95% uncertainty intervals were also complex and 
only reflected uncertainty from the modelling employed rather than due to the quality 
and number of data sources. For example, in regions where data were largely 
unavailable, the uncertainty intervals should be relatively wider than in other world 
regions with more detailed data to reflect this lack of data (Byass et al., 2013b). 
In general, many IHME data sources are unavailable and data from many parts of the 
world are incomplete, leading to reported estimates which may be more a product of 
complex modelling than a true reflection of the true burden of disease. Dr Margaret 
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Chan, the WHO Director General, explained that to arrive at population 
representative figures of the global, regional and country estimates of disease burden, 
the focus should now be on closing data gaps, especially across many low-and 
middle-income countries. If this were achieved, then  the need for complex statistical 
modelling for burden of disease estimates would become less necessary (Chan, 
2012).  
Why is my approach different from the IHME methods? 
A general concern is that in Africa, vital registration systems and health management 
information systems can be said to be in a developmental state, and too incomplete to 
provide the data needed (Byass et al., 2014). Indeed, in many parts of Africa, health 
management information systems are virtually non-existent (Byass et al., 2014). The 
data that are available in some African sub-regions tend to be mainly on causes of 
deaths and not on disease prevalence or incidence. Moreover, IHME has been 
working more on deaths (and DALYs) over the last two decades, and many concerns 
have been raised over their estimates. The sources of IHME data have also not been 
made publicly available, thus estimating other measures of disease burden, including 
prevalence and/or incidence, from their published data is often not possible. 
In terms of the stakeholders in the health sector across many parts of Africa, 
understanding of the epidemiology of NCDs in Africa is presently quite poor due to 
the lack of data and low level of research on NCDs (King and Bertino, 2008). Africa 
has recently seen a large increase in life expectancy and urbanization, which has 
been driving an increase in the NCD burden in the continent (Assah et al., 2011). 
Many studies reporting the burden of NCDs in Africa are derived, at least in part, 
from modelling based on data from other countries imputed into African countries, 
and may not be strictly based on data originating from Africa itself (Kirigia and 
Barry, 2008). This is therefore in stark contrast with the need to have useful local 
information on NCDs, with particular focus on data derived from Africa, as 
recommended in the UN’s approach to the political prioritization of the NCD burden 
(Beaglehole et al., 2011). There are also reports that African leaders and 
policymakers may be more interested in knowing the actual number of people living 
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with a disease (i.e. the prevalence or incidence) to inform policy decision-making. 
This may partly reflect the fact that the concept of DALYs, widely reported by 
IHME, are not widely understood (King and Bertino, 2008, Kirigia and Barry, 2008). 
Thus, based on this understanding, and with the already extensive estimates of 
DALYs and deaths on many diseases in Africa reported by the IHME, I decided to 
focus on estimating the prevalence and/or incidence of major NCDs in the African 
continent (discussed in Section 1.1.7). To address some of the concerns raised by 
experts on the IHME estimates, I conducted a thorough systematic search of 
literature. The data sources and all data points were clearly presented and made 
publically available (see also Appendix). Second, to address the concern about 
complex modelling applied on scarce data from the African region, a simple meta-
regression epidemiological model was applied on all data based on reported mean 
age from each study (since this was the main available confounding factor for which 
data were available in most studies). However, this still does not imply that estimates 
presented in this thesis are without limitations. A range of limiting factors is 
presented and discussed in the discussion section (Section 1.1.3). 
 
1.1.1 The Global Burden of Non-Communicable Diseases 
In 2008, according to the WHO global burden of disease (GBD) estimates, NCDs 
accounted for about 36.1 million deaths in the world (63% of global deaths) of which 
80% occurred in low- middle-income countries. They have been projected to account 
for about 52 million deaths by 2030 (World Health Organization, 2011b). 
Cardiovascular diseases (CVDs) ranked highest, accounting for 17 million deaths 
(48% of global NCDs deaths). Cancer accounted for 7.6 million deaths (21% of 
global NCDs deaths), chronic respiratory diseases (CRDs) 4.2 million deaths (11.7% 
of global NCDs deaths) and diabetes 1.3 million deaths (3.5% of global NCDs 
deaths) (Table 1.1) (World Health Organization, 2008). These four diseases, 
according to WHO records, account for almost  80% of global deaths from NCDs 
(World Health Organization, 2008). Interestingly, they are associated with four 
shared risk factors: tobacco use, physical inactivity (or sedentary lifestyle), harmful 
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use of alcohol and unhealthy diets (World Health Organization, 2011a). According to 
WHO 2008-2013 Action Plan for the Control of NCDs, about 80% of cardiovascular 
diseases, type 2 diabetes and over a third of cancers could be prevented by 
eliminating these shared risk factors (World Health Organization., 2007). 
Table 1.1. Distribution of the leading global NCD deaths by WHO regions in 
2008 






























Global 7.6  21.1 17.3 48.0 1.3 3.5 4.2 11.7 
Africa 0.4  1.1 1.3 3.5 0.2 0.5 0.3 0.9 
The Americas 1.2  3.3 1.9 5.4 0.3 0.8 0.4 1.1 
Eastern 
Mediterranean 
0.3  0.9 1.2 3.3 0.1 0.2 0.2 0.4 
Europe 1.9  5.2 4.6 12.7 0.2 0.4 0.4 1.0 
South-East Asia 1.1  3.1 3.6 10.0 0.3 0.8 1.4 3.8 
Western Pacific 2.7  7.4 4.7 13.1 0.3 0.7 1.6 4.4 
Source: WHO Global Burden of Disease 2008 (World Health Organization, 2008) 
The 2010 Institute of Health Metrics Evaluation (IHME) GBD estimates confirmed 
many reports on the increase of NCDs globally. In 1990, there were 46.5 million 
deaths from all causes globally, with NCDs accounting for 26.6 million (57.1% of 
global deaths), while of the 52.8 million global deaths from all causes in 2010, 34.5 
million (65.3% of global deaths) were attributable to NCDs (Lozano et al., 2012). On 
the measure of disabilities, there were a total of 2502.6 million DALYs in 1990 and 
1075 million (43% of global DALYs) was attributable to NCDs; this percentage was 
also relatively lower compared to a total of 2490.4 million DALYs and 1343.7 
million (54% of global DALYs) attributable to NCDS in 2010 (Murray et al., 2012), 
see Table 1.2.  
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Table 1.2. Distribution of the leading global NCD deaths and DALYs in 1990 
and 2010 





















Total 26.6 57.1 34.5 65.3 1075.3 42.9 1343.7 53.9 
CVDs 11.9 25.6 15.6 29.5 240.7 9.6 295.0 11.8 
Cancers 5.8 12.5 7.98 15.1 148.1 5.9 188.5 7.6 
CRDs 3.99 8.6 3.8 7.2  119.2 4.8 117.9 4.7 
Diabetes 0.7 1.5 1.3 2.5 27.8 1.1 46.8 1.9 
Source: (Lozano et al., 2012, Murray et al., 2012) 
 
1.1.2 The State of Non-Communicable Diseases in Africa  
The current global estimates reveal that NCDs mortality is higher than mortality that 
is attributable to other causes in all region of the world except in Africa. However, 
records still show that age standardized NCDs mortality rates were the highest in 
Africa in 2008 (males- 844/100000 and females- 724/100000), and a 20% increase in 
mortality has been projected by 2030 (World Health Organization, 2011a).  
According to the WHO GBD estimates, NCDs are the second leading cause of death 
in the African region (World Health Organization, 2008).  Across Africa, NCDs 
accounted for 30% and 25.8% of the overall 9.5 million deaths and 675.4 million 
DALYs recorded in Africa in 2011 (World Health Organization, 2014b). It was 
estimated that cardiovascular diseases accounted for 10% of all deaths in the region, 
with cancer accounting for 4%, CRDs for 3%, and diabetes for 1% (World Health 
Organization, 2014b). In exact quantitative terms, CVDs accounted for 1.3 million 
deaths (3.5% of global NCDs deaths), followed by cancer, accounting for 0.4 million 
deaths (1.1% of global NCDs deaths), CRDs, for 0.3 million deaths (0.9% of global 
NCDs deaths), and diabetes, for 0.2 million deaths (0.5% of global NCDs deaths) 
Estimating the Prevalence of NCDs in Africa 
 
Introduction  14 
(World Health Organization, 2008), see Table 1.1. In this thesis, these four major 
NCDs (CVDs, diabetes, cancer and CRDs) will be the main focus. 
Across African sub-regions, the burden is particularly higher in North Africa 
compared to sub-Saharan Africa (World Health Organization, 2011c). For example, 
the 2008 WHO estimates showed that NCDs accounted for 82% of all deaths in 
Egypt, 75% in Morocco, 63% in Algeria, 78% in Libya and 72% in Tunisia, while 
countries like Nigeria had NCDs mortality of about 27% of all deaths, Ghana 39%, 
Kenya 28%, Uganda 25%, and Zimbabwe 21% (World Health Organization, 2011c). 
Meanwhile, in 2000, the burden of NCDs in South Africa was estimated to account 
for about 21% Years of Life Lost (YLL) (Bradshaw et al., 2003). Recent studies 
show that death rates from NCDs in South Africa have actually increased from what 
was observed in 2000, accounting for 29% of all deaths in South Africa in 2008 
(almost the same range with figures in other sub-Saharan countries) (World Health 
Organization, 2011c). 
Meanwhile, the increasing trend of NCDs in Africa is thought to be partly due to 
population dynamics and demographic transitions occurring at a faster rate in Africa 
in comparison to many developed countries, and this not allowing for effective 
adaptation period in many African countries (Kengne and Mayosi, 2014). The 
differences in the capacity of African countries to effectively respond to the NCDs 
surge have also been a factor (Kengne and Mayosi, 2014). According to the WHO, 
emerging evidence suggests that NCDs is increasingly receiving the needed attention 
across Africa, with about 89% of African countries having a dedicated unit for NCDs 
within their national ministry of health (World Health Organization, 2011c). 
Nevertheless, looking at specific NCDs response, reports show that only 26% of 
African countries had a functional programme for anyone of the four major NCDs 
(CVDs, diabetes, cancer and CRDs) in Africa (World Health Organization, 2011c). 
In the absence of a concerted continent-wide intervention, WHO projects that the 
greatest increase in NCDs deaths will occur in the African region (27%) in the next 
decade, with NCDs exceeding infectious diseases as the most common cause of 
death in the region by 2030 (World Health Organization, 2008). 
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1.1.3 Heterogeneities within and between African population groups 
One important issue in estimating the burden of any disease is to arrive at estimates 
that are closely representative of the population under study, while considering a host 
of inherent demographic factors. In Africa, this may appear difficult to achieve 
owing to wide heterogeneities within and between population groups. This was 
therefore a major challenge for this thesis, as the few studies included in the thesis 
had varying degrees of heterogeneities, mostly due to differences among the 
population groups. The estimates should therefore be interpreted with caution. 
Meanwhile, urbanization, age, ethnicity, and gross domestic product (GDP) across 
Africa, and their associations with the risk factors for some NCDs will be briefly 
examined in this section in order to have a background understanding of these 
heterogeneities. 
Urbanization 
To fully understand heterogeneities in the African population with regards to urban 
versus rural dwellers, it is worthwhile to briefly mention the epidemiological 
transition in the African context. According to WHO, more than 100 countries 
worldwide are transitioning rapidly towards a greater percentage of deaths from 
NCDs and injuries, and this is now most pronounced in Africa (World Health 
Organization, 2011c). Reports show that the rate of urbanization, ageing and 
adoption of western lifestyles is fastest globally in the African continent (Apt, 2004, 
Assah et al., 2011). This has obviously resulted in a gradual reduction in the 
importance of infectious diseases and nutritional deficiencies (which are common in 
childhood) and increase in the importance of NCDs (Stern et al., 2010). 
Epidemiological transition is basically associated with industrialization and 
development, and involves the overall process by which patterns of risk factors, 
disease mortality and morbidity shifts over time (Assah et al., 2011). 
Over 530 million people reside in rural areas in sub-Saharan Africa (BeLue et al., 
2009). Studies have shown that between 1970 and 1982, African urban populations 
grew by about 6% per year, and between 1990 and 2010, this rate nearly doubled 
(BeLue et al., 2009). It is believed that rates of occurrence of NCDs tend to be much 
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lower in rural settings compared to urban settings (Assah et al., 2011). But as noted 
above, many of these rural settings are rapidly becoming urbanized (although it is 
important to note that the rate of urbanization is likely to differ markedly between 
different countries in Africa) (Niakara et al., 2007). Indeed, it is now difficult to 
strictly assign an area as a predominantly rural setting (Niakara et al., 2007).  
Meanwhile, authors have warned that rapid urbanization in many parts of Africa is 
an important psychological stressor among urban dwellers, This is due, for example, 
to the creation of mega-slums with attendant  deterioration in health and well-being, 
especially due to poor housing, sanitation, and unaffordable and limited access to 
health services  (BeLue et al., 2009). Many studies have further shown that 
hypertension, obesity, sedentary lifestyle, high salt and fats intake, smoking and 
alcohol consumption are major NCD risk factors commonly associated with urban 
dwellers (Niakara et al., 2007, Sobngwi et al., 2002, Mbanya et al., 2010). Thus, 
attention to the differing characteristics of urban or rural settings (as an important 
issue which can create heterogeneities) need to be carefully considered in any 
African study, as an inappropriate classification of these may affect the overall 
interpretation of findings of the study. 
Age 
Increasing age is a major risk factor for many NCDs (Abegunde and Owoaje, 2013). 
Many studies have reported that the prevalence rates of hypertension, stroke, COPD 
and cancer increase with increasing age (Abegunde and Owoaje, 2013, Ejim et al., 
2011, Ezenwaka et al., 1997, Hammami et al., 2011). It therefore forms an important 
heterogeneity that needs to be carefully considered across various African 
populations. According to the United Nations, Africa’s population was estimated at 
967 million in 2008, with about 42% aged below 15 years (United Nations, 2013). 
Experts believe this relatively youthful population thus provides a drive for 
population growth in the region with an annual growth rate of 2.4% (Abegunde and 
Owoaje, 2013). Africa has the youngest population worldwide, with a median age of 
19.7 years in 2012 (United Nations, 2013). Currently, about 85% of the African 
population are below 45 years of age and only 5% are aged 50 years and above 
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(BeLue et al., 2009). The significance of this is that when a predominantly young 
population in Africa continuously gets exposed over time to NCD risk factors (and 
carry the consequences of this exposure into adulthood) a greater percentage of 
adults in the productive age group in the continent (15-60 years) may be living with 
NCDs in the next two to three decades. One can also expect that premature mortality 
from NCDs in the region may be relatively higher than in other parts of the world. 
Additionally, at a time when the average global life expectancy was estimated to be 
73 years (in 2013), the average life expectancy at birth in Africa was 59 years, with 9 
African countries having life expectancies less than 55 years (World Bank, 2014b).  
Across individual African countries, Liberia, Ethiopia and Rwanda had the highest 
increase in life expectancy in Africa between 1990 and 2013 (increases being 42 to 
62 years, 45 to 64 years, and 48 to 65 years, respectively) (World Bank, 2014b). If 
this rapid increase in life expectancy in these three countries is maintained over the 
next two to three decades, one may expect a relative increase in the proportion of the 
population in the older age groups than observed presently, and consequently the 
prevalence of NCDs in the older age groups can be expected to increase.  
Among African population groups, age may become a factor with regards to place of 
residence. Across many African countries, there is a rapid efflux of young and 
educated age groups from rural areas to urban centres in search of a better livelihood 
(Stern et al., 2010). In the meantime, this may imply that the population in urban 
centres comprise a mix of rural and urban dwellers. Therefore, the observed disease 
patterns in these settings in any study may need to be cautiously interpreted. While 
over time, rural centres may become depleted and the older age groups left behind 
may actually be lacking the needed healthcare (especially care related to emotional 
and family ties) (BeLue et al., 2009). This may lead to some degrees of depression, 
dementia and some psychological disorders in the elderly population. 
Ethnic diversity 
Africa is made up of enormously diverse groups of people in terms of ethnicity, 
racial grouping, culture and language (Mathenge et al., 2010). The ethnic groups in 
Africa number in thousands and each of these have a specific culture and way of life, 
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which can be linked with their health behaviours (Mathenge et al., 2010). Therefore, 
cultural and ethnic diversity is an important part of health research that needs to be 
well understood in the estimation of disease burden. In fact, a thorough situation 
analysis aimed at understanding the cultural context in which diseases are interpreted 
and responded to by a community is vital to developing lifestyle and behavioural 
modifications that can be easily accepted by the community (BeLue et al., 2009). A 
typical example is in the interpretation of diabetes symptoms. The Akan ethnic group 
in Ghana refer to diabetes as sugar disease in Twi language (de-Graft Aikins et al., 
2010a); diabetes is referred to as disease with sugary urine and cluster of ants in 
Yoruba tribe in Nigeria (Oladapo et al., 2010); and in a separate study of 72 patients 
with diabetes, native labels for diabetes translated into sugar sick or illness that 
originates from too much sweet things (Mbanya et al., 2006).  
The cause of disease in many African ethnic groups has been attributed to witchcraft, 
punishment from gods, and poverty, among others (Assah et al., 2011). This may 
also influence the increased patronage of traditional and faith healers, as many of 
these healers are presumed to be able to tackle these causes (BeLue et al., 2009). 
They therefore offer “cure” for some NCDs (like diabetes and hypertension) based 
on this understanding and from the fact that many patients cannot afford care from 
expensive standard health facilities (BeLue et al., 2009). In fact, some communities 
now believe that herbal concoctions and home-brewed beer are the best treatment for 
hypertension and diabetes (Koopman et al., 2012).  
Meanwhile, the prevalence of some diseases is common to some specific ethnic 
groups in Africa. For example, among East Africans, oesophageal cancer is thought 
to be more common (the reasons for this not fully understood), while hypertension 
and stroke is less common (possibly due to intense physical activity in these region) 
(Madebo et al., 1994). In West Africa, the Fulani ethnic group are traditional 
nomadic pastoralists and research in this group shows they have low cardio-
metabolic risk, possibly due to the long hours each day spent walking (Oladapo et al., 
2010). 
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These are examples of the cultural and ethnic diversities that need to be well 
understood in the estimation and interpretation of disease burden data. 
Gross Domestic Product (GDP) 
Reports have shown that GDP and the average income status in a country may affect 
the occurrence of disease (Stanciole et al., 2012). Many chronic diseases have been 
said to be relatively high in Northern parts of Africa due to the better standards of 
living in these countries, as western lifestyles including smoking, alcohol 
consumption, sedentary lifestyles and high intake of salts and fats are relatively 
common (Nejjari et al., 2013). On the average, Northern African countries have a 
higher GDP than in other parts of Africa, with Egypt having a GDP of US$229.5, 
Algeria US$188.7, Morocco US$100.2, Libya US$62.4 and Tunisia US$45.9 billion, 
respectively, in 2013 (World Bank, 2014b). 
In Central, East and West African regions, however, the standard of living is lower 
with the percentage of the population living on less than US$2 per day reported at 
about 50% or more in every country (World Bank, 2014a). The increase in the 
burden of NCDs in these regions has been linked mostly to inability to access and 
afford standard health services (Stanciole et al., 2012). Sao Tome & Principe, Guinea 
Bissau, Gambia and Liberia have the some of the lowest GDPs in the African region, 
at US$0.2, US$1.0, US$1.1, US$1.2 billion, respectively, in 2013 (World Bank, 
2014b).  
In terms of country level GDPs in Africa, Nigeria and South Africa stand out as the 
two highest GDPs in Africa in 2013 at US$509.9 and US$408.2 billion, respectively 
(World Bank, 2014b). Indeed, economic activity in many sub-Saharan African 
countries was robust in 2013 with a GDP growth strengthening from 3.7% in 2012 to 
4.7% in 2013 (World Bank, 2014a). There has been very encouraging investment in 
infrastructure, including those related to health services (Stanciole et al., 2012). 
However, across many African countries, the effects on health are yet to be 
appreciated due to the negative influences of poor leadership, managerial ineptitude, 
corruption, and inequity in the distribution of resources (World Bank, 1993). GDP 
has been described as an important underlying determinant of the prevalence of 
Estimating the Prevalence of NCDs in Africa 
 
Introduction  20 
many chronic diseases. The main socio-economic stressors include unemployment, 
illiteracy, unstable power supply, and lack of potable water (World Bank, 2014a). 
In the next section, the socio-economic burden of NCDs will be examined. 
 
1.1.4 Socio-Economic Burden 
It has been observed that approximately 30% of deaths from NCDs in low- and 
middle-income countries occur in people younger than 60 years, which are actually a 
productive age group, thus bearing down heavily on socioeconomic status, the 
already stretched health systems and government finances, and family budgets in 
these regions (Clark, 2013).  
Studies have shown that NCDs and poverty may be mutually related (Schneider et 
al., 2009). NCDs, in the presence of other social determinants of health, have pushed 
millions of people below the poverty index with many living below a daily income of 
$1.25 per day in Africa (de-Graft Aikins et al., 2010b). Dr Margaret Chan states that 
billions of United States dollars (USD) were lost across many countries in 2008 due 
to NCDs owing to huge costs incurred by various national health systems (World 
Health Organization, 2008). It has also indirectly affected the United Nations 
Millennium Development Goals (UN MDGs), where MDGs 2, 4 & 5, which 
addresses poverty, maternal and child health have been difficult to achieve, 
especially in resource-poor settings (World Health Organization, 2011b).  
In financial terms, NCDs were estimated in 2005 to cost $18 billion in China, $9 
billion in India and $3 billion in Brazil. Cost analysis of NCDs burden in Africa was 
estimated in 2005 and projected to increase by over 30% in 2025, based on the health 
expenditure in China, India and Brazil (World Health Organization, 2011a). For 
example, the estimated average annual cost of managing diabetes (which is known to 
interact with many NCDs) in sub-Saharan Africa is $8836 per patient (Hall et al., 
2011). In-depth analysis based on the total African population has shown that this 
figure by Hall and colleagues corroborates with the NCDs cost estimates reported for 
Africa (Hall et al., 2011, Asaria et al., 2007).  
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1.1.5 Risk Factors 
The risk factors noted above (smoking, harmful use of alcohol, sedentary lifestyles 
and unhealthy diets) are actually behavioural risk factors, which could lead to any of 
the metabolic risk factors (increased blood pressure, plasma glucose, cholesterol, and 
body mass index (BMI)).  
Tobacco use 
According to the WHO, tobacco use accounts for over 9% of global deaths (World 
Health Organization, 2008). Studies show that Africa actually has the lowest 
smoking rate in the world with about 8% of over 1 billion smokers in the world 
(World Health Organization, 2011c). However, Africa has recently become a 
potential market target for tobacco manufacturers, thus there has been some increase 
in consumption in Africa in the last five years (Kengne et al., 2007). According to 
WHO GBD estimates, smoking is known to cause about 71% of all lung cancers, 
42% of chronic respiratory diseases and 10% of CVDs (World Health Organization, 
2008). 
Alcohol 
Harmful use of alcohol accounts for about 2.3 million deaths per year (World Health 
Organization, 2008). Alcohol consumption is largely responsible for many cancers, 
cardiovascular diseases and liver diseases. Studies show that alcohol consumption is 
gradually increasing in Africa, as people now consume it on the assumption that low-
risk pattern of alcohol consumption could be beneficial (Kengne et al., 2007). 
Diet 
Unhealthy diets and poor nutrition are very prevalent in Africa, and the relatively 
low income status and standards of living have been implicated (Cecchini et al., 
2010). Even with salt intake level of less than 5g/person/day, as recommended by 
WHO, studies show that salt intake across many elite population groups in Africa is 
quite high at about 9-12g/person/day (Asaria et al., 2007). Due to effects of 
urbanization and gradual change to western diets, cholesterol and sugar intake have 
been on the increase in many African settings, especially among urban dwellers 
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(Cecchini et al., 2010). In addition, there is generally low consumption of fruits and 
vegetables in many African settings (Lim et al., 2012). Reports show that reduced 
fruits and vegetables consumption accounted for about 1.7 million deaths (16 million 
DALYs) globally in 2008, with Africa responsible for about a third of these deaths 
(World Health Organization, 2008). 
Physical inactivity 
Physical inactivity (or sedentary lifestyle) accounted for 3.2 million deaths globally 
(32.1 DALYs) and caused about 20-30% increase in NCDs mortality annually. 
Obesity and overweight are directly related to sedentary lifestyles, and have 
accounted for 2.8 million deaths globally (35.8 million DALYs)  (Lim et al., 2012); 
this is highest in America and lowest in South-East Asia, while Africa falls between 
these regions (Lim et al., 2012).  
Infections 
Infections have been partially responsible for the high cancer burden in Africa 
(Martel et al., 2012). HIV/AIDS, Hepatitis B Virus (HBV), Human Papilloma Virus 
(HPV) and Helicobacter Pylori are the main causes (Sylla and Wild, 2011).  
-HIV/AIDS and NCDs:  The burden of HIV/AIDs in Africa may have also 
contributed to the growing burden of NCDs, as studies have shown that people with 
HIV/AIDS present with higher rates of NCDs compared with people who are HIV 
negative (Byass et al., 2013a).  There are reports of direct biological linkages 
between HIV and some specific NCDs including Kaposi’s sarcoma, HIV associated 
lymphoma, and cervical cancer; many of which are due to HIV opportunistic 
infections (UNAIDS, 2011). Other linkages have been thought to be as a result of the 
effects of HIV medications, treatment and the psychological state of the HIV patient 
(Oti, 2013). For example, in a study in Kenya, the prevalence rates of hypertension 
and obesity were significantly higher among HIV positives compared to those that 
were negative (UNAIDS, 2011). Some experts have reported that this may be due to 
lipodystrophy and metabolic consequences of some HIV treatments (Estrada et al., 
2006). For example, according to Estrada and colleagues, in a 6-month study of 156 
HIV patients on anti-retroviral treatment (ART) matched with 156 healthy controls, 
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the prevalence of lipodystrophy and metabolic syndrome was higher in HIV patients 
on ART than in the non-HIV infected healthy controls (15.8% vs 3.2%; P < .001)  
(Estrada et al., 2006). In addition, due to better health care, and with many HIV 
patients now relatively living longer,  the prevalence of NCDs is also increasing 
among HIV positives, just as has been reported in the general population (UNAIDS, 
2011). In a recent study in five African countries to examine the distribution of 
cause-specific mortality among HIV-negative and HIV-positive people using an 
InterVA-4 verbal autopsy interpretative model, Byass and colleagues reported that 
deaths from many NCDs were relatively higher among HIV positives compared to 
the negatives, with a mortality rate ratio for diabetes of 5.0, for stroke of 2.2, for 
COPD of 1.6, for asthma of 8.0 and for reproductive neoplasms of 14.3 (Byass et al., 
2013a) (see Table 1.3). One promising thing from these apparent similarities is the 
fact that a lot can be learned in the response to NCDs from the current response to 
HIV/AIDS globally. Byass and colleagues noted the fact that many developing 
countries, especially in Africa, with a relatively higher burden of HIV, also have 
burgeoning epidemics from many NCDs (Oti, 2013). Specifically, many NCD 
patients and those living with HIV tend to present with few symptoms at the early 
stages of the respective diseases (Narayan et al., 2011). Additionally, both 
HIV/AIDS and NCD patients require regular hospital visits, follow-up investigations, 
adherence to medications, and adoption of healthy or safe lifestyles (Oti, 2013). 
Thus, HIV/AIDS and NCD control programmes may share similarities in the 
development of intervention models and tools and protocols (Oti, 2013). These may 
include: promoting healthy behaviours, long-term adherence to medications, 
monitoring of treatment outcomes, and involvement of patient and family in the final 
care pathway (Narayan et al., 2011). Further discussion on infections and NCDs is 
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Table 1.3. Cause-specific mortality by HIV status using InterVA-4verbal 
autopsy interpretative model 
WHO VA cause of 
death by InterVA-4 
*Mortality rate HIV- *Mortality rate HIV+ Mortality rate ratio 
Oral neoplasms 0.01 0.14 19.2 
Digestive neoplasms 0.06 0.76 13.0 
Respiratory 
neoplasms 
0.04 0.23 6.0 
Breast neoplasms 
(female) 
0.01 0.07 9.6 
Reproductive 
neoplasms (female) 
0.02 0.34 14.3 
Other neoplasms 0.03 0.21 7.7 
Diabetes mellitus 0.06 0.28 5.0 
Stroke 0.07 0.15 2.2 
COPD 0.04 0.07 1.6 
Asthma 0.02 0.19 8.0 
Other NCDs 0.04 0.17 4.6 
*mortality rate per 1000 per year, VA-verbal autopsy 
Source: (Byass et al., 2013a) 
Age, sex and race 
Age, sex and race are non-modifiable risk factors for many NCDs. Prevalence of 
increased blood pressure is more common in Africa, among older age groups, and 
men (Edwards et al., 2000). Smoking and alcohol consumption in Africa is 6 times 
more prevalent among men, while obesity and sedentary lifestyle are common 
among women (Kengne et al., 2007, Msyamboza et al., 2011). Studies have also 
shown that Africa women have the highest risk of cervical cancers in the world 
(World Health Organization, 2011c). 
Other factors 
Many other risk factors of NCDs are associated with social determinants of health. A 
study in South Africa revealed that people may decide to change their eating patterns 
and physical activities due to socioeconomic and environmental influences (Stern et 
al., 2010). For example, a buzzing and busy urban life, which may be associated with 
night clubs, smoking and increased use of alcohol in many African cities, has been 
tagged socially informative, while weight gain and obesity, especially among African 
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women, are thought to be signs of healthy living and a good way to earn social 
respect (Stern et al., 2010).  
As noted above, several studies have shown that poverty and lower living standards 
could be responsible for the increasing trend of NCDs in Africa and vice-versa (de-
Graft Aikins et al., 2010b). The conclusions of some authors in South Africa 
suggested there could be other factors playing a role, too (Stern et al., 2010). For 
example, many behavioural risk factors of NCDs are common among people of 
lower socioeconomic status, or those who live in resource-poor settings. They often 
have a higher risk of dying from NCDs because they are constrained with worse 
access to health care, which is needed for timely diagnosis and treatment of NCDs, 
than the people in the higher socioeconomic status (Schneider et al., 2009, Di Cesare 
et al., 2013). On the contrary, the prevalence of overweight and obesity in many 
African settings has been reported to increase with rising levels of income due to 
more sedentary lifestyles and increased consumption of unhealthy diets (Dalal et al., 
2011). Moreover, based on records in high income countries, many people are also 
obese and overweight, having varying degrees of NCDs as well (Di Cesare et al., 
2013).  Hence, NCDs burden is increasing in many African countries. This may not 
only be due to lower income statuses, but also several determinants of health may be 
responsible, including the lack of timely access to health care services (Dalal et al., 
2011). The wealthy, therefore, are not immune to NCDs, but they may have the 
resources to manage them better if detected early enough (Di Cesare et al., 2013). 
Largely, the socio-economic impact of NCDs cuts across all ages, sexes, the poor 
and the rich. 
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1.1.6 Assessing the Gaps in Information, Control and Response to 
Non-Communicable Diseases in Africa 
Gaps in information 
The global target in 2005 was to reduce NCDs by 2% every year (World Health 
Organization, 2011a). Efforts toward achieving this goal have been delayed at 
various levels due to many reasons, some of which are yet to be fully identified 
(Asaria et al., 2007).  Specifically, cost-effective, evidence-based and contextually 
feasible delivery strategies for NCDs programmes have been developed at country 
levels.  However, the coverage of these interventions in Africa still remains low, 
especially due to poor health information management system, and a weak and 
fragile health system across many African countries (Kirigia and Barry, 2008). 
Recently, the world’s health ministers agreed to work towards reducing premature 
mortality from the four main NCDs (cardiovascular diseases, diabetes, cancer and 
chronic respiratory diseases) by 25% from 2010 levels by 2025 (the “25 by 25 goal”) 
(Beaglehole et al., 2013). It is important to further point out that “premature” in this 
context is defined as the probability of dying from NCDs between the ages of 30 
years and 70 years (Kontis et al., 2014). Generally, the assumption before now is that 
NCDs predominantly affected the old. However, emerging data from Africa and 
many developing countries point to a significant amount of people aged between 15-
59 years that are suffering from NCDs (Barry et al., 2009, Kengne and Mayosi, 
2014). In 2008, about 44% of all NCD deaths occurred before the age of 70 globally 
(World Health Organization, 2008). Cardiovascular diseases accounted for 39%, 
followed by cancers at 27%, diabetes 4%, and chronic respiratory diseases, digestive 
diseases and other NCDs together accounted for about 30% of these deaths (World 
Health Organization, 2008). These deaths are avoidable and may not have occurred if 
timely and effective medical intervention had been made available (Kontis et al., 
2014). In other words, significant proportions of deaths from NCDs in this age group 
may be indicative of failing national health systems, and this has apparently been the 
case in many African settings (Barry et al., 2009). With the recent goal of attaining a 
25% global reduction in premature mortality from non-communicable diseases 
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(NCDs) by 2025 (the “25 by 25 goal”), experts have further stated there may be a 
need for health system strengthening, capacity building, and establishing rigorous 
data registration, collation and monitoring systems (Beaglehole et al., 2013). 
Meanwhile, many African countries actually have a unit responsible for NCDs at 
national levels, but the effectiveness of those units remains a major source of 
concern, owing to the rising NCDs burden in the continent (World Health 
Organization, 2011c). In fact, in most African countries, the annual health 
expenditure on NCDs is relatively high, yet with very minimal impact (Asaria et al., 
2007). This is basically due to misplaced priorities, administrative negligence, and 
technical incompetence, among many others (World Health Organization, 2011a).  
For example, Nigeria, Egypt and South Africa have structures in place for NCDs, 
including those for funding, health information and reporting system, and a variety of 
program specific policies and action plans, yet the burden of NCDs in these countries 
remains high (World Health Organization, 2011a).  
Additionally, the lack of a national information system in many African countries has 
affected research output on NCDs in the continent (Gill et al., 2001). In the last two 
decades, there have been gradual increase in population-, hospital- and registry-based 
studies conducted across many parts of Africa, but the incompleteness of information 
from these studies have prevented further research from which inferences and policy 
decisions may be made (Opare et al., 2013). The few continent-wide estimates on 
NCDs are based on advanced statistical modelling, rather than the actual data on 
these diseases in Africa (Fan and Lam, 2012). Thus, the true representation of these 
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Gaps in Control 
Tobacco and Alcohol Control: Moodie and colleagues expressed that transnational 
corporations have been the major drivers of NCDs in many African countries, and 
have greatly profited from increased consumption of tobacco and alcohol products in 
these countries (Moodie et al., 2013). Due to major roles played by these 
transnational corporations in Africa, they have been involved in decisions related to 
policies (Otañez et al., 2009). It has therefore been very difficult to fully implement 
tobacco and alcohol control measures, as this may directly affect their sales (Moodie 
et al., 2013). Research findings have shown that tobacco control has been proven to 
be cost-effective in reducing NCDs compared to many other interventions globally 
(Adejuwon, 2009, Amuyunzu-Nyamongo, 2010). For example, Egypt increased 
taxes on tobacco by 87%, Turkey 77% and  Ukraine 127%; and between 2009 to 
2010, Turkey was considered one of the 17 world’s  smoke-free countries, while 
Egypt and Ukraine experienced drastic reductions in tobacco consumption and 
consequently NCDs (World Health Organization, 2011a). In addition, implementing 
four key elements of WHO 2006-2015 Framework Convention on Tobacco Control 
(FCTC), which would amount to about $0.4-1.0 per person per year in Africa, has 
been adjudged a major and affordable contribution towards the reduction of NCDs in 
the continent (Asaria et al., 2007). Moreover, increased taxes, regulatory sanctions, 
drink driving control measures are also cost effective interventions for reducing 
harmful alcohol use (World Health Organization, 2011b). While some studies 
showed varying levels of drink driving control measures in Africa, the systems in 
these countries are not well equipped to fully implement this (Amuyunzu-
Nyamongo, 2010). 
Salt, Cholesterol and Fats Control: Salt reducing policy is currently in use in the UK 
and has been very cost-effective (Asaria et al., 2007). The programme began in 2003 
and by 2008, average daily salt consumption per person had reduced from 9.5g to 
8.6g, averting over 6000 deaths. In addition, more than £1.5 million per year was 
saved (World Health Organization, 2011a). According to Asaria and colleagues, 13.8 
million deaths could be averted with a 15% individual reduction in salt intake (Asaria 
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et al., 2007). In Africa, reports reveal that many countries are yet to adopt this policy 
(Asaria et al., 2007). Meanwhile, the growth of processed foods and fast-foods 
restaurants is on the high in many African settings, and there are not yet effective 
measures to monitor the content of their products (Amuyunzu-Nyamongo, 2010). In 
fact, just like the tobacco and alcohol companies, influential processed foods 
companies are also employing similar strategies to undermine the implementation of 
healthy public polices for NCDs in Africa (Otañez et al., 2009, Moodie et al., 2013). 
According to experts, there should be no place for any unhealthy commodity 
industries in the formation of national or global policy for non-communicable 
diseases (Moodie et al., 2013, Bonita et al., 2013). The Disease Control Priority 
Project (DCPP) highlighted that ensuring only poly-unsaturated fatty acids in 
processed foods could avert one DALY from NCDs at a cost of $4012 in North 
Africa (World Health Organization, 2011a, DCPP, 2011). 
“The most sustainable method for raising additional revenue for NCD 
prevention and management is to develop a health promotion fund (or 
the equivalent) by substantially and regularly increasing the price of 
tobacco, alcohol, and unhealthy food products through large and 
phased increases in taxes”. Robert Beaglehole  (Beaglehole et al., 
2013) 
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Gaps in response 
Access to essential medicines, vaccines and screening tools: According to Hogerzeil 
and colleagues, access to essential medicines and vaccines specific for the treatment 
of NCDs is unacceptably low globally (Hogerzeil et al., 2013).  Hepatitis B Virus 
(HBV) and Human Papilloma Virus (HPV) vaccination, and routine screening for 
cancers, have been found to be cost-effective in addressing the increasing incidence 
of cancers (Sylla and Wild, 2011). However, due to the huge capital involved and 
failure to get willing international partners, many African countries have been unable 
to fully implement this (Amuyunzu-Nyamongo, 2010). Experts have advised that 
with an appropriate use of generic medicines coupled with efficient selection and 
procurement process, more medicines may be acquired within existing budget in 
Africa and many LMIC globally (Hogerzeil et al., 2013). Importantly, the success of 
existing drug initiatives in the treatment of HIV in Africa may offer valuable lessons 
that can promote access to pharmacological management of NCDs in the continent 
(Hogerzeil et al., 2013).  
Monitoring, Surveillance and Research: A NCDs surveillance framework has been 
developed by the WHO, and this involves monitoring the exposures (risk factors), 
outcomes (NCD cases and fatalities) and responses (health system capacity) towards 
developing a sustainable policy for the control, prevention and management of NCDs 
(World Health Organization, 2011a, Alwan et al., 2010). Records show that this is 
clearly lacking in many African countries, as they lack efficient data collation and 
registration system (Msyamboza et al., 2011, Unwin et al., 2001). Poor research 
output is another major challenge that has ensued from the lack of data (Dalal et al., 
2011). African governments have been tasked with the responsibility of prioritizing 
cancer prevention through regular and up to date cancer registration system, support 
and research training for people working in cancer control centres (Sylla and Wild, 
2011). Research focussing on estimation of the burden of NCDs, risk factors, and re-
organizing the health system or primary healthcare services towards providing an 
effective response to the challenges posed by NCDs could be productive (McCarthy 
et al., 2010, Maher et al., 2010).  
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Health system strengthening and capacity building: This involves a system aimed at 
improving health care (service delivery), physical (infrastructural), financial 
(funding), and human (health workforce) sectors respectively (World Health 
Organization, 2011a, Alwan et al., 2010). It cuts across many other areas of health 
system development, and may require skilled experts and efficient human resource 
personnel (Samb et al., 2010). With the current weak health systems in many African 
countries, coupled with poor funding and organization, capacity building and service 
delivery have been remarkably low (Samb et al., 2010). 
Poverty and hunger:  Research findings have shown that socio-economic status and 
many other determinants of health like poverty, hunger, uneven wealth distribution 
and illiteracy contribute to the growing burden of NCDs across many settings, 
especially in Africa (Schneider et al., 2009). The World Bank estimated that about 
one-third of the poorest two quintiles in Africa and many developing countries die 
prematurely from NCDs (World Bank, 2014a). Since this disproportionately affects 
the most economically productive age groups, families are further thrown into a 
chronic poverty trap (Schneider et al., 2009).  According to researchers, about 44% 
of the African population are under 15 years of age, and the transition to adulthood in 
a predominantly poor setting may have contributed to the high prevalence of NCDs 
(Bradshaw and Steyn, 2001). A study reported that as children grow older they carry 
along risks accumulated from sub-standard living conditions, unhealthy and risky 
behaviours, and metabolic consequences of poor feeding and under-nutrition in 
childhood (Stanciole et al., 2012). By middle-age, body systems may not be able to 
respond well to these lifestyles. This group of children may consequently become a 
sick generation with a likely early onset of diabetes, stroke, cancer and other chronic 
diseases (Bradshaw and Steyn, 2001). As noted earlier, a complex host of risk factors 
may be attributed to the development of NCDs in a population, some of which have 
been considered under risk factors and heterogeneities within and between African 
population groups. Therefore, it is important to note that continuing hunger and 
poverty to adulthood may only be contributory to this complex risk factors pattern. 
There are indeed other factors that may be considered, including those related to the 
fetal origins of adult disease (FOAD) (Skogen and Øverland, 2012). The FOAD 
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hypothesis suggests that the risks from intrauterine environmental exposures may 
affect the development of the fetus during sensitive fetal growth periods, and may 
consequently increase the risk of some diseases in adulthood (Barker, 1992). 
According to Barker, this relationship was first observed between some intrauterine 
exposures and the development of adult coronary heart disease (Barker, 1992); 
however, further studies have showed a range of links with some other chronic 
diseases (Skogen and Øverland, 2012). Although some researchers have stated that 
the relationship between intrauterine life and adult diseases remain unclear and 
perhaps independent (Ben-Shlomo and Kuh, 2002), other experts have supported this 
hypothesis, while showing further evidence that environmental exposure during 
pregnancy can actually have effects on an individual’s health during adult life 
(Whincup et al., 2008, Alati et al., 2007). 
Meanwhile, with largely weak health systems across many African settings, any co-
ordinated public health response (if at all present) may be further overwhelmed, and 
many affected individuals may still lack the financial strength to seek appropriate 
medical attention (Schneider et al., 2009). One other factor that has been reported is 
that problems and ill-effects of NCDs in Africa and other poor settings far outweigh 
what is experienced in high income countries, and this possibly points to an intrinsic 
relationship with poor living conditions (World Health Organization, 2009).  For 
example, age-standardized NCDs mortality rates have been reported to be highest in 
Africa in 2008, and are rising faster than in other world regions (World Health 
Organization, 2011a). Many poor and rural populations with NCDs are doubly 
disadvantaged in terms of access to health services (World Health Organization, 
2009). A study in Tanzania reported that Tanzanian men aged 15-64 years were three 
to six times more likely to die from stroke compared to those in the United Kingdom 
(Walker et al., 2000). There are also emerging reports that the percentage of daily 
smokers is higher in poorest countries, including those in Africa, compared to high 
income countries (Jha et al., 2002). As noted earlier, a major factor here may the lack 
of effective government action in these settings to institute appropriate counter 
smoking legislation (Adejuwon, 2009). According to WHO, NCDs may still lead to a 
further poverty trap, as 2-3% of people in low-income settings are faced with 
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catastrophic health expenditure from NCDs, and this pushes about 1-2% into further 
impoverishment (World Health Organization, 2009). Thus, many have reported that 
efforts towards achieving MDG-1 (eradicate extreme poverty and hunger) could help 
address many NCDs and in return further strengthen the achievement of this goal. 
However, while poverty and hunger may be associated with NCDs, it is also 
worthwhile to state that wealthy lifestyles and affluence may also be associated with 
major behavioural risk factors of NCDs, including unhealthy diet, sedentary 
lifestyles and obesity. Reports show that about 60-80% of NCDs in the developing 
world occur due to these behavioural lifestyles (Schneider et al., 2009). Obesity is 
currently described as a global pandemic affecting about 500 million people 
worldwide, while physical inactivity is said to have resulted in annual deaths almost 
equal in number to those caused by tobacco smoking (World Health Organization, 
2009). In urban South Africa, over 50% of adult women and 30% of adult men in the 
middle to upper socio-economic class are either obese or overweight (Bradshaw and 
Steyn, 2001). Many of these sit long hours at work every day, eat from fast food 
restaurants (with high fat and salt content food), drive in private luxurious cars, and 
engage in very limited physical activity (Lambert and Kolbe-Alexander, 2013). This 
shows that beyond poverty and hunger, wealth and affluence are also important 
drivers of the NCDs pandemic. In fact, the pandemic of NCDs may be described as a 
product of a poorly managed development process, unhealthy industrialization and 
adoption of western lifestyles, all in the presence of a health system that is 
unaffordable, unavailable and insensitive to the health needs of those who require it 
most (Bradshaw and Steyn, 2001, Schneider et al., 2009). Therefore, population-
wide measures targeting poverty and hunger may need to be implemented with 
caution. There is need for a holistic approach in the fight against NCDs in Africa, 
while carefully considering all possible contributory factors (Dalal et al., 2011, 
Schneider et al., 2009). Most African governments still do not have these 
encompassing population-wide interventions (Schneider et al., 2009).  
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Table 1.4. The six objectives of the 2008-2013 action plan on NCDs 
# Objectives 
1 To raise the priority accorded to non-communicable disease in development work at global and national 
levels, and to integrate prevention and control of such diseases into policies across all government 
departments 
2 To establish and strengthen national policies and plans for the prevention and control of non-
communicable diseases 
3 To promote interventions to reduce the main shared modifiable risk factors for non-communicable 
diseases: tobacco use, unhealthy diets, physical inactivity and harmful use of alcohol 
4 To promote research for the prevention and control of non-communicable diseases 
5 To promote partnerships for the prevention and control of non-communicable diseases 
6 To monitor non-communicable diseases and their determinants and evaluate progress at the national, 
regional and global levels 
Source: WHO 2008-2013 Action Plan (World Health Organization., 2007) 
 One vital response to the growing epidemics of NCDs globally, with particular focus 
on Africa, is the WHO 2008-2013 action plan for the global strategy for the 
prevention and control of non-communicable diseases (World Health Organization., 
2007), which basically had six objectives targeted at addressing the burden of NCDs 
at various levels (Table 1.4). Emerging research findings have further shown that 
these interventions can address many NCDs risk factors in Africa, only if relevant 
resources can be harnessed towards implementing this (McCarthy et al., 2010, Samb 
et al., 2010). Bonita and colleagues further stated that strong leadership from country 
heads of state and governments, cutting across the basic key steps of planning, 
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1.1.7 Specific NCDs reviewed in this thesis and reasons for this choice 
In this thesis, the specific NCDs reviewed are: 
i. Cardiovascular diseases (mainly hypertension and stroke) 
ii. Diabetes mellitus 
iii. Cancer (mainly cervical, breast, prostate, ovary, oesophagus, bladder, 
Kaposi, liver, stomach, colorectal, lung and non-Hodgkin lymphoma) 
iv. Chronic respiratory diseases (mainly COPD and asthma) 
According to the WHO global burden of disease (GBD) report, these four NCDs 
were estimated to be the leading causes of deaths globally, accounting for about 80% 
of global deaths from all NCDs. As noted earlier, cardiovascular diseases (CVDs) 
ranked highest, accounting for 17 million deaths (48% of global NCDs deaths) 
(World Health Organization, 2008). Cancer accounted for 7.6 million deaths (21% of 
global NCDs deaths), chronic respiratory diseases (CRDs) 4.2 million deaths (11.7% 
of global NCDs deaths) and diabetes 1.3 million deaths (3.5% of global NCDs 
deaths) (Table 1.1) (World Health Organization, 2008).  
In Africa, the pattern appears to be largely the same as that observed globally. 
Cardiovascular diseases accounted for 10% of all deaths in the African region, cancer 
accounted for 4%, CRDs 3%, and diabetes 1% (World Health Organization, 2014b). 
These translated into about 1.3 million deaths from CVDs in Africa (3.5% of global 
NCDs deaths), followed by cancer, accounting for 0.4 million deaths (1.1% of global 
NCDs deaths), CRDs, for 0.3 million deaths (0.9% of global NCDs deaths), and 
diabetes, for 0.2 million deaths (0.5% of global NCDs deaths) (World Health 
Organization, 2008), see Table 1.1.  
For cardiovascular diseases, the leading causes of deaths include stroke, ischemic 
heart disease and hypertensive heart disease (World Health Organization, 2008). 
From an initial scoping review conducted on Africa, there was very scanty literature 
on ischemic heart disease and hypertensive heart disease. Thus, the main CVD 
included in the early phase of writing this thesis was stroke. However, further 
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literature review revealed a high number of published papers on hypertension. As this is a 
leading risk factor for most CVDs, this was also included in the thesis. Thus, the reviewed 
CVDs in this thesis were hypertension and stroke.  
For the choice of cancer types reviewed, this was also based on global and regional estimates 
for Africa, respectively. According to GLOBOCAN, the top five cancers worldwide in 2008 
were lung, breast, colorectal, stomach, and liver cancer. Parkin and colleagues in a separate 
review for Africa reported that the top six cancers in Africa among women were cervical 
cancer, breast cancer, Kaposi’s sarcoma, liver cancer, non-Hodgkin lymphoma (NHL) and 
ovarian cancer, and among men, these were Kaposi’s sarcoma, liver cancer, prostate 
cancer, bladder cancer, NHL and oesophageal cancer (Parkin et al., 2008). Therefore, in an 
attempt to have a better epidemiological knowledge of cancer types in Africa and to allow 
for relevant global comparisons, I limited my review to these top causes of cancer. Data on 
cancer that were extracted and analysed therefore included the top six cancers in Africa in 
both sexes (listed above), in addition to lung, colorectal, and stomach cancers, which were 
the most important cancers globally (that were not listed in Africa by Parkin and colleagues) 
(Parkin et al., 2008). Therefore, the final cancer types reviewed were 12 in all: cervical, 
breast, prostate, ovary, oesophagus, bladder, Kaposi, liver, stomach, colorectal, lung and 
non-Hodgkin lymphoma. 
According to the WHO GBD report, about 300 million people have asthma, and 210 million 
people have COPD (World Health Organization, 2008). The WHO also estimates that COPD 
is responsible for about 3 million deaths globally in 2011 (4
th
 leading cause of deaths), 
accounting for about 9.1% of all NCDs deaths (World Health Organization, 2011a). 
Meanwhile, with an estimated 300 million people living with asthma, and current trends also 
suggesting that an additional 100 million people may be living with asthma by 2025; asthma 
has been rated the most common chronic disease affecting children (IUATLD, 2011). The 
World Health Organization (WHO) estimated about 250,000 deaths from asthma annually, 
mostly in low- and middle-income countries (LMIC) (Bousquet et al., 2010, Braman, 2006). 
With these two (COPD and asthma) being the top CRDs globally, they therefore were the 
main CRDs reviewed in this thesis. 
Each of these four NCDs under review will be briefly examined in the next four sub-
sections. 
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1.1.8 Cardiovascular Diseases 
Cardiovascular diseases rank among the leading causes of disabilities and deaths 
from non-communicable diseases (NCDs) in Africa (Lawes et al., 2006, World 
Health Organization, 2013b), with rising prevalence  and death rates now observed 
more in young and active adults (Opie and Seedat, 2005).  Recently, the African 
Union (AU) reported that cardiovascular diseases are one of the greatest health 
challenges after HIV/AIDS in the continent (WHO Regional Office for Africa, 
2006). This is in fact a priority globally as conclusions from the 2011 United Nations 
high level meeting on NCDs focus on a reduction of hypertension and other CVDs, 
especially in Africa, where the burden is rising at a faster rate compared to other 
parts of the world (Beaglehole et al., 2011). Worldwide, cardiovascular diseases 
account for about 17 million deaths, with complications from poorly controlled 
hypertension resulting in over 7.5 million deaths and 57 million disability adjusted 
life years (DALYs) (Kearney et al., 2005).  
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Hypertension 
The relatively higher prevalence of hypertension in Africa has been linked to 
population growth and ageing, rising urbanization, mass migration from rural to 
urban areas, and an increased uptake of western lifestyles including tobacco and 
alcohol consumption (Opie and Seedat, 2005, de-Graft Aikins et al., 2010b). Public 
health response from the governments of many African nations still remains low, as 
research findings show that a high number of hypertensive individuals are currently 
unaware of their condition (Kayima et al., 2013). Many African countries are yet to 
implement high blood pressure awareness and control programmes on a population-
wide scale, even to people with very high risk of cardiovascular complications 
(MacMahon et al., 2008). Even with a widely popularised availability of 
hypertension treatments in some African countries (Mohan et al., 2013), reports 
show that many rural dwellers are still faced with lack of antihypertensive 
medications and poor management of cases of hypertension (Perkovic et al., 2007). 
The WHO has recommended a need for strong public health policies, multisectoral 
approach, and available and affordable treatment options toward reducing this 
growing burden of hypertension in Africa (World Health Organization, 2013b). 
Despite reports of a higher prevalence of hypertension in Africa compared to other 
world regions (World Health Organization, 2013b), public health experts believe the 
real burden is still far from being known (Addo et al., 2007). Many studies in the 
1980s and early 1990s were based on the old definition of hypertension (≥ 160/95 
mm Hg) (Kayima et al., 2013, Addo et al., 2007). These surveys may possibly 
underestimate the prevalence of hypertension in Africa in comparison to newer 
surveys based on ≥ 140/90 mm Hg cut off level. Moreover, even within studies based 
on similar case definitions, the variation in reported estimates still suggests the need 
for more systematic and accurate estimates from larger number of studies towards 
appropriately informing health service planning and a better response to hypertension 
in Africa. For example, the WHO reported that the prevalence of hypertension in the 
African region was highest globally in 2008, with an estimated prevalence of 46% 
(World Health Organization, 2011a). This, though vital for instituting relevant public 
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health response in the continent, elucidates a conflicting state of data in comparison 
to other hypertension prevalence estimates in Africa which are relatively low 
(Kengne et al., 2012, Twagirumukiza et al., 2011). Thus, with an increased research 
output on hypertension in Africa in the last two decades, it is important to conduct 
systematic review of population-based studies towards providing an improved 
continent-wide estimate of the prevalence and awareness of the rate of hypertension 
in Africa, which hopefully may encourage healthy public health policy for a value-
added management of hypertension in the region. 
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Stroke 
The burden of stroke is increasing in many low- and middle-income countries 
(LMIC) (Feigin et al., 2014), and due to high fatality rates and overwhelming 
resource incurred by the health systems, stroke and many non-communicable 
diseases (NCDs) are now targeted public health priorities in these regions 
(Beaglehole et al., 2011, Chin, 2012). Global estimates suggest about 16 million new 
cases of stroke and 62 million stroke survivors in 2005, with deaths from stroke 
accounting for 9.7% of all global deaths (World Health Organization, 2011a). In the 
absence of significant global public health response, this is expected to increase to 
over 23 million new stroke cases and 7.8 million stroke deaths by 2030 (Strong et al., 
2007, World Health Organization, 2004). 
It has been estimated that LMIC account for over 87% disability adjusted life years 
(DALYs) from stroke, which is about seven times the DALYs lost in high-income 
countries (HIC) (Johnston et al., 2009). Africa is particularly worst hit, owing to 
population growth, unchecked industrialization and increased consumption of 
western diets. This is due to a rise in many modifiable vascular disease risk factors 
including smoking, harmful use of alcohol, physical inactivity and unhealthy diets, 
and invariably resulting in increased prevalence of hypertension, diabetes and obesity 
(Connor et al., 2007, O'Donnell et al., 2010). In 2000, two African countries, 
although recorded low stroke prevalence rates, had remarkably high stroke incidence 
rates (Truelsen et al., 2006).  According to GBD 2002 estimates, three African 
countries (Angola, Liberia and Sierra Leone) recorded the highest stroke mortalities 
and DALYs worldwide (World Health Organization, 2002, World Health 
Organization, 2004). Between 2002 and 2004, estimates further revealed an 
increasing prevalence with 8% of new stroke cases and 5% of stroke survivors 
occurring in Africa (Truelsen, 2010a).  In 2004, stroke was estimated to cause over 
3% of all deaths in the African region and about 52% of all CVD deaths (Connor et 
al., 2007). Even with this increasing burden, the public health response, accesses to 
health services and treatment options in many African countries have been poor 
(Wahab, 2008, Connor et al., 2007).  Specifically, the lack of functional stroke units, 
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neurologists, health workers, cranial computed tomography (CT) scans, magnetic 
resonance imaging (MRI) machines and echo-doppler machines, among many others, 
has negatively affected stroke outcomes (Wahab, 2008, Chin, 2012). Moreover, the 
high cost of medical care in a relatively low-income African society could have 
resulted in high stroke fatalities, as some studies have indicated that stroke 
prevalence and deaths in Africa increased due to an overtly poor socioeconomic 
status (Johnston et al., 2009). For example, a recent study revealed the incidence of 
stroke in HIC decreased by over 40% between 1970 and 2008, but with actual 
number of stroke cases increasing due to ageing of the population (Feigin et al., 
2009), while in Africa and many LMIC, stroke incidence rose by over 100% over the 
same period (Feigin et al., 2009). Furthermore, due to the high proportion of 
undiagnosed hypertension in Africa, especially among the younger population 
(Mensah, 2008), stroke incidence has also been reported to be more severe and 
higher among the active and productive population age groups (Walker, 1994). 
Meanwhile, the World Health Organization (WHO) technically supported member 
countries with methods for improved data collation and registration of hospital stroke 
cases (Mathers, 2005). Notwithstanding, another set-back in the response to the 
management of stroke in Africa is the lack of data and low research output (Mensah, 
2008, Connor et al., 2007). Stroke case ascertainment and survey methodologies 
have not, in most cases, complied with international protocols (Connor et al., 2007). 
Published research studies are characterized by poorly organized community-based 
studies, difficulties in making retrospective diagnosis, and overlapping cases of first 
and recurrent strokes (Sudlow and Warlow, 1996, Connor et al., 2007). The few 
studies on stroke, therefore, could have been marked by under-estimation of the 
stroke burden in Africa. In view of this high burden of stroke, its public health 
importance, and the relatively low research output in Africa, it is important to 
estimate the incidence and prevalence rates of stroke in Africa in order to attempt to 
quantify the burden and inform decision regarding policy responses and health 
system interventions across many countries in the region.  
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1.1.9 Diabetes 
Diabetes and other non-communicable diseases (NCDs) have been on the increase 
over the last three decades in Africa, posing huge burden on the economy of the 
continent (Kirigia et al., 2009), especially with a competing need for health resources 
from many infectious diseases (Barry et al., 2009, Beaglehole, 2011). Diabetes has 
been regarded as a disease of the affluent, and thought to be rare in Africa (Skene et 
al., 1982); however, recent reports show that diabetes is now prevalent and by 2030, 
NCDs, including diabetes and hypertension, will be among the leading causes of 
deaths in Africa (Murray and Lopez, 1996).  Many research findings have shown that 
diabetes prevalence estimates in urban Africa are similar with, or even higher than, 
what is obtained in developed countries (Beran and Yudkin, 2006); this downplays 
previous reports of lower prevalence of diabetes in Africa (Skene et al., 1982). 
Experts still report that despite a relative increase in diabetes research in Africa, there 
still not enough epidemiological evidence to estimate the prevalence of diabetes in 
the region; most estimates have been based on sophisticated modelling, and may not 
necessarily reflect the true burden of the disease (World Health Organization, 2006).  
According to International Diabetes Federation (IDF) atlas, about 151 million people 
were estimated to have diabetes globally in 2000 (International Diabetes Federation, 
2000), 194 million in 2003 (International Diabetes Federation, 2003), 246 million in 
2006 (International Diabetes Federation, 2006), 285 million in 2010 and a projected 
increase to 439 million in 2030 (Walker et al., 2011, International Diabetes 
Federation, 2009), which is an increase of 54% from the 2010 figures. This global 
increase was also documented in Africa; this has been linked with the fast 
demographic changes, uncontrolled urbanization and the gradual adoption of western 
lifestyle (Mbanya et al., 2010). Wild and colleagues estimated 7.1 million diabetic 
cases in Africa in 2000, and a projected increase to 18.6 million in 2030 (161% 
increase) (Wild et al., 2004). IDF also reported about 10.8 million diabetic cases in 
2006 (International Diabetes Federation, 2006), 12.1 million in 2010 and a projected 
estimate of 18.7 million in 2025, and 23.7 million in 2030 (International Diabetes 
Federation, 2009, Shaw et al., 2010), giving about 98% increase between 2010 and 
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2030, doubling the estimated global increase. Mbanya et al. also reported that 
diabetes prevalence is increasing in sub-Saharan Africa, with a regional prevalence 
of 2-3% in mid-1990s increasing to about 4.6% in 2010 (Mbanya et al., 2010). Based 
on IDF estimates, the top 5 countries with highest diabetes population in Africa in 
2000 were Nigeria (1.71 million), South Africa (0.81 million), Ethiopia (0.79 
million), Algeria (0.43 million) and Ghana (0.30 million) (International Diabetes 
Federation, 2000). 
As noted earlier, the high burden of HIV/AIDS has relatively affected the occurrence 
of many NCDs, including diabetes, in Africa, with a reported similar trend in the 
mortality rate of diabetes and HIV/AIDS in the region (Kalk and Joffe, 2008, Levitt 
and Bradshaw, 2006). In fact, emerging evidence in western and eastern parts of 
Africa points to a stable or diminishing spread of HIV/AIDS, it may therefore be 
assumed that the burden of diabetes is also decreasing. However, comparative 
models in Southern Africa, where HIV/AIDS burden is highest in Africa, have 
shown an increasing prevalence of diabetes mainly due to population changes and 
increased life expectancies, irrespective of the impact of HIV/AIDS (Levitt and 
Bradshaw, 2006, Panz and Joffe, 1999). Based on the recent GBD estimates 
however, deaths from diabetes globally increased from 16.3/100000 to 19.5/100000, 
and DALYs also increased from 523/100000 to 680/100000 between 1990 and 2010, 
respectively (Lozano et al., 2012, Murray et al., 2012). In Africa, however, there 
have not been many studies on diabetes mortality (Mbanya et al., 2006); the few 
reports have shown that the main causes of deaths are from complications and 
overriding infections (Mbanya and Ramiaya, 2006). The health cost from diabetes in 
Africa has also been huge (Mbanya and Mbanya, 2003, Chale et al., 1992); Kirigia 
and colleagues estimated that the 7.1 million cases of diabetes reported in Africa in 
2000 accounted for a regional economic loss of about 25.5 billion US dollars ($), 
equivalent to about $3633 per diabetic case (Kirigia et al., 2009). The need for 
insulin and other medications was responsible for the bulk of the direct cost, 
accounting for about $8.1 billion ($1154/diabetic case) (Kirigia et al., 2009, Mbanya 
and Mbanya, 2003). Indirect cost was higher, with permanent disability from diabetic 
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complications largely indicated, accounting for about $17.4 billion (Kirigia et al., 
2009). 
From available evidence in Africa, Type 1 diabetes prevalence appears to be rarer, 
though experts still call for more studies involving larger population to validate this 
(Mbanya et al., 1997). In 1992, Nigeria reported prevalence of 0.33/1000 (Afoke et 
al., 1992), and in a 1989 survey of school children (aged 7-11 years) in Sudan, the 
prevalence was 0.95/1000 (Elamin et al., 1989). Tanzania had a low incidence of 
1.5/100000/year in 1993 (Swai et al., 1993), while Elamin and colleagues reported 
incidence of 10.1/100000/year in Sudan in 1997 (Elamin et al., 1997). The huge 
contrast is believed to be due to ethnic differences and study designs, as the 
Tanzanian population were mainly indigenous Africans, while the Sudanese study 
had a mixture of Arab and African populations (Mbanya et al., 2010, Mbanya and 
Ramiaya, 2006). The age of onset of type 1 diabetes is quite later than what is 
obtained in developed countries (Beran and Yudkin, 2006). From studies conducted 
in Tanzania, South Africa and Ethiopia, the peak age at onset ranges between 22-29 
years (Mbanya et al., 2006). There is still little evidence on the sex preference of type 
1, though a female preponderance was reported in South Africa (Levitt, 2008). 
As reported in many parts of the world, type 2 is the most common diabetes type in 
Africa (Levitt, 2008, Mbanya et al., 2010, World Health Organization, 2006), and 
prevalence now appears to be approaching what is obtained in western Europe 
(Levitt, 2008). Mbanya and Ramiaya reported that prevalence of type 2 diabetes was 
below 1% in most parts of Africa between 1960 and 1980, excluding Cote d’Ivoire 
(5.7%) and South Africa (0.6-3.6%) (Mbanya and Ramiaya, 2006). In 1990, type 2 
cases reached about 3 million (King and Rewers, 1993), and projected to experience 
a 2-3 fold increase by 2010 (Wild et al., 2004). The prevalence of type 2 diabetes 
was highest among populations of Indian origins in South Africa and Tanzania, 
ranging between 12-15% in 1991 (Mbanya et al., 2010, Levitt, 2008). Generally, as 
of year 2000, type 2 prevalence ranged between 1% and 6% in most parts of Africa 
(Shaw et al., 2010). 
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Gestational diabetes has not been documented much in Africa. It is believed that 
about 7% of all pregnancies in Africa may be complicated by hyperglycemic 
episodes (Jiwani et al., 2012, Mamabolo et al., 2007). Impaired Glucose Tolerance 
(IGT) and Impaired Fasting Glycemia (IFG) prevalence varies across various age 
groups in most parts of Africa; rates between 5% and 10% are quite common, with 
IGT affecting more women than men, and IFG vice-versa (World Health 
Organization, 2006).  Reports show that regions with relatively low diabetes 
prevalence but with fairly high prevalence of IGT and IFG may be at an early phase 
of diabetes epidemic (Mbanya et al., 2006). This was observed in Cameroon and 
Tanzania, both having low diabetes prevalence and raised IGT, and reportedly 
having high endemicity index of 83% and 88.4% respectively (Mbanya et al., 1997, 
McLarty et al., 1989). In an 11-year follow-up study of IGT cases in Mauritius, 30% 
returned back to normal blood glucose values, 35% still had IGT, 5% developed IFG 
and 5% developed diabetes; while in a similar follow-up of IFG cases, 40% reverted 
back to normal, 15% remained as IFG, 20% developed IGT and 25% eventually 
developed diabetes (Soderberg et al.). 
Research findings have shown that complications from diabetes are high in Africa 
(Mbanya and Sobngwi, 2003). Acute complications of diabetes, mainly diabetic 
ketoacidosis (DKA), hyperosmolar non-ketotic coma (HONC) and hypoglycaemia, 
are frequent causes of hospital emergencies with high mortalities (Idemyor, 2010). In 
Tanzania and Kenya, DKA accounted for 25% and 33% diabetic emergencies 
respectively, with most cases presenting due to lack of insulin (Levitt, 2008). HONC 
is a common complication of type 2 diabetes, occurring due to combined effects 
from the lack of insulin, infection, and non-compliance with medications or diet; it 
accounts for about 10% of diabetic emergencies in Africa and other developing 
countries (Mbanya and Mbanya, 2003). Hypoglycemia occurs less frequently, with 
missed meals and inappropriate medications accounting for the observed cases 
(Levitt, 2008). Africa has high prevalence of chronic diabetic complications; 
retinopathy accounts for about 13%-55% of chronic complications, nephropathy 
32%-57%, and foot ulceration 12%-20% (Mbanya and Ramiaya, 2006). 
Cardiovascular diseases may also complicate diabetes, commonly due to co-existing 
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hypertension (Mbanya et al., 2006); in an African study, about 15% of stroke patients 
were known diabetics (Aspray and Unwin, 2001).  
Age and ethnicity are non-modifiable risk factors of diabetes. Diabetes increases 
with age, with peak age in Africa occurring in the age groups 20-44 years and 45-64 
years (Aspray and Unwin, 2001, Mbanya et al., 2010). Indigenous Africans present 
with lower prevalence of diabetes than Africans living abroad; this also reflects 
influence of environmental factors (Swai et al., 1990). A comparative study showed 
higher diabetes prevalence among African populations in the Caribbean, United 
Kingdom and United States, compared with indigenous African populations in 
Western Africa (McLarty et al., 1990b, Palmer et al., 2012). As noted, environment 
factors have been associated with diabetes, especially in Western Europe, where 
seasonal viral infections reportedly led to increased incidence of hyperglycemic 
episodes (World Health Organization, 2006). In Africa, McLarty et al. reported 
seasonality of type 1 diabetes in Tanzania in 1989 (McLarty et al., 1989). 
Family history of diabetes, including genetic and immunological predisposition, is 
another risk factor. Many type 2 diabetic cases discovered across various studies in 
Cameroon, South Africa, Nigeria, and Tanzania had about 5-10% positive family 
history of diabetes (Mbanya et al., 2010), with evidence suggesting linkage in four 
regions on chromosome 12, 19 and 20 (Rotimi et al., 2004). Type 1 diabetes in 
Africa is associated with human leucocyte antigens (HLA) DR3 and DR4, and also 
linked positively in some African populations with alleles DQB*0201/0302 and 
DRB*0301/0401, and negatively with DQB*0501 (Mbanya et al., 2001). Type 1 
diabetes mainly results from islet cells auto-antibodies (McLarty et al., 1990a); 
however, across many studies in Tanzania, Nigeria, South Africa, and Ethiopia, type 
1 diabetes also had immunologic links with glutamic acid decarboxylase and 
insulinoma associated protein-2 antibodies (McLarty et al., 1990a, Lutale et al., 
2007, Panz et al., 2000). According to IDF, sex distribution of diabetes varies widely 
in Africa, with no specific trend (Shaw et al., 2010). 
As indicated, rapid urbanization has been suggested as a major reason for increased 
prevalence of diabetes and other NCDs in Africa, as people tend to gradually adopt 
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western lifestyles including reduced physical activity, increased fats consumption, 
tobacco and alcohol consumption (Mbanya et al., 2010, Levitt, 2008). Improved 
standards of living also tends to make people take better medical care, with 
consequent increased life expectancies, change in population structure and increased 
prevalence of NCDs (McLarty et al., 1990b). Worldwide, Africa is experiencing 
fastest rate of urbanization, with over a third of the population currently residing in 
urban areas; this is expected to increase to about 45% by 2025 (World Bank, 1993, 
United Nations, 2012). It is believed that increased physical activity, usually from 
farming and walking, contributed to low prevalence of diabetes and hypertension in 
many rural African populations (Abubakari and Bhopal, 2008, Abubakari et al., 
2009).  
Increased adiposity, measured from body mass index (BMI), waist-hip circumference 
(WHC) or waist-hip ratio (WHR), is also a known diabetes risk factor in Africa 
(Abubakari and Bhopal, 2008). In South Africa, many studies reported high rates of 
obesity among diabetic patients, ranging between 58% and 65% (Levitt, 2008). 
Increased physical inactivity, high fat diets and urban environments may indirectly 
contribute to increased adiposity among Africans (Abubakari and Bhopal, 2008). 
Cultural beliefs and traditional norms have also contributed to increased burden of 
diabetes in Africa (Beran and Yudkin, 2006). The knowledge, attitude and perception 
on diabetes have been poor; people still alternate between modern and traditional 
medications, with this negatively affecting diabetes control and prevention 
programmes (Levitt, 2008). 
As highlighted earlier, economic burden from diabetes has been really high; there is 
still the need for more research on economic cost of diabetes and other NCDs 
(Bloom et al., 2011). In a survey of 46 African countries in 2009, direct cost of 
diabetes care per individuals was about 25% of gross national income (GNI) per head 
for the 12 wealthiest countries, and a massive 125% of GNI per head for the 
remaining 34 poorest countries (Kirigia et al., 2009). According to the survey, 
diabetes presents huge financial burden on individuals, the society and government. 
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South Africa, Kenya, Zimbabwe, Nigeria and Ghana top the list of African countries 
spending hugely on diabetes in Africa (Walker et al., 2011).   
Meanwhile, public health experts believe information on diabetes epidemiology over 
the last 10 years has increased in Africa, but is still limited in many areas (Unwin et 
al., 2010). WHO reports there is still a need for more research on the burden of 
diabetes, including country specific response to diabetes treatment and management, 
and anthropological and cultural perspectives of diabetes in Africa (World Health 
Organization, 2006). With a growing epidemic of diabetes in Africa, and many of 
these research gaps remaining unaddressed (World Health Organization., 2007), this 
study thus aims to estimate the prevalence of diabetes in Africa towards giving 
appropriate policy recommendations that can improve overall management of 
diabetes in the continent. 
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1.1.10 Cancer 
The burden of cancer is increasing worldwide and currently a major contributor to 
global morbidities and mortalities (Arbyn et al., 2011). Cancer was previously 
thought to be a disease of the industrialized nations (Arbyn et al., 2011, World 
Health Organization, 2013a), however, evidence now shows that most new cases of 
cancers are found in low- and middle-income countries (LMIC), increasing from 
15% in 1970, to 56% in 2008, and projected to reach about 70% by 2030 (Farmer et 
al., 2010). One major challenge is in the overall response to this growing burden in 
many LMIC, with poor health system response and consequently, low survival rates 
reported in many LMIC, compared to an improved response and survival rates in the 
developed countries (Coleman et al., 2008). In fact, due to rapid population growth, 
increasing life expectancy, and progressively westernized lifestyles in developing 
countries, and coupled with overall population ageing globally, the burden of cancer 
is expected to continue to rise (Parkin et al., 2003), with about 27 million incident 
cases, 17 million deaths, and over 75 million prevalent cases of cancers expected by 
2030 (Ferlay et al., 2010). According to the 2011 United Nations high level 
committee on NCDs, the focus of many stakeholders has turned towards addressing 
the growing burden of cancer and other non-communicable diseases (NCDs) 
(Beaglehole et al., 2011), especially in Africa and other LMIC, where an existing 
high burden from infectious diseases has contributed to a double burden of disease 
(de-Graft Aikins et al., 2010b).  
Over the last 20 years, an increasing trend has been observed in the incidence and 
deaths from different cancers globally, owing to changes in geographic and 
environmental features, lifestyles and behavioural changes, and the relatively poor 
response of the health system, especially in LMIC (Parkin et al., 2001b, Bray et al., 
2012), see Table 1.5 for details.  
According to Parkin, there were 10.1 million new cancer cases and 6.2 million deaths 
in 2000, with Africa accounting for 6.3% and 6.4% of the global new cancer cases 
and deaths, respectively (Parkin, 2001). Parkin and colleagues reported that lung 
cancer was the main cancer globally with over 1.2 million new cases and 1.1 million 
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deaths, and breast cancer was the second most common with about 1.05 million new 
cases and about 373,000 deaths (Parkin et al., 2001b). Other top cancers were 
colorectal cancer with 876,000 new cases and 492,000 deaths, stomach cancer with 
876,000 new cases and 647,000 deaths, and liver cancer with 564,000 new cases and 
549,000 deaths, respectively  (Parkin et al., 2001b). Oncologists have noted that the 
relatively favourable prognosis of breast cancer was due to better response from the 
health sector, and this has resulted in a relatively lower death rates compare to other 
cancers with higher incidence rates (Coleman et al., 2008). 
In the 2002 GLOBOCAN study, reported estimates further underpinned the 
increasing burden of cancer globally (Parkin et al., 2005). Worldwide, there were 
10.9 million new cancer cases and over 6.7 million deaths, and Africa accounted for 
about 6.0% and 7.5% of global new cancer cases and deaths, respectively (Parkin et 
al., 2005).  From the report, lung cancer still presented with the highest burden with 
1.35 million new cases and 1.18 million deaths, breast cancer had 1.15 million new 
cases and 411,000 deaths, colorectal cancer had 1.02 million new cases and 529,000 
deaths, stomach cancer had 934,000 cases and 700,000 deaths, and liver cancer had 
626,000 cases and 598,000 deaths. Again, breast cancer was the most prevalent 
cancer, with about 4.4 million survivors over a 5-year period. 
Meanwhile, from the 2008 GLOBOCAN estimates, there were a total of 12.7 million 
new cancer cases and 7.6 million deaths, with Africa accounting for 5.6% and 7.1% 
of global new cancer cases and deaths respectively (Ferlay et al., 2010). For specific 
cancers, the pattern was still the-same with the estimates reported in 2000 and 2002. 
Lung cancer presented with the highest burden with 1.61 million new cases and 1.38 
million deaths, breast cancer 1.38 million new cases and 458,000 deaths, colorectal 
cancer 1.23 million new cases and 608,000 deaths, stomach cancer had 989,000 
cases and 738,000 deaths, and liver cancer had 748,000 cases and 696,000 deaths 
(Ferlay et al., 2010).  
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Table 1.5. Reported new cases and deaths for top five cancers globally (1990-
2008)  
Site 1990 (estimates in 
millions) (Parkin 
et al., 1999) 
2001 (estimates in 
millions) (Parkin 
et al., 2001b) 
2002 (estimates in 
millions) (Parkin 
et al., 2005) 
2008 (estimates in 











All - - 10.1 6.2 10.9 6.7 12.7 7.6 
Lung  1.04 - 1.2 1.1 1.35 1.18 1.61 1.38 
Breast 0.796 - 1.05 0.373 1.15 0.411 1.38 0.458 
Colorectal 0.782 - 0.945 0.492 1.02 0.529 1.23 0.608 
Stomach 0.798 - 0.876 0.647 0.934 0.7 0.989 0.738 
Liver 0.437 - 0.564 0.549 0.626 0.598 0.748 0.696 
Source: GLOBOCAN (Ferlay et al., 2010) 
According to Soerjomatoram et al., about 169.3 million years were lost due to 
cancers in 2008, with  colorectal, lung, breast and prostate cancers respectively being 
the main contributors to global DALYs (disability adjusted life years) 
(Soerjomataram et al., 2012). As noted above, the 2008 CONCORD study of cancers 
in 5 continents showed the 5 year survival rate was highest for breast cancer, 
followed by colorectal and prostate cancers, respectively (Coleman et al., 2008).  
Cancer is increasingly becoming a major public health burden in Africa due to the 
rapid urbanization and associated lifestyle changes, increasing life expectancies, and 
high prevalence of HIV/AIDS (Jemal et al., 2012). It is believed that one out of five 
deaths from NCDs among people aged >45 years in Africa is caused by cancer 
(Parkin et al., 2008).  The incidence of cancer in Africa varies across countries, and it 
is still difficult to say, with all certainty, the true incidence of cancer in many parts of 
Africa due to the lack of data (Bray et al., 2012). Experts still report that with the few 
data available, evidences are pointing to an increasing burden (Bray et al., 2012). In 
2008, WHO reported that the annual diagnosis of cancer in Africa was estimated at 
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650,000 cases out of a total population of 965 million (Parkin et al., 2008). 
Variations have been observed in the patterns of cancers in Africa, especially 
between northern Africa and sub-Saharan Africa (SSA) (Morhason-Bello et al., 
2013), as reports have shown that the burden of cancers is even rising at a faster rate 
in SSA compared to the northern parts of Africa due to relatively higher prevalence 
rates of infectious disease, unhealthy diets and poverty in SSA (World Health 
Organization, 2013a). WHO estimated about 551,000 new cases of cancer in sub-
Saharan Africa (SSA) in 2008 with about 421,000 deaths (World Health 
Organization, 2013a). However, the GLOBOCAN 2008 study reported a total of 
715,600 new cases of cancer and 541,800 deaths, with eastern Africa accounting for 
the highest burden at 221,000 new cancer cases and 173,700 deaths, followed by 
western Africa at 184,100 new cancer cases and 139,300 deaths (Ferlay et al., 2010), 
see Table 1.6 for details. 
Table 1.6. Distribution of new cancer cases and deaths in Africa  
African region New cases (in 1000s) Deaths (in 1000s) 
Men Women Total Men Women Total 
All Africa 324.9 390.7 715.6 267.0 274.8 541.8 
Eastern Africa 100.8 120.2 221.0 85.4 88.3 173.7 
Central Africa 29.5 37.4 66.9 25.6 27.6 53.2 
Northern 
Africa 
81.5 82.9 164.4 65.4 55.4 120.8 
Southern 
Africa 
40.6 38.6 79.2 29.3 25.5 54.8 
Western Africa 72.5 111.6 184.1 61.3 78.0 139.3 
Source: GLOBOCAN (Ferlay et al., 2010) 
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In the 1980s, cervical cancer was the main cancer among women, however with 
increasing life expectancy and better care for breast cancers, the prevalence of breast 
cancer is increasing in Africa due to presence of more survivors (Coleman et al., 
2008). Experts have further reported that the incidence of cancer in Africa is 
changing with the spread of HIV in the region (Hirschhorn et al., 2012). The 
incidence rates of cervical cancer, Kaposi’s sarcoma and non-Hodgkin’s lymphoma 
(NHL), which are all AIDS-defining illnesses, have increased in the last two decades 
(Hirschhorn et al., 2012). According to Parkin et al., the top five cancers among 
women in Africa in 2008 were cervical cancer (23.3%), breast cancer (19.2%), 
Kaposi’s sarcoma (5.1%), liver cancer (5.0%) and NHL (3.7%); while among men, 
liver cancer (14.8%), Kaposi’s sarcoma (12.9%), prostate cancer (9.5%), bladder 
cancer (6.1%) and NHL (5.7%) were the top five cancers (Parkin et al., 2008). 
Morhason-Bello et al. reported that the incidence of breast cancer shows regional 
variation between northern Africa and SSA; breast cancer is the leading cancer 
among women in northern Africa, but second to cervical cancer in SSA (Morhason-
Bello et al., 2013). In addition, prostate cancer was reported as the leading cancer 
among African men especially in the northern parts, while Kaposi’s sarcoma was a 
leading cancer in SSA (Morhason-Bello et al., 2013, Center et al., 2012). As noted 
above, the variations between these two African regions further reflects the presence 
of infectious diseases in SSA, notably HIV/AIDS, and possibly reflects the higher 
prevalence rates of cervical cancer and Kaposi’s sarcoma in SSA.   
Challenges faced in Africa include late presentation of patients to health facilities 
(usually at advanced stages of the malignancy), poor and inappropriate treatment, 
high cost of medications, lack of adequate follow-up, and the innate social norms and 
beliefs (many people prefer herbal practitioners), poverty, and poor standards of 
living (Adebamowo and Akarolo-Anthony, 2009). Besides, another important 
problem is the lack of data and poor record keeping (Parkin, 2006a). Reports show 
that few countries have population-based cancer registries, with the few available 
data sourced from the few hospital-based registries, which are not regularly updated 
(Parkin, 2006a, Jedy-Agba et al., 2012). Largely, this has resulted in a poor response 
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from the health system, and obviously reflecting in greater morbidity and mortality 
rates in Africa compared to other world regions (Jemal et al., 2012). The global 
cancer study (GLOBOCAN) predicts that the global cancer burden will continue to 
increase and by 2030, developing world, especially Africa, will account for about 
56% and 63% of new cancer cases and deaths, respectively (Ferlay et al., 2010). 
Causes of cancer in Africa 
The causes of cancers in Africa vary and have been linked to several factors, 
including ineffective health systems, poor living conditions, and poverty (Sitas et al., 
2008). However, epidemiologists have reported that infections are the main causes of 
cancers in Africa, and was responsible for about 25.0-32.7% of new cancer cases in 
2008 (Sitas et al., 2008, Ferlay et al., 2010).  
Infections: HIV is a main cause of cancer in Africa, responsible for Kaposi’s 
sarcoma, cervical cancer and other AIDS-defining cancers (Chokunonga et al., 
1999). In 2007, 22.5 million people were living with HIV/AIDS in Africa, with the 
prevalence ranging from 5% in Nigeria to 38% in Botswana (Hirschhorn et al., 
2012). HIV ranks among the leading causes of deaths in Africa, accounting for about 
1.6 million deaths in 2007, with AIDS-defining cancers contributing hugely to this 
(Adebamowo and Akarolo-Anthony, 2009). Other infectious agents include Hepatis 
B & C viruses (liver cancers), Human Papiloma Virus (cervical cancer), Epstein Barr 
Virus (Burkitts lymphoma), helicobacter pylori (stomach cancer), Kaposi’s Sarcoma-
associated Herpes Virus, formerly HHV-8 (Kaposi’s sarcoma and primary effusion 
lymphoma), Human T-lymphotropic Virus (adult T-cell leukemia), and human 
polyomaviruses (brain tumours and mesotheliomas) (Pagano et al., 2004). 
Smoking and harmful use of alcohol: Tobacco is regarded the most preventable cause 
of cancer globally (Pampel, 2008). In Africa, the prevalence of smoking has been 
increasing, especially in the younger population age groups, owing to lack of 
effective government policies on tobacco sales and consumption (Pampel, 2008, 
Saloojee and Dagli, 2000). According to Pampel, the prevalence of smoking in 
Africa ranges between 8.0% in Nigeria to about 27.3% in Madagascar (Pampel, 
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2008). Moreover, the consumption of alcohol in many African countries is increasing 
(Pisa et al., 2010), with about 20-30% of liver cancers related to this (Sitas et al., 
2008). 
Unhealthy diets, physical inactivity and obesity: Due to the rapid urbanization in 
many African countries, there has been a corresponding increase in related western 
lifestyles, which are main risk factors for many NCDs, including cancers (Assah et 
al., 2011). In addition, many people are increasingly becoming physically inactive 
due to long sitting hours (mostly in offices), coupled with reduced walking and 
exercise (Assah et al., 2011). Consequently, there is increase prevalence of 
overweight and obesity. Besides, efforts towards enlightening people on the risks of 
obesity have been met with challenges, as this is seen as a sign of healthy living in 
some African settings (Cecchini et al., 2010). About 30-40% of cancers are related to 
unhealthy diets, physical inactivity and obesity (Sitas et al., 2008). 
Industrialization and environmental pollution: In many African countries, there is 
virtually no policy on environmental pollution (Wichmann and Voyi, 2012). Carbon 
monoxide and many industrial toxic wastes are known carcinogens (Mortimer et al., 
2012, Adebamowo and Akarolo-Anthony, 2009). Albrecht further reported that in 
some African settings, up to 90% of cancers may be due to chemicals released into 
the atmosphere from various sources of environmental pollution (Albrecht, 2011). 
In view of the uncertainties surrounding the burden of cancers in Africa and the over 
reliance on GLOBOCAN estimates by researchers and stakeholders, it is important 
to conduct a detailed review of specific cancers in Africa towards attempting to 
provide improved estimate of the incidence in the region. 
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1.1.11 Chronic Respiratory Diseases 
Globally, chronic respiratory diseases (CRDs) are among the top causes of deaths 
and disabilities among NCDs, accounting for 4.7% of global disability-adjusted life 
years (DALYs), of which chronic obstructive pulmonary disease (COPD) is 
responsible for about two-thirds (Murray et al., 2012). According to WHO global 
burden of disease (GBD) estimates, over 600 million people have allergic rhinitis, 
300 million people have asthma, and 210 million people have COPD (World Health 
Organization, 2008). The WHO also estimates that COPD is responsible for about 3 
million deaths globally in 2011, accounting for about 9.1% of all NCDs deaths 
(World Health Organization, 2011a). Globally, COPD is rated the fourth leading 
cause of death and by 2030, it is projected to become the third leading cause of death 
(World Health Organization, 2011a). Moreover, it is expected to overtake HIV/AIDS 
as the leading cause of death in Africa at this point (Bouayad et al., 2006). 
Worldwide, an estimated 300 million people are living with asthma, and current 
trends suggest that an additional 100 million people may be living with asthma by 
2025; it has been rated the most common chronic disease affecting children 
(IUATLD, 2011). The World Health Organization (WHO) estimated about 250,000 
deaths from asthma annually, mostly in low- and middle-income countries (LMIC) 
(Bousquet et al., 2010, Braman, 2006) 
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Chronic Obstructive Pulmonary Disease (COPD) 
The increasing burden of COPD, and other respiratory diseases in Africa can be 
attributed to fast rates of urbanization, tobacco smoking, environmental pollution, 
exposure to combustion products of biomass fuels (from coal, firewood and 
agricultural residue), occupational dusts, tuberculosis, and long-term sequelae of 
childhood respiratory infections (van Gemert et al., 2011). Attempts at reducing this 
burden have been hindered mainly due to: inadequate standards of health promotion 
and other health services; insufficient attention from health planners, government 
regulators and media; absence of national guidelines on the management of COPD 
and lack of funds (Mehrotra et al., 2009, Finney et al., 2013). In fact, in many urban 
African settings, reports reveal an increasing consumption of tobacco products (van 
Gemert et al., 2011), which is made worse due to lack of government regulations on 
tobacco sales and use (Mehrotra et al., 2009). In some mixed, urban and rural 
settings, most households still use firewood and charcoal for domestic cooking and 
many countries are yet to implement control strategies for biomass fuel exposure 
(van Gemert et al., 2011, Finney et al., 2013). The treatment of COPD in many 
resource-poor settings has also been a huge challenge (Stanciole et al., 2012). Inhaled 
steroids, which are an effective treatment of COPD, have been included in the 
amended WHO list of essential medicines (van Gemert et al., 2011).  However, these 
are mostly unavailable and/or unaffordable in many African settings (Nafti et al., 
2009). In fact, policymakers in some African countries have stated that it may be 
unrealistic to assume that essential drugs for treating COPD and other CRDs can be 
given free to patients (Finney et al., 2013). This raises critical questions of equity and 
priority setting since drugs for HIV/AIDS and tuberculosis are typically supplied free 
in Africa (Mehrotra et al., 2009).  
Moreover, there is a lack of standard treatment guidelines and protocols for the 
management of COPD, and when available, health workers have not been adequately 
trained to identify and treat the disease (IUATLD, 2011). Lung function assessment 
is vital to COPD diagnosis and in quantifying airflow obstruction, and this is often 
needed to differentiate COPD from other obstructive airway diseases (Mehrotra et 
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al., 2009). It has been reported that spirometer, peak flow meter, and simple lung 
function test apparatus are scarcely available in many African settings and most 
treatments have mainly been based on acute exacerbations rather than an overall 
disease management plan (Mehrotra et al., 2009, Abdool-Gaffar et al., 2011). 
Therefore, delayed diagnosis of COPD typically follows lengthy periods of hesitation 
from doctors and concerns raised by patients and their families (van Gemert et al., 
2011).  
The understanding of the epidemiology of COPD on the African continent is still 
very limited (Mehrotra et al., 2009). Although systematic reviews have been 
conducted on COPD in Africa (van Gemert et al., 2011, Mehrotra et al., 2009, 
Finney et al., 2013), only one of them is about the continent-wide burden of COPD 
while two other two focused on sub-Saharan Africa. These reviews mainly provided 
a systematic presentation of the available evidence, but there is still a need to further 
analyse the available studies to understand the appropriateness of the case definition 
used (spirometry vs non-spirometry data) and the effects of covariates such as sex, 
age, year of the study and country of the study. Researchers, policy makers and other 
stakeholders in Africa could be assisted with such information in designing further 
studies. Therefore, it is important to provide a deeper insight in the problem of 
COPD in Africa, by examining and comparing the two available types of data 
(spirometry-based and other) and investigating the role of covariates on the 
prevalence of COPD in Africa. 
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Asthma 
Asthma is widely known as a multifactorial respiratory disorder with both genetic 
and environmental underlying risk factors (Bousquet et al., 2010). Exposure to 
common allergens (including pollens, dust mites and animal furs) and indoor and 
outdoor air pollution from various sources (e.g. traffic pollution, combustion of 
fossils and biomass fuels, workplace dust) have all been implicated as triggers of the 
disease (ECRHS, 2012). Second hand tobacco smoking is a confirmed risk factor in 
paediatric patients (Cazzoletti et al., 2010, van Gemert et al., 2011). Viral infections, 
a major cause of upper respiratory tract infections and “common cold”, are also a 
common risk factor in children (Wong et al., 2010, Dagoye et al., 2003). As noted, 
helminthic infections are relatively common in Africa and are associated with 
bronchial hyper-responsiveness and asthma (Perzanowski et al., 2002, van Gemert et 
al., 2011); this is perhaps due to the presence of related raised immunoglobulin E 
(IgE) and a prominent Th2 immune response (van Gemert et al., 2011, Wjst and 
Boakye, 2007). The International Study of Asthma and Allergies (ISAAC) reported 
that asthma prevalence among children is increasing in Africa and has contributed 
most to the burden of disease through its effects on quality of life (Bousquet et al., 
2010). In-patient admissions and purchase of medications account for most of the 
direct costs on government, while loss of productivity, due to absenteeism from work 
and school, are responsible for most of the indirect costs (Stanciole et al., 2012, 
Bahadori et al., 2009). 
Studies on asthma are few in Africa, with most publications mainly from South 
African and Nigerian populations (Wjst and Boakye, 2007). One main factor 
affecting research output is the diagnosis of asthma, which still remains a challenging 
issue (Patel et al., 2008, Martins et al., 2009).  The World Health Organization 
(WHO) has emphasized that this has limited on-going research efforts globally 
(Martins et al., 2009, Braman, 2006). The International Union against Tuberculosis 
and Lung Diseases (IUATLD) published one of the first diagnostic and survey 
guidelines for asthma in 1984, but experts subsequently reported concerns about its 
precision and reliability (Burney et al., 1989). According to the Global Initiative for 
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Asthma (GINA), detailed history, physical examination and spirometric lung 
function tests are vital to the diagnosis and management of asthma (Masoli et al., 
2004, Cazzoletti et al., 2010). Generally, a reduction in forced expiratory volume in 
one second (FEV1) and peak expiratory flow (PEF) may be indicative of asthma, 
with the amount of reduction proportional to the severity of asthma (Braman, 2006). 
GINA proposed that an increase in FEV1 of >12% and 200ml in about 15-20 minutes 
following the inhalation of 200-400μg of salbutamol or a 20% increase in PEF from 
baseline can be employed as a standardized criteria in diagnosis of asthma 
(Cazzoletti et al., 2010). This, however, lacks sensitivity, as many asthmatics, 
especially those on treatment, may not exhibit an increase in FEV1 and PEF when 
assessed (Martins et al., 2009, Ehrlich et al., 1998). Thus, although asthma is 
characterized by significant reversibility of airway obstruction, an absence of 
reversibility may not always exclude the presence of asthma (Ehrlich et al., 1998). 
The International Study of Asthma and Allergies in Childhood (ISAAC), established 
in 1991, remains the largest epidemiological study among children globally 
(IUATLD, 2011). ISAAC methodologies and scoring are currently the most widely 
employed by researchers in Africa (IUATLD, 2011, Braman, 2006). This involves 
both video and written questionnaires, as there were reports that video and pictorial 
representations of asthma symptoms may contribute to improved case recognition in 
younger children (IUATLD, 2011). However, this is still a subject of debate among 
experts (Wandalsen et al., 2009). The European Community Respiratory Health 
Survey (ECRHS), which assesses the prevalence of atopy and symptoms of airway 
disease among older age groups in Western Europe, has been widely implemented 
and has reported significant geographic variations in the prevalence of asthma and 
atopy (ECRHS, 2012). Despite these revised guidelines, both ISAAC and ECRHS 
research groups have reported challenges in achieving high sensitivity and specificity 
in case ascertainment with the symptom “wheeze at rest in the last12 months” (also 
regarded as current wheeze, or active wheeze) yielding the highest sensitivity and 
specificity (IUATLD, 2011). 
In Africa, problems including those arising from the over-utilization of health 
services, lack of trained staff and diagnostic apparatus, and non-availability and 
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unaffordability of inhaled medications have hindered efforts to improve the 
management of asthma (Musafiri et al., 2011b, Uijen et al., 2008). The lack of 
organized health promotion programmes, such as effective control strategies for 
environmental triggers, air pollutants, and occupational dusts have also contributed 
to the growing burden (Reddel et al., 2009). The WHO has reported that the levels of 
asthma control and health responses in the continent have been below recommended 
standards, and that these have contributed to the size of the disease burden (Bousquet 
et al., 2010, Braman, 2006). In addition, although many African countries have 
national guidelines for the management of asthma and other CRDs, these guidelines 
have not been implemented in most rural areas (Mash et al., 2009, Ait-Khaled et al., 
2007a). Economic analyses in many African settings have shown that direct costs 
from asthma are usually greater than the indirect costs. However, indirect costs 
represent a relatively higher proportion of total costs among paediatric than in adult 
patients (Stanciole et al., 2012). Moreover, the wider economic burden on 
individuals, families, employers and society, due to loss of future potential source of 
livelihood, has also been devastating in many resource-poor settings (Musafiri et al., 
2011b). It is believed that many children with asthma in Africa may fail to achieve 
their full potential if proper management and control measures are not put in place 
(IUATLD, 2011). It has been suggested that education of healthcare providers and 
the public is a vital element of the response to the challenge posed by asthma in 
Africa (Braman, 2006, Ndiaye et al., 2004). 
An increase in world’s urban population from 45% to 59% is expected by 2015, with 
over half of this occurring in Africa (Stanciole et al., 2012). It is also expected that 
the prevalence of asthma and many chronic diseases in Africa will increase due to 
this growing population size and from effects of accompanying urbanization and 
adoption of western lifestyles (Beaglehole, 2011). In light of this, and of the low 
research output and poor availability of health services data on the burden of asthma 
in Africa, it is important to analyse the available data through a systematic review of 
the literature in order to attempt to quantify the burden, guide health priority settings 
and inform the formulation of an appropriate health policy response.
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1.2 AIM AND OBJECTIVES 
As identified under the gaps in information, control and response to NCDs in Africa; the 
understanding of the burden of NCDs in Africa is presently quite poor due to the relative 
lack of data and low level of research on NCDs in the continent. Africa has recently seen 
large increase in life expectancy and urbanization, all of which is driving the NCD 
burden in the continent. Experts believe underestimation of disease burden in many parts 
of Africa may be inevitable due to extrapolation and over-modelling of the scarce data 
(King and Bertino, 2008). It is also evident that some studies reporting the burden of 
NCDs in Africa are derived from modelling based on data from other countries imputed 
into African countries, and may not be strictly based on data originating from Africa 
itself (Kirigia and Barry, 2008). This is in stark contrast with the need to have useful 
information on NCDs, with particular focus on data derived from Africa, according the 
UN’s political prioritization of NCD burden (Beaglehole et al., 2011). This thesis will, 
therefore, be focussing on understanding the prevalence, and/or where there are available 
data, the incidence, of four major NCDs in Africa, which have contributed highly to the 
burden of NCDs, not only in Africa, but also across the world.  
I have chosen to estimate the prevalence of NCDs mainly because data on these are far 
more available across Africa than data on other measures of disease burden (including 
deaths, DALYs and risk factors). Second, the IHME has been involved in estimation of 
mortalities and morbidities (mainly DALYs) of diseases globally, but their estimates of 
disease prevalence have not been made public. Additionally, their sources of data, from 
which disease prevalence rates could have been estimated, are hardly available. Third, 
due to availability of more data on NCD prevalence in Africa, the health service 
consequence and the overall response from governments of many African nations have 
been driven more by the few available data on NCD prevalence. It is therefore important 
to systematically review all available evidence and gather more data aimed at arriving at 
an improved estimate of the prevalence of NCDs in Africa that fairly represents the 
African population, towards prompting better and appropriate policy response across the 
continent.  
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1.2.1 Aim 
This thesis aims to systematically review available literature on NCDs in Africa, 
gather and critically appraise available evidence, and provide a population 
representative estimate of the prevalence and/or incidence of major non-
communicable diseases in Africa. This thesis will mainly review and provide 
estimates for the four major non-communicable diseases in Africa, which have 
earlier been identified as the leading NCDs in the continent according to the WHO 
GBD estimates. These are: cardiovascular diseases (hypertension and stroke), 
diabetes, major cancers, and chronic respiratory diseases (COPD and asthma).  
1.2.2 Objectives 
The objectives are: 
i. To conduct a systematic search and provide detailed review of literature 
(published and unpublished) on four major NCDS in Africa; 
ii. To provide estimates of the prevalence and/or incidence of four major NCDs 
in Africa using an epidemiological model and the United Nation population 
demographics, and critically discuss the findings; and  
iii. To discuss i and ii in terms of the gaps in information, control and response to 
NCDs in Africa, and suggest ways to address these in the continent. 
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2.1 OVERVIEW 
This chapter describes the methodologies applied in this dissertation, which have 
been categorized according to each broad NCD under review, namely: 
Cardiovascular Diseases (hypertension and stroke), Diabetes, Cancers, and Chronic 
Respiratory Disease (COPD and Asthma). Generally, the method employed for each 
systematic review follows the pattern below: 
i. Search strategy and data sources: This is a summary of how searches were 
conducted and the databases sourced. Tables of search terms are included in this 
section.  
ii. Study selection criteria: This describes the process of study selection, 
including the inclusion and exclusion criteria, respectively. 
iii. Quality criteria and grading: This explains how selected studies were graded 
in terms of the quality of individual studies. 
iv. Case definitions: This gives an overview of various case definitions on the 
selected NCD. 
v. Data extraction: This is a description of the collation and extraction of data 
from selected studies 
vi. Data analysis: This describes how the extracted data were analysed and the 
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2.2 CARDIOVASCULAR DISEASES 
2.2.1 Hypertension 
Search strategy and data sources 
After identifying Medical Subject Headings (MESH) and keywords following 
consultations with a librarian, a final search strategy was developed. A systematic 
search of Medline, EMBASE and Global Health was conducted, with publication 
dates set from January 1980 up to December 2013. The list of African countries 
included in the searches was based on the World Bank list of economies (October 
2013) (World Bank, 2014b). A further search was conducted on Google Scholar to 
identify unpublished studies. Experts on cardiovascular research in Africa were also 
contacted to seek their opinion on relevant African databases, links and websites. For 
identified key authors and relevant search terms, an e-mail alert was registered and 
new publications were automatically sent to my e-mail. Hand-searching of reference 
lists of relevant publications, and key journals, were finally done to identify more 
studies that could have been omitted from the databases’ searches. The search terms 
employed on Medline are shown in Table 2.1, while search terms for EMBASE and 
Global Health are shown in Appendix 1a and 1b, respectively.  
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Table 2.1. Search terms for studies on hypertension in Africa (Medline) 
# Search terms 
1 africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or 
central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or 
sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or 
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or 
benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or 
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2 exp vital statistics/ or exp incidence/ 
3 (incidence* or prevalence* or morbidity or mortality).tw. 
4 (disease adj3 burden).tw. 
5 exp "cost of illness"/ 
6 exp quality-adjusted life years/ 
7 QALY.tw. 
8 Disability adjusted life years.mp. 
9 (initial adj2 burden).tw. 
10 exp risk factors/ 
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 exp hypertension/ or peripheral vascular diseases/ or elevated blood pressure/ or cardiovascular diseases/ or 
heart diseases/ or borderline hypertension 
13 Hypertensive heart disease.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
14 12 or 13  
15 1 and 11 and 14 
16 limit 15 to (humans and yr="1980 -Current") 
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Study selection criteria 
The inclusion criteria were: 
i. Original population-based, cohort or cross-sectional studies on hypertension;  
ii. Studies conducted in urban, rural, or mixed settings mainly within African 
population groups;  
iii. Studies providing numerical estimates on the prevalence and / or awareness 
of hypertension; and 
iv. Studies that provided clearly defined, unambiguous methodologies.  
The exclusion criteria were: 
i. Studies that were mainly hospital-based;  
ii. Studies that had non-human subjects;  
iii. Studies conducted before 1980; and 
iv. Studies that were mainly reviews, viewpoints or editorials.  
No language restrictions were applied. 
Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. Basically, this assesses methods of estimation of sample size and 
sampling methods across studies, and the methods of dealing with design specific 
issues such as: training of study investigators, adherence to standardized protocol for 
blood pressure measurement (Box 2.1), pre-testing and reviewing questionnaires 
before data entry, and addressing recall and interviewer’s bias appropriately; 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods employed across studies in the estimation of hypertension prevalence; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
iv. Generalizability to the African population: This broadly assesses if the 
sample size was representative of a larger population that can be generalized to the 
total African population 
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For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as 
follows: 
i. High quality: Studies with the entire four criteria, or any three including 
“study design”, highlighted above well represented; 
ii. Moderate quality: Studies with any three of the four criteria, or any two 
including “study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of 
the four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
The Joint National Committee on prevention, detection, evaluation, and treatment of 
high blood pressure (JNC) and the World Health Organization/ International Society 
of Hypertension (WHO/ISH) have provided clearer definitions of hypertension with 
appropriate staging of severity (JNC, 1997, JNC, 2003, Whitworth, 2003). 
Hypertension in adults is generally defined as systolic blood pressure ≥140 mm Hg 
and/or diastolic blood pressure ≥90 mm Hg, with measurements taking on two or 
more blood pressure readings taken at each of two or more visits after initial 
screening.  
Based on the general definition above, diagnostic criteria in the selected studies 
needed to comply with the following:  
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i. the sixth and seventh report of the Joint National Committee on prevention, 
detection, evaluation, and treatment of high blood pressure (JNC 6 & 7) (JNC, 1997, 
JNC, 2003); and/or 
ii. the 1999 and 2003 World Health Organization/ International Society of 
Hypertension (WHO/ISH) definitions and classification of blood pressure levels 
(Whitworth, 2003). 
See Table 2.2 for details of classification of blood pressures in adults, and Box 2.1 
for summary of blood pressure measurement protocols. 
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Table 2.2. Classification of blood pressure for adults 
Category JNC WHO/ISH 
6 7 1999 2003 
SBP DBP SBP DBP SBP DBP SBP DBP 
Optimal <120 and 
<80 





<120 and <80 <130 <85 - - 













85-89 - - 
Hypertension (JNC) / 
Grade 1 (WHO/ISH) 
≥140 or  
≥90 












140-159 or 90-99 140-
149 
90-94 - - 















Stage 3 (JNC) / or Grade 
3 (WHO/ISH) 
≥180 or  
≥110 
- - ≥180 ≥110 ≥180 ≥110 
JNC: Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, WHO/ISH: World 
Health Organization/ International Society of Hypertension, SBP: systolic blood pressure, DBP: diastolic blood pressure 
Box 2.1. The JNC standard blood pressure measurement protocol (Source: (JNC, 
1997, JNC, 2003)) 
1. Subjects should be seated in a chair with their backs supported and their arms bared 
and supported at heart level. Subjects should refrain from smoking or ingesting caffeine 
during the 30 minutes preceding the Measurement 
2. Blood pressure measurement should begin after at least 5 minutes of rest 
3. The appropriate cuff size must be used to ensure accurate measurement. The bladder 
within the cuff should encircle at least 80 percent of the arm. Many adults will require a 
large adult cuff  
4. Measurements should be taken preferably with a mercury sphygmomanometer; 
otherwise, a recently calibrated aneroid manometer or a validated electronic device can be 
used 
5. Both SBP and DBP should be recorded. The first appearance of sound (phase 1) is 
used to define SBP. The disappearance of sound (phase 5) is used to define DBP 
6. Two or more readings separated by 2 minutes should be averaged. If the first two 
readings differ by more than 5 mm Hg, additional readings should be obtained and averaged. 
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Defining the awareness of hypertension 
As noted in the introduction, many studies on hypertension in Africa have reported 
that patients were mostly unaware of their hypertension status, with hypertension 
diagnosed when they present in hospital for unrelated ailments. I therefore think it 
may be worthwhile in this review to include estimates on the general awareness of 
hypertension in Africa. An understanding of the awareness rate of hypertension may, 
in fact, be relatively reflective of the control and treatment response to hypertension 
across many African settings. Therefore,  for the purpose of estimating the awareness 
rate of hypertension in this review, awareness of hypertension was defined as self-
report by respondents of any prior diagnosis of hypertension by a doctor or certified 
health care professional, and excluding women diagnosed during pregnancy, as 
described by the WHO (Whitworth, 2003).  
Data extraction 
All extracted data were stored in 2010 Microsoft Excel file format. To allow for 
consistency, a parallel search (and double extraction) was conducted. Data were 
abstracted systematically on sample size, mean age or age range, number of 
hypertension cases, and the respective age- and sex-specific prevalence rates. These 
were sorted into mixed, urban and rural settings (based on studies that reported 
them). For studies conducted on the same study site, population or cohort, the first 
chronologically published study was selected, and all additional data from other 
studies were included in the selected paper. 
Data analysis 
A random effects meta-analysis (DerSimonian and Laird method) was conducted on 
extracted crude prevalence and awareness rates of hypertension (DerSimonian and 
Laird, 1986). This was reported separately for mixed, urban and rural settings, all 
expressed as percentages. As there were more data points to allow for detailed 
analysis, these were then further categorized into 1990, 2000 and 2010, as obtained 
from studies conducted before 1995, from 1995 to 2004, from 2005 to 2013, 
respectively.  
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Rationale for choosing random effects meta-analysis 
As discussed in the ‘Introduction’ under ‘Section 1.1.3- Heterogeneities within and 
between African population subgroups’, Africa consists of diverse groups of people 
each with specific demographic characteristics, including those related to residence 
(urban versus rural), age distribution, ethnicity and culture, GDP and income status. I 
also stated that these need to be carefully considered in the estimation of disease 
burden in Africa, and indeed, any population group. One other factor is the lack of 
data and low research output on NCDs in Africa, meaning that a good number of the 
included studies were selected following rigorous systematic literature search. Even 
with a thorough quality grading of included studies, some of the selected studies may 
not be of high quality. Furthermore, characteristics of study populations differ widely 
across studies. Other sources of variations include study designs, sampling, case 
definitions, and statistical analysis, among others. Therefore, an ideal analysis that 
involves pooling estimates from various studies must account for these 
heterogeneities, and each measure of heterogeneity can then further assist in 
appropriately interpreting the estimates reported. One meta-analytic approach that 
fits these conditions is the Random Effects Model described by DerSimonian and 
Laird (DerSimonian and Laird, 1986). In the random effects model, the assumption is 
that the true effect size varies across studies and that the studies included represent a 
random sample of the effect sizes (prevalence estimates) that could have been 
observed. In this model, a small study is not discounted by giving it a small weight 
and a large study is not over-represented by giving it a large weight (which is what is 
observed in a fixed effect model). In other words, the pooled (summary) prevalence 
is estimated from a range of studies while avoiding that this pooled estimate is 
influenced by specific characteristics in an individual study. This is further noted in 
the study limitations. 
The use of weighted means 
In the estimation of overall systolic and diastolic blood pressure (SBP and DBP), 
weighted means were applied. The ‘weighted’ in this context does not refer to the 
whole of the African population or the country population in which the study was 
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conducted. It mainly implies the use of respective sample sizes reported in each 
study to arrive at the SBP and DBP, i.e. the estimated mean SBP and DBP is 
weighted towards the sample size. Thus, the estimated SBP and DBP is only 
representative of the study samples. The import of this is that when large samples 
dominate selected studies (or data points), and those large samples do not represent 
the larger country or regional population, extrapolating these data to the whole of 
Africa may therefore need to be interpreted with caution. This is also noted in the 
discussion. 
Analysing the awareness rate of hypertension 
As noted above, awareness of hypertension was defined as number of people who 
reported being aware of their hypertension status. From each study, awareness rate of 
hypertension was estimated as number of people who reported being hypertensive, 
expressed as a percentage of total number of people in the study population adjudged 
to have hypertension. Pooled awareness rates of hypertension for 1990, 2000, and 
2010, and rates across mixed, urban and rural settings were estimated, respectively. 
Description of the modelling 
For the modelling and estimation of hypertension cases in Africa, a meta-regression 
epidemiological model was developed, and applied on crude prevalence rates, 
sample sizes and respective mean age from all data points. See Appendix 2 for all 
data used in modelling. 
General approach to the meta-regression epidemiological modelling: In this model, 
all data points (mainly the crude prevalence rates and mean age) were plotted on a 
graph on Microsoft Excel, with all extracted crude prevalence rates plotted on the y-
axis, i.e. dependent variable, and mean ages corresponding to each prevalence rate 
are plotted on the x-axis, i.e. independent variable. To account for variation in sample 
sizes from each data point, bubbles were generated on the graph, with the size of 
each bubble corresponding to the respective sample size reported (see Figure 2.1). 
Estimating the Prevalence of NCDs in Africa 
 
Methods  75 
 
Figure 2.1. A template of the meta-regression epidemiological model 
Although, it is well known that the prevalence of many NCDs in the population 
significantly increases with age (Anderson, 1999), the relationship between age and 
the disease may not be necessarily linear. Therefore I experimented with the models 
based on linear, logarithmic, exponential, Poisson, polynomial, power function and 
moving average statistical analyses, respectively, and chose the one which was the 
most predictive, i.e. in which the proportion of variance (R
2
) of the disease 
prevalence explained by age was the greatest. In most cases, this was power function 
or exponential, but there were also diseases where linear or polynomial relationship 
showed better prediction and were used instead. 
The use of mean age or age-specific prevalence estimates in the modelling 
As noted, the model was based explicitly on age. A preferred approach would have 
been to use all the age-specific estimates from a study. However, not all studies 
reported age-specific prevalence estimates. Many studies reported single age 
estimates (usually the mean age of the study population) without mentioning what 
the prevalence looks like across various age groups in the population. Thus, in the 
model, I applied the mean age (or the single age) when only this was reported, and if 
a study reported age-specific estimates across the population, all these age-specific 
estimates were incorporated into the model. The disadvantage of using mean age 
only is that some selected studies do have extreme ages in the study population (very 
old and very young). This, therefore, automatically renders the mean age 
inappropriate. The use of mean age can only be truly appropriate when the study 
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population is normally distributed. In an actual research context, however, this is not 
the case. This is noted further in the study limitations. 
Best fit for hypertension prevalence estimation: On the epidemiological model for 
hypertension, a trend-line was inserted, and the fitted curve explaining the largest 
proportion of variance (best fit) was applied. In this particular model the best fit 
applied was exponential, and this was used in the estimation of hypertension 
prevalence and cases in Africa. The equation generated from the fitted curve was 
then used to determine the prevalence of hypertension in Africa at midpoints of the 
United Nations (UN) population 5-year age-group population estimates for Africa, 
for the years 1990, 2000, 2010, respectively (United Nations, 2013).  
Equation: This implies that prevalence of hypertension and corresponding cases (for 
the ages 20 years and above, which were predominantly the age groups from most 
studies) were estimated based on the UN population estimates for Africa  for the ages 
20-24, 25-29, 30-34, etc, at midpoints 22, 27, 32, etc. Therefore, if the equation 
generated from the actual epidemiological analysis was the same as that in the 
template model above (i.e. y = 2.3878e
0.0144x
), then y = estimated prevalence (%); x = 
midpoints of UN age group. Hence, Equation 1 gives the estimated number of 
hypertension cases. All statistical analyses were conducted on 2010 Microsoft Excel 
and Stata 13.1 (Copyright 1985-2013 Stata Corp LP).  
Equation 1 
Number of hypertension cases in Africa in 2010 = 
y × UN population for Africa in 2010 / 100 
For the calculation of Confidence Interval (CI) of the prevalence rates, I applied the 
Kirkwood and Sterne Confidence Interval for Rate (Kirkwood and Sterne, 2003), 
page 238, see Equation 2. 
Equation 2 
95% CI (prevalence) = (prevalence/EF) to (prevalence×EF) 
Where EF= Error Factor= exp(1.96/√hypertension cases) 
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2.2.2 Stroke 
Search strategy and data sources 
Following initial consultation with a librarian, and identification of relevant Medical 
Subject Headings (MESH) and keywords, a final search strategy was developed.  A 
systematic search of Medline, EMBASE and Global Health was conducted, with 
publication dates set from 1970 up to December 2013 (to allow for screening of more 
studies). A further search was conducted on Google Scholar. The list of African 
countries included in the searches was based on the World Bank list of economies 
(October 2013) (World Bank, 2014b). Experts on cardiovascular research in Africa 
were also contacted to seek their opinion on key journals and relevant African 
databases, links and websites. For identified key authors and relevant search terms, 
an e-mail alert was registered and new publications were automatically sent to my e-
mail. Hand-searching of reference lists of relevant publications, and key journals, 
were finally done to identify more studies that could have been omitted from the 
databases’ searches. The search terms employed on Medline are shown in Table 2.3, 
while search terms for EMBASE and Global Health are shown in Appendix 1c and 
1d, respectively.  
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
stroke/ or brain infarction/ or brain stem infarctions/ or cerebral infarction/ or stroke, lacunar/ 
13  







12 or 13 or 14 or 15 
17  
1 and 11 and 16 
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Selection criteria 
The inclusion criteria were: 
i. Original population-based (cohort, cross-sectional or community door-to-
door surveys), demographic health surveys, hospital records and outpatient clinics 
studies on stroke (this wide variety was allowed for due to paucity of data);  
ii. Studies conducted in urban, rural, occupational, or mixed settings mainly 
within African population groups;  
iii. Studies providing numerical estimates on the incidence and/or prevalence of 
stroke; and 
iv. Studies that provided clearly defined, unambiguous methodologies.  
The exclusion criteria were: 
i. Studies that had non-human subjects;  
ii. Studies conducted before 1970 (also allowed for due to paucity of data); and 
iii. Studies that were mainly reviews, viewpoints or editorials.  
No language restrictions were applied. 
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Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. Basically, this assesses methods of estimation of sample size and 
sampling methods across studies, and the methods of dealing with design specific 
issues such as: training of study investigators, adherence to standardized protocol for 
identifying stroke cases in the population, pre-testing and reviewing questionnaires 
before data entry, and addressing recall and interviewer’s bias appropriately; 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods employed across studies in the estimation of the incidence  and/or 
prevalence of stroke; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
iv. Generalizability to the African population: This broadly assesses if the study 
site was representative of a larger population that can be generalized to the total 
African population 
For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as 
follows: 
i. High quality: Studies with the entire four criteria, or any three including 
“study design”, highlighted above well represented; 
ii. Moderate quality: Studies with any three of the four criteria, or any two 
including “study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of 
the four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
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further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
As noted in the introduction, diagnosis of stroke on population wide scale has proved 
difficult to researchers (this is highlighted further in the discussion). Across many 
studies, subjects were asked on symptoms suggestive of previous episodes of stroke 
or cerebrovascular events, and if diagnosed by a doctor. This included sudden 
weakness of any part of the body, difficulty in speaking, raising hands or walking, 
blurred vision, etc., and this were linked to the WHO definition of stroke to make a 
diagnosis. 
Based on this understanding, the final stroke case ascertainment complied with the 
following: 
i. WHO definition, defined as “rapidly developing clinical signs of focal (or 
global) disturbance of cerebral function lasting longer than 24 hour, unless 
interrupted by death, with no apparent cause other than that of vascular origin” 
(Hatano, 1976, WHO MONICA Project Investigators, 1988); and/or  
ii. Studies in which recovery within 24 hours were highlighted, such as those 
that excluded Transient Ischemic Attack, defined as “an acute loss of focal cerebral 
or ocular function with symptoms lasting less than 24 hours and which after adequate 
investigation is presumed to be embolic or thrombotic vascular disease” (Hatano, 
1976, WHO MONICA Project Investigators, 1988). 
New cases of stroke were defined as number of people presenting with first ever 
stroke in a given period, while stroke survivors were the total number of people who 
have had stroke or living with its sequelae at a given time (World Health 
Organization, 1990, WHO MONICA Project Investigators, 1988). 
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Data extraction 
All extracted data was stored in a 2010 Microsoft Excel file format. Data were 
abstracted systematically on study location, study period, mean age or age range, 
person years or sample size, incident cases of stroke or number of stroke survivors, 
and their respective age- and sex-specific incidence or prevalence rates. These were 
sorted into population-based or hospital-based data separately for analysis. For 
studies conducted on the same study site, population or cohort, the first 
chronologically published study was selected, and all additional data from other 
studies were compared for consistency and included in the selected paper. 
Data analysis 
From reported overall crude incidence or prevalence of stroke in a given cohort, a 
random effect meta-analysis was conducted with pooled effect of stroke expressed 
per 100,000 person years or population respectively (DerSimonian and Laird, 1986). 
The rationale for using random effects meta-analysis has been earlier described. Each 
measure of heterogeneity and appropriateness of combining heterogeneous studies is 
further described under study limitations. The overall estimates of age- and sex-
specific prevalence and incidence from all studies were used in the epidemiological 
modelling (Appendix 3). The use of age-specific estimates and mean age (and 
limitations) has been highlighted earlier. This is further described under study 
limitations. 
Description of the modelling 
The general approach to the epidemiological modelling has already been described. 
In this particular model, exponential function was used for the estimation of stroke 
incidence and prevalence rates as it showed the greatest prediction power. The 
equations generated from the modelled curves were then separately used to estimate 
the new cases of stroke and number of stroke survivors in 2010 at midpoints of the 
United Nation (UN) population 5-year age groups (United Nations, 2013), see 
Equation 3. Africa populations were determined from the 2012 United Nations 
population demographics (United Nations, 2013). This further implies that 
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prevalence of stroke and corresponding cases (for the ages 20 years and above, 
which were predominantly the age groups from most studies) were estimated based 
on the UN population estimates for Africa  for the ages 15-19, 20-24, 25-29, 30-34, 
etc, at points 17, 22, 27, 32, etc. See Appendix 3 for all data used in modelling. All 
statistical analyses were conducted on 2010 Microsoft Excel and Stata 13. 1 
(Copyright 1985-2013 Stata Corp LP) 
Equation 3 
Number of new stroke cases (stroke survivors) in Africa in 2010 = 
Estimated incidence (or prevalence) from epidemiological model × UN 
population for Africa in 2010 / 100000 
For the calculation of Confidence Interval (CI), I applied the Kirkwood and Sterne 
Confidence Interval for Rate (Kirkwood and Sterne, 2003), page 238, see Equation 
2. 
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2.3 DIABETES 
Search strategy and data sources 
An initial consultation with a librarian was done, and following identification of 
Medical Subject Headings (MESH) and keywords, a final search strategy was 
drafted. A systematic search of Medline, EMBASE and Global Health was 
conducted, with publication dates set from 1980 up to December 2013. A further 
search was conducted on Google Scholar. The list of African countries included in 
the searches was based on the World Bank list of economies (October 2013) (World 
Bank, 2014b). Experts on endocrinology and diabetes research in Africa were also 
contacted to seek their opinion on key journals and relevant African databases, links 
and websites. For identified key authors and relevant search terms, an e-mail alert 
was registered and new publications were automatically sent to my e-mail. Hand-
searching of reference lists of relevant publications, and key journals, were finally 
done to identify more studies that could have been omitted from the databases’ 
searches. The search terms employed on Medline are shown in Table 2.4, while 
search terms for EMBASE and Global Health are shown in Appendix 1e and 1f, 
respectively.  
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp glucose metabolism disorders/ or exp diabetes mellitus/ or exp diabetes mellitus, type 1/ or exp 
diabetes mellitus, type 2/ or exp diabetes, gestational/ or exp diabetic ketoacidosis/ or exp prediabetic 
state/ or exp glycosuria/ or exp hyperglycemia/ or exp glucose intolerance/ 
13  
1 and 11 and 12 
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Study selection criteria 
The inclusion criteria were: 
i. Original population-based, cohort or cross-sectional studies on diabetes, 
Impaired Glucose Tolerance (IGT) or Impaired Fasting Glycemia (IFG) ;  
ii. Studies conducted in urban, rural or mixed settings mainly within African 
population groups;  
iii. Studies providing numerical estimates on the prevalence of diabetes, IGT or 
IFG; and 
iv. Studies that provided clearly defined, unambiguous methodologies.  
The exclusion criteria were: 
i. Studies that were hospital-based;  
ii. Studies that had non-human subjects;  
iii. Studies conducted before 1980; and 
iv. Studies that were mainly reviews, viewpoints or editorials.  
No language restrictions were applied. 
Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. Basically, this assesses methods of estimation of sample size and 
sampling methods across studies, and the methods of dealing with design specific 
issues such as: training of study investigators, adherence to standardized protocol for 
blood glucose measurement in epidemiological surveys, pre-testing and reviewing 
questionnaires before data entry, and addressing recall and interviewer’s bias 
appropriately; 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods employed across studies in the estimation of the prevalence of diabetes, IGT 
or IFG; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
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iv. Generalizability to the African population: This broadly assesses if the study 
site was representative of a larger population that can be generalized to the total 
African population 
For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as 
follows: 
i. High quality: Studies with the entire four criteria, or any three including 
“study design”, highlighted above well represented; 
ii. Moderate quality: Studies with any three of the four criteria, or any two 
including “study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of 
the four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
Generally, many have stated that diagnosis of diabetes appear quite straight forward 
as this could be based on blood glucose values following overnight fast or 2 hours 
after a 75g oral glucose challenge (OGTT) (Mbanya and Ramiaya, 2006).  However, 
in the conduct of epidemiological surveys, several other factors including blood 
sample collection and medical history, among others, need be considered to ensure 
standard diagnostic protocols are followed (Sobngwi et al., 2001).   
According to IDF, diabetes is a chronic metabolic condition, usually characterized by 
raised blood glucose, resulting from impairment in secretion of insulin, its action, or 
both (International Diabetes Federation, 2000, International Diabetes Federation, 
2003, International Diabetes Federation, 2006, International Diabetes Federation, 
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2009). Diabetes presents in various forms in humans, the three main categories are 
type 1, type 2 and gestational diabetes, respectively (Sobngwi et al., 2001). Type 1 
diabetes has autoimmune aetiology, usually from destruction of pancreatic beta cells, 
with consequent loss of production of insulin; previously referred to as insulin 
dependent diabetes mellitus (IDDM) (Mbanya et al., 2006). Type 2 diabetes results 
from insulin resistance, and or, abnormal insulin secretion; this was also previously 
referred to as non-insulin dependent diabetes mellitus (NIDDM) (Mbanya and 
Ramiaya, 2006). Gestational diabetes mellitus is generally described as any degree of 
blood glucose intolerance diagnosed first during pregnancy (Jiwani et al., 2012). 
Type 2 diabetes is also characterized by intermediate hyperglycaemic episodes, 
namely Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG). 
IGT is an elevated non-diabetic levels of blood glucose, and can be confirmed 2 
hours following a 75g oral glucose tolerance test (OGTT), while IFG is an elevated 
non-diabetic fasting blood glucose (World Health Organization, 2006). IGT and IFG 
have both been reported as transitional stages in the development of type 2 diabetes 
(Mbanya and Ramiaya, 2006).  
Most survey and diagnostic criteria for diabetes have been based on WHO 1980, 
1985 and 1998 criteria respectively (Mbanya et al., 2010, World Health 
Organization, 1985, Alberti and Zimmet, 1998). In 1997, the American Diabetic 
Association (ADA) proposed diagnostic criteria for clinical and epidemiological 
studies; this was revised in 2003 (Gabir et al., 2000, Levitt et al., 2000). Experts have 
examined their predictive values during epidemiologic surveys (Kumar, 2002, Levitt 
et al., 2000); for example, Gabir and colleagues reported from a study of 5,023 
Indian adults using fasting plasma glucose (FPG) and 2-hour post load plasma 
glucose (2-h PG) concentrations, that the prevalence of diabetes using 1997 ADA 
criteria was 12.5%, much lower than 1985 WHO criteria (14.6%) and 1998 WHO 
criteria (15.3%) (Gabir et al., 2000). They further discovered that both FPG and 2-h 
PG have almost the same predictive values, and the observed prevalence of IFG and 
IGT could help at early identification of people at high risk of diabetes. In 2006, 
WHO and IDF spelled out recommendations for diabetes epidemiological surveys 
and clinical diagnosis- Diabetes was defined as FPG ≥7.0mmol/l (126mg/dl) or a 2-h 
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PG ≥11.1mmol/l (200mg/dl); IGT defined as  FPG <7.0mmol/l (126mg/dl) or a 2-h 
PG 7.8-11.1mmol/l (140-200mg/dl); and IFG was given as FPG 6.1-6.9mmol/l (110-
125mg/dl) or a 2-h PG <7.8mmol/l (140mg/dl) (World Health Organization, 2006). 
The committee further recommends that venous plasma glucose should be gold 
standard for measuring and reporting blood glucose values, while conversion 
estimates may be employed for capillary glucose, which is commonly used in low 
resource settings. In addition,bar 2-h PG following an oral glucose tolerance test 
(OGTT) should still be employed in diagnosing diabetes, as FPG may give a false 
negative results in about 30% of cases, while emphasizing that OGTT remains the 
only means of diagnosing people with IGT (World Health Organization, 2006).  
The use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes is thought to 
be a better predictor of micro- and macro-vascular events compared to FPG or 2-hPG 
following a 75g OGTT (Mbanya and Ramiaya, 2006). Other advantages include its 
ability to reflect the mean plasma glucose in an individual over a period of 2 to 3 
months, its ease of conduct, and ability to carry out the test at any time of the day 
(Sobngwi et al., 2001). However, there are still no sufficient evidence on the use of 
glycated haemoglobin (HbA1c) in population studies based in Africa, as HbA1c is 
thought to be very expensive to carry out on a population-wide scale (Mbanya et al., 
2010, World Health Organization, 2011d). Refer to Table 2.5 for details of diabetes 
diagnostic criteria. 
Therefore based on the above, the final case definition for retained studies needed to 
comply with: 
i. WHO 1985 or 1998 diabetes diagnostic criteria; or 
ii. ADA 1997 or 2003 diabetes diagnostic criteria; and/or 
iii. WHO-IDF 2006 diabetes diagnostic criteria.  
Generally, from the initial scoping review conducted, it was observed that there were 
not too major differences in these criteria, and that many epidemiological surveys 
after 1985 were conducted based on one or a combination of these criteria.  See 
Table 2.5 for more details on diabetes diagnostic criteria.
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Data extraction 
All extracted data were stored in 2010 Microsoft excel file format. From each 
selected study, data extracted included the study location and country, study period 
and setting, study design, diagnostic criteria. The numerical data included sample 
size, mean age or age range, number of diabetes, IGT or IFG cases and their 
respective age- and sex-specific prevalence estimates. For studies conducted on the 
same study site, population or cohort, the first chronologically published study was 
selected, and all additional data from other studies were included in the selected 
paper. 
All extracted data were sorted by country, study period, age, and their respective case 
numbers, sample sizes and prevalence estimates. Data were broadly grouped into 
mixed, rural and urban settings, and extracted figures on diabetes, IGT and IFG were 
separately recorded into these groups, when provided. 
Data analysis 
A random-effect meta-analysis was conducted on extracted crude prevalence rates of 
diabetes, IGT and IFG (DerSimonian and Laird, 1986). Pooled prevalence rates were 
further estimated for data on mixed, rural and urban settings respectively, to allow 
for comparisons with our modelled estimates. All estimates were reported in 
percentages. The rationale for using random effects meta-analysis has been earlier 
described. Each measure of heterogeneity and appropriateness of combining 
heterogeneous studies is further described under study limitations. The overall 
estimates of age- and sex-specific prevalence and incidence from all studies were 
used in the epidemiological modelling (Appendix 4). The use of age-specific 
estimates and mean age (and limitations) has been highlighted earlier. This is further 
described under study limitations. 
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Table 2.5. Diabetes diagnostic criteria 
Diagnostic criteria Blood glucose indices Glucose concentration mmol/l (mg/dl) 
Whole blood Plasma 
Venous Capillary Venous Capillary 
WHO 1985 (World 
Health Organization, 
1985) 
Diabetes  Fasting ≥6.7 (≥120) ≥6.7 (≥120) ≥7.8 (≥140) ≥7.8 (≥140)  
2-h PG ≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) ≥12.2 (≥220) 
IGT  Fasting <6.7 (<120) <6.7 (<120) <7.8 (<140) <7.8 (<140) 
2-h PG 6.7-10.0 (120-180) 7.8-11.1 (140-200) 7.8-11.1 (140-200) 8.9-12.2 (160-220) 
ADA 1997 (Gabir et al., 
2000) 
Diabetes Fasting - ≥7.0 (≥126) - - 
2-h PG - ≥11.1 (≥200) - - 
Casual  - ≥11.1 (≥200) - - 
IGT 2-h PG - 7.8-11.1 (140-200) - - 
IFG Fasting - 6.1-6.9 (110-125) -  
WHO 1998 (Alberti and 
Zimmet, 1998) 
Diabetes  Fasting ≥6.1 (≥110) ≥6.1 (≥110) ≥7.0 (≥126) - 
2-h PG ≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) - 
IGT  Fasting <6.1 (<110) <6.1 (<110) <7.0 (<126) - 
2-h PG 6.7-10.0 (120-180) 7.8-11.1 (140-200) 7.8-11.1 (140-200) - 
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IFG Fasting 5.6-6.1 (100-110) 5.6-6.1 (100-110) 6.1-7.0 (110-126) - 
2-h PG <6.7 (<120) <7.8 (<140) <7.8 (<140) - 
ADA 2003 (Gabir et al., 
2000) 
Diabetes Fasting - - ≥7.0 (≥126) - 
2-h PG - - ≥11.1 (≥200) - 
Casual  - - ≥11.1 (≥200) - 
IGT 2-h PG - - 7.8-11.1 (140-200) - 
IFG Fasting - - 5.6-6.9 (100-125) - 





Fasting - - ≥7.0 (≥126) - 
2-h PG - - ≥11.1 (≥200) - 
IGT  Fasting - - <7.0 (<126) - 
2-h PG - - 7.8-11.1 (140-200) - 
IFG Fasting - - 6.1-6.9 (110-126) - 
2-h PG - - <7.8 (<140) - 
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Description of the modelling 
For the modelling, due to more data points, and to allow for an understanding of the 
changing prevalence of diabetes over the last two decades, all data before 1995, from 
1995 to 2004, and from 2005 to 2013 were used to estimate diabetes cases for the 
years 1990, 2000 and 2010, respectively. 
As noted earlier, the general approach to the epidemiological modelling has already 
been described. In this particular model, exponential function was used for the 
estimation of diabetes prevalence rates and cases in Africa as it showed the greatest 
prediction power. The equation generated was used to determine the prevalence of 
diabetes in Africa at midpoints of the United Nation population 5-year age-group 
population estimates for Africa, for the years 1990, 2000, 2010, respectively (United 
Nations, 2013), see Equation 4. This further implies that prevalence of diabetes and 
corresponding cases (for the ages 15 years and above, which were predominantly the 
age groups from most studies) are estimated based on the UN population estimates 
for Africa  for the ages 15-19, 20-24, 25-29, 30-34, etc, at points 17, 22, 27, 32, etc.  
See Appendix 4 for all data used in modelling. All statistical analyses were 
conducted on 2010 Microsoft Excel and Stata 13.1 (Copyright 1985-2013 Stata Corp 
LP). 
Equation 4 
Number of diabetes cases in Africa in 2010 = 
Estimated prevalence from epidemiological model * UN population for Africa in 
2010 / 100 
For the calculation of Confidence Interval (CI), I applied the Kirkwood and Sterne 
Confidence Interval for Rate (Kirkwood and Sterne, 2003), page 238, see Equation 
2. 
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2.4 CANCER 
Search strategy and data sources  
Medical Subject Headings (MESH) and keywords were identified after initial 
consultations with a librarian, and a final search strategy was developed. A 
systematic search of Medline, EMBASE and Global Health was conducted, with 
publication dates set from 1980 up to December 2013. A further search was 
conducted on Google Scholar.  
As most cancer studies were registry-based, I conducted additional searches of 
International Association of Cancer Registries (IACR), International Agency for 
Research on Cancer (IARC), and WHO African region websites to gather more data 
as most cancer registries send their data to these organizations. Global publications 
on cancer were further reviewed, including: the “GLOBOCAN studies”, “Cancer 
Incidence in Five Continents (CI5) series”, and “Cancer in Africa: Epidemiology and 
Prevention”, and relevant publications from these studies were selected. For studies 
that have been identified in the databases’ searches, any additional data (when 
available) on these studies were extracted from these global publications.  
Experts on cancer research in Africa were also contacted to seek their opinion on key 
journals and other relevant African databases, links and websites. For identified key 
authors and relevant search terms, an e-mail alert was registered and new 
publications were automatically sent to my e-mail. Hand-searching of reference lists 
of all relevant publications, and key journals, were finally done to identify more 
studies that could have been omitted from the databases’ searches. The list of African 
countries included in the searches was based on the World Bank list of economies 
(October 2013) (World Bank, 2014b). The search terms employed on Medline are 
shown in Table 2.6, while search terms for EMBASE and Global Health are shown 
in Appendix 1g and 1h, respectively.  
 As noted in the introduction, the top five cancers worldwide in 2008 were lung, 
breast, colorectal, stomach, and liver cancer. Based on Parkin et al., the top six 
cancers in Africa among women were cervical cancer, breast cancer, Kaposi’s 
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sarcoma, liver cancer, non-Hodgkin lymphoma (NHL) and ovarian cancer, and 
among men, these were Kaposi’s sarcoma, liver cancer, prostate cancer, bladder 
cancer, NHL and oesophageal cancer (Parkin et al., 2008). Therefore, to have a better 
understanding of the cancer burden in Africa and to allow for relevant global 
comparisons, I limited my review to the top cancers in Africa that have contributed 
highly to the cancer burden in the continent, based on these previous studies. Data on 
cancer that were extracted and analysed therefore included top six cancers in Africa 
in both sexes listed above, in addition to lung, colorectal, and stomach cancers, 
which were the other top cancers globally, that were not listed in Africa by Parkin 
and colleagues (Parkin et al., 2008). Therefore, the cancer types reviewed were 
cervical, breast, prostate, ovary, oesophagus, bladder, Kaposi, liver, stomach, 
colorectal, lung and non-Hodgkin lymphoma. 
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Table 2.6. Search terms for studies of cancer in Africa (Medline) 
# Searches 
1  
africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or 
central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or 
sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or 
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or 
benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or 
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp neoplasms/ or exp leukemia/ or exp lymphoma, non-hodgkin/ or exp burkitt lymphoma/ or exp 
sarcoma/ or exp sarcoma, kaposi/ or exp breast neoplasms/ or exp breast neoplasms, male/ or exp 
carcinoma, ductal, breast/ or exp "hereditary breast and ovarian cancer syndrome"/ or exp inflammatory 
breast neoplasms/ or exp gastrointestinal neoplasms/ or exp esophageal neoplasms/ or exp intestinal 
neoplasms/ or exp colorectal neoplasms/ or exp adenomatous polyposis coli/ or exp colonic neoplasms/ or 
exp sigmoid neoplasms/ or exp colorectal neoplasms, hereditary nonpolyposis/ or exp rectal neoplasms/ or 
exp anus neoplasms/ or exp ileal neoplasms/ or exp jejunal neoplasms/ or exp stomach neoplasms/ or exp 
liver neoplasms/ or exp adenoma, liver cell/ or exp carcinoma, hepatocellular/ or exp lung neoplasms/ or 
exp bronchial neoplasms/ or exp carcinoma, bronchogenic/ or exp carcinoma, non-small-cell lung/ or exp 
small cell lung carcinoma/ or exp pleural neoplasms/ or exp pleural effusion, malignant/ or exp solitary 
fibrous tumor, pleural/ or exp tracheal neoplasms/ or exp uterine neoplasms/ or exp uterine cervical 
neoplasms/ or exp prostatic neoplasms/ or exp kidney neoplasms/ or exp urinary bladder neoplasms/ 
13  
1 and 11 and 12 
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Selection criteria 
The inclusion criteria were: 
i. Population-based studies (registry or cross-sectional surveys) on cancer or 
specific cancer types ;  
ii. Studies conducted primarily on African population groups;  
iii. Studies providing numerical estimates on the incidence of cancers; and 
The exclusion criteria were: 
i. Studies that had non-human subjects;  
ii. Studies conducted before 1980; and 
iii. Studies that were mainly reviews, viewpoints or editorials.  
No language restrictions were applied. 
Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. As studies here were mainly registry-based, the quality checks here 
included active or passive cancer registration process, and cancer diagnosis and/or 
morphologic verification 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods in the estimation of cancer incidence; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
iv. Generalizability to the African population: This broadly assesses if the study 
site was representative of a larger population that can be generalized to the total 
African population 
For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as 
follows: 
i. High quality: Studies with the entire four criteria, or any three including 
“study design”, highlighted above well represented; 
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ii. Moderate quality: Studies with any three of the four criteria, or any two 
including “study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of 
the four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
From the initial scoping review, it was evident that there were not many original 
population bases cross-sectional or cohort studies on cancers in Africa. Most of the 
relevant studies were mainly population-based or hospital-based registries’ surveys. 
It was identified that the difficulties in diagnosis of cancers and lack of trained health 
staffs (including oncologists) in many parts of Africa have limited ongoing research 
efforts. This understanding ultimately shaped the scope of this systematic review on 
cancers in Africa.  
In my search, I looked for studies that identified cancers based on doctor’s diagnosis, 
clinical diagnosis, or laboratory (histological/cytological) diagnosis. These were not 
always provided due to incompleteness of many cancer registries in Africa.  
Based on the above, the case definitions needed to comply with these: 
i. Studies reporting diagnosis of cancer confirmed by a recognized medical 
practitioner, with the inclusion of terms synonymous to cancers. This include, albeit 
not limited to: "malignancy," "carcinoma," "sarcoma," "leukemia," and "lymphoma"; 
or 
ii. Studies reporting laboratory-confirmed cases evident from positive histology 
or cytology; and/or 
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iii. Studies reporting compatibility with the International Classification of 
Diseases for Oncology (ICD-O) and/or the appropriate International Classification of 
Diseases (ICD) applied for analysis (World Health Organization, 1976, IARC, 1987, 
Percy et al., 1990) 
This implies that, in these studies, incident cases of cancers have been classified 
according to the primary anatomic site (topography) and cellular characteristics 
(morphology including histology, behaviour, and grade) in accordance to ICD-O and 
ICD. 
Data extraction 
All extracted data were stored in 2010 Microsoft Excel file format.  
Data was extracted systematically on study location, study period, mean age or age 
range, person years or sample size, incident cases of cases of cancers, and where 
given, the respective age-, sex- and cancer-specific incidence rates. As noted above, 
to ensure extracted figures from published studies were consistent all through, data 
on cancer incidence in Africa were further checked from websites of the WHO 
African Region, International Association of Cancer Registries (IACR), International 
Agency for Research on Cancer (IARC), and relevant publications on cancers in 
Africa including “GLOBOCAN studies”, “Cancer Incidence in Five Continents 
(CI5) series” and “Cancer in Africa: Epidemiology and Prevention”. 
As noted in the introduction, the top five cancers worldwide in 2008 were lung, 
breast, colorectal, stomach, liver cancers, and based on Parkin et al, the top six 
cancers in Africa among women were cervical cancer, breast cancer, Kaposi’s 
sarcoma, liver cancer, non-Hodgkin’s lymphoma (NHL) and ovarian cancer, and 
among men, these were Kaposi’s sarcoma, liver cancer, prostate cancer, bladder 
cancer, NHL and oesophageal cancer (Parkin et al., 2008). Therefore, to have a better 
understanding of the cancer burden in Africa and to allow for relevant global 
comparisons, the final analysis included top six cancers in Africa in both sexes, in 
addition to lung, colorectal, stomach cancers, which were the other top cancers 
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globally, that were not initially listed in Africa by Parkin and colleagues (Parkin et 
al., 2008). 
Data analysis 
As noted in the introduction, incidence rates of cancer types have been the major 
studies conducted in Africa, and this have mainly been based on data collated from 
registries. Prevalence studies on cancer are almost non-existent in Africa (African 
Organization for Research and Training in Cancer, 2013). Therefore, this analysis is 
mainly restricted to the available data, which are mainly incidence data from 
registry-based studies.  
From extracted incidence rates of cancers in a given site, I conducted a random effect 
meta-analysis for specific cancers (DerSimonian and Laird, 1986), sorted according 
to sex, with pooled effect of cancer incidence rates expressed per 100,000 person 
years. All statistical analyses were conducted on Microsoft Excel and Stata 13.1 
(Copyright 1985-2013 Stata Corp LP). 
As many studies did not provide age group cancer incidence rates, no further 
modelling was conducted, as the epidemiological model earlier described is plotted 
along the with subjects age. Therefore, for the systematic review of cancer in Africa 
in this thesis, I have only provided the meta-estimate of incidence rates in the results, 
and the number of cases of the specific cancer was estimated from this. 
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2.5 CHRONIC RESPIRATORY DISEASES 
2.5.1 Chronic Obstructive Pulmonary Disease (COPD) 
Search strategy and databases 
After an initial scoping review with further useful hints from a librarian, relevant 
medical subject headings (MeSH) and keywords were identified; a final search 
strategy was developed.  
A systematic search of Medline, EMBASE and Global Health was conducted, with 
publication dates set from 1980 up to December 2013. A further search was 
conducted on Google Scholar. The list of African countries included in the searches 
was based on the World Bank list of economies (October 2013) (World Bank, 
2014b). Experts on chronic respiratory diseases and COPD research in Africa were 
also contacted to seek their opinion on key journals and relevant African databases, 
links and websites. For identified key authors and relevant search terms, an e-mail 
alert was registered and new publications were automatically sent to my e-mail. 
Hand-searching of reference lists of relevant publications, and key journals, were 
finally done to identify more studies that could have been omitted from the 
databases’ searches. The search terms employed on Medline are shown in Table 2.7, 
while search terms for EMBASE and Global Health are shown in Appendix 1i and 
1j, respectively.  
.  
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  






exp bronchitis, chronic/ or exp pulmonary disease, chronic obstructive/ or exp pulmonary 
emphysema/ 
15  
12 or 13 or 14 
16  
1 and 11 and 15 
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Study selection criteria 
The inclusion criteria were: 
i. Original population-based, cohort or cross-sectional studies on COPD and/or 
chronic bronchitis;  
ii. Studies conducted in urban, rural, occupational, or mixed settings mainly 
within African population groups;  
iii. Studies providing numerical estimates on the prevalence of COPD and/or 
chronic bronchitis; and 
iv. Studies that provided clearly defined, unambiguous methodologies.  
The exclusion criteria were: 
i. Studies that were hospital-based;  
ii. Studies that had non-human subjects;  
iii. Studies conducted before 1980; and 
iv. Studies that were mainly reviews, viewpoints or editorials.  
Generally, no language restrictions were applied. 
Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. Basically, this assesses methods of estimation of sample size and 
sampling methods across studies, and the methods of dealing with design specific 
issues such as: training of study investigators, adherence to standardized protocol for 
COPD estimation by spirometry and/or symptomatic case definitions, pre-testing and 
reviewing questionnaires before data entry, and addressing recall and interviewer’s 
bias appropriately; 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods employed across studies in the estimation of the prevalence of COPD; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
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iv. Generalizability to the African population: This broadly assesses if the study 
site was representative of a larger population that can be generalized to the total 
African population 
 
For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as 
follows: 
i. High quality: Studies with the entire four criteria, or any three including 
“study design”, highlighted above well represented; 
ii. Moderate quality: Studies with any three of the four criteria, or any two 
including “study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of 
the four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
Primary research on COPD in Africa has been very limited. This has in part been 
linked to challenges in the accurate diagnosis of this condition and the heterogeneity 
of published research protocols (Aisanov et al., 2012). Furthermore, existing reviews 
have identified only ten countries in Africa that have conducted and published 
research findings on COPD and these are mainly from selected populations and 
occupational settings where the case definitions were mostly based on respiratory 
symptoms (Mehrotra et al., 2009, Musafiri et al., 2011a, van Gemert et al., 2011). 
These have all limited on-going research efforts towards determining the true burden 
of COPD in Africa. 
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Various published reports have noted that symptoms of COPD and other obstructive 
airway diseases do overlap, which often complicates the case ascertainment during 
epidemiological surveys. For example, some clinical studies show that patients with 
bronchial inflammation and obstruction could present with signs and symptoms of 
asthma, chronic bronchitis and emphysema (Musafiri et al., 2011a). In fact, COPD 
has previously been described in this regard, i.e. in terms of its clinical and 
pathological presentation, mainly as “chronic bronchitis” and “emphysema” 
(Menezes et al., 2004, Vijayan, 2013). The British Medical Research Council 
(BMRC) defines chronic bronchitis as: 
“a chronic productive cough for three months in each of two 
successive years in a patient in whom other causes of chronic cough 
have been excluded” (MRC, 1965) 
And Emphysema as: 
“an abnormal and permanent enlargement of the airspaces distal to the 
terminal bronchioles that is accompanied by destruction of the 
airspace walls, without obvious fibrosis” (MRC, 1965) 
These definitions, however, have not adequately explained the basic physiological 
impairment of the lungs in a COPD patient that, according to pulmonologists, can be 
traced to a reduced expiratory volume compared to the vital capacity of the lungs 
(Aisanov et al., 2012). As a rule, patients having chronic bronchitis, emphysema, or 
both may not be considered to have COPD unless there are evidences of airflow 
limitation (Aisanov et al., 2012, Vijayan, 2013). 
Asthma is another obstructive airway disease that shares many clinical and 
physiologic overlaps with COPD. According to the Global Initiative for Asthma 
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“Asthma is a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role. The chronic inflammation 
is associated with airway responsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night or in the early morning. These episodes are 
usually associated with widespread, but variable, airflow obstruction 
within the lung that is often reversible either spontaneously or with 
treatment” (Masoli et al., 2004) 
For clinical clarifications, pulmonologists have further stated that asthma patients 
presenting with a completely reversible airflow obstruction may not be considered to 
have COPD (Masoli et al., 2004). 
Meanwhile, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is a 
scheme introduced by the National Heart, Lung, and Blood Institute (NHLBI) and 
the World Health Organization (WHO). According to GOLD, COPD is defined as: 
“a common preventable and treatable disease, is characterized by 
airflow limitation that is usually progressive and associated with an 
enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases. Exacerbations and comorbidities contribute 
to the overall severity in individual patients." (GOLD, 2005) 
However, for the definitive evaluation and diagnosis of COPD, pulmonary function 
tests (PFTs), particularly spirometry, have been described as the main stay (GOLD, 
2005). PFTs also further helps in determining disease severity, staging, disease 
progression and response to treatment (Aisanov et al., 2012). In the use of spirometry 
for evaluating suspected COPD cases, a pre- and post-bronchodilator is administered 
(e.g. inhalation of albuterol 400 µg) to help ascertain if the airflow limitation is fully 
or partially reversible (GOLD, 2005). The main spiromery indices employed in 
diagnosis are the forced expiratory volume in one second (FEV1) and the forced vital 
capacity (FVC). Based on these two indices, the Global Initiative on Obstructive 
Lung Disease (GOLD) and the ‘American Thoracic Society/ European Respiratory 
Society’ (ATS/ERS) have provided clearer quantitative definitions of COPD, which 
is defined as a ratio of post bronchodilatory forced expiratory volume in one second 
to forced vital capacity that is less than 70% (PBD FEV1/FVC <0.7) (GOLD, 2005, 
Gjevre et al., 2006). While PBD FEV1/FVC <0.7 has been considered the gold 
standard in the diagnosis of COPD, evidences suggests that the ratio of FEV1 to FVC 
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decreases with age, this may therefore need careful interpretation in older age groups 
(GOLD, 2005, Gjevre et al., 2006). The use of lower limit of normal (LLN) of the 
FEV1/FVC has therefore been advocated in some quarters, stating that the distinction 
between LLN and 0.7 in older age groups may not lead to significant differences in 
COPD diagnosis, especially  since most clinical diagnoses are usually combined with 
physiologic assessments (Musafiri et al., 2011b).  
Based on the above understanding of COPD, in the selection of studies for the 
estimation of COPD in Africa, the following were considered: 
i. Studies considering presence of symptoms suggestive of COPD. For 
example, dyspnea at rest or on exertion, cough with or without sputum production, 
and progressive limitation of activity 
ii. Studies that employed spirometry in determining airflow limitation, mainly 
from FEV1/FVC <0.7 or FEV1/FVC <LLN 
Therefore, based on i and ii above, the final case definitions of selected studies 
needed to comply with: 
i. the Global Initiative on Obstructive Lung Disease (GOLD) criteria; or 
ii. the American Thoracic Society/ European Respiratory Society (ATS/ERS) 
criteria (21);  
(with GOLD and ATS/ERS criteria both broadly defined as a post-bronchodilatory 
(PBD) ratio of forced expiratory volume in one second to forced vital capacity of less 
than 70% (PBD FEV1/FVC <0.7)); or 
iii. FEV1/FVC <LLN; and/or 
iv. the 1965 British Medical Research Council (BMRC) definition of chronic 
bronchitis. 
See Table 2.8 for detailed diagnostic criteria.   
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Table 2.8. GOLD and ATS/ERS COPD diagnostic criteria 
GOLD criteria   
Stage Definition 
I FEV1/FVC < 0.7; FEV1≥ 80% predicted 
II FEV1/FVC < 0.7; FEV150-80% predicted 
III FEV1/FVC < 0.7; FEV130-50% predicted 
 
IV 
FEV1/FVC <0.7; FEV1<30% predicted or FEV1< 50% 
predicted plus chronic respiratory failure 
 




 Patients who: 
-Smoke/Pollutant exposure 
-Cough/Sputum/Dyspnoea 
-Family history of respiratory disease 
 
 
Post-bronchodilator FEV1/FVC > 0.7 
FEV1≥ 80% predicted 
Mild COPD Post-bronchodilator FEV1/FVC ≤0.7 ; FEV1≥ 80% 
predicted 
Moderate COPD Post-bronchodilator FEV1/FVC ≤0.7; FEV150-80% 
predicted 
Severe COPD Post-bronchodilator FEV1/FVC ≤0.7; FEV130-50% 
predicted 
Very Severe COPD Post-bronchodilator FEV1/FVC ≤0.7; FEV1<30% predicted 
ATS: American Thoracic Society, ERS: European Respiratory Society, FEV1: forced expiratory volume in one 
second, FVC: forced vital capacity, GOLD: Global Initiative for chronic Obstructive Lung Disease 
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Data extraction 
Relevant data were extracted from the retained studies and saved in 2010 Microsoft 
Excel file format. Data extracted included corresponding country, the study period, 
the mean age (and any age groups that were studied specifically), the number of 
cases, the sample size and the prevalence of the COPD (expressed as percentages). 
Studies were broadly grouped into "spirometric" (defined as complying with case 
definitions ‘i, ii and iii’, as mentioned above) and "non-spirometric" (defined as 
complying with case definitions ‘iv’). For studies conducted on the same study site, 
population or cohort, the first chronologically published study has been considered, 
with all additional new data from more recent studies further added.  
Data analysis 
Due to very limited data points, and heterogeneities across the few selected 
spirometry studies (designs, spirometry procedures, study populations clearly vary 
across these spirometry studies), no pooled estimate and further epidemiological 
modelling was conducted. 
From individual studies, estimation of COPD prevalence was conducted based on 
spirometry or survey of obstructive airways symptoms across different population 
groups, ranging from a general population, occupational settings to populations 
involving only women. Therefore, to allow for an understanding of the prevalence of 
COPD across these populations, the prevalence of COPD was separately investigated 
from "spirometric" and "non-spirometric" sets of studies and the effect of covariates 
(e.g., mean age, gender, the year of study and the country) were analysed.  I therefore 
generated box plots of spirometric and non-spirometric prevalence based on gender, 
and also generated scatter plots of spirometric and non-spirometric prevalence based 
on mean age. The prevalence of COPD from the two types of studies ("spirometric" 
and "non-spirometric") was then compared. In addition, Pearson correlation 
coefficients, t-test on equality of means, and Mann-Whitney test for equality of 
medians were used to study the effects of case definition and other covariates on the 
prevalence of COPD.  
Finally, as I could not generate pooled or modelled estimates (and confidence 
intervals) from these datasets, I applied the median and inter-quartile prevalence 
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range from spirometry-based studies, which is the gold-standard diagnostic 
procedure for COPD, and the United Nation (UN) Population Division's population 
figures (United Nations, 2013), to estimate the number of COPD cases in the year 
2010, see Equation 5.  All statistical analyses were conducted on 2010 Microsoft 
Excel, SPSS and Stata 13.1 (Copyright 1985-2013 Stata Corp LP). 
Equation 5 
Number of COPD cases in Africa in 2010 = 
Median prevalence * UN population for Africa in 2010 / 100 
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2.5.2 Asthma 
Search strategy and data sources 
After an initial consultation with a librarian, relevant medical subject headings 
(MeSH) and keywords were identified, and a final search strategy was developed.  
A systematic search of Medline, EMBASE and Global Health was conducted, with 
publication dates set from 1980 up to December 2013. A further search was 
conducted on Google Scholar. The list of African countries included in the searches 
was based on the World Bank list of economies (October 2013) (World Bank, 
2014b). Experts on chronic respiratory diseases and asthma research in Africa were 
also contacted to seek their opinion on key journals and relevant African databases, 
links and websites. For identified key authors and relevant search terms, an e-mail 
alert was registered and new publications were automatically sent to my e-mail. 
Hand-searching of reference lists of relevant publications, and key journals, were 
finally done to identify more studies that could have been omitted from the 
databases’ searches. The search terms employed on Medline are shown in Table 2.9, 
while search terms for EMBASE and Global Health are shown in Appendix 1k and 
1l, respectively.  
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ 
or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or 
senegal/ or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp asthma/ or exp asthma, aspirin-induced/ or exp asthma, exercise-induced/ or exp asthma, 
occupational/ or exp status asthmaticus/ or wheezing/ 
13  
1 and 11 and 12 
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Study selection criteria 
The inclusion criteria were: 
i. Original population-based, cohort or cross-sectional studies on asthma;  
ii. Studies conducted in urban, rural, occupational, or mixed settings mainly  
within African population groups;  
iii. Studies providing numerical estimates on the prevalence of asthma; and 
iv. Studies that provided clearly defined, unambiguous methodologies.  
The exclusion criteria were: 
i. Studies that were hospital-based;  
ii. Studies that had non-human subjects;  
iii. Studies conducted before 1980; and 
iv. Studies that were mainly reviews, viewpoints or editorials.  
No language restrictions were applied. 
Quality criteria and grading 
Quality of studies was assessed based on the following criteria: 
i. Study design: Under this, flaws in the design and execution of study were 
examined. Basically, this assesses methods of estimation of sample size and 
sampling methods across studies, and the methods of dealing with design 
specific issues such as: training of study investigators, adherence to 
standardized protocol for asthma diagnosis by spirometry and/or symptomatic 
case definitions, pre-testing and reviewing questionnaires before data entry, and 
addressing recall and interviewer’s bias appropriately; 
ii. Study analysis: This assesses the appropriateness of statistical and analytical 
methods employed across studies in the estimation of the prevalence of asthma; 
iii. Study limitations: This assesses if the study stated the limitations, as this may 
further guide in the choice of selection; and 
iv. Generalizability to the African population: This broadly assesses if the study 
site was representative of a larger population that can be generalized to the total 
African population 
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For the quality grading, I adapted the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines (Balshem et al., 2011), as follows: 
i. High quality: Studies with the entire four criteria, or any three including “study 
design”, highlighted above well represented; 
ii. Moderate quality: Studies with any three of the four criteria, or any two including 
“study design”, highlighted above well represented; 
iii. Low quality: Studies with any two of the four criteria, or “study design” only, 
highlighted above well represented; and 
iv. Very low quality: Studies with only one (excluding “study design”) or none of the 
four criteria highlighted above well represented. 
As a basic rule, all studies that were graded as high and moderate quality were 
included in the quantitative analysis. Some low quality studies were also included in 
the quantitative analysis on the basis of good study designs, and were described 
further in the discussion section. However, all very low quality studies have been 
excluded from the review.  
Case definitions 
As noted in the introduction, defining asthma has posed huge challenge to 
researchers, and this often has affected the conduct of epidemiological surveys, 
especially in Africa, where health workers have not been trained, or exposed to 
standard equipment needed for the diagnosis of asthma (Reddel et al., 2009). 
Realistically, experts have stated there is really no straight forward definition of 
asthma, as most surveys diagnostic criteria are based on respiratory symptoms, 
experience in the management of asthma, and doctors’ diagnosis (Gjevre et al., 2006, 
Bousquet et al., 2010). One interesting way to improved identification of asthma in 
the community could be focusing more on survey of incident cases rather than 
prevalent cases of asthma, respectively (Reddel et al., 2009, Trepka et al., 2009). 
This offers the researcher to ask questions on recent episodes of asthma, emerging 
etiologic and risk factors could be more appreciated, and the health system may be 
prompted towards establishing asthma surveillance, notification and registration 
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system that can subsequently help in asthma diagnosis during future prevalence 
studies, as the case in the United States (Trepka et al., 2009). 
According to GINA, asthma is defined as: 
“a chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role. The chronic inflammation is associated 
with airway responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness, and coughing, particularly at night or in 
the early morning. These episodes are usually associated with 
widespread, but variable, airflow obstruction within the lung that is often 
reversible either spontaneously or with treatment” (Masoli et al., 2004) 
For ease of diagnosis, GINA proposed a holistic approach involving detailed history, 
physical examination and spirometry. An increase in FEV1 of ≥12% and ≥200ml 
after a bronchodilator is indicative of reversible airflow limitation, which is 
consistent with asthma (Masoli et al., 2004). Other diagnostic methods that may be 
indicative of asthma include peak expiratory flow (PEF) with an improvement of 
60l/min (or ≥20% of the pre-bronchodilator PEF) after a bronchodilator, or a diurnal 
variation in PEF of more than 20% (with twice daily readings more than 10%) 
(Masoli et al., 2004, Gjevre et al., 2006). Other non-specific diagnostic tests include 
methacholine or histamine test, inhaled mannitol or exercise challenge, skin prick 
test and measurement of serum IgE (Gjevre et al., 2006).   
In this review and based on the understanding of the variations and challenges in the 
diagnosis of asthma, studies based on respiratory symptoms suggestive of asthma (as 
described by GINA) were finally included. However, it is important to note that these 
symptoms were mainly surveyed for across retained studies based on the written 
questionnaires (mainly conducted among adolescents and adults) or video 
questionnaires (usually conducted among children), which were initially proposed by 
the ISAAC study groups (Zar et al., 2007). See Table 2.10 for further details on 
asthma terms and definitions. 
Diagnostic criteria therefore needed to comply with: 
i. Studies based on symptoms of asthma as described by GINA, e.g wheeze at rest, 
wheeze on exercise, nocturnal wheeze, nocturnal cough, or severe wheeze ; and/or 
ii. Studies based on doctor or self-reported diagnosis of asthma 
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Table 2.10. Asthma symptoms and related definitions 
Terms Definition 
Wheeze A high pitched whistling sound originating from obstructed airways (IUATLD, 2011). 
“Wheeze at rest-12 months” refers to the prevalence of wheeze in a person in the last 12 
months (IUATLD, 2011) 
Asthma A chronic airway disease characterized by wheezing (a high pitched whistling sound 
originating from obstructed airways). Patient usually present with chronic airways 
inflammation, bronchial hyper-responsiveness and reversible airflow obstruction, 
resulting in the recurrent attacks of wheeze, chest tightness, breathlessness, and 
occasionally cough and sputum production, all of varying severity and frequency from 
person to person (Masoli et al., 2004). Asthma ever refers to cummulative prevalence of 
asthma in a person (IUATLD, 2011) 
Asthma exacerbation Also known as acute asthma. A sudden progressive episodes of shortness of breath, 
usually characterized  by chest tightness, wheezing, cough or sputum production 
(Reddel et al., 2009) 
Moderate asthma 
exacerbation 
An event that, when recognized, should result in a temporary change in treatment, in an 
effort to prevent the exacerbation from being severe (Reddel et al., 2009) 
Severe asthma 
exacerbation 
Events that require urgent action on the part of the patient and physician to prevent a 
serious outcome, such as hospitalization or death  (Reddel et al., 2009) 
Severe asthma Uncontrolled asthma which can result in risk of frequent severe exacerbations (or 
death), and/or adverse reactions to medications, and/or chronic morbidity, including 
impaired lung function or reduced lung growth in children  (Reddel et al., 2009) 
Asthma control  Extent to which the various manifestation of asthma are reduced or removed by 
treatment   (Reddel et al., 2009) 
FEV1: forced expiratory volume in one second, GINA: Global Initiative for Asthma, IgE: immunoglobulin E, 
PEF: peak expiratory flow 
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Data extraction 
Relevant data were extracted from retained studies and saved in 2010 Microsoft 
Excel file-format. All extracted data were sorted by country, study period, age, and 
their respective case number, sample size and prevalence estimate (expressed as 
percentages). Extracts were grouped into data from written questionnaires or video 
questionnaires, both including data based on doctor or self-reported asthma 
diagnosis, and/or its symptoms (wheeze at rest, wheeze on exercise, nocturnal 
wheeze, nocturnal cough, or severe wheeze). For studies conducted on the same 
study site, population or cohort, the first chronologically published study was 
selected, with all additional data from other studies added to that of the selected 
paper. 
Data Analysis 
As noted in the introduction, asthma diagnosis based on doctor or self-reported 
diagnosis of asthma (asthma ever or cumulative lifetime asthma prevalence) and the 
symptom “current wheeze” (wheeze at rest- 12 months) have mostly been used 
across many studies (Yemaneberhan et al., 1997, IUATLD, 2011). Therefore, in the 
analysis, and to allow for a comparison with the modelled estimates, random effect meta-
analysis was conducted on crude prevalence rates of asthma estimated from doctor or self-
reported diagnosis of asthma (asthma ever), and symptoms (wheeze at rest, wheeze on 
exercise, nocturnal wheeze, nocturnal cough, or severe wheeze) (DerSimonian and Laird, 
1986). These were mainly from studies based on written questionnaire, as these provided 
more data points that can allow for detailed analysis. Furthermore, due to more data points in 
the written questionnaires among urban and rural dwellers, pooled prevalence estimates of 
“asthma ever” and “current wheeze” were further calculated in these population sub-groups. 
The rationale for using random effects meta-analysis has been earlier described. Each 
measure of heterogeneity and appropriateness of combining heterogeneous studies is further 
described under study limitations. The overall estimates of age- and sex-specific prevalence 
and incidence from all studies were used in the epidemiological modelling (Appendix 5). 
The use of age-specific estimates and mean age (and limitations) has been highlighted 
earlier. This is further described under study limitations. 
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However, in line with reports suggesting that asthma prevalence estimates based on “current 
wheeze” (wheeze at rest- 12 months) provided higher sensitivities and specificities for 
asthma diagnosis during epidemiological surveys (IUATLD, 2011), extracted crude 
prevalence rates from studies based on this was employed in the overall modelling.  
Description of the Modelling 
Just as noted in previous sections, the general approach to the epidemiological modelling has 
already been described. In this particular model, polynomial function was used for the 
estimation of asthma prevalence rates and cases in Africa as it showed the greatest prediction 
power. The model was applied on all data points reporting crude prevalence of asthma based 
on the symptom “current wheeze” (wheeze at rest- 12 months), which has been shown to 
have highest sensitivity in the estimation of asthma prevalence in the population (IUATLD, 
2011). The equation generated was used to determine the prevalence of asthma in Africa at 
midpoints of the United Nation population 5-year age-group population estimates for Africa, 
for the year 2010 (United Nations, 2013), see Equation 6. This implies that prevalence of 
asthma and corresponding cases are estimated based on the 2010 UN population estimates 
for Africa  for the ages 0-4, 5-9, 10-14, 15-19, etc, at points 2, 7, 12, 17, etc.  See Appendix 
5 for all data used in modelling. All statistical analyses were conducted on 2010 Microsoft 
Excel and Stata 13.1 (Copyright 1985-2013 Stata Corp LP). 
Equation 6 
Number of asthma cases in Africa in 2010 = 
Estimated prevalence from epidemiological model * UN population for Africa in 
2010 / 100 
For the calculation of Confidence Interval (CI), I applied the Kirkwood and Sterne 
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3.1 OVERVIEW 
This part of the thesis also follows the same pattern presented in the methods. For 
each of the diseases under review (cardiovascular diseases (hypertension and stroke), 
diabetes, cancer, and chronic respiratory disease (COPD and asthma)), I have 
presented the results of the systematic review, study characteristics, pooled 
prevalence or incidence estimates, and modelled prevalence or incidence estimates, 
where there are enough data available to allow for this. 
3.2 CARDIOVASCULAR DISEASES 
3.2.1 Hypertension 
Systematic Review 
The search returned 7680 publications: 2205 in Medline, 4073 in EMBASE, and 
1402 in Global Health. An additional 3 studies were included from other sources 
(Google Scholar and reference list of relevant reviews). After excluding duplicates, 
5227 studies remained. On screening titles for relevance (hypertension studies 
conducted primarily in an African population setting), 4936 articles were excluded, 
giving a total of 291 full texts that were assessed.  82 articles did not report 
hypertension prevalence or population denominators from which prevalence rates 
can be calculated,   75 articles did not specify study designs and / or clarify case 
definitions of hypertension, and 42 articles were based on blood pressures base-line 
of 160/90mmHg. A total of 92 studies were finally retained for qualitative synthesis 
and quantitative analysis (Figure 3.1) 
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Figure 3.1. Flow diagram of search results for hypertension 
studies in Africa 
199 full-text articles 
excluded 
82 articles did not report 
hypertension prevalence 
or population numerical 
estimates from which 
prevalence can be 
calculated 
75 articles did not 
specify study designs and 
/ or clarify case 
definitions of 
hypertension 
42 articles were based 
on blood pressures base-
line of 160/90mmHg 
  
92 studies included 
in qualitative 
synthesis  
92 studies included in 
quantitative analysis 
and modelling  
7680 records identified through 
database searching (Medline 2205, 
EMBASE 4073 & Global Health 1402) 
4 additional records 
identified through other 
sources  
5227 records after duplicates 
removed  
5227 records screened  
4936 records excluded  
291 full-text articles 
assessed for eligibility  
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Study characteristics 
There were 92 studies conducted across 101 study sites in 31 African countries. 
Central Africa had 10 study sites, Eastern Africa 21, Northern Africa 12, Southern 
Africa 15, and Western Africa 43. Nigeria had the highest number of publications 
with 26 study sites; Ghana and South Africa followed with 7 study sites each, while 
Cameroon, Tanzania and Tunisia had 6 study sites each (see Table 3.1 and Figure 
3.2 for details). 
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Table 3.1. Characteristic distribution of retained hypertension studies in Africa 
Characteristics Country Study sites 
Central Africa (10 study sites) Cameroon 6 
Chad 1 
DR Congo 2 
Rwanda 1 
















South Africa 7 
Zambia 1 
Western Africa (43 study sites) Benin 1 
Burkina Faso 1 
Gambia 1 
Ghana 7 
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Duration of study  
<1 year 74 
1-3 years 22 
>3 years 5 








*sites overlap with urban and rural settings 
73% of studies were completed within a one year, with over 50% carried out in urban 
settings. The overall sample size from all retained studies was 197,734, with a mean 
and median of 1958 and 1200 respectively. For the diagnosis of hypertension, 
retained studies were restricted to the inclusion criteria, i.e. studies based on the cut-
off “≥140/90 mm Hg” (see Tables 3.1 and 3.2). From all studies, the weighted mean 
systolic and diastolic blood pressures were 129.6 mm Hg and 78.0 mm Hg 
respectively. Studies were mostly conducted on people aged ≥20 years, with an 
estimated overall mean age of 47.4 years. For the age determination of subjects 
across selected studies, birth certificates were mostly employed, and in the absence 
of valid age-verification documents, subjects’ age were determined from historical 
landmarks.
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Country, Setting Year Age 
(years)  
Prevalence %  
 
All Men Female 
Central  1) Cameroon, Mixed (Cooper et al., 1997) 1995 49.5 16.9 17.7 16.3 
2) Cameroon, Mixed (Cruickshank et al., 2001) 1991 41.75 7.07 8.92 5.69 
3) Cameroon, Mixed (Fezeu et al., 2010) 1994 54.5 18.8 20.2 17.8 
4) Cameroon, Mixed (Fezeu et al., 2010) 2003 54.5 38.34 40.9 36.5 
5) Cameroon, Urban (Kamadjeu et al., 2006) 2003 31.35 24.6 25.6 23.1 
6) Cameroon, Urban (Kamadjeu et al., 2006) 2004 31.35 20.8 - - 
7) Chad, Rural (Dionadji et al., 2010) 2004 35 16.4 12.2 21.8 
8) DR Congo, Mixed (Katchunga et al., 2011) 2009-10 54.5 40.2 - - 
9) DR Congo (M'Buyamba-Kabangu et al., 1986) 1983-84 42.5 16.7 22.1 12.4 
10) Rwanda, Rural (de Ramirez et al., 2010) 2007 42.2 16.0 16.0 16.0 
East 11) Eritea, Mixed (Mufunda et al., 2006c) 2004 39.5 16.0 16.88 15.28 
12) Ethiopia, Mixed (Giday and Tadesse, 2011) 2008 36.08 9.9 - - 
13) Ethiopia, Urban (Awoke et al., 2012) 2012 51.4 28.3 26 30.3 
14) Ethiopia, Urban (Nshisso et al., 2012) 2009 50.5 19.1 22 14.9 
15) Ethiopia, Urban (Tesfaye et al., 2009) 2006 49.5 30.0 31.5 28.9 
16) Ethiopia, Urban (Tran et al., 2011) 2009-2010 42.9 17.7 20.0 14.3 
17) Kenya, Rural (Hendriks et al., 2012) 2009-11 40.9 20.2 - - 
18) Kenya, Mixed (Mathenge et al., 2010) 2007-08 69.5 50.1 - - 
19) Kenya, Urban (Van De Vijver et al., 2013) 2009-09 48.5 12.3 12.7 12 
20) Seychelles, Mixed (Bovet et al., 2006) 2004 44.5 31.6 38.4 24.8 
21) Sudan, Urban (Ahmed, 1990) 1988-89 35 7.5 - - 
22) Tanzania, Urban (Bovet et al., 2002) 1998-99 54.5 28.9 27.1 30.2 
23) Tanzania, Rural (de Ramirez et al., 2010) 2007 42.8 27 28 24 
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24) Tanzania, Rural (Dewhurst et al., 2013b) 2009-2010 76 69.9 62.2 75.8 
25) Tanzania, Rural (Edwards et al., 2000) 1996 39.95 29.2 30 28.6 
26) Tanzania, Rural (Edwards et al., 2000) 1996 54.5 31.9 32.2 31.5 
27) Tanzania, Urban (Hendriks et al., 2012) 2009-11 36.8 19 - - 
28) Uganda, Rural (Maher et al., 2011a) 2008-09 32.75 22.3 22.5 22.6 
29) Uganda, Rural (Mayega et al., 2012) 2011 42.5 20.5 20.7 20.4 
30) Uganda (Musinguzi and Nuwaha, 2013) 2012 35.15 21.8 22.3 21.7 
31) Uganda, Rural (Wamala et al., 2009) 2006 42 30.4 25.4 34 
North 32) Algeria, Rural) (Hamida et al., 2013) 2010 58.5 50.2 51.3 49.7 
33) Algeria, Urban (Latifa and Kaouel, 2007) 2004-05 54.5 32.7 24.5 40.6 
34) Algeria, Peri-urban (Temmar et al., 2007) 2006-07 55 44 41.2 46.7 
35) Egypt, Mixed (Ibrahim et al., 1995) 1991-93 45.6 26.3 25.7 26.9 
36) Egypt, Rural (Mohamed et al., 2000) 1999-00 42.5 27.9 - - 
37) Morocco, Mixed (Tazi et al., 2003) 2000 51 39.6 37.2 41.3 
38) Tunisia, Mixed (Allal-Elasmi et al., 2012) 2004-05 44.6 31.07 25.0 36.1 
39) Tunisia, Mixed (Ben Romdhane et al., 2012) 2004-05 49.6 30.6 27.3 33.1 
40) Tunisia, Mixed (Ben Romdhane et al., 2005) 2002-03 54.5 44.3 38.7 48.2 
41) Tunisia, Urban (Ghannem and Fredj, 1997) 1995 54.5 28.9 30 28.4 
42) Tunisia, Rural (Hammami et al., 2011) 2008-09 72.3 52 45 55.5- 
43) Tunisia, Mixed (Laouani Kechrid et al., 2004) 2002-03 69 69.3 - - 
South 44) Angola, Urban (Capingana et al., 2013) 2009-10 44.5 45.2 46.3 44.2 
45) Angola, Mixed (Pires et al., 2013) 2011 41.5 23 26.4 19.8 
46) Madagascar, Urban (Mauny et al., 2003) 1996-97 32.75 23.3 24.9 21.7 
47) Malawi, Rural (de Ramirez et al., 2010) 2007 38.4 23 24.5 22 
48) Malawi, Mixed (Msyamboza et al., 2012) 2009 45.5 33.2 36.9 29.9 
49) Mozambique, Mixed (Damasceno et al., 2009) 2005 54.5 33.1 35.7 31.2 
50) Namibia, Urban (Hendriks et al., 2012) 2009-11 36.9 32 - - 
51) South Africa, Rural (Alberts et al., 2005) 2004-05 59.5 28.0 24.5 29.2 
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52) South Africa, Rural (Malaza et al., 2012) 2010 54.5 26.2 20.8 28.5 
53) S/Africa (Peltzer and Phaswana-Mafuya, 2013) 2008 65 77.3 74.4 79.6 
54) South Africa, Mixed (Steyn et al., 1986) 1982 41 41.6 45.6 37.75 
55) South Africa, Mixed (Steyn et al., 1996) 1990 40.5 21.5 19.2 23.4 
56) South Africa, Peri-urban (Steyn et al., 2004) 1996 42 27.1 31.9 23.4 
57) South Africa, Rural (Thorogood et al., 2007) 2002 59.5 32.6 - - 
58) Zambia, Urban (Goma et al., 2011) 2009-10 57 34.8 38 33.3 
West 59) Benin, Mixed (Houinato et al., 2012) 2008 42.7 27.9 - - 
60) Burkina Faso, Urban (Niakara et al., 2007) 2004 54.5 40.2 - - 
61) Gambia, Mixed (van der Sande et al., 2000) 1998-99 43.7 18.4 - - 
62) Ghana, Rural (Addo et al., 2006) 2004-05 42.4 25.4 24.1 25.9 
63) Ghana, Mixed (Agyemang, 2006) 2004 35.9 29.4 31.04 28.07 
64) Ghana, Rural (Burket, 2006) 2003 53 32.8 - - 
65) Ghana, Mixed (Cappuccio et al., 2004) 2001 54.7 28.7 29.9 28 
66) Ghana, Rural (Cook-Huynh et al., 2012) 2006-07 53.5 35 37.2 34.1 
67) Ghana, Rural (Koopman et al., 2012) 2002-10 66 24.1 25.7 22.5 
68) Ghana, Rural (Williams et al., 2013) 2012 53.84 44.7 - - 
69) Guinea, Mixed (Balde et al., 2006) 2003 62 31.4 - - 
70) Guinea, Rural (N'Gouin-Claih et al., 2003) 2001 45.5 45.2 - - 
71) Liberia, Rural (Giles et al., 1994) 1991-92 54.5 12.5 - - 
72) Nigeria, Mixed (Abegunde and Owoaje, 2013) 2010-11 71.1 34.7 - - 
73) Nigeria, Semi-urban (Adedoyin et al., 2008) 2007-08 44.2 36.57 36.79 36.39 
74) Nigeria, Semi-urban (Adedoyin et al., 2012) 2011-12 41.5 25.2 24.7 24.7 
75) Nigeria, Rural (Ahaneku et al., 2011) 2010-11 57.3 44.5 49.3 42.3 
76) Nigeria, Rural (Alikor et al., 2013) 2012-13 41.3 20.2 20.5 20.1 
77) Nigeria, Urban (Amira et al., 2012) 2006-10 41.9 33 38.3 27.8 
78) Nigeria, Mixed (Amole et al., 2011) 2008 48.7 50.5 52 49.3 
79) Nigeria, Rural (Asekun-Olarinmoye et al., 2013) 2011 49.7 13.2 15 11.9 
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80) Nigeria, Urban (Bunker et al., 1992) 1987-88 36.35 31.1 34 17 
81) Nigeria, Mixed (Cooper et al., 1997) 1995 49.5 14.5 14.7 14.3 
82) Nigeria, Rural (Ejim et al., 2011) 2005-06 59.8 46.4 50.2 44.8 
83) Nigeria, Semi-urban (Ekanem et al., 2013) 2012 31.7 47 30.1 16.8 
84) Nigeria, Mixed (Ekwunife et al., 2010) 2009 34.9 21.1 - - 
85) Nigeria, Semi-urban (Erhun et al., 2005) 2002-03 55 21 23.3 16.4 
86) Nigeria, Rural (Hendriks et al., 2012) 2009-11 45.3 21 - - 
87) Nigeria, Mixed (Isezuo et al., 2011) 2009-10 38.9 24.8 25.9 23.6 
88) Nigeria, Semi-urban (Mbah et al., 2013) 2011-12 50 32.5 - - 
89) Nigeria, Urban (Odugbemi et al., 2012) 2009-10 43.88 34.8 - - 
90) Nigeria, Mixed (Ogah et al., 2013) 2011-12 41.7 31.8 33.5 30.5 
91) Nigeria, Urban (Oghagbon et al., 2008) 2006-07 50.5 27.1 28.4 22.9 
92) Nigeria, Rural (Oladapo et al., 2010) 2002-05 42.1 20.8 21.1 20.5 
93) Nigeria, Urban) (Omorogiuwa et al., 2009) 2007-08 41.6 33 28.1 36.4 
94) Nigeria, Rural (Omuemu et al., 2007) 2004-05 30.7 20.2 24.8 13.2 
95) Nigeria, Semi-urban (Suleiman et al., 2013) 2011 50.5 15 18.8 12.5 
96) Nigeria, Mixed (Ulasi et al., 2010) 2007-08 40.8 32.8 - - 
97) Nigeria, Mixed (Ulasi et al., 2011) 2009-10 38.02 42.2 46.3 37.7 
98) Senegal, Urban (Astagneau et al., 1992) 1989-90 31.45 22.5 23.6 21.5 
99) Senegal, Urban (Macia et al., 2012) 2009 69.5 65.4 63.9 67.1 
100) Togo, Urban (Baragou et al., 2012) 2009-10 39 26.6 25.7 27.6 
101) Togo, Urban (Yayehd et al., 2013) 2011 40.8 36.7 34.6 38.4 
JNC: Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, 
WHO/ISH : World Health Organization/ International Society of Hypertension
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Details of quality criteria and grading of retained hypertension studies in Africa 
Of the selected 92 studies, there were 5 low quality studies (Table 3.3). As noted in 
the methods, these low quality studies were included in the meta-analysis and 
modelling due to the well explained study designs, and because their exclusion do 
not provide any significant change in the overall pooled prevalence of hypertension. 
Table 3.3. Quality assessment of retained hypertension studies in Africa 












49, 51, 52, 





Well explained, excluding 
46 and 68 (where 
training/questionnaire pre-










representative of a 
larger African 
population across all 
studies 
High 
5, 6, 9, 12, 
17, 21, 27, 
36, 42, 43, 
50, 53, 59, 
64, 69, 70, 
78, 88, 89, 
96 
Well explained, excluding 
21, 64, and 78 (where 
there was no clear 





6, 17, 36, 42, 
50, 53, 88 




12, 27, 43, 
59, 69, 70, 
89 
Study population not 
representative of a 
larger African 
population, excluding 
21, 64 and 78 that were 
based on elderly 
population groups 
Moderate 
8, 54, 56, 
60, 71 




Study population not 
fairly representative of 
a larger African 
population 
Low 
*see Table 3.2 for details of Study ID 
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Hypertension prevalence distribution in individual studies 
Across all study settings, an elderly South African site recorded the highest 
prevalence of hypertension in 2008 (77.3%, mean age 65 years) (Peltzer and 
Phaswana-Mafuya, 2013). Other settings reporting higher prevalence rates of 
hypertension were also in older adult population surveys in Tanzania in 2010 
(69.9%, mean age 76 years), Tunisia in 2003 (69.3%, mean age 69 years), and 
Senegal in 2009 (65.4%, mean age 69.5 years) respectively (Dewhurst et al., 2013b, 
Laouani Kechrid et al., 2004, Macia et al., 2012). The lowest prevalence rates of 
hypertension were recorded in Sudan (7.5%, mean age 35 years) and Ethiopia (9.9%, 
mean age 36.1 years) in 1989 and 2008 respectively (Ahmed, 1990, Giday and 
Tadesse, 2011) (See Table 3.2 for overall study characteristics). 
Overall pooled prevalence of hypertension in Africa 
The overall pooled crude prevalence of hypertension for Africa was: 
i. 20.5% (95%CI: 14.4-26.6, I2=99.3, p=0.000), males 23.0%, females 20.2% in 
1990;  
ii. 31.0% (95%CI: 26.8-35.3, I2=98.9, p=0.000), males 26.9, females 28.4 in 
2000; and  
iii. 31.9 (95%CI: 28.6-35.3, I2=99.5, p=0.000), males 29.7%, females 31.4% in 
2010.  
Further analysis by study settings did not reveal a large difference in hypertension 
prevalence between urban and rural dwellers. In 2000 and 2010, urban and rural 
dwellers had a prevalence of 26.1% versus 26.3%, and 29.6% versus 29.0%, 
respectively. However, in 1990, urban dwellers recorded a prevalence of 17.2% 
(males 21.1%, females 15.1%), compared to 11.1% (males 9.4%, females 8.3%) 
recorded among rural dwellers (see Table 3.4 for details). 
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Pooled prevalence of hypertension in African sub-regions 
The pooled crude prevalence in Northern Africa was higher than in sub-Saharan 
Africa (SSA), with hypertension prevalence of 33.3% in Northern Africa and 27.8% 
in sub-Saharan Africa. In other parts of SSA, Southern Africa recorded the highest 
prevalence, with a prevalence of 34.6% (males 35.4%, females 34.2%). Western 
Africa had a prevalence of 27.3% (males 29.6, females 28.2), Central Africa 
recorded 21.1% (males 21.5%, females 19.3%), and Eastern Africa had 26.8% 
(males 25.0, females 26.1) (see Table 3.5 for details).  
Awareness rate of hypertension in Africa 
Generally, across studies, participants with hypertension were considered aware of 
their condition if they responded "yes" to the question "Have you ever been told by a 
doctor or certified health care professional that you had hypertension?" 
Across selected studies, there is evidence suggesting the awareness of hypertension 
among people living with the disease has been increasing since 1990; however, the 
overall awareness rate still remains relatively low in many parts of Africa. From the 
analysis, pooled awareness rate (expressed as a percentage of the cases of 
hypertension) of 16.9% was estimated in 1990, 29.2% in 2000 and 33.7% in 2010 
(see Table 3.4). However, from the regional awareness rate of hypertension, Eastern 
Africa had the highest pooled awareness rate at 40.9%, followed by Northern Africa 
with an awareness rate of 36.2%, Southern Africa 26.4%, Central Africa 25.1%, and 
Western Africa 21.7% (see Table 3.5). 
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Figure 3.3. Forest plot showing overall pooled hypertension prevalence in Africa in 1990 
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Figure 3.4. Forest plot showing overall pooled hypertension prevalence in Africa in 2000 
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Figure 3.5. Forest plot showing overall pooled hypertension prevalence in Africa in 2010 
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Table 3.4. Overall pooled hypertension prevalence in Africa 
se: standard error 








Mean Blood Pressure Prevalence of hypertension Awareness 









Male (se) Female 
(se) 




169429 46.4 125.6 (0.9) 78.9 (0.5) 27.8 (1.4) 27.8 (1.6) 27.8 (1.7) 30.6 (3.1) 
Central 24206 43.7 119.2 (1.8) 75.4 (0.9) 21.1 (2.7) 21.5 (3.1) 19.3 (2.9) 25.1 (4.2) 
East 53312 46.0 127.5 (2.2) 79.3 (0.8) 26.8 (2.9) 25.0 (2.8) 26.1 (3.4) 40.9 (6.9) 
South 34753 47.5 123.5 (2.3) 79.4 (0.9) 34.6 (4.2) 35.4 (5.1) 34.2 (4.6) 26.4 (7.0) 
West 57417 46.9 128.2 (0.9) 79.8 (0.8) 27.3 (1.5) 29.6 (1.8) 28.2 (1.9) 21.7 (2.7) 
se: standard error 
 















Male (se) Female 
(se) 
1990 Mixed 21416 44.1 123.8 (2.2) 77.5 (1.1)  20.5 (2.9) 23.0 (3.3) 20.2 (3.5) 16.9 (3.9) 
Urban  6925 39.4 17.2 (3.5) 21.1 (4.0) 15.1 (3.5) 
Rural 5796 48.8 11.1 (2.1) 9.4 (3.0) 8.3 (4.4) 
2000 Mixed 38294 51.2 126.9 (1.8) 77.2 (0.9) 31.0 (2.1) 26.9 (2.1) 28.4 (2.5) 29.2 (4.5) 
Urban  20898 45.7 26.1 (1.9) 26.8 (1.5) 23.9 (1.9) 
Rural 11377 55.2 26.3 (2.3) 24.5 (3.2) 25.7 (3.1) 
2010 Mixed 126754 47.1 126.9 (1.1) 79.4 (0.5) 31.9 (1.6) 29.7 (1.9) 31.4 (2.1) 33.7 (3.9) 
Urban  44114 47.4 29.6 (2.1) 28.2 (2.3) 28.4 (2.5) 
Rural 46669 48.6 29.0 (2.3) 26.9 (2.7) 30.1 (2.9) 
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Modelled estimates of hypertension prevalence and cases in Africa 
The epidemiological modelling indicated the overall cases and prevalence of 
hypertension in Africa has been increasing since 1990 (See Appendix 2 for summary 
of data used in modelling). In adults aged ≥20 years, 54.6 million cases of 
hypertension were estimated in 1990 with an age-adjusted prevalence of 19.1% 
(13.9, 25.5), 92.3 million cases in 2000 with an age-adjusted prevalence of 24.3% 
(23.3, 31.6), and 130.2 million cases in 2010 with an age-adjusted prevalence of 
25.9% (23.5, 34.0). The general sex distribution revealed the prevalence of 
hypertension were higher among men than women. Among men, about 29.8 million 
cases of hypertension were estimated in 1990 (21.2%, 95%CI: 16.5-29.6), 46.8 
million cases in 2000 (25.1%, 95%CI: 22.9-31.0), 64.8 million cases in 2010 (26.1%, 
95%CI: 23.6-33.6). However, among women, about 24.8 million cases of 
hypertension were estimated in 1990 (17.1%, 95%CI: 13.4-27.0), 45.5 million cases 
in 2000 (23.6%, 95%CI: 21.5-33.3), 65.4 million cases in 2010 (25.7%, 95%CI: 
21.7-35.4) (see Tables 3.6-3.8, and Figures 3.6-3.8) 
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Table 3.6. Estimated hypertension prevalence rates and cases in Africa in both sexes (estimates derived from epidemiological 
model and the UN population demographics)  
Age (years) 1990 2000  2010 
Prevalence (%) = 8.7962e0.0161x Hypertension cases (000) Prevalence (%)  = 11.822e0.0177x 
 
Hypertension cases (000) Prevalence (%)  = 9.796e0.0235x Hypertension cases (000) 
20-24  12.5 6961.279 17.5 13134.411 16.4 15969.503 
25-29  13.6 6319.733 19.1 11761.160 18.5 15499.070 
30-34  14.7 5722.049 20.8 10540.253 20.8 14395.931 
35-39  15.9 5125.030 22.8 9662.284 23.4 12993.072 
40-44  17.3 5293.178 24.9 8844.815 26.3 11868.440 
45-49  18.7 4770.732 27.2 7956.942 29.6 11178.983 
50-54  20.3 4416.345 29.7 7076.878 33.2 10531.041 
55-59  22.0 4015.862 32.4 6135.655 37.4 9602.545 
60-64  23.9 3546.226 35.4 5372.853 42.1 8458.233 
65-69  25.9 2935.649 38.7 4436.133 47.3 6989.765 
70-74 28.0 2333.696 42.3 3326.293 53.2 5546.874 
75-80  30.4 1713.440 46.2 2078.889 59.8 3809.200 
80+ 35.7 1462.513 55.1 1997.851 75.7 3327.737 
Total 20+ (95% CI) 19.1 (13.9-25.5) 54615.730 24.3 (23.3-31.6) 92324.390 25.9 (23.5-34.0) 130170.401 
x=mid-point of UN population 5-year age group 
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Table 3.7. Estimated hypertension prevalence rates and cases in Africa among men (estimates derived from epidemiological 
model and the UN population demographics)    
Age 1990 2000 2010 
Prevalence (%) = 10.505e0.0175x Hypertension cases (000) Prevalence (%)  = 17.771e0.0088x Hypertension cases (000) Prevalence (%)  = 10.334e0.0223x Hypertension cases (000) 
20-24  15.4 4287.483 21.6 8141.867 16.9 8241.670 
25-29  16.9 3901.526 22.5 6946.029 18.9 7934.829 
30-34  18.4 3542.458 23.6 5932.465 21.1 7345.081 
35-39  20.1 3187.968 24.6 5185.153 23.6 6596.039 
40-44 21.9 2865.689 25.7 4513.438 26.4 5943.763 
45-49 23.9 2535.072 26.8 3859.029 29.5 5490.843 
50-54 26.1 2303.794 28.1 3261.431 32.9 5063.796 
55-59  28.5 2061.997 29.3 2667.812 36.8 4529.248 
60-64 31.1 1755.050 30.7 2197.312 41.2 3918.656 
65-69  33.9 1365.244 32.0 1718.733 46.0 3154.577 
70-74  37.0 978.408 33.5 1201.287 51.5 2424.530 
75-80  40.4 589.023 34.9 695.730 57.5 2238.964 
80+  48.2 411.868 38.2 464.571 71.9 1917.733 
Total 20+ (95% CI) 21.2 (16.5 -29.6) 29785.580 25.1 (22.9-31.0) 46784.860 26.1 (23.6-33.6) 64799.730 
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Table 3.8. Estimated hypertension prevalence rates and cases in Africa among women (estimates derived from epidemiological 
model and the UN population demographics) 
Age (years)  1990 2000 2010 
Prevalence (%)  = 7.631e0.0195x Hypertension cases (000) Prevalence (%)  = 14.879e0.0115x 
 
Hypertension cases (000) Prevalence (%)  = 7.6974e0.0279x Hypertension cases (000) 
20-24 11.7 3253.603 19.2 7188.909 14.2 6879.980 
25-29  12.9 3018.326 20.3 6265.350 16.3 6839.885 
30-34  14.2 2791.264 21.5 5463.243 18.8 6477.360 
35-39  15.7 2548.505 22.8 4870.534 21.6 5970.342 
40-44  17.3 2320.801 24.1 4347.172 24.8 5617.575 
45-49  19.1 2108.716 25.5 3814.806 28.7 5480.796 
50-54  21.1 1978.743 27.1 3309.921 32.8 5355.558 
55-59 23.2 1800.967 28.7 2818.021 37.8 5053.976 
60-64 25.6 1593.129 30.4 2429.126 43.4 4600.255 
65-69 28.2 1289.237 32.2 1960.988 49.9 3955.928 
70-74 31.1 976.8551 34.1 1457.391 57.4 3280.345 
75-80 34.3 630.250 36.1 906.116 65.9 2970.846 
80+  41.6 519.756 40.5 707.961 87.2 2887.797 
Total 20+ (95% CI) 17.1 (13.4-27.0) 24830.150 23.6 (21.5-33.3) 45539.541 25.7 (21.7-35.4) 65370.642 
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Figure 3.6. Epidemiological model showing relationship between age and 
crude prevalence of hypertension in both sexes in Africa, with size of bubble 
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Figure 3.7. Epidemiological model showing relationship between age 
and crude prevalence of hypertension among men in Africa, with size 
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 Figure 3.8. Epidemiological model showing relationship between age 
and crude prevalence of hypertension among women in Africa, with 
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3.2.2 Stroke 
Systematic review 
The literature search returned 1227 publications from Medline (286), EMBASE 
(731) and Global Health (210). A further 5 studies were included from other sources 
(Google Scholar and reference lists of relevant publications). 927 studies remained 
after removing duplicates. On screening titles for relevance (stroke studies conducted 
primarily on African populations), 839 studies were excluded, giving a total of 88 
full texts that were assessed. After applying the quality criteria, 69 studies were 
further excluded (32 articles did not provide numerical estimates on incidence and/or 
prevalence of stroke, and 37 articles did not clarify study designs and survey 
methodologies). A total of 19 studies were finally retained for the review; all the 19 
for qualitative synthesis and 18 for quantitative analysis (Figure 3.9). 
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Figure 3.9. Flow diagram of search results for stroke studies 
in Africa 
69 full-text articles 
excluded 
32 articles did not 
report incidence and/or 
prevalence of stroke   
37 articles did not 
specify study designs 
and / or clarify case 
definitions of stroke 
19 studies included in 
qualitative synthesis  
18 studies included in 
quantitative analysis and 
modelling  
927 records after duplicates removed  
927 records screened  839 records excluded  
88 full-text articles 
assessed for eligibility  
1227 records identified through 
database searching (Medline 286, 
EMBASE 731 & Global Health 210) 
5 additional records identified 
through other sources  
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Study characteristics 
The retained 19 studies were conducted across the main regions of Africa (east, 
north, west and south), but with Northern Africa having the highest output (7 
studies). 10 African countries were represented; Egypt and Nigeria ranked highest 
with 4 studies each, Libya, South Africa and Tanzania had two studies each, while 
Benin, Ethiopia, Mozambique, Tunisia and Zimbabwe had one study each (Table 3.9 
and Figure 3.10).  About 57.9% of retained studies (11 studies) were conducted in 
predominantly urban settings and completed within one year period, respectively. 
Most studies (18 studies) had a sample size >3000; the total sample size from all 
retained studies was over 6.3 million, with a mean and median sample size of 
332,277 and 60,820 respectively. 14 studies were population-based, of which 8 were 
community-based door-to-door surveys and 2 studies each were based on 
demographic health surveys, population/ community-based stroke registries and 
cross-sectional population-based surveys. There were 5 hospital-based studies with 
only one from a hospital-based stroke registry. Studies comply with the WHO case 
ascertainment or a modified definition, while some studies employed cranial 
computed tomography (CT) or magnetic resonance imaging (MRI) to confirm 
diagnosis (Tables 3.9 and 3.10). Most studies were conducted on the entire study 
population with an overall mean age of 55.9 years. Across retained studies, age 
determination of subjects were determined from documented age-verification 
records, and in the absence of such, historical landmarks were employed.  
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Figure 3.10. Map of Africa with asterisks showing countries of the retained 
stroke studies 
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Table 3.9. Characteristic distribution of retained stroke studies in Africa 
Characteristics Country Study sites 
East (3 studies) Ethiopia 1 
Tanzania 2 
North (7 studies) Egypt 4 
Libya 2 
Tunisia 1 
South (4 studies) Mozambique 1 
South Africa 2 
Zimbabwe 1 
West (5 studies) Benin 1 
Nigeria 4 
Duration of study  
<1 year 11 
1-3 years 5 
>3 years 3 








Study methods  
Hospital-based 5 
Population-based 14 
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Table 3.10. Overall characteristics of retained stroke studies 
African 
region 













1986-88 A door-to-door survey WHO definition 
2) Tanzania, 
Hai District, Rural 








Point prevalence of stroke 
estimated from a cross-
sectional two-phased 
community 
epidemiological survey.  
 
WHO International 
Statistical Classification of 
Diseases and Related 




Hai district & Dares 
Salaam, Mixed Rural 




2003-06 Stroke Incidence 
measured in two well 
defined demographic 
surveillance sites (DSS) 
over a 3-year period. 
Patients who 
had first-ever or recurrent 
strokes were included. 
Patients were excluded in 
suspected cases of 
infection or a space-
occupying lesion 
WHO definition 
North 4) Egypt, Al 
Kharga district, Mixed 
(Farghaly et al., 2013) 
Farghaly et 





A door-to-door screening 
including every door was 
carried 
out using a standardized 
questionnaire 
WHO definition 
5) Egypt, Al 
Quseir. Urban (El 
Tallawy et al., 2013) 
El Tallawy 





A door-to-door survey of 




Assuit, Urban (Khedr et 
al., 2013) 







using a three phase door-
to-door survey 
WHO definition 
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7) Egypt, 
Sohag, Mixed Urban 
and Rural (Kandil et al., 
2006) 
Kandil et al. 
2006 
January 




random sampling using a 
door-to-door survey 
WHO definition. 
Diagnosis confirmed by 




Benghazi, Urban (El 
Zunni et al., 1995) 
El Zunni et 





Survey conducted on 
patients referred from the 
walk-in polyclinics to the 
four university hospitals 
and to a rehabilitation 
center for 
the handicapped.  
Cranial CT scan was 
performed on all cases 
within the first 
week of onset of stroke 
9) Libya, 
Benghazi, Urban (Ashok 
et al., 1986) 








conducted on referred 
patients with neurological 
problems  
Cranial CT was performed 
on cases within the first 
week of onset of stroke. 
Survey based on the US 
National Survey of Stroke 
guidelines 
10) Tunisia, 
Kelibia, Mixed Urban 
and Rural (Attia 
Romdhane et al., 1993) 
Attia 
Romdhane 
et al. 1993 
1985 Population-based survey WHO definition and 
neurologic tool 
South 11) Mozambique, 
Maputo, Urban 
(Damasceno et al., 2010) 
Damasceno 






using the STEPS Stroke 
questionnaire. Both first-
ever and recurrent stroke 
events were registered 
WHO definition: “a focal 
(or at times global) 
neurological impairment 
of sudden onset, and 
lasting more than 24 hours 
(or leading to death), and 
of presumed vascular 
origin.”  
12) South Africa, 
Agincourt Health and 
Population Unit, 
Limpopo province, 














WHO definition: “rapidly 
developing signs of focal 
(or global) disturbance of 
cerebral function, leading 
to death or lasting longer 
than 24 hours, with no 
apparent cause other than 
vascular”. Person’s first-
ever-in-a-lifetime event 
was recorded  
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13) South Africa, 
Atteridgeville 
and Mamelodi suburban 








based survey. Included all 
strokes (first-ever and 
recurrent) 









A hospital-based stroke 
registry survey. Only 
first-ever strokes were 
included 
Stroke was defined 
according to the WHO 
definition. None had CT 
West 15) Benin, 
Cotonou, Urban (Cossi 
et al., 2012) 







door study was performed 
Diagnosis of stroke was 




(Osuntokun et al., 1979) 
Osuntokun 
et al. 1979 





(Osuntokun et al., 1987) 
Osuntokun 
et al. 1987 














based stroke registry 
enrolling hospitalized and 
non-hospitalized 
first-ever in a lifetime 
stroke cases presenting at 
all health facilities 
Stroke was defined using 
the WHO clinical criteria 
‘sudden onset of focal 
neurological deficit lasting 
longer than 24 h or leading 
to death with no other 
cause other than a 
vascular event’ 
19) Nigeria, 









to-door survey using 
modified WHO 
questionnaire 
Stroke defined as “a focal 
(or at times global) 
neurological impairment 
of sudden onset, and 
lasting more than 24 hours 
(or leading to death), and 
of presumed vascular 
origin.”  
CT: computed tomography, ICD: International Classification of Disease, WHO: World Health Organization  
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Details of quality criteria and grading of retained stroke studies in Africa 
Of the retained 19 studies, only one study was graded as low quality (Table 3.11). 
Despite a generally well-explained study design, this study was not included in the 
meta-analysis due to the relatively small sample size as other studies were mainly 
based on the general population with mean age ranging between 50 and 60 years 
Table 3.11. Quality assessment of retained stroke studies in Africa 

























explained in 1 
Not well-
presented in 10 
and 17 
Study population not 
representative of a 
larger African 
population in 1, and 17 
Moderate 




Study population not 
fairly representative of 
a larger African 
population. Study was 
basically based on an 
elderly population >70 
years 
Low 
*see Table 3.10 for details of Study ID 
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Pooled estimates of reported crude stroke incidence rates in Africa 
Across studies reporting crude incidences of stroke, there were 6 
population/community-based and 5 hospital-based studies. Population-based 
incidence rates were generally higher ranging from 25.2/100,000 person years (py) 
and 26.0/100,000 py in Lagos and Ibadan Nigeria in 2007 and 1979 respectively 
(Danesi et al., 2013, Osuntokun et al., 1979), to 250/100,000 py in Al-Kharga Egypt 
in 2007 (Farghaly et al., 2013). The hospital-based studies reported lower incidence 
rates ranging from 30/100,000 py in Harare Zimbabwe in 1991 (Matenga, 1997), to 
148.7/100,000 py in Maputo Mozambique in 2006 (Damasceno et al., 2010) (Table 
3.12). The pooled incidence from random effect meta-analysis of crude population-
based incidence rates was 112.94/100,000 py (95% CI= 90.7-135.17, I
2
= 97.5%, p = 
0.000) (Figure 3.11). The hospital-based meta-analysis was lower with a pooled 
estimate of 77.39/100,000 py (95% CI= 51.31-103.48, I
2
= 99.1%, p = 0.000) (Figure 
3.12). 
Pooled estimates of reported crude stroke prevalence rates in Africa 
There were 11 studies (all population/community-based) reporting crude prevalences 
of stroke survivors with prevalence rates ranging from 15/100,000 population in 
Ethiopia in 1988 (Tekle-Haimanot et al., 1990), to 963/100,000 population in 2010 
(Khedr et al., 2013) (Table 3.13). Random effect meta-analysis yielded a pooled 
prevalence rate of 387.93/100,000 population (95% CI= 284.16- 491.70, I
2
= 98.8%, 
p = 0.000) (Figure 3.13). As noted in the quality grading, a Tanzanian study reported 
a prevalence of 2300/100,000 among people aged 70 years above in Hai district in 
2010 (Dewhurst et al., 2013a), this was not included in the meta-analysis due to the 
relatively small sample size as other studies were mostly based on the general 
population with mean age ranging between 50 and 60 years (Table 3.13) 
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Figure 3.11. Forest plot showing overall pooled incidence of stroke (per 100,000 person years) from population-based studies in 
Africa. 
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Figure 3.12. Forest plot showing overall pooled incidence of stroke (per 100,000 person years) from hospital-based studies in 
Africa 
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Table 3.12. Summary of data from studies reporting crude incidence of stroke in Africa 


















Danesi et al. 2013 2007 All 189 750000 25.2 118 417000 28.3 71 333000 21.3 
El Tallawy et al. 2013 2012 20+ 36 19848 181 21 9916 212 15 9932 150 
Walker et al. 2010a 2006 All 453 159814 94.5 532 71916 106.7 10 87898 76.7 
Walker et al. 2010b 2006 All 183 56517 107.9 266 25433 115.2 122 31084 99.7 
Osuntokun et al. 1979  1975 All 318 1223077 26 229 538462 25 89 684615 13 
Kandil et al. 2006a 1993 All 39 25000 180 21 21000 100 18 21176 85 
Kandil et al. 2006b 1993 All 11 8464 150 7 7778 90 4 7547 53 
Kandil et al. 2006c 1993 All 20 11228 210 9 9278 97 11 9244 119 
Farghaly et al. 2013 2007 All 156 62583 250 86 32165 270 70 30418 230 
HOSPITAL-BASED 
Ashok et al. 1986 1984 15+ 329 518745 63 184 267590 69 145 251155 58 
Damasceno et al.  2010  2006 15+ 651 437794 148.7 342 197007 173.6 309 240787 128.3 
El Zunni et al. 1995 1993 15+ 921 1918750 48 379 1196154 52 322 722596 42 
Matenga. 1997 1991 All 273 889250 30.7 142 478114 29.7 131 411136 32 
Rosman 1986 1985 20+ 116 114931 101 65 60343 108 51 54588 93 
Walker et al. 2010a: Hai district (rural setting), Walker et al. 2010b: Dares Salaam district (urban setting) 
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Figure 3.13. Forest plot showing overall pooled prevalence of stroke survivors (per 100,000 population) from population-based 
studies in Africa. 
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Table 3.13. Summary of data from studies reporting crude prevalence of stroke survivors in Africa (all population/community-
based) 





















Connor et al, 
2004 
2002 15+  103 42378 243 37 20042 185 66 22336 296 
Cossi et al. 2012 2009 15+  70 15155 460 38 6293 610 32 8862 360 
Danesi et al. 
2007 
 2006 All 15 13127 114 11 7295 151 4 5832 69 
Dewhurst et al. 
2013* 
2010 70+   51 2232 2300 29 976 2971 22 1256 1752 
El Tallawy et al. 
2013 
2012 All 130 19848 655 85 9916 860 48 9932 480 
Farghaly et al. 
2013a 
2009 All 351 62583 560 196 32165 610 155 30418 510 
Farghaly et al. 
2013b 
2009 All 257 44600 580 142 22908 620 115 21692 530 
Farghaly et al. 
2013c 
2009 All 94 17983 520 54 9257 580 40 8726  458 
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Kandil et al. 
2006a 
1993 All 127 25000 508 65 12500 520 62 12500 490 
Kandil et al. 
2006b 
1993 All 35 8464 410 20 4348 460 15 4116 470 
Kandil et al. 
2006c 
1993 All 61 11228 540 29 5686 510 32 5542 570 
Khedr et al. 2013 
 
2010 All 57 5920 963 36 3066 1174 21 2854 736 
Attia Romdhane 
et al. 1993 
 
1985 All 15 34874 42 - - - - - - 
Osuntokun et al. 
1987 
1982 All 11 18954 58 - - - - - - 
Tekle-Haimanot 
et al. 1990 
1988 20-
85 
9 60820 15 - - - - - - 
*not included in meta-analysis, a: mixed setting, b: urban setting, c: rural setting 
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Modelled estimates of new stroke cases and incidence rates in Africa 
Based on the epidemiological model and UN population demographics, new stroke 
cases and incident rates were estimated for the year 2010.  
There were over 496 thousand new cases of stroke in Africa in 2010 among people 
aged 15 years or more equivalent to 81.3 (13.2-94.9) /100,000 py, with over 312 
thousand and over 183 thousand new cases of stroke equivalent to 103.4 (20.7-109.2) 
/100,000 py and 59.6 (6.9-84.3) /100,000 py among men and women, respectively 
(Table 3.14 and Figure 3.14). Based on the same incidence rates, comparable 
figures for the year 2000 would amount to 378 thousand new stroke cases, also 
suggesting an increase of 24% between 2000 and 2010 that is attributable to growth 
and ageing of the African population alone.  
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Table 3.14. Estimated new stroke cases and incidence rates in Africa in 2010 




Both sexes Men Women 
y = 1.8928e0.0793x Stroke cases 
(000) 
y = 0.9001e0.0889x Stroke cases 
000) 
y = 0.7204e0.0887x Stroke cases 
000) 
15-19 7.3 7.880 4.1 6.135 3.3 1.745 
20-24 10.8 10.531 6.4 8.078 5.1 2.453 
25-29 16.1 13.510 9.9 10.205 7.9 3.305 
30-34 23.9 16.587 15.5 12.345 12.3 4.242 
35-39 35.6 19.788 24.1 14.489 19.2 5.299 
40-44 52.9 23.893 37.7 17.135 29.9 6.758 
45-49 78.7 29.747 58.7 20.811 46.6 8.935 
50-54 116.9 37.040 91.6 25.207 72.6 11.833 
55-69 173.8 44.644 142.9 29.510 113.1 15.134 
60-64 258.4 51.978 222.9 33.309 176.2 18.669 
65-69 384.2 56.777 347.6 35.019 274.5 21.758 
70-74 571.2 59.556 542.2 35.104 427.7 24.452 
75-79 849.1 54.060 845.6 30.343 666.4 23.718 










y= incidence (per 100,000 person years), x=midpoint of age group 
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Figure 3.14. Epidemiological model showing relationship between age and crude 
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Modelled estimates of stroke survivors and prevalence rates in Africa 
Based on the UN population demographics and bubble graphs derived from all data 
points, the estimated number of stroke survivors in Africa in 2010 was 1.94 million 
among people aged 15 years or more with a prevalence of 317.3 (314.0-
748.2)/100000 population. There were over 1 million and 922 thousand stroke 
survivors equivalent to 335.2 (302.3-702.7) /100,000 and 299.7 (268.4-579.0) 
/100,000 among men and women, respectively (Table 3.15 and Figure 3.15). Based 
on the same prevalence rates, comparable figures for the year 2000 would amount to 
1.48 million stroke survivors respectively, also suggesting an increase of 23.7% 
between 2000 and 2010 that is attributable to growth and ageing of the African 
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Table 3.15. Estimated number of stroke survivors and prevalence in Africa in 
2010 (estimates derived from epidemiological model and the UN population 
demographics) 
Age (years) Both sexes Men Women 
 y = 10.045e0.0738x Stroke cases 
(000) 
y = 3.5546e0.093x Stroke cases 
(000) 
y = 1.9743e0.0979x Stroke 
cases (000) 
15-19 35.2 15.007 17.3 9.415 10.4 5.592 
20-24 50.9 21.660 27.5 13.429 17.0 8.231 
25-29 73.7 30.024 43.8 18.411 27.8 11.613 
30-34 106.6 39.876 69.7 24.270 45.3 15.606 
35-39 154.1 51.449 111.0 31.037 73.9 20.412 
40-44 222.9 67.082 176.7 39.827 120.5 27.255 
45-49 322.4 90.128 281.2 52.394 196.7 37.735 
50-54 466.2 121.133 447.8 68.808 320.9 52.325 
55-69 674.3 157.713 712.8 87.642 523.5 70.071 
60-64 975.2 198.489 1134.8 107.981 854.1 90.508 
65-69 1410.5 234.235 1806.7 123.786 1393.4 110.448 
70-74 2039.9 265.449 2876.2 135.482 2273.4 129.967 
75-79 2950.3 260.579 4579.0 128.582 3709.0 131.997 
80+ 5324.5 384.268 9635.8 173.456 8117.0 210.812 








y=prevalence (per 100,000 population), x=midpoint of age group 
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Figure 3.15. Epidemiological model showing relationship between age and crude 
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3.3 DIABETES 
Systematic review 
The main literature search returned 3701 publications, with Medline yielding 1183 
records, EMBASE 2084, and Global Health 434. Three additional publications were 
added from other sources including Google Scholar and reference lists of relevant 
publications identified from an initial scoping review. 2537 records remained after 
duplicates were excluded. After screening titles for relevance, 2252 studies were 
excluded, leaving 285 full text articles that were assessed for eligibility. On applying 
our inclusion, exclusion and quality criteria, 237 studies were excluded (101 articles 
did not provide prevalence of diabetes or relevant estimates from which prevalence 
can be calculated , and 136 articles did not specify study designs and / or clarify 
diabetes case definitions). A total of 48 studies were retained for qualitative and 
quantitative synthesis (Figure 3.16) 
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Figure 3.16. Flow diagram of search results of diabetes studies in 
Africa 
237 full-text articles 
excluded 
101 articles did not 
provide prevalence of 
diabetes or relevant 
estimates from which 
prevalence can be 
calculated  
136 articles did not 
specify study designs 
and / or clarify diabetes 
case definitions 
48 studies included in 
qualitative synthesis  
 
48 studies included in 
quantitative analysis 
and modelling   
2537 records after duplicates removed  
2537 titles screened for 
relevance 
 
2252 records excluded  
285 full-text articles 
assessed for eligibility  
 
3701 records identified through 
database searching (Medline 1183, 
EMBASE 2084 & Global Health 434) 
3 additional records identified 
through other sources  
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Study characteristics 
The 48 studies were from 28 African countries, spreading across all parts of Africa. 
Central Africa had 4 studies, Eastern Africa 9, Northern Africa 7, Southern Africa 
12, and Western Africa 16. South Africa and Nigeria had the highest number of 
studies (7 each), Ghana and Tanzania follows with 3 studies each, while Cameroon, 
Sudan, Algeria, and Morocco all had 2 studies each (Table 3.16 and Figure 3.17). 
 
Figure 3.17. Map of Africa with asterisks showing countries of the retained 
diabetes studies 
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Table 3.16. Characteristic distribution of retained diabetes studies in Africa 
Characteristics Country Study sites 
Central (4 studies) Cameroon  2 
Chad  1 
DR Congo  1 
East (9 studies) Ethiopia  1 
Kenya  1 
Seychelles  1 
Sudan  2 
Tanzania  3 
Uganda  1 
North (7 studies) Algeria  2 
Egypt  1 
Libya  1 
Morocco 2 
Tunisia  1 
South (12 studies) Angola  1 
Mauritius  1 
Mozambique 1 
South Africa 7 
Zambia  1 
Zimbabwe  1 
West (16 studies) Benin   1 
Ghana  3 
Guinea  1 
Mali  1 
Mauritania  1 
Nigeria  7 
Senegal  1 
Sierra Leone  1 
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Duration of study  
<1 year 21 
Years 16 
>3 years 11 








Diagnostic criteria (studies overlap)  
WHO 1985 16 
WHO 1998 23 
WHO-IDF 2006 5 
ADA 1997 9 
ADA 2003 4 
*overlaps with rural and urban sites 
44% of studies were completed within one year, with over 50% carried out in mixed 
study settings. The total sample size from all retained studies was 102,517. Across 
individual studies, about 50% of the sample sizes were below 1000, with a mean and 
median of 1017 and 432 respectively. Many studies applied the WHO 1985 and 
WHO 1998 diabetes criteria, both representing over 68% of all criteria used. Studies 
were mostly conducted on people age greater than or equal to 20 years, with an 
estimated overall mean age of 51.1 years (see Table 3.17). For the age determination 
of subjects across selected studies, birth certificates were mostly employed, and in 
the absence of valid age-verification documents, subjects’ age were determined from 
historical landmarks. 
Estimating the Prevalence of NCDs in Africa 
 
Results  170  
Table 3.17. Overall characteristics of retained diabetes studies in Africa 
African 
region 












Central 1) Cameroon, urban 
(Echouffo-Tcheugui et al., 
2012) 
2011  WHO 1998 43.7 14.4 41.2 
2) Cameroon, mixed 
(Mbanya et al., 1997) 
1995 WHO 1985  49 1.02 80 
3) Chad, rural 
(Dionadji et al., 2010) 
2004 WHO 1998 59.4 7.4 - 
4) DRCongo, mixed 
(On'Kin et al., 2008) 
2005 WHO 1998; ADA 
1997/2003  
46 10 93.5 
5) Ghana (Amoah et 
al., 2002) 
2000-01 WHO 1998 & 
ADA 1997 
44.3 6.4 69.7 
East 6) Ethiopia, mixed 
(Nshisso et al., 2012) 
2009-10 WHO-IDF 2006 57 6.5 - 
7) Kenya, mixed 
(Christensen et al., 2009) 
2005 WHO 1998  38.6 4.2 36 
8) Seychelles, mixed 
(Faeh et al.) 
2004-05 ADA 2003  45.2 11.5 46 
9) Sudan, mixed 
(Elbagir et al., 1996) 
1994-95 WHO 1985  59.5 3.4 63.6 
10) Sudan, mixed 
(Elbagir et al., 1998) 
1997 WHO 1985 59.4 8.3 61.4 
11) Tanzania, mixed 
(Aspray et al., 2000) 
1996-97 WHO 1998 54.5 2.8 80 
12) Tanzania, rural 
(McLarty et al., 1989) 
1987 WHO 1985  37 0.87 - 
13) Tanzania, urban 
(Njelekela et al., 2009) 
2007 WHO 1998  59.7 6.0 - 
14) Uganda, rural 
(Maher et al., 2011b) 
2008-09 WHO 1998 & 
ADA 1997 
48 0.4 56.5 
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North 15) Algeria, mixed 
(Malek et al., 2001) 
2000 WHO 1998 & 
ADA 1997 
47 8.2 50.0 
16) Algeria, mixed 
(Zaoui et al., 2007) 
2006 WHO 1998 59.5 14.2 - 
17) Egypt, mixed 
(Herman et al., 1995) 
1992-94 WHO 1985 59.7 9.3 43.0 
18) Libya, urban 
(Kadiki and Roaeid, 2001) 
2000 WHO 1998 & 
ADA 1997 
57 14.1 64.7 
19) Morocco, mixed 
(Essiarab et al., 2011) 
2010 WHO 1998  54.48 38.6 - 
20) Morocco, mixed 
(Tazi et al., 2003) 
2000 ADA 1997 57 8.4 - 
21) Tunisia, mixed 
(Gharbi et al., 2002) 
2001 WHO 1998 42.5 7.2 33.3 
South 22) Angola, rural 
(Evaristo-Neto et al., 2010) 
2008-09 WHO 1998  54.3 2.8 - 
23) Mauritius, mixed  








mixed  (Silva-Matos et al., 
2011)  
2005 WHO 1998 44.5 3.5 87.0 
25) South Africa, 
mixed (Charlton et al., 1997) 
1993 WHO 1985 73.8 28.7 25 
26) South Africa, 
urban (Erasmus et al., 2001) 
1992 WHO 1985 57 18.1 18.1 
27) South Africa, 
urban (Erasmus et al., 2012) 
2000 WHO 1998 67 2.45 - 
28) South Africa, rural 
(Groenewald et al., 2007a) 
2007 WHO-IDF 2006  46 7.6 32.8 
29) South Africa, 
mixed (Levitt et al., 1993)  
1990 WHO 1985  56 6.3 - 
30) South Africa, rural 
(Motala et al., 2008)  
2003 WHO 1985/1998; 
ADA 1997/2003  
46.9 4.6 - 
31) South Africa, 
urban (Peer et al., 2012) 
2008-09 WHO 1998 43.3 14.9 36.9 
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32) Zambia, urban 
(Nsakashalo-Senkwe et al., 
2011) 
2007  ADA 1997 & 
2003 
59.7 5.1 27.0 
33) Zimbabwe, mixed 
(Hakim et al., 2005) 
2005 WHO 1998 59.7 3.7 34 
West 34) Benin, urban 
(Djrolo et al., 2012) 
2011 WHO-IDF 2006  59.4 4.6 75.3 
35) Ghana, rural 
(Cook-Huynh et al., 2012) 
1998 WHO 1998  52 7.7 - 
36) Ghana, mixed 
(Vuvor et al.) 
2009-10 WHO 1998 55 3.85 - 
37) Guinea, mixed 
(Balde et al., 2007) 
2003 WHO 1998 & 
ADA 1997 
49.4 6.1 70.2 
38) Mali, rural (Fisch 
et al., 1987) 
1987 WHO 1985 59.4 0.92 - 
39) Mauritania, mixed 
(Ducorps et al., 1996) 
1984-85  WHO 1985  34.6 1.88 71.4 
40) Nigeria, mixed 
(Ezenwaka et al., 1997) 
1994-95 WHO 1985 60.8 1.6 - 
41) Nigeria, mixed 
(Nyenwe et al., 2003) 
2000 WHO 1998  48.9 6.8 - 
42) Nigeria, urban  2010-11 WHO-IDF 2006 49 4.7 - 
43) Nigeria, rural 
(Ojewale and Adejumo, 2012) 
2002-05 WHO-IDF 2006 42.1 2.5 26.5 
44) Nigeria, urban 
(Olatunbosun et al., 1998) 
1995 WHO 1985 40.8 0.8 71.4 
45) Nigeria, urban 
(Dahiru et al., 2008) 
2007 WHO 1998 59.4 2.0 - 
46) Nigeria, rural 
(Owoaje et al., 1997) 
1995 WHO 1985 62 2.8 - 
47) Senegal, urban 
(Duboz et al., 2012) 
2009  ADA 1997  57 17.8 90.7 
48) Sierra Leone, 
mixed (Ceesay et al., 1997) 
1996 WHO 1985 35.7 1.2 - 
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Details of quality criteria and grading of retained diabetes studies in Africa 
Of the retained 48 studies, only two studies were adjudged low quality (Table 3.18). 
These studies were included in the analysis and modelling due to the well explained 
general study design, as exclusion does not present any significant change in the 
pooled prevalence of diabetes. 
Table 3.18. Quality assessment of retained diabetes studies in Africa 


















a larger African 
population  
High 




explained in 39 
Not well-





of a larger 
African 
population in the 
three studies 
Moderate 







a larger African 
population 
Low 
*see Table 3.17 for details of Study ID 
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Distribution of diabetes prevalence rates in Africa across retained studies 
In a separate analysis of individual studies, isolated high prevalence rates of diabetes 
were observed in Northern Africa. Across all studies, Morocco recorded highest 
prevalence (38.4%) in 2011 (Essiarab et al., 2011). Relatively higher diabetes 
prevalence were also observed in Algeria (14.2%) in 2006 (Zaoui et al., 2007), and 
Libya (14.1%) in 2000 (Kadiki and Roaeid, 2001). In sub-Saharan Africa, South 
Africa reported high diabetes prevalence; 28.7% in 1993 (Charlton et al., 1997), 
18.1% in 1992 (Erasmus et al., 2001), and 14.9 in 2009 (Peer et al., 2012). Other 
high diabetes prevalence estimates (≥14%) were reported in Senegal in 2009 (Duboz 
et al., 2012), and Cameroon in 2011 (Echouffo-Tcheugui et al., 2012). DR Congo 
had the highest prevalence of IGT, reporting 26.6% in 2005, while corresponding 
prevalence of diabetes same year was 10.0% (On'Kin et al., 2008). Seychelles 
recorded highest prevalence (24.2%) of IFG in 2005, and corresponding prevalence 
of diabetes same year was 11.5% (Faeh et al.) (See Table 3.17 for details). 
Prevalence distribution of newly diagnosed diabetes mellitus across retained studies 
There is high prevalence of undiagnosed diabetes across many studies. The mean and 
median prevalence rates of newly diagnosed diabetic cases from all studies 
(expressed as percentage of overall diabetic cases) were 54.9% and 54.75%, ranging 
from 18.1% in South Africa (Erasmus et al., 2001), to an alarming 93.5% in DR 
Congo (On'Kin et al., 2008) (see Table 3.17) 
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Pooled prevalence estimates of diabetes in Africa 
Across all studies, crude prevalence rates of diabetes were consistently lower in 
females. A random effect meta-analysis of crude prevalence estimates from all 
studies yielded a diabetes prevalence of 7.5% (95% CI: 6.3-8.7, I-square=97.9%, p = 
0.000), with a male prevalence of 7.8% (3.7-11.8) and female prevalence of 6.9% 
(2.9-10.9) (Figure 3.18). IGT was more common than IFG, and also noted that IGT 
was higher in women than men and IFG vice versa. The estimated IGT prevalence 
was 10.2% (95% CI: 7.0, 13.5, I-square=99.7%, p = 0.000) with a male prevalence of 
9.9% (7.5-12.3), and a female prevalence of 11.3% (8.4-14.2) (Figure 3.19). The 
estimated IFG prevalence was 5.7% (95% CI: 4.3-7.1, I-square=97.9%, p = 0.000), 
with a male prevalence of 7.1% (3.9-10.4), and a female prevalence of 4.3% (2.4-
6.2) (Figure 3.20). Table 3.19 shows a detailed representation of the pooled 
prevalence estimates  





















Diabetes 49.3 50 7.5 (6.3-8.7) 40 7.8 (3.7-11.8) 40 6.9 (2.9-10.9) 
IGT 49.4 21 10.2 (7.0-13.5) 18 9.9 (7.5-12.3) 18 11.3 (8.4-14.2) 
IFG 50.5 18 5.7 (4.3-7.1) 13 7.1 (3.9-10.4) 13 4.3 (2.4-6.2) 
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Figure 3.18. Forest plot showing overall pooled prevalence of diabetes in Africa 
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Figure 3.19. Forest plot showing overall pooled prevalence of IGT in Africa 
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Figure 3.20. Forest plot showing overall pooled prevalence of IFG in Africa 
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Rural versus Urban diabetes prevalence in Africa 
The rural-urban variation was marked for diabetes; we estimated a prevalence of 
2.6% (1.3, 4.0) for rural settings, while urban settings had a prevalence of 10.1% 
(8.0, 12.2) (Table 3.20).  
For IGT, the rural and urban prevalence were 2.9% (0.9, 4.8) and 7.0% (3.1, 11.0) 
respectively, while IFG prevalence were 4.6% (3.1, 6.0) and 4.5% (1.4, 7.5) among 
rural and urban dwellers respectively (Table 3.20). 





















Diabetes Rural 48.8 21 2.6 (1.3-4.0) 13 1.3 (0.8-1.8) 13 1.4 (0.5-2.3) 
Urban 51.5 26 10.1 (8.0-12.2) 16 8.2 (5.4-10.9) 16 7.6 (4.5-10.6) 
IGT Rural 47.6 7 2.9 (0.9-4.8) 5 5.3 (3.5-7.0) 5 5.4 (3.0-7.8) 
Urban 49.3 7 7.0 (3.1-11.0) 4 6.0 (1.0-10.9) 4 6.4 (1.7-11.1) 
IFG Rural 47.4 7 4.6 (3.1-6.0) 6 6.1 (4.4-7.8) 6 2.9 (2.2-3.7) 
Urban 53.7 9 4.5 (1.4-7.5) 5 2.8 (1.8-3.7) 5 2.4 (0.8-3.9) 
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Modelled prevalence estimates 
The modelling showed the prevalence of diabetes has been increasing since 1990, 
with a higher prevalence and diabetes cases observed among women in 2000 and 
2010 (See Appendix 4 for summary of all data used in modelling). In 1990, the 
prevalence of diabetes was 2.4% (0.9, 4.1), with an estimated 8.5 million diabetes 
cases among people aged ≥15 years in both sexes, 4.4 million cases among men and 
4.1 million cases among women. By 2000, the prevalence slightly increased to 2.9% 
(1.7, 3.9) accounting for 13.5 million diabetes cases among people aged ≥15 years in 
both sexes, 6.4 million cases among men and 7.1 million cases among women. This 
was however doubled in 2010, with prevalence increasing to 4.0% (2.7, 6.4) and 
number of people living with diabetes reaching 24.5 million in both sexes, 11.3 
million cases among men and 13.2 million cases among women (see Tables 3.21, 
3.22, and 3.23, and Figures 3.21, 3.22, and 3.23). 
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Table 3.21. Prevalence and cases of diabetes in Africa in both sexes (estimates derived from epidemiological model and UN 
population demographics) 
Age (years) 1990 2000 2010 
y = 0.289e
0.0505x
 Diabetes cases (000) y = 0.5542e
0.0361x
 Diabetes cases (000) y = 0.798e
0.04x
 Diabetes cases (000) 
15-19 0.7 450 1.3 1138 1.6 1705 
20-24 0.9 482 1.5 1143 1.9 1855 
25-29  1.1 520 1.8 1119 2.3 1961 
30-34  1.5 559 2.2 1107 2.9 1961 
35-39  1.9 594 2.6 1118 3.5 1934 
40-44  2.4 629 3.2 1122 4.3 1941 
45-49  3.1 669 3.8 1105 5.2 1994 
50-54 4.0 723 4.5 1070 6.4 2019 
55-59  5.1 777 5.4 1025 7.8 1980 
60-64  6.6 790 6.5 977 9.5 1868 
65-69  8.5 749 7.8 896 11.6 1677 
70-74  11.0 641 9.3 728 14.2 1442 
75-79 14.1 469 11.2 510 17.4 1097 
80+  21.7 453 15.2 446 24.4 1100 
Total 15+  (95% CI) 2.4 (0.9, 4.1)   8 503 2.9 (1.7, 3.9)   13 505 4.0 (2.7, 6.4)   24 534 
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Table 3.22. Prevalence and cases of diabetes in Africa among men (estimates derived from epidemiological model and UN 
population demographics) 
Age (years) 1990 2000 2010 
y = 0.2307e
0.0496x
 Diabetes cases (000) y = 0.2148e
0.0524x
 Diabetes cases (000) y = 0.6403e
0.0424x
 Diabetes cases (000) 
15-19  0.8 256 0.8 343 1.4 764 
20-24 1.0 271 1.0 373 1.7 837 
25-29  1.3 290 1.3 395 2.1 891 
30-34  1.6 309 1.7 422 2.6 903 
35-39  2.1 327 2.2 462 3.3 902 
40-44  2.7 343 2.8 498 4.0 911 
45-49  3.4 360 3.7 530 5.0 938 
50-54  4.4 383 4.8 552 6.2 947 
55-59 5.6 405 6.2 564 7.6 933 
60-64 7.2 404 8.1 574 9.4 875 
65-69  9.2 372 10.5 562 11.7 776 
70-74  11.8 310 13.7 483 14.4 658 
75-79  15.1 218 17.8 356 17.8 490 
80+  23.0 190 27.8 334 25.5 464 
Total 15+ 2.6 (0.4,3.8)   4 438 2.8 (1.4, 3.3)   6 449 3.8 (2.2, 5.9)   11 289 
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Table 3.23. Prevalence and cases of diabetes in Africa among women (estimates derived from epidemiological model and UN 
population demographics) 
Age (years) 1990 2000 2010 
y = 0.1174e
0.06x
 Diabetes cases (000) y = 0.6243e
0.0329x
 Diabetes cases (000) y = 0.4617e
0.0504x
 Diabetes cases (000) 
15-19  0.4 143 1.4 635 1.3 649 
20-24  0.6 161 1.7 629 1.7 732 
25-29  0.8 183 2.0 607 2.2 780 
30-34  1.1 207 2.4 594 2.8 814 
35-39  1.4 231 2.8 592 3.6 866 
40-44  2.0 257 3.3 590 4.7 941 
45-49  2.6 291 3.9 573 6.0 1025 
50-54  3.6 332 4.6 552 7.7 1081 
55-59  4.8 378 5.4 528 9.9 1120 
60-64  6.5 409 6.3 503 12.8 1138 
65-69  8.8 415 7.5 460 16.4 1133 
70-74  11.8 380 8.8 376 21.2 1047 
75-79  16.0 300 10.4 266 27.2 829 
80+ 26.6 336 13.7 238 41.8 1126 
Total 15+ 2.3 (0.2, 3.2)   4 073 3.0 (1.8, 4.2)   7 144 4.9 (2.9, 7.1)   13 230 
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Figure 3.21. Epidemiological model showing relationship between age and crude 
prevalence of diabetes in both sexes in Africa, with size of bubble corresponding 
to sample size (A: 1990, B: 2000, C: 2010) 
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Figure 3.22. Epidemiological model showing relationship between age and crude 
prevalence of diabetes among men in Africa, with size of bubble corresponding 
to sample size (A: 1990, B: 2000, C: 2010) 
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Figure 3.23. Epidemiological model showing relationship between age and crude 
prevalence of diabetes among women in Africa, with size of bubble 
corresponding to sample size (A: 1990, B: 2000, C: 2010)  
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3.4 CANCER 
Systematic review 
The literature search returned 9762 publications identified from three databases: 
Medline (3437), EMBASE (4604) and Global Health (1721). A further 4 studies 
were selected from other sources, which included studies identified from Google 
Scholar, the “GLOBOCAN studies”, “Cancer Incidence in Five Continents (CI5) 
series”, and “Cancer in Africa: Epidemiology and Prevention”). No further studies 
were identified from additional searches of websites of International Association of 
Cancer Registries (IACR), International Agency for Research on Cancer (IARC), 
and WHO African region, as I could not access these data. However, some of the 
global cancer publications noted above reported data from these registries, which 
were extracted.  After all studies have been collated and duplicates removed, 6108 
records remained. On screening titles for relevance (cancer studies conducted 
primarily on African populations), 5806 studies were excluded, giving a total of 302 
full texts that were assessed. After applying the quality criteria, 263 studies were 
excluded (134 articles did not provide numerical estimates on incidence of cancers, 
and 129 articles did not clarify cancer registration process). A total of 39 studies (33 
included for meta-analysis) were finally retained for the review (Figure 3.24). The 
relative lower number of studies retained (compared to the initial output of 9762) 
was because most of the studies screened were not reporting incidence rates of 
cancer or comparable figures from which incidence rates may be estimated.
Estimating the Prevalence of NCDs in Africa 
 






















 Figure 3.24. Flow diagram of search results for cancer studies in 
Africa 
263 full-text articles 
excluded 
134 articles did not 
report incidence of all 
or specific childhood 
cancers   
129 articles did not 
specify study designs 
and / or clarify cancer 
registration process 
39 studies included in 
qualitative synthesis  
 
33 studies included in 
quantitative analysis 
9762 records identified through 
database searching (Medline 3437, 
EMBASE 4604 & Global Health 1721) 
4 additional records identified 
through other sources  
 
6108 records after duplicates removed  
6108 records screened  
 
5806 records excluded  
302 full-text articles 
assessed for eligibility  
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Study characteristics 
The retained 39 studies were conducted across 20 African countries, with Egypt and 
South Africa highest having highest number of studies (5 studies each) (Table 3.24). 
Across African regions, Central Africa had 3 studies conducted in 3 African 
countries, Eastern Africa had 5 studies conducted in 3 African countries, Northern 
Africa had 11 studies conducted in 4 African countries, Southern Africa had 11 
studies conducted in 5 African countries, and Western Africa had 9 studies 
conducted in 5 African countries (Figure 3.25).  
 
Figure 3.25. Map of Africa with asterisks showing countries of the retained 
cancer studies 
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Of the 39 studies, data from 36 studies were collated from 27 population-based 
cancer registries, which do not necessarily cover an entire country population; some 
only cover provinces, districts or major cities within the country. 3 studies were 
based on cross sectional population-based surveys (Kocheleff et al., 1984, Menendez 
et al., 2010, Fonn et al., 2002). Periods of studies range from 1 year to 13 years with 
a median study period of 5 years. The cancer registries in the retained studies cover a 
population of about 33 million. Cancer registrations comply with the ICD-O or the 
ICD coding system, with studies mainly using the ICD-O (1-3) and the ICD (9 & 
10). Few studies reported methods of confirming cancer diagnosis, mainly through 
morphological/ histological verification, death certificates only (DCO) or active/ 
passive case finding (Table 3.25). 
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Table 3.24. Characteristic distribution of retained cancer studies in Africa 
Characteristics Country Study sites 
Central Africa (3 study sites) Burundi 1 
Cameroon 1 
Rwanda 1 
Eastern Africa (5 study sites) Kenya 2 
Mauritius 1 
Uganda 2 




Southern Africa (11 study sites) Malawi 1 
Mozambique 1 
South Africa 5 
Swaziland  1 
Zimbabwe 3 





Duration of study  
<1 year 7 
1-3 years 11 
>3 years 21 
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Table 3.25. Overall characteristics of retained studies reporting incidence rates 
of cancer in Africa 
African 
Region 




Diagnostic criteria Confirmation of 
diagnosis (%)  
Central 
 
1) Burundi** (Kocheleff et 
al., 1984)  
1983-1984 851,412 Alpha Feto Protein (AFP) 
Screening to detect liver 
cancer 
AFP  
2) Cameroon, Yaounde 
(Enow Orock et al., 2012) 
2004–2006/ 
2010–2011 
1,299,369 CanReg5 Morphologically 
verified (89%) 
3) Rwanda, Butare (Newton 
et al., 1996) 
1991-1994  - ICD-9  - 
East 
 
4) Kenya, Eldoret* (Tenge et 
al., 2009) 
1999-2006 1,400,000 Cases are identified from 
the disease index 
(completed by records staff 
in ICD-10) and details of 
cases abstracted from case 
records 
 - 
5) Kenya, Greater Meru 
(McFarlane et al., 2001) 
1991-1993 1,144,594 ICD-10  - 
6) Mauritius (Manraj et al., 
1998) 
1989-1993 1,035,806  ICD  - 
7) Uganda, Kampala (Parkin 
et al., 2010) 
1991-2006 1,674,384 ICD-O-2  - 
8) Uganda, Kyadondo 
(Wabinga et al., 2000) 
1990-1997  - ICD-O (Percy et al. 1990); 







9) Algeria, Setif* (Hamdi 
Cherif et al., 2010) 
1986-2005  - CanReg4  - 
10) Egypt, Menofeia (Soliman 
et al., 1999) 
1992-1996 2,755,000 SEER and combined 
diagnoses by  tumor site 




11) Egypt, Nile Delta 
(Fedewa et al., 2009) 




12) Egypt (Dey et al., 2010) 1999-2002 - ICD-9 - 
13) Egypt, Alexandria (Abdel-
Fattah and Yassine, 2007) 
1995-2004  - ICD-10  - 
Estimating the Prevalence of NCDs in Africa 
 
Results  193  
14) Egypt, Gharbiah (Lehman 
et al., 2008) 
1999–2003 4,200,000 ICD-10, ICD-O-3 - 
15) Libya, Benghazi (El 
Mistiri et al., 2007) 
2003 660,147 ICD-O-3 Microscopically 
/ histologically 
verified (79%) 
16) Libya, Eastern region (El 
Mistiri et al., 2010) 
2004  - ICD-10  - 
17) Tunisia, Souse (Missaoui 
et al., 2010) 
1993-2006 2,760,900 ICD-10 Morphologically 
verified (97%) 
18) Tunisia, North-eastern 
(Ben Abdallah et al., 2009) 
1994-1998 - Can Reg, ICD 9 - 
19) Tunisia, Central (Missaoui 
et al., 2012) 




20) Malawi, Blantyre (Banda 
et al., 2001) 
1994-98 782,000 Histopathology, ultrasound 
and endoscopy, 
radiography, biochemical 
tests (AFP). ICD-O-2 used 
for data entry, but 
converted to ICD-10 for 







21) Mozambique, Manhica** 
(Menendez et al., 2010) 
2000 36,000 ICD-9 - 
22) South Africa (Somdyala et 
al., 2003) 
1991-1995  - Data were computerised 
and coded at the time of 
entry, following the tumour 




of case finding 
23) South Africa, Eastern 
Cape (Somdyala et al., 2010) 
1998-2002 1,292,959 ICD-10, ICD-O Histologically 
verified (42.8%) 
24) South Africa, 
Johannesburgh (Mqoqi, 2004) 
1998-1999  - ICD-9, ICD-O Active case 
finding 
25) South Africa** (Fonn et 
al., 2002) 
2002  20603 ICD- 9  - 
26) South Africa, Northern 
Cape (Wentink et al., 2010) 
2002-2009 1,102,200 ICD-10, ICD-O - 
27) Swaziland (Parkin et al., 
2008) 
1996-1999  -  ICD-O  - 
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28) Zimbabwe, Harare 
(Chokunonga et al., 2000) 
1993-1995  - ICD-O, converted to ICD-
10 for analysis 
Histologically 
verified (62.2%) 
29) Zimbabwe, Harare 
(Bassett et al., 1995) 
1990-1992  - ICD-O, ICD-10 Death 
certificates only 
(DCO) 
30) Zimbabwe (Marimo and 
Hille, 2006) 
1988-1997 1,412,548 ICD 10  - 
West 
 
31) Cote d'Ivoire, Abidjan 
(Echimane et al., 2000) 
 1995-1997  1,000,342 Histopathology- coded 
using ICD-0 2nd edition, 





32) Gambia (Bah et al., 2001) 1988-1997 1,340,000 ICD-0, ICD 10 Histologically 
verified (21.0%) 
33) Gambia (Sighoko et al., 
2011) 
1998–2006   ICD-10, ICD-O-3  - 
34) Gambia* (Sighoko et al., 
2010) 
1998-2006 1,310,681 CanReg 4  - 
35) Guinea, Conakry 
(Koulibaly et al., 1997) 
1992-1995 6,700,000 Tumor site and histology 
have been coded using the 
ICD-0 first edition (WHO, 
1976). These codes were 
converted to ICD-9  for 
tabulation (although cases 
of Kaposi’s sarcoma were 
given a separate category.  
Morphologically 
verified (26.7%) 
36) Mali, Bamako (Bayo et 
al., 1990) 
1987-1988 646,163  ICD-O (WHO 1976), ICD-




37) Nigeria, Ibadan & Abuja 
(Jedy-Agba et al., 2012) 2009-2010  3,955,504 ICD-O-3  - 
38) Nigeria, Maiduguri 
(Nggada et al., 2008) 2001-2005  -  ICD  - 
39) Nigeria (Ogunbiyi and 
Shittu, 1999)  1980-1996  -  ICD-9 - 
*not included in meta-analysis, **population-based study, ICD: International Classification of Diseases, ICD-O: 
International Classification of Diseases for Oncology 
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Details of quality criteria and grading of retained cancer studies in Africa 
Of the retained 39 studies, three studies were graded low quality (Table 3.26). These 
studies, despite having well explained study designs were not included in the meta-
analysis due to incomplete data needed for the estimation of incidence of cancer. 
There were 3 other studies graded as medium quality, however, they were not 
included in that meta-analysis as these were mainly cross-sectional population based 
studies. All data included in the meta-analysis were from population/hospital-based 
cancer registries. 
Table 3.26. Quality assessment of retained cancer studies in Africa 



















a larger African 
population  
High 









of a larger 
African 
population in the 
three studies 
Moderate 







a larger African 
population 
Low 
*see Table 3.25 for details of Study ID 
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Pooled incidence rates of major cancers in Africa 
From the 36 studies conducted on population-based cancer registries, 3 studies had 
incomplete data and or without denominators from which incidence rates can be 
estimated. 33 studies were therefore included in the meta-analysis, with specific 
cancer incidence rates estimated for men and women. Among women, the top five 
cancers were cancers of the cervix, breast, Kaposi, liver and colorectal, while cancers 
of the prostate, Kaposi, oesophagus, liver and lungs were the top five cancers among 
men (Table 3.27). The reported crude incidence rates were not modelled as many 
studies did not report age-specific incidence rates of cancers. All reported crude 
incidence rates are estimated per 100,000person years. 
Table 3.27. Overall summary of pooled incidence rates of major cancers in 
Africa 
Cancer site Incidence per 100,000 person years Heterogeneities (I2 
(%)) 
Estimated new cancer 
cases in 2010† 
Male (95% CI) Female  (95% CI) Male Female Male Female 
Kaposi 14.3 (11.9, 16.7) 6.5 (5.2, 7.8) 99.0 95.3 73668 29743 
Liver 12.6 (10.0, 15.3) 5.7 (4.4, 7.0) 97.8 95.3 64910 26042 
Colorectal 5.3 (4.0, 6.5) 3.9 (2.9, 4.9) 93.6 94.0 27098 17864 
Stomach 5.6 (4.2, 7.1) 3.8 (2.9, 4.6) 95.0 95.6 29004 17362 
Lung 9.3 (6.8, 11.7) 1.9 (1.3, 2.5) 97.5 90.8 47704 8772 
NHL 3.9 (2.8, 5.0) 2.9 (2.1, 3.7) 94.1 93.6 20143 13113 
Oesophagus 13.4 (10.2, 16.6) - 98.8 - 69032 - 
Bladder 5.8 (4.2, 7.4) - 95.9 - 29879 - 
Cervix 28.2 (22.1, 34.4) 99.0 128841 
Breast 17.7 (13.0, 22.4) 99.1 80868 
Ovary 3.6 (2.7, 4.4) 89.0 16448 
Prostate 14.5 (10.9, 18.0) 98.8 74698 
†estimated cases based on pooled incidence rates, NHL: non-Hodgkins lymphoma 
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3.4.1 Cervical cancer 
There were 24 data points from 16 African countries with a pooled incidence rate of 
28.230/100,000 (22.056, 34.404), I
2
 = 99.0%, p = 0.000 (Figure 3.26). In 2010, this 
would amount to about 129,000 new cases of cervical cancer in Africa.  
 
NOTE: Weights are from random effects analysis
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Figure 3.26. Forest plot showing pooled incidence rate of cervical cancer in 
Africa
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3.4.2 Breast cancer 
There were 26 data points from 17 African countries with a pooled incidence rate of 
17.727/100,000 (13.016, 22.438), I
2
= 99.1%, p = 0.000 (Figure 3.27). In 2010, this 
would amount to about 81 thousand new cases of breast cancer among women in 
Africa.  
NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.1%, p = 0.000)
El Mistiri et al.
Bayo et al.
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Figure 3.27. Forest plot showing pooled incidence rate of female breast cancer 
in Africa 
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3.4.3 Ovarian cancer 
There were 21 data points from 15 African countries with a pooled incidence rate of 
3.6/100,000 (2.7, 4.4), I
2
 = 89.0%, p = 0.000 (Figure 3.28). In 2010, this would 
amount to over 16 thousand new cases of ovarian cancer in Africa 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 89.0%, p = 0.000)
Mqoqi et al
El Mistiri et al.
Sighoko et al.



























































































Figure 3.28. Forest plot showing pooled incidence rate of ovarian cancer in 
Africa 
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3.4.4 Prostate cancer 
There were 24 data points from 16 African countries with a pooled incidence rate of 
14.461/100,000 (10.949-17.972), I
2
 = 98.8%, p = 0.000 (Figure 3.29). In 2010, this 
would amount to about 75 thousand new cases of prostate cancer in Africa. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 98.8%, p = 0.000)
Echimane et al.
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Figure 3.29. Forest plot showing pooled incidence rate of prostate cancer in 
Africa 
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3.4.5 Cancer of the Oesophagus  
Men 
There were 23 data points from 14 African countries with a pooled incidence rate of 
13.39/100,000 (10.214, 16.575), I
2
 = 98.8%, p = 0.000 (Figure 3.30). In 2010, this 
would amount to over 69 thousand new cases of cancer of the oesophagus among 
men in Africa,  
NOTE: Weights are from random effects analysis















































































Figure 3.30. Forest plot showing pooled incidence rate of cancer of the 
oesophagus among men in Africa 
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3.4.6 Bladder Cancer  
Men 
There were 18 data points from 13 African countries with a pooled incidence rate of 
5.821/100,000 (4.202, 7.440), I
2
 = 95.9%, p = 0.000 (Figure 3.31). In 2010, this 
would amount to about 30 thousand new cases of bladder cancer among men in 
Africa. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 95.9%, p = 0.000)
Bah et al.
Basset et al.
















































































Figure 3.31. Forest plot showing pooled incidence rate of bladder cancer among 
men in Africa 
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3.4.7 Kaposi sarcoma  
i. Men 
There were 16 data points from 10 African countries with a pooled incidence rate of 
14.297/100,000 (11.888-16.706), I
2
= 99.0%, p = 0.000 (Figure 3.32). In 2010, this 
would amount to about 74 thousand new cases of Kaposi sarcoma among men in 
Africa. 
NOTE: Weights are from random effects analysis











































































Figure 3.32. Forest plot showing pooled incidence rate of Kaposi sarcoma 
among men in Africa 
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ii. Women 
There were 16 data points from 10 African countries with a pooled incidence rate of 
6.514/100,000 (5.180, 7.849), I
2
 = 95.3%, p = 0.000 (Figure 3.33). In 2010, this 
would amount to about 30 thousand new cases of Kaposi sarcoma among women in 
Africa. 
NOTE: Weights are from random effects analysis











































































Figure 3.33. Forest plot showing pooled incidence rate of Kaposi sarcoma 
among women in Africa 
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3.4.8 Liver cancer  
i. Men 
There were 23 data points from 14 African countries with a pooled incidence rate of 
12.631/100,000 (9.995, 15.268), I
2
= 97.8%, p = 0.000 (Figure 3.34). In 2010, this 
would amount to about 65 thousand new cases of liver cancer among men in Africa. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 97.8%, p = 0.000)






































































































Figure 3.34. Forest plot showing pooled incidence rate of liver cancer among 
men in Africa 
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ii. Women 
There were 21 data points from 14 African countries with a pooled incidence rate of 
5.703/100,000 (4.380, 7.026), I
2
= 95.3%, p = 0.000 (Figure 3.35). In 2010, this 
would amount to over 26 thousand new cases of liver cancer among women in 
Africa. 
NOTE: Weights are from random effects analysis
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Figure 3.35. Forest plot showing pooled incidence rate of liver cancer among 
women in Africa 
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3.4.9 Lung cancer  
i. Men 
There were 20 data points from 14 African countries with a pooled incidence rate of 
9.258/100,000 (6.784, 11.732), I
2
 = 97.5%, p = 0.000 (Figure 3.36). In 2010, this 
would amount to about 48 thousand new cases of lungs cancer among men in Africa. 
NOTE: Weights are from random effects analysis



























































































Figure 3.36. Forest plot showing pooled incidence rate of lungs cancer among 
men in Africa
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ii. Women 
There were 20 data points from 14 African countries with a pooled incidence rate of 
1.916/100,000 (1.347, 2.484). I
2
 = 90.8%, p = 0.000 (Figure 3.37). In 2010, this 
would amount to about nine thousand new cases of lung cancer among women in 
Africa. 
NOTE: Weights are from random effects analysis



























































































Figure 3.37. Forest plot showing pooled incidence rate of lungs cancer among 
women in Africa
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3.4.10 Colorectal cancer  
i. Men 
There were 23 data points from 16 African countries with a pooled incidence rate of 
5.257/100,000 (4.037, 6.476), I
2
= 93.6%, p = 0.000 (Figure 3.38). In 2010, this 
would amount to over 27 thousand new cases of colorectal cancer among men in 
Africa. 
NOTE: Weights are from random effects analysis







































































































Figure 3.38. Forest plot showing pooled incidence rate of colorectal cancer 
among men in Africa
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ii. Women 
There were 23 data points from 16 African countries with a pooled incidence rate of 
3.908/100,000 (2.939, 4.878), I
2
 = 94.0%, p = 0.000 (Figure 3.39). In 2010, this 
would amount to about 18 thousand new cases of colorectal cancer among women in 
Africa. 
NOTE: Weights are from random effects analysis







































































































Figure 3.39. Forest plot showing pooled incidence rate of colorectal cancer 
among women in Africa 
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3.4.11 Stomach cancer  
i. Men 
There were 21 data points from 15 African countries with a pooled incidence rate of 
5.627/100,000 (4.195, 7.060), I
2
 = 95.0%, p = 0.000 (Figure 3.40). In 2010, this 
would amount to over 29 thousand new cases of stomach cancer among men in 
Africa. 
NOTE: Weights are from random effects analysis































































































Figure 3.40. Forest plot showing pooled incidence rate of stomach cancer among 
men in Africa
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ii. Women 
There were 21 data points from 14 African countries with a pooled incidence rate of 
3.8/100,000 (2.939, 4.661), I
2
= 95.6%, p = 0.000 (Figure 3.41). In 2010, this would 
amount to over 17 thousand new cases of stomach cancer among women in Africa. 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 95.6%, p = 0.000)






























































































Figure 3.41. Forest plot showing pooled incidence rate of stomach cancer among 
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3.4.12 Non-Hodgkin lymphoma  
i. Men 
There were 21 data points from 14 African countries with a pooled incidence rate of 
3.906/100,000 (2.845, 4.967), I
2
 = 94.1%, p = 0.000 (Figure 3.42). In 2010, this 
would amount to over 20 thousand new cases of non-Hodgkin’s lymphoma among 
men in Africa. 
NOTE: Weights are from random effects analysis
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Figure 3.42. Forest plot showing pooled incidence rate of non-Hodgkin’s 
lymphoma among men in Africa
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ii. Women 
There were 21 data points from 14 African countries with a pooled incidence rate of 
2.865/100,000 (2.068, 3.663), I
2
= 93.6%, p = 0.000 (Figure 3.43). In 2010, this 
would amount to over 13 thousand new cases of non-Hodgkin’s lymphoma among 
women in Africa. 
NOTE: Weights are from random effects analysis































































































Figure 3.43. Forest plot showing pooled incidence rate of non-Hodgkin’s 
lymphoma among women in Africa 
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3.5 CHRONIC RESPIRATORY DISEASES 
3.5.1 Chronic Obstructive Pulmonary Disease (COPD) 
Systematic review 
The main literature search returned 243 studies, with Medline (66), EMBASE (144), 
and Global Health (33). 179 records remained after excluding duplicates. Two 
additional studies were included from the search of google scholar and the reference 
lists of relevant publications. On screening titles for relevance, 109 records were 
excluded, giving a total of 71 full-text articles assessed for eligibility. After applying 
the quality criteria, 58 studies were excluded; 33 articles did not provide prevalence 
of COPD or any relevant estimates from which prevalence can be calculated, and 25 
articles did not specify study designs and / or clarify COPD case definitions. A total 
of 13 studies that met the overall selection criteria were finally retained for both 
qualitative synthesis and quantitative analysis (Figure 3.44). 
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Figure 3.44. Flow diagram of search results for COPD in Africa 
58 full-text articles 
excluded 
33 articles did not 
provide prevalence of 
COPD or relevant 
estimates from which 
prevalence can be 
calculated  
25 articles did not 
specify study designs and 
/ or clarify COPD case 
definitions 
13 studies included in 
qualitative synthesis  
 
13 studies included in 
quantitative synthesis   
243 records identified through database 
searching (Medline 66, EMBASE 144 & 
Global Health 33) 
2 additional records identified 
through other sources  
 
179 records after duplicates removed  
179 records screened  
 
108 records excluded  
71 full-text articles 
assessed for eligibility  
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Study characteristics 
The retained 13 studies were from 8 African countries, all spread across the main 
regions of Africa. South Africa and Nigeria had the highest number of studies 
retained, both with a total of 7 studies. Algeria, Ethiopia, Malawi, Morocco, Rwanda 
and Tunisia were the other countries from which retained studies were conducted, all 
with one study each (Figure 3.45).  
 
Figure 3.45. Map of Africa with asterisks showing countries of the retained 
COPD studies. 
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On the type of study, there were 5 spirometric and 10 non-spirometric (other) studies, 
both study types with 13 and 20 data points, respectively. Two studies reported both 
spirometric and non-spirometric estimates (Tables 3.28 and 3.29).  
Table 3.28. Characteristic distribution of retained COPD studies in Africa 
Characteristics Country Number of studies 
Central (1 study) Rwanda 1 
East (1 study) Ethiopia 1 
North (3 studies) Algeria 1 
Morocco 1 
Tunisia 1 
South (5 studies) Malawi 1 
South Africa 4 
West (3 studies) Nigeria 3 
Study type  
Spirometric 5 
Nonspirometric  10 
Reporting both  2 
Study setting  
Rural  2 
Urban  1 
Mixed 6 
Occupational  4 
Study duration  
<1 year  7 
1-3 years   5 
>3 years  2 
Sample size  
<1000  9 
1001-3000  2 
>3000  2 
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Table 3.29. Overall characteristics of retained COPD studies in Africa 







Kigali (Musafiri et al., 
2011b) 




FEV1/FVC < LLN. LLN= 
lower limit of normal, 
which is 5th percentile 
(1.645 SD below 
predicted); BMRC criteria: 
cough with phlegm every 
day for at least 3 months a 







Occupational 1997-1998 37±8.0 years BMRC (1965) & ATS 
(1962) criteria: productive 
cough for >3 months/year 




Algiers (Khelafi et al., 
2011) 
Mixed 2009 21-89 years GOLD criteria: 
postbronchodilator 
FEV1/FVC < 0.7 
4) Morocco, 
Rabat (Laraqui Hossini 
et al., 2002) 
Occupational  2001-2002 ≥15 years  BMRC criteria: cough with 
phlegm every day for at 
least 3 months a year for at 
least 2 successive years 
5) Tunisia, 
Tunis (Tabka et al., 
1999) 
Occupational 1998 ≥15 years BMRC criteria: productive 
cough for >3 months/year 






(Fullerton et al., 2011) 
Mixed Urban 
and Rural 





FEV1/FVC < 0.7 
7) South 
Africa, National DHS 
(Ayo-Yusuf et al., 
2008) 
Mixed 1998 ≥25 years BMRC criteria: cough with 
phlegm every day for at 
least 3 months a year for at 
least 2 successive years 
8) South 
Africa, Cape town 
(Buist et al., 2007) 
Mixed 2004-2006 ≥40 years  GOLD criteria: 
postbronchodilator  
FEV1/FVC < 0.7 
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(Ehrlich et al., 2004) 
Mixed 2004 ≥15 years BMRC criteria: cough with 
phlegm every day for at 
least 3 months a year for at 
least 2 successive years 
10) South 
Africa, Basotho 
(Girdler-Brown et al., 
2008) 
Occupational  2007-2008 Mean age 
49.4 years 
ATS/ERS criteria: 
FEV1/FVC < 0.7; BMRC 
criteria: cough with phlegm 
every day for at least 3 




Ekiti State (Desalu, 
2011) 
Rural  2009 ≥35 years 
(mean age 
55.5±10.2) 
BMRC criteria: cough with 
phlegm every day for at 
least 3 months a year for at 
least 2 successive years 
 
12) Nigeria, 
Ijero-Ekiti (Desalu et 
al., 2010) 
Rural 2009 55 ± 10 years  ECRHS & BMRC criteria: 
cough with phlegm every 
day for at least 3 months a 
year for at least 2 
successive years 
13) Nigeria, 
Benin (Gathuru et al., 
2002) 




FEV1/FVC < 0.7; BMRC 
criteria: cough with phlegm 
every day for at least 3 
months a year for at least 2 
successive years 
ATS: American Thoracic Society, BMRC: British Medical Research Council, DHS: Demographic and Health 
Survey, ECRHS: European Community Respiratory Health Survey, ERS: European Respiratory Society, FEV1: 
Forced Expiratory Volume in 1 second, FVC: Forced Vital Capacity, GOLD: Global Initiative for chronic 
Obstructive Lung Disease, LLN: lower limit of normal 
 
The mean ages of subjects from retained studies were 55.2 years and 49.2 years in 
spirometric and non-spirometric studies, respectively. For the verification of ages 
cross most studies, birth certificates were usually employed in determining the age of 
subjects, and in the absence of any valid birth certificates or age-verification 
documents, historical landmarks associated with the birth of the subject were 
employed in estimating the age.  
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Periods of study were mostly within one year (7 studies). The total sample size from 
all retained studies was 24,747. Across individual studies, the mean sample size from 
all studies was 1241 (median 416), and the study settings were mainly mixed (6 
studies) (see Tables 3.28 and 3.29). 
Details of quality criteria and grading of retained COPD studies in Africa 
Of the retained 13 studies, four studies were graded as low quality (Table 3.30). 
These studies had well explained study designs, however, study population were not 
representative of a larger population group, these studies were based on purposive 
sampling and were mainly conducted within occupational settings, and thus they 
could be potential sources of heterogeneities if a pooled COPD prevalence was 
estimated.  
Table 3.30. Quality assessment of retained COPD studies in Africa 
Study ID* Study design Study analysis Study limitations Generalizability to 
Africa 
Grading 
1, 3, 8, 9, 11-13 Well explained 
across all studies 
Well explained 
across all studies 
Well-presented 
across all studies 
Study population 























*see Table 3.29 for details of Study ID 
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Distribution of crude prevalence estimates of COPD in Africa 
The COPD prevalence reported by spirometric studies was generally higher than the 
non-spirometric (other) studies. Across the spirometric study, the highest COPD 
prevalence was reported in South Africa in 2006 (prevalence 23.8%, mean age 53.5 
years) (Buist et al., 2007), while the lowest COPD prevalence was reported in 
Algeria in 2009 (prevalence 9.2%, mean age 55 years) (Khelafi et al., 2011). Across 
non-spirometric (other) studies, the highest COPD prevalence was reported among 
cement factory workers in Morocco in 2002 (prevalence 25.2%, mean age 44.5 
years) (Laraqui Hossini et al., 2002), while the lowest COPD prevalence was 
reported in Nigeria in 1999 (prevalence 1.7%, mean age 48.8 years) (Gathuru et al., 
2002). 
From the analysis and to allow for detailed comparisons, the estimates of COPD 
prevalence rates for the two types of data were reported separately for spirometry-
based and non-spirometric (other) studies, respectively (Table 3.31; Figure 3.46). 
As noted in the methods, due to the significant heterogeneities among retained 
studies, a meta-analysis (pooled estimate) and modelling could not be conducted, a 
descriptive statistics is therefore reported (Table 3.31). The mean prevalence of 
COPD from spirometry-based studies is 15.6% (standard deviation of 7.9%), while 
the median prevalence 13.4% (IQR: 9.4%-22.1%). From the non-spirometric (other) 
studies, the estimated mean prevalence of COPD is 7.0% (standard deviation of 
7.2%), while the median prevalence is 4.0% (IQR: 2.1%-8.9%). This difference is 
statistically significant (p=0.001 for comparison of medians and p=0.003 for 
comparison of means). For other covariates, such as the year of study, mean age, the 
number of cases and sample sizes, the descriptive statistics are shown in Table 3.31.  
When the estimates from spirometric studies was applied to the appropriate age 
group as observed from selected studies (40 years or more), which accounted for 
196.4 million people in Africa in 2010, the estimated median prevalence (13.4%) 
translates into 26.3 million (18.5-43.4 million) cases of COPD. Comparable figures 
for the year 2000 based on the same prevalence rates would amount to 20.0 million 
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(14.1-33.1), suggesting an increase of 31.5% over a decade that is attributable mainly 
to ageing and growth of the African population.  
Table 3.31. Descriptive statistics for year, mean age, number of cases, sample 
size and prevalence of COPD in Africa for the spirometry-based studies and 
non-spirometric (other) studies 
Spirometry-based studies 
Statistics Year Mean age No. of 
cases 
Sample size % prevalence 
of COPD 
Data points 13 13 13 13 13 
Mean 2004.85 55.2462 55.57 389.85 15.5946 
Median 2006.00 53.5000 45.00 290.00 13.4000 
Std. Deviation 3.934 11.49461 50.329 285.518 7.91887 
Range 10 39.50 191 896 24.15 
Percentiles 25 2000.00 46.9000 20.11 160.00 9.3700 
75 2008.50 62.0000 77.84 633.00 22.0500 
Other studies 
Statistics Year Mean age No. of 
cases 
Sample size % prevalence 
of COPD 
Data points 20 20 20 20 20 
Mean 2004.65 49.1750 68.52 1797.10 7.0015 
Median 2004.00 49.1000 55.50 516.00 4.0350 
Std. Deviation 4.043 14.29497 84.273 3044.636 7.18240 
Range 11 60.00 358 13411 23.80 
Percentiles 25 2002.50 39.5000 6.81 116.75 2.1225 
75 2009.00 58.5000 80.00 2260.50 8.8500 
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Figure 3.46. Boxplots of the prevalence of COPD in Africa for spirometric and 




Figure 3.47. Boxplots of COPD prevalence in Africa by gender for spirometric 
studies 
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COPD prevalence estimates in Africa by gender 
From studies based on spirometry, the mean COPD prevalence among men was 
19.7% (standard deviation 8.4%), and the median prevalence was 17.5% (IQR: 
2.7%-32.3%). While the mean COPD prevalence among women was 13.9% 
(standard deviation 9.8%), and the median prevalence was 11.2% (IQR: 2.5%-
26.4%) (Table 3.32 and Figure 3.47). 
Table 3.32. Analysis of COPD prevalence in Africa by gender for spirometric 
studies 
Sex Statistics % prevalence of 
COPD 
male Mean 19.7360 
95% Confidence Interval for Mean Lower Bound 13.7212 
Upper Bound 25.7508 
Median 17.5000 




Interquartile Range 14.84 
female Mean 13.8650 
95% Confidence Interval for Mean Lower Bound 6.8850 
Upper Bound 20.8450 
Median 11.1550 




Interquartile Range 15.17 
Estimating the Prevalence of NCDs in Africa 
 
Results  226  
Meanwhile, from studies based on other definitions (non-spirometirc), the mean 
COPD prevalence among men was 3.2% (standard deviation 1.8%), and the median 
prevalence was 2.4% (IQR: 0.9%-9.0%). While the mean COPD prevalence among 
women was 3.6% (standard deviation 2.0%), and the median prevalence was 3.3% 
(IQR: 1.1%-6.8%) (Table 3.33 and Figure 3.48). 
Table 3.33. Analysis of COPD prevalence in Africa by gender for non-
spirometric studies 
Sex Statistics % prevalence of 
COPD 
male Mean 3.2178 
95% Confidence Interval for Mean Lower Bound 1.8307 
Upper Bound 4.6049 
Median 2.4000 




Interquartile Range 2.57 
female Mean 3.5640 
95% Confidence Interval for Mean Lower Bound 2.1220 
Upper Bound 5.0060 
Median 3.2500 




Interquartile Range 3.45 
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Figure 3.48. Boxplots of COPD prevalence in Africa by gender for non-
spirometric studies 
Further comparisons of spirometric and non-spirometric data 
A further analysis of COPD prevalence and the estimated mean age revealed a 
significant positive correlation between the prevalence of COPD and the mean age in 
the spirometry-based set of studies (see Table 3.34 and Figure 3.49), with the 
Pearson correlation coefficient of 0.645 (p-value = 0.017). This is a plausible finding 
as observed from many epidemiological surveys, and further suggests internal 
consistency of spirometry-based estimates. 
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Table 3.34. Pearson correlation coefficient between prevalence of COPD and 
mean age (spirometric studies)  
 Mean age % prevalence of COPD 
% prevalence of COPD Pearson Correlation .645* 1 
Sig. (2-tailed) .017  
N 13 13 
*. Correlation is significant at the 0.05 level (2-tailed). r = 0.645, p = 0.017 -> significant positive correlation 
 
 
Figure 3.49. Plot of the prevalence of COPD in Africa versus the mean age from 
the spirometry-based studies. 
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There was no significant correlation between prevalence and age in non-spirometric 
(other) studies, with Pearson correlation coefficient of -0.011 (p>0.05) (see Table 
3.35 and Figure 3.50).  
Table 3.35. Pearson correlation coefficient between prevalence of COPD and 
mean age (non-spirometric studies) 
 Mean age % prevalence of 
COPD 
% prevalence of COPD Pearson Correlation -.011 1 
Sig. (2-tailed) .964  
N 20 20 
p > 0.05: no significant correlation with age 
 
Figure 3.50. Plot of prevalence of COPD versus mean age from non-spirometric 
studies 
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3.5.2 Asthma 
Systematic review 
The main search initially returned 790 studies, with Medline yielding 246, EMBASE 
370, and Global Health 174. Three additional records were identified from other 
sources (Google Scholar and reference lists of relevant publications). 522 studies 
remained after duplicates were removed. After screening the titles for relevance (i.e. 
asthma studies conducted primarily in an African population setting), 375 studies 
were excluded, giving a total of 147 full-texts articles that were assessed. On 
applying the quality criteria, 102 full-text articles excluded (54 articles did not 
provide prevalence of asthma or wheeze or related asthma symptoms or relevant 
estimates from which prevalence can be calculated , and 48 articles did not specify 
study designs and / or clarify asthma symptoms used for diagnosis). A total of 45 
studies were finally retained for the review (Figure 3.51). The relatively higher 
number of retained studies (compared to initial output of 790) was because many of 
these studies were broadly based on all or any of the respiratory symptoms of asthma 
as described by GINA, which included: wheeze at rest, wheeze on exercise, 
nocturnal wheeze, nocturnal cough, or severe wheeze. 
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Figure 3.51. Flow diagram of search results for asthma in Africa 
102 full-text articles 
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45 studies included in 
qualitative synthesis  
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Study characteristics 
The 45 retained studies were from 24 African countries spread across the main 
African regions. South Africa (11 study sites) and Nigeria (8 study sites) had the 
highest publication outputs. Ethiopia and Kenya closely followed with 6 and 5 study 
sites respectively, while Algeria, Morocco and Tunisia in North Africa had 4 study 
sites each (Figure 3.52). In all, there were a total of 64 study sites, with the ISAAC 
study I and III (Ait-Khaled et al., 2007b, Zar et al., 2007), providing about 50% of 
the data points employed in the final analysis 
 
Figure 3.52. Map of Africa with asterisks showing countries of the retained 
asthma studies
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14 studies were conducted in collaboration with the ISAAC group (31 studies did not 
have any collaboration). However, on the overall, 39 studies followed the general 
guidelines for the conduct of epidemiological surveys on asthma proposed by the ISAAC 
group, which involved both written and video questionnaires, respectively.  
Many studies were conducted within one year (23 studies). The total sample size from 
all retained studies was 187,904. Across individual studies, sample sizes were mostly 
less than 1000 (mean 3243; median 2067).  The study settings were predominantly 
mixed (urban and rural) (36 studies) (Tables 3.36 and 3.37). 
Many studies were conducted mainly on paediatric subjects, mostly defined as less than 
15 years of age, with a mean and median age of 13.7 years and 13.5 years, respectively. 
For the age determination of subjects from most studies, birth certificates were usually 
employed. 
Table 3.36. Distribution of retained asthma studies in Africa 
Characteristics Country Study sites 
Central (6 study sites) Cameroon 1 
Cape Verde 1 
Congo Brazzaville 1 
DR Congo 2 
Rwanda 1 
East (14 study sites) Ethiopia 6 
Kenya 5 
Sudan 2 
Tanzania  1 




South (13 study sites) Madagascar 1 
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Mozambique 1 
South Africa 11 
West (18 study sites) Burkina Faso 2 
Cote d’Ivoire 3 
Gabon  1 
Gambia  1 
Ghana  1 
Guinea  1 
Nigeria 8 
Togo 1 
Duration of study  
<1 year 23 
1-3 years 16 
>3 years 6 









Study type  
ISAAC guidelines 14 
Non-ISAAC guidelines 31 
Written questionnaire 39 
Video questionnaire 6 
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Table 3.37. Overall characteristics of retained asthma studies 
African region Country Study 
Period 
Study Setting  Age range/  
Mean age 
Diagnosis 
Central 1) ISAAC III study 
(selected countries in 
Africa) (Ait-Khaled 
et al., 2007b) 
2000-
2003 
Mixed 6-7 years; 
13-14 
years 
ISAAC guidelines and 
scores: based on asthma 
symptoms (wheeze at rest, 
wheeze after/during 
exercise, nocturnal wheeze, 
nocturnal cough, severe 
wheeze with speech 
limitation) using written or 
video questionnaires  
2) ISAAC I study 
(selected countries in 




Mixed 6-7 years; 
13-14 
years 
ISAAC guidelines and 
scores: based on asthma 
symptoms (wheeze at rest, 
wheeze after/during 
exercise, nocturnal wheeze, 
nocturnal cough, severe 
wheeze with speech 
limitation) using written or 
video questionnaires 
3) Cape Verde 
(Morais de Almeida 
et al., 2001) 
1993 Mixed 6-10 years GINA criteria; “Asthma 
ever was defined as the 
cumulative lifetime 
diagnosis. Active asthma 
identified in children with 
symptoms during the 
previous year, and current 
asthma was considered if a  
positive bronchial 
challenge test was found in 
children with active 
asthma" 
4) DR Congo 
(Nyembue et al., 
2012) 
2010 Mixed 29±16 
years 
GINA criteria; Asthma 
symptoms, physician's 
diagnosis, skin prick test, 
written questionnaire 
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5) Rwanda 












< LLN and a positive 
reversibility test meaning 
an increase in FEV1 of 200 
ml and 12% with respect to 
pre-bronchodilator FEV1 
after 400 mcg of 
salbutamol) 
East 6) Ethiopia 
(Dagoye et al., 2003) 
2003 Mixed 1-5 years ISAAC guidelines, 
physician's diagnosis, 
written questionnaire 
7) Ethiopia (Hailu 
et al., 2003) 
1997 Mixed 13-14 
years 













22.8 years IUATLD (1984) 
questionnaire 
10) Kenya (Esamai 
and Anabwani, 
1996) 




11) Kenya (Esamai 
et al., 2002) 




12) Kenya (Ng'ang'a 
et al., 1998) 
1996 Mixed 10.6 years 6 min free running test 
(6MFRT), drop in post 
exercise PEFR ≥15% or 
>=10% classified as EIB 
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13) Kenya 










(Berntsen et al., 
2009) 
2008 Mixed 9-10 years ISAAC guidelines and 
scores: based on asthma 
symptoms (wheeze at rest, 
wheeze after/during 
exercise, nocturnal wheeze, 
nocturnal cough, severe 
wheeze with speech 
limitation) using mainly 
video questionnaires 
North 15) North Africa- 
Algeria, Morocco & 
Tunisia (AIRMAG 
study) (Nafti et al., 
2009) 
2008 Mixed 13-14 
years; >25 
years 
GINA criteria "Have you 
had an asthma attack or 
asthma symptoms in the 
previous twelve months? 
Have you taken medication 
for asthma attacks (eg pills, 
inhaled powders, aerosols 
etc) in the previous twelve 
months? Have you taken 









et al., 2011) 
2010 Mixed 10-12 
years 
 6 min free running test 
(6MFRT), drop in post 
exercise PEFR >=15% 
classified as EIB 
18) Egypt (Georgy 
et al., 2006) 
2005 Mixed 11-15 
years 
ISAAC guidelines, written 
questionnaire 
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19) Morocco 
(Bennis et al., 1992) 
1991 Rural < 15 years Questionnaires based on: 
"Have you ever had 
whistling noises in the 
chest?", "Have you ever 
had a sensation of 
respiratory difficulty or 
suffocation with a whistling 
noise in the chest?", "Have 
you ever had asthma?"  
20) Morocco 
(Laraqui Hossini et 
al., 2002) 
2001 Occupational >20 years ISAAC guidelines, written 
questionnaire 
21) Tunisia (Khaldi 
et al., 2005) 
2004 Mixed 13-14 
years 
ISAAC guidelines, written 
questionnaire 
22) Tunisia (Sallaoui 
et al., 2007) 
2003 Mixed 20.8±2.7 
years 
EIB classified as decrease 
of at least 15% in forced 
expiratory volume in one 
second (FEV1) after 8-min 
running at 80–85% 
South 23) Madagascar 
(Wolff et al., 2012) 
2010 Urban 7-14 years  Modified ISAAC 
questionnaire; 
bronchodilator response 
(BDR) to establish 
reversible obstruction 




2005 Mixed 13-14 
years 
ISAAC guidelines, video 
questionnaire 
25) South Africa 
(Ehrlich et al., 1995) 
1994 Mixed <18 years Asthma symptoms, 
physician's diagnosis, 
written questionnaire 
26) South Africa 
(Ehrlich et al., 1998) 
1997 Mixed 5-12 years Asthma symptoms, 
physician's diagnosis, 
written questionnaire (filled 
by parents) 
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27) South Africa 
(Ehrlich et al., 2005) 
2004 Mixed >18 years ECRHS guidelines, 
physician's diagnosis, 
written questionnaire 
28) South Africa 
(Mashalane et al., 
2006) 
2005 Mixed 9-10 years Free Running Asthma 
Screening Test (FRAST); 
drop in post exercise PEFR 
≥15% classified as EIB 





Mixed 8-16 years Free Running Asthma 
Screening Test (FRAST 
drop in post exercise PEFR 
≥10% on more than 2 
occasions classified as EIB 
30) South Africa 
(Terblanche and 
Stewart, 1990) 
1990 Mixed 5-15 years 6MFRT, 10% decline in 
forced expiratory volume in 
1 second after exercise 
classified as EIB 
31) South Africa 










32) South Africa  
(Nriagu et al., 1999) 
1997-98 Urban >15 years Asthma symptoms using 
standard questionnaire 
recommended by the World 
Health Organization for 
asthma studies 
33) South Africa 
(Poyser et al., 2002) 




West 34) Burkina Faso 
(Miningou et al., 
2002) 





35) Burkina Faso 
(Miszkurka et al., 
2012) 




36) Cote d'Ivoire 
(Koffi et al., 2000) 
1998 Urban 13-14 
years 
ISAAC guidelines, written 
questionnaire 
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37) Cote d'Ivoire 
(Roudaut et al., 
1992) 












>15 years IUATLD questionnaire; 
"Asthma defined by a 
medical history revealing 
the periodic occurrence of 
wheezing and/or (morning) 
dyspnoea and/or coughing 
in combination with a 
decrease of >20% in the 
FEV1 after provocation 
with methacholine 
inhalation at a range of 
concentrations up to 16 
mg/mL, or a 15% increase 
in FEV1 from baseline 15 
min after administering 400 
mg inhaled salbutamol. 
Wheeze was defined as 
periodic whistling or 
tightness in the chest. 
'Current wheeze' referred to 
wheezing in the previous 
12 months" 
39) Ghana (Addo-
Yobo et al., 2007) 
1993; 
2003 
Mixed 9-16 years  6 min free running test 
(6MFRT), drop in post 
exercise PEFR ≥12.5% 
classified as EIB 
40) Nigeria (Falade 
et al., 2004) 
1995 Mixed 13-14 
years 
ISAAC guidelines, written 
questionnaire 
41) Nigeria (Faniran 
et al., 1999) 
1998 Urban 8-11 years ISAAC guidelines, written 
questionnaire (modified 
from Institute of 
Respiratory Medicine, 
University of Sydney) 
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42) Nigeria (Aguwa 
et al., 2007) 
2006 Occupational >20years Asthma symptoms, 
physician's diagnosis, 
written questionnaire & 
spirometry (PEFR) 
43) Nigeria (Desalu 







with FEV1 <80% of 
predicted, FEV1/FVC < 
80%, or one asthma 
symptom were subjected to 
PEF variability testing  
44) Nigeria (Erhabor 
et al., 2006) 
 
2005 Mixed 15-35 
years 
IUATLD (1984) & BMRC 
(1965) criteria 
45) Nigeria 
(Mustapha et al., 
2011) 
2004 Mixed 7-14 years Asthma symptoms, 
physician's diagnosis, 
written questionnaire 
6MFRT: 6 minute free running test, ATS: American Thoracic Society, BMRC: British Medical Research Council, 
EIB: exercise induced bronchospasm, ECRHS: European Community Respiratory Health Survey, FEV1: forced 
expiratory volume in one second, FRAST: free running asthma screening test, FVC: forced vital capacity, GINA: 
Global Initiative for Asthma, ISAAC: The International Study of Asthma and Allergies in Childhood, IUATLD: 
International Union Against Tuberculosis and Lung Diseases, LLN: lower limit of normal, PEFR: peak 
expiratory flow rate 
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Details of quality criteria and grading of retained asthma studies in Africa 
Based on the quality grading criteria, most studies retained were graded as high 
quality. Due to the variations in diagnostic criteria for asthma, many studies adhered 
to the ISAAC guidelines for epidemiological surveys of asthma, and this allowed for 
some consistencies across all studies (Table 3.38) 
Table 3.38. Quality assessment of retained asthma studies in Africa 



















a larger African 
population  
High 







a larger African 
population 
Medium 
*see Table 3.37 for details of Study ID 
 
Distribution of crude prevalence of asthma in Africa from retained studies 
Across retained studies, the prevalence rates of asthma in some parts of Africa were 
comparable with those reported from surveys in high-income settings. From studies 
based on written questionnaires, “asthma ever” (cumulative prevalence of asthma) 
was highest in South Africa (53%, 5-12 years) in 1997 (Ehrlich et al., 1998), 
followed by Egypt (26.5%, 11-15 years) in 2005 (Georgy et al., 2006), Nigeria 
(18.4%, 15-35 years) in 1995 (Erhabor et al., 2006), and Ethiopia (16.3%, >20 years) 
in 1997 (Mengesha and Bekele, 1998). The lowest prevalence was recorded in 
Gambia (1.9%, >15 years) in 1997 (Walraven et al., 2001). “Current wheeze” 
(wheeze at rest-12 month) was consistently high in South Africa, 26.8% (13-14 
years) in 1994, 23.9% (5-12 years) in 1998, and 20.3% (13-14 years) in 2003 
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(Ehrlich et al., 1998, Ait-Khaled et al., 2007b, Poyser et al., 2002). From studies 
based on video questionnaires, “current wheeze” was highest in Morocco (12.9%, 6-
7 years) in 2003 (Ait-Khaled et al., 2007b), and Tanzania (12.3%, 9-10 years) in 
2008 (Berntsen et al., 2009), with South Africa recording the lowest prevalence 
(6.5%, 6-7 years) in 1995 and 2000 respectively (Poyser et al., 2002, Ait-Khaled et 
al., 2007b); there was no reported prevalence of “asthma ever” from studies based on 
video questionnaires (see Tables 3.36 and 3.37).  
Pooled prevalence estimates of asthma in Africa 
For the random effect meta-analysis, asthma diagnostic criteria based on “current 
wheeze” (wheeze at rest within 12 months) and “asthma ever” (cumulative 
prevalence of asthma) were employed, as these two criteria provided near clinical 
case diagnosis of asthma (Bousquet et al., 2010, IUATLD, 2011). In addition, data 
sets from written questionnaires were mainly used, due to the very limited data sets 
from video questionnaires, which could have allowed for more detailed comparisons. 
From all studies, the pooled crude prevalence for “current wheeze” was 13.5% (95% 
CI: 11.7-15.4, I=99.2%, p=0.000), with a mean age of 15.8 years. The pooled crude 
prevalence “asthma ever” was 9.5% (95% CI: 8.1-11.0, I=99.4%, p=0.000), mean 
age 19.6 years. The higher prevalence estimate from current wheeze may be 
indicative of the reported higher sensitivities from many asthma epidemiological 
surveys (Figures 3.53 and 3.54). 
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NOTE: Weights are from random effects analysis
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Figure 3.53. Pooled crude prevalence of asthma based on "current wheeze" 
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.4%, p = 0.000)
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Figure 3.54. Pooled crude prevalence of asthma based on "asthma ever" 
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It was observed that the pooled crude prevalence rates were consistently higher 
among urban dwellers than rural dwellers. “Current wheeze” was 9.6% (male 12.1%, 
female 7.0% (mean age 19.6 years)) in urban settings and 7.0% (male 5.5%, female 
3.8% (mean age 17.5 years)) in rural settings. “Asthma ever” prevalence was 5.9% 
(male 5.6%, female 3.9% (mean age 22.9 years)) and 5.1% (male 4.2%, female 3.1% 
(mean age 17.5 years)) in urban and rural dwellers respectively (Table 3.39).  
As noted in the literature review, defining asthma has proved difficult to many 
researchers and this has limited on-going research efforts globally, especially in 
Africa. To allow for detailed comparisons of various asthma symptoms, a pooled 
prevalence of these symptoms that were reported in retained studies have been 
included in this thesis (Table 3.40). 
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Modelled estimates of asthma prevalence and symptoms in Africa 
As noted above, researchers have reported that using the symptoms current wheeze 
(wheeze at rest- 12 months) yielded better sensitivities from many epidemiological 
surveys, this is therefore employed in the modelling (See Appendix 5 for summary 
of data used in modelling). The modelled prevalence rates and cases of asthma were 
only estimated for the population under the age of 45 years, as most population 
groups fall under this age.   
In both sexes, there were a total of 29.7 million asthma cases (7.0%; 95% CI: 3.2, 
8.5) in children <15 years, and 28.5 million asthma cases (6.2%; 95% CI: 2.6-7.1) 
among people aged 15-44 years. Among males, there were about 14 million asthma 
cases (6.5%; 95% CI: 2.8-7.2) in children <15 years, and 16 million asthma cases 
(7.0%; 95% CI: 3.1-7.7) among males aged 15-44 years. Among females, there were 
about 14 million asthma cases (7.5%; 95% CI: 3.9-8.7) in children <15 years, and 
12.5 million asthma cases (6.2%; 95% CI: 2.5-7.3) among people aged 15-44 years 
(Figure 3.55 and Table 3.41). 
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 *ever means cumulative prevalence of symptom 
 
Asthma symptoms Mean Age (years) Pooled estimate % (95% CI) 
Both sexes Male Female 
Wheeze at rest (12 month) 15.9 13.5 (11.7-15.4) 13.7 (7.7-14.9)) 13.2 (8.1-15.1) 
Asthma (ever)* 19.6 9.5 (8.1-10.9) 9.9 (8.9-15.5) 8.1 (8.7-14.3) 
Wheeze after exercise (12month) 12.3 23.8 (15.9-31.7) 14.7 (4.4-33.8) 24.6 (11.0-38.2) 
Wheeze after exercise (ever) 12.0 8.9 (5.1-12.8) 6.5 (5.3-7.8) 6.5 (4.1-7.9) 
Nocturnal wheeze (12 month) 15.4 4.9 (2.4-7.4) 9.1 (7.7-11.1) 10.0 (8.6-11.9) 
Nocturnal wheeze (ever) - - - - 
Nocturnal cough (12 month) 14.1 24.2 (18.3-30.0) 24.5 (11.5-37.4) 28.1 (13.2-43.2) 
Nocturnal cough (ever) 10.8 9.3 (7.2-11.4) 10.3 (8.1-12.2) 8.5 (6.5-9.9) 
Severe wheeze (12 month) 13.1 4.7 (3.7-5.6) 6.0 (4.6-7.4) 3.0 (0.8-5.2) 
Severe wheeze (ever) 12.2 8.8 (5.9-11.6) 7.2 (6.0-9.7) 5.2 (4.1-7.3) 
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Figure 3.55. Epidemiological model showing distribution of asthma 
prevalence according to age in Africa in 2010 (A: both sexes, B: male, 
C: female) 
A 
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Table 3.41. Modelled estimates of asthma prevalence and cases in Africa in 2010 (derived from epidemiological model and UN 
population estimates for Africa) 
Age (years) All Male Female 
Prevalence (%)  Asthma cases (000) Prevalence (%) Asthma cases (000) Prevalence (%) Asthma cases (000) 
0-4 3.2 5206 3.8 3132 2.8 2004 
5-9  9.2 12809 7.1 5015 10.8 6636 
10-14  9.6 11728 9.5 5868 9.9 5389 
15-19  9.4 10172 9.9 5405 9.6 4707 
20-24  7.7 7378 8.7 4212 7.2 3097 
25-29  6.4 5365 7.2 3001 6.1 2172 
30-34  4.9 3362 5.8 1983 5.2 1502 
35-39  3.1 1726 4.3 1188 2.8 669 
40-44  1.0 476 0.8 181 1.5 303 
Total (<15) 7.0 (3.2, 8.5)* 29 743 6.5 (2.8, 7.2) 14 016 7.5 (3.9, 8.7) 14 029 
Total (15-44) 6.2 (2.6, 7.1) 28 479 7.0 (3.1, 7.7) 15 969 6.2 (2.5, 7.3) 12 451 
Total (<45) 6.6 (2.4, 7.9) 58 221 6.8 (2.9, 7.5) 29 985 6.8 (2.7, 7.6) 26 479 
*95%CI  
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This chapter has provided findings of the systematic review of the four major NCDs: 
cardiovascular diseases (hypertension and stroke), diabetes, cancers, and chronic 
respiratory disease (COPD and asthma). From studies reporting prevalence rates, 
hypertension, with a total sample size of 197734, accounted for 130.2 million cases in 
2010. This is followed by asthma, with a sample size of187904, accounting for 58.2 
million cases; COPD, with a sample size of 24747, accounting for 26.3 million cases; 
diabetes, with a sample size of 102517, accounting for 24.5 million cases; and stroke, 
with a sample size of about 6.3 million, accounting for 1.94 million cases. From studies 
reporting incidence rates, stroke accounted for 496 thousand new cases in 2010. The 
overall incidence of the 12 cancer types was higher at 775 thousand new cases, estimated 
from registry-based data covering a total population of about 33 million. Among women, 
cervical cancer and breast cancer had 129 thousand and 81 thousand new cases, 
respectively; and men, prostate cancer and Kaposi sarcoma closely follows with 75 
thousand and 74 thousand new cases, respectively (see Table 3.42). 
Let me state clearly here that the representativeness of all these estimates with regards to 
the entire African population could not be ascertained. For example, a sensitivity 
analysis would have given an idea of how truly reflective these estimates are. There are 
various approaches to conducting sensitivity analysis. One approach is to run the 
analysis more than once while substituting range of values from studies with arguable 
eligibility criteria (that is including only studies that are definitely known to be eligible). 
As noted earlier, until recently, there have not been many studies on NCDs in Africa, 
and the overall quality of the few studies available is low. In addition, restricting my 
analysis to studies that have the same study design, same sampling frame and same case 
definition is also almost impossible. Another approach is to consider median and 
interquartile range (IQR) of extracted data while observing how these differ from the 
modelled estimates. Both are then further compared with another set of completely 
different published estimates on Africa. This approach tends to find arguments in 
support of the upper and lower limits of my estimate. For example, the incidence of 
stroke estimated in this thesis (along with the median and IQR) may be compared with 
another set of published estimates on Africa reporting mortality and case fatality rates. 
Based on the explanation in Section 1.1, where case fatality ratio (CFR) is defined as 
mortality divided by incidence rate: then, Incidence rate = Mortality rate/CFR. This 
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approach to sensitivity analysis has been applied by Rudan et al. and Nair et al. in the 
global estimates of clinical pneumonia and Respiratory Syncytial Virus infections in 
children, respectively (Nair et al., 2010, Rudan et al., 2004). This can also not be 
conducted in this thesis, as, to the best of my knowledge, there are yet to be such 
published comparable estimates of NCDs in Africa. However, the median and IQR from 
the extracted raw data are further shown in Table 3.42 to allow for some comparisons 
with the modelled estimates. 
Table 3.42. Summary of prevalence/incidence rates and number of cases for the 
reviewed studies 
Disease Age Prevalence studies (%, unless stated) Incidence studies (per 100000 py) 








Hypertension 20+ years 130.2 
million 
25.9 (23.5, 34.0) 30.6 (21.8-
36.7) 
- - - 










Diabetes 15+ years 24.5 
million 









Breast cancer All 
(Women) 
















COPD* 40+ 26.3 
million 
- 13.4 (9.4, 
22.1) 
- - - 
Asthma <45 years 58.2 
million 
6.6 (2.4, 7.9) 13.9 (9.5-
16.3) 
- - - 
*No pooled prevalence estimate was reported for COPD due to the limited number of spirometry studies retained 
(only five) and significant heterogeneity between these studies; estimated COPD cases were only based on 
median COPD prevalence from retained studies (this has been explained earlier in the methods, and further 
noted in the study limitations) 
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This chapter is a discussion of the findings from this review, with references to 
studies that have published similar findings before this review. It also follows the 
sequence earlier described in the methods and results: cardiovascular diseases 
(hypertension and stroke), diabetes, cancers, and chronic respiratory disease (COPD 
and asthma). 
4.1 CARDIOVASCULAR DISEASES 
4.1.1 Hypertension 
This review provides an improved continent-wide estimate of the prevalence and 
awareness rates of hypertension in Africa using epidemiological modelling adjusted 
for age and sample size of the respective study population. Having included studies 
conducted across various parts of Africa, the estimates may provide a close 
representation of the prevalence and the number of cases of hypertension in the 
continent.  
The IHME GBD study reported an increasing burden of hypertension globally 
between 1990 and 2010 (Murray et al., 2012, Lozano et al., 2012). Deaths from 
hypertension increased by 47.8%, from 591 thousand deaths in 1990 to 873 thousand 
deaths in 2010, while DALYs increased by 37.4%, from 11.2 million DALYs in 
1990 to 15.3 million DALYs in 2010 (Murray et al., 2012, Lozano et al., 2012). 
Generally, this increase cannot be compared directly to the prevalence of 
hypertension in Africa in the current study, as these are global estimates and the 
outcome measured were not strictly related to hypertension prevalence. In sub-
Saharan Africa however, IHME estimated that DALYs from hypertension increased 
from 893.6 thousand in 1990 to 1.4 million in 2010 (58.3% increase), while deaths 
increased by 67.6% from 34600 to 58000 thousand over the same period, 
respectively (Murray et al., 2012, Lozano et al., 2012). It is also important to state 
that the sources of IHME data were explored from supplementary files, but there 
were no data on prevalence of hypertension that could have allowed for further direct 
comparisons and possibly assist further in estimating the prevalence of hypertension 
in Africa. 
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From all studies, I estimated weighted mean systolic and diastolic blood pressures of 
129.6 mm Hg and 78.0 mm Hg, respectively, and an overall mean age of 47.4 years. 
As noted in the methods, the SBP and DBP are only weighted towards the study 
sample and do not reflect a larger country or regional estimate. For example, most 
selected studies were conducted in Western Africa and Southern Africa, the overall 
SBP and DBP may possibly reflect more the high blood pressure status in these 
regions. However, these may still not be overtly representative of these regions. For 
example, a South African study had the largest sample size at 11786 (Malaza et al., 
2012), and this study was conducted in a rural population known for high HIV 
prevalence. The estimates reported from this study may be assumed to be 
confounded by the HIV prevalence and may therefore be difficult to generalize to 
other African population groups with relatively lower HIV prevalence. Meanwhile, 
this estimate may still be compared with the estimates reported by Danaei and 
colleagues on the global trends of systolic blood pressure, with an overall mean SBP 
in SSA ranging 129.2-132.7 mm Hg and 132.6-134.8 mm Hg among men and 
women, respectively, between 1981 and 2008  (Danaei et al., 2011). This study may 
further support my finding of a high prevalence of hypertension in Africa, with the 
highest value of SBP globally estimated in SSA (along with central and eastern 
Europe)  (Danaei et al., 2011). 
Across selected studies, higher prevalence rates of hypertension were reported with 
increasing age of subjects. This is underpinned by previous research findings where 
increasing age is associated with significant increase in the prevalence of 
hypertension, especially in people aged ≥60 years (Anderson, 1999, Addo et al., 
2007). A higher prevalence of hypertension was reported in Northern Africa with a 
pooled prevalence of 33.3% compared to a prevalence of 27.8 % in SSA. This could 
be partly explained by age difference, with a mean age of 54.3 years in Northern 
Africa, compared to 46.4 years in SSA. In the 2009 hospital-based Epidemiological 
Trial of Hypertension in North Africa (ETHNA), a high prevalence (45.4%, mean 
age 49.2 years) was also reported for Northern Africa (Nejjari et al., 2013); this 
further supports findings of this study.  
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A higher prevalence of hypertension was noted among urban dwellers from the 
pooled estimates mainly in 1990 (urban 17.2%, rural 11.1%), while the prevalence 
was virtually the same in years 2000 and 2010. The narrowing of prevalence gaps 
between urban and rural dwellers in years 2000 and 2010 could be due to a possible 
reverse rural-urban migration, which has been reported when urban dwellers fail to 
cope with the economic challenges and vulnerabilities associated with urban life, and 
may prefer to return to natural resource-rich rural settlements (Institute for Security 
Studies, 2010). In addition, there are reports that even in rural settings, the apparent 
remote and traditional styles do not seem to protect them again, as more of these 
rural settings are gradually becoming semi-urbanized (Opie and Seedat, 2005). Opie 
and colleagues also argued that many site-specific hypertension prevalence estimates 
in Africa may not truly reflect the burden in these settings, as there are still doubts on 
the proportion of Africans that truly reside in rural settings (Opie and Mayosi, 2005). 
Meanwhile, an increasing, yet low, awareness rate of hypertension in Africa was 
reported, with pooled awareness rate of 16.9% in 1990, 29.2% in 2000 and 33.7% in 
2010. This estimate, to the best of my knowledge, remains the first continent-wide 
awareness rate of hypertension reported in Africa, and thus forms an important 
finding of this study. The low awareness rate reported may still reflect a poor 
response to management of hypertension in the continent (Seedat and Rosenthal, 
2006). Kayima et al. corroborates this, reporting a very low awareness rate of 
hypertension, ranging between 8% and 10% in Africa in the early 2000s (Kayima et 
al., 2013).  
In this review, the general sex distribution showed that the prevalence of 
hypertension were higher among men than women. This is also in line with many 
reports in Africa (Kayima et al., 2013, Opie and Seedat, 2005). This may be because 
the overall mean age from all selected studies was 47.4 years, which is just about a 
reported mean menopause age of 49.4 years among African women (Ozumba et al., 
2004), and there is established evidence of a steeper blood pressure rise in men than 
women before the age of menopause (Hajar et al., 2006). Danaei and colleagues 
reported similar findings between 1981 and 2008, where, in contrast to a 
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predominant rise in mean SBP among men, the mean SBP among women increased 
only in two countries globally between 1981 and 2008 (Danaei et al., 2011). The 
current estimate may therefore just be reflective of a continuation in this trend. Still, 
from the modelling, over 54.6 million cases of hypertension were estimated in 1990 
(19.1%), 92.3 million cases in 2000 (24.3%), and 130.2 million cases in 2010 
(25.9%). These estimates are higher than the 20 million reported by WHO African 
regional office (AFRO) in 2005 (WHO Regional Office for Africa, 2005). The WHO 
AFRO estimate was based on ≥160/95 and this is probably the reason for the low 
hypertension cases reported. However, reports show that this figure has often been 
quoted in many official documents as the number of hypertension cases in Africa 
(WHO Regional Office for Africa, 2006).  
As noted in the methods, R-squared (also called the coefficient of determination) is a 
measure of how close the prevalence rates reported in each study are to the fitted line 
(Cameron and Windmeijer, 1995). It is defined as the percentage of the response 
variable variation that is explained by the fitted line (Cameron and Windmeijer, 
1995). It is usually between 0 (indicating that the model explains none of the 
variability of the plotted data around its mean) and 100% (indicating that the model 
explains all of the variability of the plotted data around its mean) (Cameron and 
Windmeijer, 1995). In other words, the higher the R
2
 the better the model fits the 
plotted data. For the hypertension modelling, an exponential, non-linear model was 
applied (other models in this thesis are also non-linear, see methods). The R
2
 for the 
three years (1990, 2000 & 2010) were less than 50%, ranging from 6%-37%; this 
may apparently mean that the model does not fit the data well. However, according 
to some authors, a low R
2
 may not mean the model is not well-fitted (Oles et al., 
2012) (Cameron and Windmeijer, 1995). Some have argued that R
2
 does not indicate 
whether a model is adequate, and in such instances a good model may present with a 
low R
2
 and a poor model may have a high R
2 
(Higgins et al., 2009).  In fact, many 
have reported that R
2 
is more appropriate for linear regression (Oles et al., 2012, 
Higgins et al., 2009). In a typical linear regression, the variance is approximately 
equal at every point along the scale, hence, the sum of regression sum of squares 
(SSR) and sum of squared deviations (SSD) is always equal to total sum of squares 
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(SST) (i.e. SST=SSR+SSD) (Cameron and Windmeijer, 1995). According to experts, 
this is quite logical, as the variance that the linear regression model accounts for, and 
the error variance adds up to equal the total variance (Cameron and Windmeijer, 
1995). Based on this therefore, R
2 
is calculated as: 
R
2
= 1- (regression sum of squares / Total sum of squares), OR 1-(SSR/SST) 
As noted above, this equation must arithmetically produce values between 0 and 
100% in a straight-forward linear regression. According to statisticians, this linear R
2 
equation is what is usually available in many statistical packages. Making inferences 
from this R
2
 in a non-linear model may therefore be misleading. In a non-linear 
model, the sum of regression sum of squares (SSR) and sum of squared deviations 
(SSD) is not always equal to total sum of squares (SST) (i.e. SST≠SSR+SSD), as the 
underlying assumptions are completely different from a linear model. Thus, R
2 
for 
non-linear models may not actually fall between 0 and 100%, there may be negative 
figures (Cameron and Windmeijer, 1995, Oles et al., 2012). Spiess and Neumeyer 
performed over a thousand simulations to show that using R
2 
to evaluate the fit of 
non-linear model may lead to inaccurate deductions (Spiess and Neumeyer, 2010). 
They found out that: (i) R
2 
tends to be consistently high for both very bad and very 
good models; (ii) even with improved non-linear models, R
2 
do not always increase; 
and (iii) using R
2
 to choose the final model only gave a representative prediction in 
about 28 to 43% of analyses (Spiess and Neumeyer, 2010). The question then is what 
form of R
2
 should then be used for non-linear regression (like applied in this thesis)? 
Again, statisticians reported that there is no straightforward R
2
 for non-linear 
regression (Cameron and Windmeijer, 1995). Quasi (or pseudo) R
2
 has been applied 
in some advanced statistical modelling, which tends to adjust for the non-linearity in 
the model. However, as noted in the introduction and methods, this thesis is based on 
simple modelling, particularly due to paucity of data on many NCDs in Africa and 
widespread concerns about extrapolation and over-modelling of the scarce data in 
Africa in other studies. Hence, I did not apply an advanced modelling with a quasi 
(or pseudo) R
2
 in my analysis. There are, however, varying forms of pseudo R
2
 that 
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can be applied in a non-linear model. One approach is a form of generalization of the 
R
2
 formula, which approximates the usual R
2
 using multiple regression analysis. 
Quasi R-Squared = (ModelSS - MeanSS)/(TotalSS-MeanSS) 
where MeanSS is the sum of squares due to the mean, ModelSS is the 
sum of squares due to the model, and TotalSS is the total 
(uncorrected) sum of squares of Y (the dependent variable) (Spiess 
and Neumeyer, 2010). 
In this approach, the R
2
 may explain how well the non-linear model performs after 
removing the influence of the mean of Y. The limitation here is that many non-linear 
models may not clearly include a parameter for the mean of Y; therefore, the R
2 
may 
be negative, and in this case, the statistical package will set the R
2 
to zero, thus 
rendering it difficult to interpret (Spiess and Neumeyer, 2010). 
Another approach to calculating R
2
 is to square the correlation between the actual y 
values and the predicted y values (Cameron and Windmeijer, 1995). This approach 
may only be useful as long as the model is close to a linear model (Cameron and 
Windmeijer, 1995). In fact, the ability of any quasi R
2
 to accurately predict a good fit 
has been said to be based on the closeness of the model to a linear model. This thus 
still explains why some statisticians do not rely on any form of R
2
 to interpret a non-
linear model (Spiess and Neumeyer, 2010, Cameron and Windmeijer, 1995). 
Meanwhile, a close look at the model shows an increasing trend in hypertension 
prevalence from 20 years to 80+ years: 12.5% to 35.7% in 1990, 17.5% to 55.1% in 
2000, and 16.4% to 75.7% in 2010. Increasing age has been reported as a major risk 
factor for hypertension and many other chronic diseases (Ejim et al., 2011). The 
overall prevalence also increased from 19.1% in 1990 to 25.9% in 2010. While I 
understand that there are lots of demographic factors that can affect these estimates, 
the pattern presented by the model may not be too far from what is happening in the 
African population, especially with regards to the rise in prevalence of hypertension 
with increasing age, which has been reported by researchers (Ejim et al., 2011). 
Epidemiologists have explained that in the application of a model for data analysis, it 
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is important not only to look at the R
2
 and how well the model fits the data, but also 
to closely examine if the model is a reasonable prediction in a scientific context, 
which in this case may be linked to published evidence on increasing age and the 
prevalence of chronic diseases (Spiess and Neumeyer, 2010). 
Meanwhile, Twagirumukiza et al. estimated about 75 million cases (16.2%) of 
hypertension among people aged ≥15 years in SSA in 2008, and projected to increase 
to 125.5 million cases (17.4%) in 2025 (Table 4.1) (Twagirumukiza et al., 2011). 
While I did not provide prevalence estimates beyond 2010, however, going by 
population demographics and ageing alone, these figures are relatively lower 
compared to the current estimates. It is understandable that these estimates were for 
SSA and that the mean age of the study was low (40 years), they may still yet not 
reflect the true burden of hypertension in the continent, as their review and analysis 
mainly included studies from 11 countries in Africa. Another reviewer further noted 
my concerns, and  agreed the estimates were very low compared to recent prevalence 
rates reported in Africa, and may be erroneously interpreted that the burden of 
hypertension in the continent is low (Poulter, 2011). However, Kearney et al. 
reported higher hypertension estimates, with about 79.8 million hypertension cases 
(27.6%)  estimated among people aged ≥20 years in 2000 and projected to reach 
about 150.7 million cases (27.7%) in 2025 (Kearney et al., 2005), see Table 4.1. 
These prevalence rates are comparable with the current estimates, but as noted 
above, the difference in the number of hypertension cases may be due to the fact that 
I considered the UN demographic changes in my overall estimates.  
Table 4.1. Comparable estimates of hypertension prevalence rates from selected 
studies 
 Current Study * Kearney et al. * (6) Twagirumukiza et al. ** (15) 
2000  2010 2000 2025 2008 2025 
Prevalence   rate in 







27.6 27.7 16.2 17.4 
*20years (all Africa), **15+years (sub-Saharan Africa) 
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Study limitations 
The study aimed to provide an improved continent-wide estimate of hypertension in 
Africa using current definitions (≥ 140/90mm Hg), however, there are a number of 
factors that could have limited this. First, the modelling was age-dependent, as there 
are other health determinants that could have resulted in varying estimates if 
considered, including the overall population characteristics, socio-economic factors 
and general living conditions (Negin et al., 2011). I already noted in the methods that 
single age (usually mean age) was mostly employed in the modelling. There were 
only 6 studies out of the 92 selected studies (6.5%) that reported age-specific 
prevalence estimates that were employed in the modelling (Abegunde and Owoaje, 
2013, Hendriks et al., 2012, Fezeu et al., 2010, Edwards et al., 2000, Cruickshank et 
al., 2001, de Ramirez et al., 2010). This thus means that hypertension prevalence of 
people in the extreme age groups (very young and very old) may not be well 
represented when the mean age was only employed. This is therefore a major 
limitation in this study.  
I
2
 is the measure of heterogeneity reported in this thesis, and was first described in 
the Cochrane Reviews. I
2
 describes the percentage of total variation across studies 
that are due to heterogeneity rather than chance. For the hypertension pooled 
prevalence, I
2
 was 99.5%. This implies that there is very high heterogeneity across 
selected studies; and at p<0.0001, the heterogeneity is statistically significant. There 
is therefore strong evidence against the null hypothesis that studies are evaluating the 
same effect. For a combination of studies with such high heterogeneity, it may not be 
appropriate to pool a summary effect. However, as reported earlier, there is very low 
research output in Africa, and the few studies have not been conducted under strict 
international guidelines, so heterogeneities can be expected. In addition, restricting 
my analysis to studies that have the same study design, same sampling frame and 
same case definition is almost impossible. However, despite this high heterogeneity, 
it is important to note that the overall quality check employed involved closely 
examining individual study designs, analyses, case definitions, and the 
generalizability of the estimates to a larger African population group. 
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In addition, the overall mean age was 47.4 years, which could also have resulted in a 
lower prevalence estimate, as research evidences show significant increase in 
hypertension prevalence in people aged ≥60 years (Anderson, 1999). Second, all 
studies included in our modelling were based on ≥140/90mmHg and/ or self-reported 
use of antihypertensive medications; notwithstanding, some studies have varying 
designs and blood pressure measuring protocols, which could have affected the 
quality of the current estimates.  Moreover, while I ensured all studies that were 
graded as high and moderate quality were included in the quantitative analysis, some 
low quality studies were also included in the quantitative analysis on the basis of 
good study designs; I think this could potentially affect the overall estimates. Third, 
not all studies reported age- and sex- specific estimates, including urban or rural site-
specific estimates, as an epidemiology of the prevalence of hypertension in these 
sub-groups could have been further helpful. Furthermore, the incompleteness of data 
across many studies prevented me from providing estimates on the control and 
treatment of hypertension in Africa; I still hope that providing a continent-wide 
estimate of the awareness rate of hypertension may further give a general view of the 
public health response to the disease in the continent.  Lastly, despite including 92 
studies conducted in 31 African countries and with a consideration of the United 
Nations population demographics in the modelling (refer to Table 3.2 and Appendix 
2), I still cannot say with all certainty how closely representative my estimates were 
of the African population. 
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Public health response to hypertension in Africa 
Recent reports show that the World Heart Federation, supported by the Pan African 
Society of Cardiology (PASCAR), has been actively building capacities across 
Africa to address the rising burden of hypertension and other cardiovascular diseases 
in the continent (World Heart Federation, 2008). However, collaborations and 
response within Africa remains poor, as hypertension still ranks low among health 
priorities, owing to competition for the limited resources from a co-existing high 
burden of infectious diseases (Beaglehole et al., 2011). Moreover, in countries with 
some levels of care for hypertension, the standards of health service delivery is poor 
(Opie and Seedat, 2005). Many cases of hypertension are detected late, treatments 
rarely follow standard guidelines, and the costs of medications are generally high 
(Hajar et al., 2006). Besides, health care seeking behaviour has also been affected, 
with people often preferring low-cost substandard health facilities (Suhrcke et al., 
2012). This is particularly a problem in rural settings where the prevalence of 
hypertension has been reported to be on a gradual increase (Kayima et al., 2013). 
Further reports show that even with a relatively lower prevalence of hypertension 
among rural dwellers, the detection and overall management are poor in comparison 
to urban dwellers (Opie and Seedat, 2005). Additionally, many African countries are 
yet to implement population-wide control measures to address risk factors for 
hypertension (van der Sande et al., 2001), even with confirmed reports of high salts 
and fats consumption in the region and evidence showing cost-effectiveness of 
interventions targeting this (Mezue, 2013, Gaziano et al., 2005). The WHO now 
recommends country-specific initiatives and legislation concerning food labelling 
and products formulation, including sodium and saturated fats content in processed 
foods (World Health Organization, 2013b, World Heart Federation, 2008). 
This study suggests a high prevalence of hypertension in Africa, and the awareness 
of the disease, though increasing, still remains low. Hypertension deserves to be on 
the health priority lists of African nations, and problems with funding may possibly 
be reduced by partnering with leading international bodies for cardiovascular 
diseases. Essentially, policy makers and stakeholders in the health sector need to 
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institute nationwide population-based strategies towards creating awareness on 
hypertension and educating people on the main risk factors such as smoking, harmful 
use of alcohol, sedentary lifestyles and unhealthy diets. It is hoped that the findings 
of this review may prompt appropriate policy response at country level towards 
improved detection, control and overall management of hypertension in Africa. 
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4.1.2 Stroke 
Some systematic reviews have been published on the burden of stroke in Africa but 
without a continent-wide estimate of stroke incidence and prevalence rates (Connor 
et al., 2007, Kengne and Anderson, 2006). There are also global reviews of stroke 
with few studies on Africa population included (Feigin et al., 2009, Feigin et al., 
2003, Aho et al., 1980). For example, in a systematic review of 56 population-based 
studies globally, only one African site (Ibadan, Nigeria) was considered. The result 
from this survey may not necessarily reflect the overall burden of stroke in Africa 
(Feigin et al., 2009). However, to the best of my knowledge, this study provides the 
first continent-wide estimate of the incidence and prevalence rates of stroke in 
Africa. The estimates were based on an epidemiological model with appropriate 
consideration of reported mean ages and sample sizes from individual studies. One 
important thing about this review was that despite the few studies retained, the 
estimates provided in this study were based on a total sample size of about 6.3 
million. Moreover, having applied the UN population demographics in the final 
model, the current estimates fairly reflect the total African population and may help 
policymakers across several African countries institute effective public health 
response to the growing burden. 
Generally, crude incidence rates of stroke from population/community based-studies 
were higher, with the two low incidence rates recorded obtained from population-
based stroke registries in Nigeria (Danesi et al., 2013, Osuntokun et al., 1979) (Table 
3.12). Despite over 3 decades of potential improvement in stroke registration 
between the two studies (1975-2007), the low incidence rates may still be indicative 
of incompleteness of stroke registries in many Africa settings, and that data obtained 
from these registries may be unreliable and inappropriate for estimation of stroke 
burden. In contrast, in many high income countries where there is active registration 
of stroke cases, population-based stroke registries have been reliable sources of data 
for estimation of stroke incidences (Connor et al., 2007, The Global Burden of 
Disease Stroke Expert Group, 2012).  
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In this study, the pooled crude incidence rate from community-based studies was 
higher at 112.9 per 100,000 person years compared to 77.4 from hospital-based 
studies. The difference suggests a likely under-estimation of stroke incidence rates 
from hospital-based studies, which has also been observed by some previous studies, 
particularly due to the very few stroke cases presenting to standard health facilities 
(Chin, 2012). The observed prevalence rates of stroke survivors were generally high 
(all prevalence studies were population-based) with a pooled crude prevalence rate of 
387.9/100,000 population. The low prevalence rate recorded in Ethiopia in 1988 may 
not be unconnected with the high mortality rates from stroke in the region, which has 
generally been reported in many parts of Africa  (Tekle-Haimanot et al., 1990, 
Bonita and Truelsen, 2003). 
The modelling showed a rising incidence and prevalence rates of stroke with 
increasing age and higher figures recorded among men, which is in line with several 
research findings on stroke burden (Dewhurst et al., 2013a). Over 496 thousand new 
cases of stroke with an incidence rate of 81.3/100,000 py (men 103.4, women 59.6), 
and about 1.94 million stroke survivors with a prevalence rate of 317.3/100000 
population (men 335.2, women 299.7), both among people aged 15 years or more 
were estimated in 2010.  In the modelling applied for stroke, the R
2
 for both 
incidence and prevalence of stroke were above 50%, at 66% and 71% respectively. 
These are relatively high values, but just as explained earlier under hypertension 
discussion, this may not necessarily imply that the model fits the data very well (Oles 
et al., 2012). The model shows an increasing trend from 15 years to 80+ years: 7.3 to 
1601.3 per 100,000 person years (incidence), and 35.2 to 5324.5 per 100,000 
populations (prevalence). The fact on age still applies here: increasing age has been 
reported as a major risk for many NCDs (Hammami et al., 2011). While this model 
may reflect some intrinsic population characteristics with regards to age and 
occurrence of stroke in a population, there is still need to be aware of other intrinsic 
population characteristics related to stroke that are not explained by this model 
especially on correctly identifying first and recurrent cases of stroke. Additionally, 
the inability to appropriately account for urbanization and many NCD risk factors are 
also important factors that must be considered. Largely, examining R
2
 and how well 
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the model fits the data may not be the most important thing in data analysis, but also 
to closely examine if this is a reasonable prediction in a scientific context (Cameron 
and Windmeijer, 1995). 
Meanwhile, a report in 2004 suggested that about 8% of all first-ever strokes (about 5 
million) occurred in Africa and 5% of over 30 million stroke survivors worldwide 
were in Africa (Truelsen, 2010b, World Health Organization, 2004), and this 
amounts to about 400 thousand new stroke cases and 1.5 million stroke survivors. A 
systematic review in sub-Saharan Africa on studies published between 1966-2006 
showed age-standardized prevalence rates of 114–315/100,000 populations and 154–
281/100,000 population among men and women, respectively (Connor et al., 2007). 
Another review in 2006 showed that the prevalence of stroke survivors ranges from 
200-300/100,000 population in sub-Saharan Africa, and incidence rates ranges from 
15-68/100,000 py (Kengne and Anderson, 2006). These figures are comparable with 
the current estimates, which further underpins a near representation of the burden of 
stroke in Africa. The few differences may probably be due to the study periods, age 
groups, fewer data-points, focus on sub-Saharan Africa, and the fact that these were 
largely qualitative reviews and not based on a detailed statistical synthesis.  
Meanwhile, according to the GBD estimates by Feigin and colleagues, over a 100% 
increase in the total number of new stroke cases and stroke survivors was recorded 
between 1990 and 2010 in LMIC, with an estimated incidence rate of 281.1/100,000 
py and prevalence rate of 393.4/100,000 population in 2010 (Feigin et al., 2014). 
While it is understandable that not all LMIC have contextual similarities with 
African countries and direct comparisons may be inappropriate, it may however still 
be logical to conclude that the estimates from this study reflect the current stroke 
burden in many LMIC. In sub-Saharan Africa however, IHME estimated that 
DALYs from stroke increased from 5.9 million in 1990 to 7.8 million in 2010 
(32.2% increase), while deaths increased by 47.0% from 223.8 thousand to 328.9 
thousand over the same period, respectively (Murray et al., 2012, Lozano et al., 
2012).  
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Study limitations 
While this study aimed to provide an evidence-based continent-wide estimation of stroke 
incidence and prevalence rates in Africa through simple statistical analysis, the study has 
some important limitations. The modelling was strictly based on age. As noted in the 
methods that single age (usually mean age) was mostly employed in the modelling. 
However, of the 19 studies selected, 9 studies (47.4%) reported age-specific 
prevalence estimates that were employed in the modelling (Connor, 2004, Cossi et 
al., 2012, Danesi et al., 2007, Danesi et al., 2013, El Tallawy et al., 2013, Farghaly et 
al., 2013, Kandil et al., 2006, Walker et al., 2010, Osuntokun et al., 1979). This thus 
means that stroke prevalence and/or incidence of people in the extreme age groups 
(very young and very old) may not be well represented from the other studies that the 
mean age was only employed. This could therefore a major limitation in this study. 
In particular the low research output and quality of selected studies from Africa 
constrained the overall analysis. There were 19 studies covering only 10 countries in 
Africa with an overall sample size of over 6.3 million.  Moreover, stroke case 
ascertainment was not well defined across some studies, and this has been documented 
in some reviews (The Global Burden of Disease Stroke Expert Group, 2012). Due to 
these limited data and with some full texts assessed showing evidence of a detailed 
epidemiological exercise, an inclusion of some of these studies in the final analysis was 
allowed, as contained in the quality criteria and grading. In addition, some reported 
stroke incidence data were based on both first stroke and recurrent stroke events, and not 
all reported prevalence rates were strictly based on stroke survivors. Importantly, this 
study could have been limited by  the inability to account for  the consequences of stroke 
on conditions other than acute stroke, as a wide range of overt and occult 
cerebrovascular disease have been recognised to contribute to Alzheimer's disease, 
vascular dementia and other cognitive disease (O'Neill, 2014). Diseases under this 
category may therefore be unaccounted for.  
For the pooled stroke estimates, I
2
 was 97.5% for incidence rate, and 98.8% for 
prevalence rate. This thus implies that there is very high heterogeneity across 
selected studies; and at p<0.0001, the heterogeneity is statistically significant. There 
is therefore strong evidence against the null hypothesis that studies are evaluating the 
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same effect. For a combination of studies with such high heterogeneity, it may also 
not be appropriate to pool a summary effect. However, as reported earlier, there is 
very low research output in Africa, and the few studies have not been conducted 
under strict international guidelines, so heterogeneities can be expected. In addition, 
restricting my analysis to studies that have the same study design, same sampling 
frame and same case definition is almost impossible. Lastly, I cannot say with all 
certainty how closely representative these estimates were of the larger African 
population (refer to Table 3.10 and Appendix 3).  
Public health response to stroke in Africa 
The prevention of stroke and many non-communicable diseases in Africa has been 
affected mainly by weak health systems and poor government response (Bonita and 
Truelsen, 2003).   To date, the priorities of many African countries remain infectious 
diseases: mainly HIV/AIDS, malaria and tuberculosis (Beaglehole et al., 2011), 
despite the availability of affordable and cost effective stroke prevention initiatives 
(Walker et al., 2013, Mensah, 2003). For example, Walker and colleagues reported 
that African countries do not have national strategies to address smoking, alcohol, 
physical inactivity and unhealthy diets including reducing salt and fat contents of 
processed foods (Walker et al., 2013); and stroke units, where the awareness on these 
risk factors could have been raised, are rarely available (Wahab, 2008, Kolapo and 
Vento, 2011). The INTERSTROKE study findings show that hypertension is the 
main risk factor of all stroke subtypes with odds of about 2.64 (O'Donnell et al., 
2010), this is more prominent  among young Africans who present with stroke 
unaware of their high blood pressure status (Walker, 1994). Truelsen argues that the 
prevalence of stroke in Africa might increase due to substantial changes in major 
stroke risk factors in the presence of a biased focus on the prevention and control of 
infectious diseases, at the expense of many NCDs (Truelsen, 2010a). 
The diagnosis of stroke in many African settings remains a huge challenge (Kengne 
and Anderson, 2006). Some hospital surveys in sub-Saharan Africa have shown that 
CT scans are only conducted on less than half of patients presenting with stroke, and 
this is mainly among those that can afford it (Kengne and Anderson, 2006, 
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Olubunmi, 2007).  In fact, experts have reported that the unavailability and/or high 
costs of cranial CT imaging in many parts of Africa have limited information on the 
pathologic profiles of different stroke types in the continent, with this often affecting 
the diagnosis, treatment and the overall management of the disease (Olubunmi, 
2007).  Reports further show that in some areas with better population-wide access to 
CT scans, as the case in Tanzania, Ghana, and the Medical University of Southern 
African (MEDUNSA) Stroke Data Bank (MSDB), there have been improvements in 
diagnosis of stroke, with varying cases of ischaemic and haemorrhagic strokes 
reported (Joubert, 1991, Matuja et al., 2004, Nyame et al., 1994). Moreover, the 
challenges of appropriately distinguishing first from recurrent stroke episodes have 
also affected stroke case ascertainment, especially during epidemiological surveys 
(Connor et al., 2007)  Neurologists have noted the importance of proper planning 
during community surveys, active registration and follow-up of new stroke cases 
identified, and training and re-training of health workers on stroke diagnosis (Sudlow 
and Warlow, 1996); arguing that the absence of these in many African settings have 
resulted in increased number of stroke cases in the community who have never had 
contact with standard health facilities, and inability to categorize these as first or 
recurrent strokes, including relating such existing stroke cases to a particular period 
during surveys (Sudlow and Warlow, 1996, Connor et al., 2007). 
As noted earlier, a systematic review has suggested that income is a strong predictor 
of stroke risk and fatalities (Johnston et al., 2009). For example, the average cost of a 
cranial CT in Uganda was approximately $60 USD between 2000 and 2010 (Chin, 
2012). This is expensive in most African population groups where many still live 
below the poverty index of less than $1.25/day (World Bank, 2014a). In fact, the 
high cost of health services in the absence of an effective health insurance schemes 
and adequate resources allocated for stroke prevention and management has affected 
healthcare seeking behaviour in some African settings (Connor et al., 2007, Walker 
et al., 2000). Many stroke patients have been managed at home due to lack of 
hospital funds, with only few presenting to standard health facilities several days 
after the onset of symptoms having tried low-priced under-resourced clinics (Chin, 
2012). For those who manage to get to standard health facilities, there are also 
Estimating the Prevalence of NCDs in Africa 
 
Discussion  271 
challenges arising from poor quality of care, as several studies have reported massive 
gaps exist in the management of acute stroke in Africa compared to many high 
income countries (Lemogoum et al., 2005, Adoukonou et al., 2010). 
The unavailability of data with low research output has been a major setback in the 
management of stroke in Africa (Truelsen, 2010a). Experts have reported that 
reliable data from which evidence-based policy decisions can be made are sparse in 
Africa (Owolabi, 2012). For example, in an attempt to quantify number of 
publications on stroke up till 2009, Holmes and colleagues reported that there were 
14 population-based cross-sectional studies on stroke in Africa, accounting 0.06 
studies per million people with stroke in Africa, and this only representing 0.6% of 
the total publications on stroke in the United States (Holmes et al., 2010). Many have 
argued that no study in Africa can be regarded as an ideal stroke study (Sudlow and 
Warlow, 1996), adding that there were no proper stroke registries and demographic 
health surveys which invariably limit active registration, follow-up of cases and 
conduct of community-based studies (The Global Burden of Disease Stroke Expert 
Group, 2012). Based on the current findings, hospital-based studies and door-to-door 
surveys were mainly conducted in Africa and despite the rigour of these few 
epidemiological surveys, gaps have been identified with regards to case  
ascertainment and study protocols (Bonita and Truelsen, 2003).  
The findings in this study suggest an increasing burden of stroke in Africa. However, 
with the current low availability of data, there is still need for more research on 
stroke, and related vascular disease risk factors to appropriately quantify this burden. 
An investment in research capacity, basically to conduct and fund higher quality 
research may help raise awareness on stroke burden in Africa. An awareness and fair 
understanding of stroke burden and disease pattern in Africa may further prompt 
appropriate policy response and scale up current intervention programmes. 
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4.2 DIABETES 
In the current analysis, statistical methods were employed involving pooling diabetes 
prevalence from all studies, and applying the epidemiological model, while 
considering the mean ages and sample sizes of the respective study population. As 
noted in preceding sections, epidemiological surveys have revealed significant 
association between the prevalence of many NCDs and age of patients (Beaglehole, 
2011). Besides, by using the UN demographics, this study may have considered 
effects of urbanization, changing population dynamics and increased life 
expectancies on the prevalence of diabetes in Africa. The current figures could 
represent a realistic estimate of the prevalence and number of cases of diabetes in 
Africa. 
Across individual studies, higher prevalence rates of diabetes were reported in 
Northern Africa. Although the very high prevalence (38.4%) observed in Morocco 
may not be plausible, as diabetes was surveyed alongside other cardiovascular risk 
factors, and the case definitions and study population were not well defined (Essiarab 
et al., 2011).  
Meanwhile, DR Congo and Seychelles had the highest prevalence of IGT and IFG 
across selected studies, with a diabetes prevalence of 10.0% and 11.7 % respectively.  
Interestingly, the two countries had high prevalence of diabetes, with a diabetes 
prevalence of 10% in DR Congo and 11.5% in Seychelles. This finding (high IGT 
and IFG prevalence with a relatively high diabetes prevalence) may suggest that the 
two countries are at the early phase of diabetes epidemic, which further supports the 
findings reported by Mbanya and colleagues (Mbanya et al., 2010). Additionally, 
from the pooled estimates of IGT and IFG across all studies, a higher prevalence of 
IGT was observed among women, while IFG was more prevalent among men (Table 
3.17). This pattern has also been reported by WHO, but experts can still not say with 
certainty the reason for this (World Health Organization, 2006).  
On the study settings, several reports have shown positive association between 
diabetes and urban areas (Aspray et al., 2000, Levitt, 2008, Mbanya and Ramiaya, 
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2006). Sobngwi et al. estimated a diabetes prevalence of 1% in rural Africa and 2%-
6% in urban Africa in 2002 (Sobngwi et al., 2002). In the current study, there was no 
test of association between the study settings and diabetes prevalence rates. 
However, the pooled estimates revealed a 4 fold increase in diabetes prevalence 
among urban dwellers (10.1%) compared to rural dwellers (2.6%) (Table 3.19). This 
is in line with many previous reports and is believed to be due to increase risks of 
NCDs associated with urban life, as noted in the introduction (Mbanya et al., 2010). 
Based on the current study, a pooled diabetes prevalence of 7.5% was estimated from 
crude prevalence rates reported in all studies. Varying degrees of heterogeneities 
from some of these studies including those related to individual population structure, 
residence (differences between urban and rural areas), mean age and other social 
determinants of health, that were ignored or not fully accounted for in the random 
effects analysis, could have possibly resulted in this high estimate (and vice-versa). 
However, as noted in the methods, the epidemiological model incorporated the age 
and sample sizes which only relatively represent some features of the study 
population (and not the larger regional or country population). Estimated figures 
from this model showed an increasing prevalence of diabetes since 1990, with 
marked increase noted between 2000 and 2010; this agrees with findings of other 
studies conducted in Africa where an increasing prevalence has been documented 
over the last three decades (Mbanya et al., 2010, Levitt, 2008, Beran and Yudkin, 
2006).   Meanwhile the reported high prevalence of undiagnosed diabetes also 
reflects the current low level of response to the disease in Africa. This finding may 
therefore support the view that many people in Africa with diabetes still remain 
unaccounted for (Sobngwi et al., 2001, Mbanya et al., 2010).  
From the modelling, it was observed that the prevalence of diabetes and absolute 
number of cases in females were rising at a faster rate compared to males, with the 
female prevalence actually higher than male prevalence in 2000 and 2010. This may 
reflect concerns of some experts who have noted an increase in metabolic syndrome 
among females, especially in many LMIC (Mbanya et al., 2010). It may also point to 
an increasing prevalence of overweight and obesity among African women, which 
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are prominent risk factors for diabetes and many NCDs (Beaglehole, 2011, Mbanya 
and Ramiaya, 2006). In fact, obesity is even now more prevalent among African 
women as this relatively portrays a wealthy status (Mbanya et al., 2010). 
On the properties of the model, the R
2
 for the three years (1990, 2000 & 2010) was 
less than 50%, ranging from 23%-37%. This may mean that the model does not fit 
the data well. The estimates should therefore be cautiously interpreted. However, 
some authors have stated that a low R
2
 may not mean the model is not well-fitted 
(Cameron and Windmeijer, 1995). A detailed discussion on R
2
 has been included 
earlier under hypertension discussion. The model shows an increasing trend in 
diabetes prevalence from 15 years to 80+ years: 0.7% to 21.7% in 1990, 1.3% to 
15.2% in 2000, and 1.6% to 24.4% in 2010. The overall prevalence also increased 
from 2.4% in 1990 to 2.9% in 2000 and 4.0% in 2010. As noted above, increasing 
age has been reported as a major risk for chronic diseases, including diabetes 
(Mbanya et al., 2010). However, this model may need to be cautiously interpreted 
especially with the ongoing rapid epidemiological transition across Africa. The 
inability to appropriately account for urbanization and many NCD risk factors are 
also important factors that must be considered. As noted, it is important not only to 
look at the R
2
 and how well the model fits the data, but also to closely examine if this 
is a reasonable prediction in a scientific context (Cameron and Windmeijer, 1995). 
Meanwhile, increasing prevalence of diabetes was observed in the last two decades 
from the modelled estimates, with an estimated diabetes prevalence of 2.4% in 1990 
increasing to 4.0% in 2010, this accounting for 40% increase in diabetes prevalence 
between 1990 and 2010. These figures are comparable with findings from other 
studies, with an estimated diabetes prevalence of 3.8% (Shaw et al., 2010), and 5% 
(Whiting et al., 2011), both reported by IDF for the year 2010 estimates. In South 
Africa, which many reviews have suggested has the highest diabetes prevalence in 
sub-Saharan Africa (Mbanya et al., 2010), a systematic review reported a prevalence 
of 5.5% among people aged ≥ 30 years (Bradshaw et al., 2007), this estimate is not 
too different from the estimate in the current study. On the number of diabetes cases, 
8.5 million diabetes cases were estimated in Africa among people aged ≥15 years in 
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1990, 13.5 million in 2000, and 24.5 million in 2010. The higher estimates in this 
study (in comparison to previous reports) may be due to ageing and population 
growth (reflecting from the UN population demographics employed in the 
modelling), and failure to account for over-representation of studies with high 
diabetes prevalence, for example from urban areas where diabetes prevalence is 
higher. Looking at previous reports, Wild and colleagues estimated about 7.1 million 
people living with diabetes in sub-Saharan Africa in 2000 and projected to increase 
to 18.6 million by 2030 (Wild et al., 2004); Shaw and colleagues reported a 
prevalence of 12.1 million diabetes cases in Africa in 2010 and projected to increase 
to 23.9 million by 2030 (Shaw et al., 2010); while Whiting and colleagues estimated 
14.7 million diabetes cases in Africa in 2010 and projected to increase to 28 million 
by 2030 (Whiting et al., 2011), see Table 4.2. 
In sub-Saharan Africa however, IHME estimated that DALYs from diabetes 
increased from 2.3 million in 1990 to 4.3 million in 2010 (87% increase), while 
deaths increased by over 100% from 61.1 thousand to 123.7 thousand over the same 
period, respectively (Murray et al., 2012, Lozano et al., 2012).  
Table 4.2. Estimated diabetes prevalence and cases in Africa from different 
studies 
Year Current study* Wild et al.† Shaw et al.*† Whiting et al.*† 
1990 8.5 million (2.4% 
(0.9, 4.1)) 
7.1 million  - - 
2000 13.5 million 
(2.9% (1.7, 3.9)) 
- - - 
2010 24.5 million 
(4.0% (2.7, 6.4)) 




2030 - 18.6 million  23.9 million 
(4.7%) 
28 million (5.9%) 
*Africa (15+ years), †sub-Saharan Africa (all population), *†Africa (20-79 years)  
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Based on these studies (Table 4.2), from 2004 to 2011, the authors reported 
different, yet higher diabetes cases and prevalence rates, for the same reviewed year, 
across the three studies. Just as observed from my estimate, this may reflect 
availability of more data, improved study designs and consideration of demographic 
changes in the continent. However, the two recent studies of Shaw et al. and Whiting 
et al. (conducted in collaboration with the IDF atlas committee) were conducted 
across the whole African continent, but were based on ages 20-79 years. The 
difference in reported estimates of the two studies, within one year separating both 
studies (2010 and 2011), could also point to the fact that newer reports may give 
fairly higher and close estimates of the prevalence of diabetes in Africa, and this 
argument has been noted in several reviews (Sobngwi et al., 2001, Mbanya et al., 
2010).  
Meanwhile, based on Table 4.2, the number of diabetes cases in Africa reported in 
the current study was almost double those reported by IDF in 2010 and 2011. Asides 
the fact that the IDF estimates were reported for people aged 20 to 79 years, the 
current estimates (though based on age 20 years and above) may still not be 
plausible. One main reason is that the epidemiological model did not account for 
demographic variations in an African population, especially with regards to study 
settings and residence, as diabetes prevalence in urban areas is considered to be 
approximately double that in rural areas (Whiting et al., 2011). Over 55% of the 
selected studies were from urban, wealthy centres, and the model did not 
appropriately assign urban estimates to urban population, and rural estimates to rural 
population. As noted in preceding sections, this is a fact that can possibly affect other 
estimates reported in this thesis.  Another factor that could have affected this 
estimate is that the case definition in respective studies could have been more 
inclusive. Additionally, the screening test for cases of diabetes in an individual study 
could have had a sub-optimal test-to-actual positives ratio (TAP ratio). According to 
Campbell and colleagues, the TAP ratio is a parameter or measure of potential bias in 
a disease frequency estimates that summarizes the properties of a diagnostic test and 
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true prevalence of a disease in a population (i.e. ratio of those who test positive to the 
screening test, to the actual number of people who have the disease in the population) 
(Campbell et al., 2008). 
Study limitations 
While the current study endeavoured to give population representative estimates of 
the prevalence of diabetes in Africa for the years 1990, 2000 and 2010, this however 
could have been limited by a number of factors.  
For the pooled diabetes prevalence, I
2
 was 97.9%. This also implies that there is very 
high heterogeneity across selected studies; and at p<0.0001, the heterogeneity is 
statistically significant. There is therefore strong evidence against the null hypothesis 
that studies are evaluating the same effect. For a combination of studies with such 
high heterogeneity, it may also not be appropriate to pool a summary effect. 
However, as reported earlier, there is very low research output in Africa, and the few 
studies have not been conducted under strict international guidelines, so 
heterogeneities can be expected. . In addition, restricting my analysis to studies that 
have the same study design, same sampling frame and same case definition is almost 
impossible.  
Another important limitation is the inability to assess how closely representative 
these estimates were of the larger African population. Importantly, the prevalence 
from individual studies mainly reflect intrinsic characteristics specific to the study 
settings, and should not necessarily be viewed as representative of the region of 
country in which the study was conducted. The estimates should therefore be 
interpreted with caution. Moreover, despite the relatively high number of studies, 
data from many studies were incomplete. This affected my analysis, as results of 
potentially good studies, with clear sampling strategy and study designs, were not 
always detailed and therefore could not be explored further. In addition, some 
authors did not state clearly the diagnostic methods employed. Any of the diabetes 
criteria (earlier described in Methods) were ascribed to these studies if they were 
highly comparable. Age- and sex-specific prevalence could not, in detail, be 
reported, including corresponding prevalence on urban and rural settings, as these 
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were not always provided. As noted in the methods, single age (usually mean age) 
was mostly employed in the modelling. However, of the 45 studies selected, only 4 
studies (8.9%) reported age-specific prevalence estimates that were employed in the 
modelling (Amoah et al., 2002, Duboz et al., 2012, Olatunbosun et al., 1998, Mbanya 
et al., 1997). This means that the estimated diabetes prevalence from the modelling 
may not well represent those of people from individual studies in the extreme age 
groups, i.e. very young and very old. This is a major limitation of this model. 
Determining the mean ages of study samples were also challenging. Some studies 
only gave the lower age limits, and in this case, the UN population estimates for that 
country and the year under review were employed to determine a possible age range. 
One important limitation of this study is the inability to separate the analysis for type 
1 and type 2 diabetes respectively. Most studies were non-specific on the type of 
diabetes being reviewed. This could have given a clearer picture of type-specific 
diabetes in Africa, especially with confirmed reports of higher prevalence of type 2 
diabetes in the continent (Motala et al., 2003).  
However, in view of the increasing prevalence of diabetes with age in Africa, and 
relative association of type 2 with adults, we included studies conducted among 
people aged greater than or equal to 15 years in the final review and analysis. The 
estimates may therefore point to the burden of type 2 diabetes in Africa, for which 
previous studies have reported a higher prevalence in Africa. Additionally, the 48 
selected studies spread across 28 countries in Africa with a total sample size of 
102,517, and all extracted data from these studies have been included in the 
modelling (refer to Table 3.17 and Appendix 4).  
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Public health response to diabetes in Africa 
On the global scene, international organizations have responded well to diabetes 
control and its overall management in Africa, as this is clearly where the disease 
burden is growing fastest in the world (Unwin et al., 2001).  In 2006, WHO and IDF 
jointly came up with recommendations aimed at addressing the rising burden of 
diabetes. Their main focus was on availability and pricing of insulin; they 
recommended equity pricing scheme for insulin for resource poor settings, and also 
encouraged twinning initiatives between high-income countries and LMIC towards 
achieving sustainable diabetes control projects (World Health Organization, 2006). 
The twinning initiative has been successful in some parts of Africa; Diabetes UK 
currently supports diabetes care in Mozambique, Norwegian Diabetes Association 
has been linked with successful diabetes control programmes in Zambia (Beran et al., 
2010, Yudkin et al., 2009), and Novo Nordisk has also led many diabetes control 
initiatives in Africa (Mbanya and Ramiaya, 2006). There have also been some 
reports of support from non-governmental organizations (NGOs); International 
Insulin Federation and Diabetes Mali have helped establish sustainable programmes 
for insulin access and diabetes care in Mozambique, Zambia and Mali (Levitt, 2008, 
Silva-Matos and Beran, 2012b).  
On this premise, many African governments have generally pointed to an appreciable 
increase in the management of diabetes in the continent. It is however clear, based on 
widespread hospital records, and results of epidemiological surveys, the statement 
was far too generalized and merely political, stating that a structured and organized 
health care system for diabetes in still lacking (Beaglehole, 2011, Mbanya and 
Ramiaya, 2006).   
Challenges affecting diabetes control in Africa include poor financing, lack of 
awareness, inherent cultural beliefs, lack of trained health staffs, dearth of 
information on diabetes, poor data management system, and state of health systems, 
among others (Sobngwi et al., 2001). More donors and high political involvement 
have been advocated towards improving the financial strengths of resource-poor 
settings (Mbanya and Ramiaya, 2006). In many areas, due to high cost of oral 
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hypoglycemic drugs, many still cannot afford or do not have access to newer and 
more effective drugs (Idemyor, 2010).  
A high discrepancy has been observed in health care access and diabetes 
management between rural and urban areas (Levitt, 2008). This has been linked to 
lack of awareness in many rural areas, especially on availability of facilities for 
detection and monitoring diabetes (Mbanya and Ramiaya, 2006). In fact, many still 
patronize alternate healing centres, due to inherent cultural beliefs, and patients often 
present back to standard health facilities at advanced stages of illness  (Mbanya et al., 
2006). In urban areas, many health centres cannot adequately screen and treat the 
complications of diabetes (Mbanya et al., 2006). Most health centres do not have 
endocrinologists, and when they are available, there are no facilities or well-equipped 
diabetic units to manage patients (Beran and Yudkin, 2006, Levitt, 2008). In many of 
these settings, most causes of diabetes deaths could have been preventable (Mbanya 
and Sobngwi, 2003).  
Experts have reported that the hallmark for improvement in diabetes care and 
management in Africa lies in the development of favourable policy for diabetes at 
various country levels in Africa (Mbanya et al., 2006). Reports show that many 
African countries do not have a policy framework for diabetes control and this has 
affected the management and control of the disease in the continent (Beran and 
Yudkin, 2006).  
This study has reported an increasing prevalence of diabetes in Africa, and this has 
presented a huge burden on individuals, society and government. The rapid rise in 
urbanization, population and life expectancies across the African continent, without 
any counter control measures has been hugely responsible for this increasing 
prevalence. It has been identified that information on diabetes epidemiology has 
increased; however, there is still dearth of data especially on chronic complications 
of diabetes (retinopathy, nephropathy and neuropathy). For example, Holmes and 
colleagues reported that, up till 2009, there were 84 population-based cross-sectional 
studies on diabetes in Africa, accounting for 7 studies per million people with 
diabetes in Africa, and this represent 8% of the total publications on diabetes in the 
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United States (Holmes et al., 2010). Therefore, more research on diabetes is still 
needed to adequately quantify the burden in the region. Largely, collaborations 
encompassing government, policymakers, diabetes associations, NGOs, donors and 
many stakeholders across several parts of the world may be effective in Africa. We 
hope the findings of this research can address these challenges, encourage more 
research and networks among experts, and help towards improved management and 
control of diabetes in Africa 
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4.3 CANCER 
This study attempted to provide continent-wide pooled estimates of major cancers in 
Africa. Data employed were mainly from population based cancer registries. In the 
current study, I reported estimates of 12 major cancers in Africa (cervical, breast, 
prostate, ovary, oesophagus, bladder, Kaposi, liver, stomach, colorectal, lung and 
non-Hodgkin lymphoma). As data employed in the analysis were based on 
population based registries, the pooled estimates provided were based on a total 
population of about 33 million. This is the largest sample size from which estimates 
have been provided in this thesis. 
The pooled estimate revealed that cervical cancer, breast cancer, Kaposi sarcoma, 
liver cancer and colorectal cancer were the top five cancers among women, while 
prostate cancer, Kaposi sarcoma, cancer of the oesophagus, liver cancer and lungs 
cancer were the top five cancers among men (Table 4.3). These orders of top cancers 
reported in this study are similar to those reported by the GLOBOCAN studies. For 
example, in 2002, GLOBOCAN reported that the top cancers among women in 
Africa were cervix, breast, liver, stomach and Kaposi; and among men, prostate, 
liver, Kaposi, stomach and lungs (Parkin et al., 2005, Parkin et al., 2008). The 2008 
GLOBOCAN study did not specify the incidence rates of Kaposi sarcoma among 
men and women, however, the top five cancers among women in Africa were cervix, 
breast, liver, colorectal and non-Hodgkin, and among men, prostate, liver, lungs, 
colorectal and oesophagus (Ferlay et al., 2010, Jemal et al., 2011) (Table 4.3). While 
these GLOBOCAN studies have provided estimates on major cancer types in Africa 
over the years, there are still concerns if their modelling truly reflects the burden of 
cancers in the African population. Some of their limitations include non-availability 
of incidence and mortality data from certain parts of Africa. Estimates provided were 
said to be based on large data sets which have been modelled to account for 
incidence and mortality rates by age, country and year. Sources of these datasets are 
said to be from cancer registries’ data submitted to the International Agency for 
Research on Cancer (IARC) and the International Association of Cancer Registries 
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(IACR). As noted earlier in my methods, these data are not readily available and 
could not afford me further opportunity for direct comparisons. Besides, other details 
on the statistical analysis and modelling are not usually provided. This point to the 
general observation in the introduction that there is little or no reliable data to work 
with in Africa and that most global models (like the GLOBOCAN) are based on data 
from other non-African countries (in this case, the large data set) inputted into 
African countries. 
Meanwhile, according to the 2010 IHME GBD estimates, the top five cancers 
contributing to global DALYs and deaths were lungs, liver, stomach, colorectal and 
breast (Table 4.4). It may be inappropriate to make direct comparisons with these 
estimates as they are global estimates and may not necessarily be applicable 
specifically to the African region.  
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Table 4.3. Summary of cancer incidence rates (per 100,000 person years) among 
men and women from selected published reports 
Site 1990 (Parkin et al., 
1999) 
2000* (Parkin et 
al., 2001a) 
2002 (Parkin et 
al., 2005, Parkin 
et al., 2008) 
2008 (Ferlay et 
al., 2010, Jemal et 
al., 2011) 
2014 Current study 
(95% CI) 
 M F M F M F M F M F 

































Lung 1.2-18.1 0.5-5.6 4.9 1.8 2.4-
23.1 

















4.5 6.7 5.8 (4.2, 7.4) 
Cervix 7.3-30.4 31 29.3 28.0 28.2 (22.1, 34.4) 
Breast 8.6-22.8 22 23.4 25.2 17.7 (13.0, 22.4) 
Ovary 2.0-4.7 - 4.3 4.2 3.6 (2.7, 4.4) 
Prostate 2.6-16.9 19.8 16.0 17.5 14.5 (10.9, 18.0) 
*sub-Saharan Africa, ⱡ range values given 
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Table 4.4. Global and Sub-Saharan African DALYs and deaths from major 
cancers 
CANCERS GLOBAL SUB-SAHARAN AFRICA 
DALYs (millions) DEATHS (millions) DALYs (thousands) DEATHS (thousands) 
1990 2010 1990 2010 1990 2010 1990 2010 
All sites 148.1 188.5 5.8 8.0 7406.5 11033.0 231.2 352.0 
Oesophagus 8.1 8.9 0.34 0.4 498.8 620.3 18.7 24.3 
Stomach  18.5 16.4 0.77 0.75 512.2 622.4 18.9 24.1 
Liver  13.2 19.1 0.46 0.75 1047.7 1395.1 32.4 45.0 
Lung 23.9 32.4 1.03 1.53 378.3 521.1 14.3 20.1 
Breast  8.8 12.0 0.32 0.44 358.6 727.3 11.5 23.3 
Cervix  5.6 6.4 0.19 0.23 1040.8 1387.1 33.0 45.0 
Ovary  3.0 4.1 0.11 0.16 93.7 167.8 3.0 5.4 
Prostate 2.4 3.8 0.16 0.26 100.2 219.7 5.6 12.3 
Colorectal 10.6 14.4 0.49 0.71 257.8 483.7 9.4 17.7 
Bladder  2.4 3.0 0.12 0.17 96.7 125.6 3.8 5.0 
NHL 4.5 5.9 0.14 0.21 444.1 694.0 9.3 15.3 
Source: (Lozano et al., 2012, Murray et al., 2012)
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4.3.1 Observations relevant to some specific types of cancers in Africa 
In the current study however, the pooled incidence rate for cervical cancer was 28.2 
per 100,000py, which was also the highest cancer incidence reported. This is 
comparable with the 2002 and 2008 GLOBOCAN estimates for Africa at 29.3 and 
28.0 per 100,000py respectively, which were also the highest incidence rates 
reported by the respective studies (Ferlay et al., 2010, Parkin et al., 2005), further 
underpinning the high burden in the continent (Table 4.3). This is further supported 
by previous reports, in which cervical cancer is rated the second leading cancer 
among women, but however the most common cancer in Africa and many low- and 
middle-income countries (Ferlay et al., 2010, Parkin et al., 2008).  In a related study, 
Forouzanfar and colleagues reported that the cumulative probability of incidence of 
cervical cancer between 1980 and 2010 was highest in sub-Saharan Africa, ranging 
from 2.7 in West to 4.1 in Central Africa, respectively (Forouzanfar et al., 2011). 
Having been established that almost all cervical cancer cases result from human 
papilloma virus (HPV) infection (Ferlay et al., 2010, Parkin et al., 2005), it is 
believed that the low coverage of HPV vaccine, low cost cervical screening and other 
interventions targeted at HPV may have, in most instances, led to the relatively high 
burden of cervical cancer in the region (Forouzanfar et al., 2011). For example, 
according to the WHO, HPV vaccine was only introduced in 41 countries globally in 
2012, and there was no detail of an African country that is fully involved in this 
immunization scheme (World Health Organization, 2014c). However, in a recent 
review in sub-Saharan Africa, only six countries were identified to have met the 
GAVI Alliance requirements for supporting the introduction of HPV vaccine 
(Perlman et al., 2014). Meanwhile, according to the 2010 IHME GBD estimates, 
there were about 6.4 million DALYs and 230 thousand deaths from cervical cancer 
worldwide in 2010 (Lozano et al., 2012, Murray et al., 2012). This is not based on 
the African population; therefore their estimates cannot be compared to the current 
study. In sub-Saharan Africa however, IHME estimated that DALYs from cervical 
cancer increased from 1 million in 1990 to 1.4 million in 2010 (40% increase), while 
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deaths increased by 36.4% from 33,000 to 45,000 over the same period, respectively 
(see Table 4.4 for details) (Murray et al., 2012, Lozano et al., 2012). 
Previous reports have shown that breast cancer is the leading cancer among women 
and second most common cancer globally (Jemal et al., 2011). It also has the highest 
survival rates due to improved medication and treatment response (Soerjomataram et 
al., 2012, Coleman et al., 2008). According to the 2010 IHME GBD estimates, there 
were about 12 million DALYs and 440 thousand deaths from breast cancer 
worldwide in 2010 (Lozano et al., 2012, Murray et al., 2012). Again, this cannot be 
compared to the current estimates in this study, as they broadly based on the total 
world population. In sub-Saharan Africa however, IHME estimated that DALYs 
from breast cancer increased from 358,600 in 1990 to 727,300 in 2010 (over 100% 
increase), while deaths also increased by over 100% from 11,500 to 23,300 over the 
same period, respectively (see Table 4.4 for details) (Murray et al., 2012, Lozano et 
al., 2012). The pooled estimate from this study was 17.7 per 100,000py. This is also 
the second highest incidence rate reported in this study, but however remarkably 
lower than the GLOBOCAN 2002 and 2008 estimates at 23.4 and 25.2 per 
100,000py respectively (Table 4.3). The relatively lower estimate reported in this 
study in comparison to previous reports may be because this is not an age-
standardized statistical synthesis and in fact does not include any further modelling 
and consideration of population demographics. However, higher breast cancer 
incidence rates generally in most parts of Africa may be due to higher prevalence of 
obesity, estrogen exposures, smoking, and fats consumption, which is peculiar 
among urban African dwellers. In this study, we could not explore this further as 
most studies did not provide incidence rates separately for urban and rural dwellers. 
Meanwhile, Forouzanfar and colleagues further reported that the cumulative 
probability of incidence of breast cancer between 1980 and 2010 was second highest 
in sub-Saharan Africa, ranging from 2.9 in Central and West to 5.6 in Southern 
Africa, respectively (Forouzanfar et al., 2011). 
There has been a gradual increase in the incidence of prostate cancer in Africa in the 
last two decades. In 1990, incidence rates of prostate cancer were between 2.6 and 
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16.9 per 100,000 across the main African regions in 1990 (Center et al., 2012, Pisani 
et al., 1999). In 2007, reports show that prostate cancer incidence rates rate ranges 
from 4.7-19.8 per 100,000py in West Africa to 10.7-38.1 per 100,000py in East 
Africa (Chu et al., 2011). GLOBOCAN estimated an incidence rate of 16.0 per 
100,000 accounting for 10.6% of all male cancers in 2002 (Parkin et al., 2005), and 
an incidence of 17.5 per 100,000py accounting for over 12% of male cancers in 2008 
(Ferlay et al., 2010). From this study, the estimated incidence rate was 14.5 per 
100,000py. The relatively lower estimate reported may still reflect the lack of 
detailed modelling and a consideration of age and rapidly population demographics 
in Africa. Meanwhile, according to the 2010 IHME GBD estimates, there were about 
3.8 million DALYs and 260 thousand deaths from prostate cancer worldwide in 2010 
(Lozano et al., 2012, Murray et al., 2012). In sub-Saharan Africa however, IHME 
estimated that DALYs from prostate cancer increased from 100,200 in 1990 to 
219,700 in 2010 (over 100% increase), while deaths also increased by over 100% 
from 5,600 to 12,300 over the same period, respectively (see Table 4.4 for details) 
(Murray et al., 2012, Lozano et al., 2012).  
The high prevalence of HIV/AIDs in Africa is the single most important factor for an 
increase in HIV-associated cancers, mainly Kaposi sarcoma caused by Kaposi's 
sarcoma-associated herpes virus (KSHV) (Feller et al., 2010, Mosam et al., 2009). 
Many studies have reported interactions between HIV/AIDS and many NCDs, 
especially cancers (UNAIDS, 2011). According to Byass and colleagues, the 
mortality rates of many NCDs are relatively higher among HIV positives compared 
to negatives. For cancers, oral neoplasms had the highest mortality rate ratio at 19.2, 
followed by reproductive neoplasms (female) 14.3, digestive neoplasms 13.0, breast 
neoplasms (female) 9.6, respiratory neoplasms 6.0 and other unspecified neoplasms 
7.7(Byass et al., 2013a). It is believed that a better understanding of this interaction, 
while drawing from the HIV control experience, may help in instituting appropriate 
response to the growing burden of NCDs in Africa. Further details on HIV and 
NCDs are in Section 1.1.4 and Table 1.3. 
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Meanwhile, in this study, the incidence rates of Kaposi sarcoma were 14.3  and 6.5 
per 100,000 among men and women respectively, which is higher than the incidence 
rate reported in the 2002 GLOBOCAN (12.3 and 4.6 per 100,000) (Table 4.3) 
(Parkin et al., 2005). The current estimate shows that Kaposi sarcoma is rated the 
second commonest cancer among men (after prostate cancer at 14.5 per 100,000py), 
and third commonest cancer among women (after cervical and breast cancers at 28.2 
and 17.7 per 100,000py, respectively). This is almost in line with previous reports, in 
which Kaposi sarcoma is rated the most common cancer among men and second 
most common cancer among women (Parkin et al., 2008). Meanwhile, in Eastern and 
Southern Africa, with higher prevalence rates of HIV/AIDS, Kaposi sarcoma is the 
most commonly diagnosed cancer with incidence rate 20 times as high as in other 
parts of Africa (Parkin et al., 2008, Chokunonga et al., 1999). 
Cancer of the oesophagus is a leading cause of cancer among southern and eastern 
African men, with incidence rates seven times higher than observed in central, 
northern and western Africa (Parkin et al., 2008, Madebo et al., 1994, Sumeruk et al., 
1992). In Africa, a geographical predisposition has been thought to be responsible for 
the high incidence especially in Kenya and the Eastern Cape province in South 
Africa where a remarkably high incidence (76.6/100,000py) was recorded among 
men in the 1990s (Parkin et al., 2008, Parkin et al., 2003). The pooled estimate from 
this study is 13.4 per 100,000 among men, which is relatively higher than the 2002 
and 2008 GLOBOCAN estimates at 7.8 and 6.7 per 100,000py, respectively (Table 
4.3) (Ferlay et al., 2010, Parkin et al., 2005). This may be indicative of a gradually 
increasing burden of oesophageal cancers among men in these sub-regions. Reports 
show that increased smoking, harmful use of alcohol, HPV infection, poor 
consumption of fruits and vegetables, consumption of foods contaminated with 
Fusarium verticillioides, a filamentous fungus that produces carcinogenic mycotoxin 
fumonisin B2 are indicative (Hendricks and Parker, 2002). Meanwhile, according to 
the 2010 IHME GBD estimates, there were about 8.9 million DALYs and 400 
thousand deaths from oesophageal cancer worldwide in 2010 (Lozano et al., 2012, 
Murray et al., 2012). In sub-Saharan Africa however, IHME estimated that DALYs 
from oesophageal cancer increased from 498,800 in 1990 to 620,300  in 2010 (24.4% 
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increase), while deaths increased by 30% from 18,700 to 24,300 over the same 
period, respectively (see Table 4.4 for details) (Murray et al., 2012, Lozano et al., 
2012).  
Liver cancer is rated among the leading causes of cancers in Africa due to its 
infective aetiology and association with aflatoxin B1, which are relatively more 
prevalent in Africa (Parkin et al., 2003). The pooled estimate from this study was 
12.6 and 5.7 per 100,000py among men and women, respectively. This is quite 
comparable with the GLOBOCAN 2002 and 2008 estimates at 14.8 and 11.6 per 
100,000 among men, and 6.2 and 5.3 per 100,000py among women, respectively 
(Ferlay et al., 2010, Parkin et al., 2005) (Table 4.3). As noted above, the high 
incidence of liver cancer in Africa reported is believed to be due to chronic infections 
from hepatitis B virus (HBV) and hepatitis C virus (HCV) in most parts of Africa, 
where it is rated the most common cancer, constituting about 25% of all cancers in 
men and women (Mbakop et al., 1992, Parkin, 1994). Available evidence shows that 
interventions addressing these chronic viral infections in Africa are poor (Burnett et 
al., 2011).  
According to the WHO, the global coverage of Hepatitis B vaccine was about 79%, 
covering 181 countries in 2012, following its recommended introduction into routine 
immunization schedules of all endemic countries in 1992 (World Health 
Organization, 2014c). However, an estimated 22.6 million infants are still missing 
out on three doses of the vaccine, with most of these residing in Africa (World 
Health Organization, 2014c). Hepatitis B vaccine is now also among the routine 
infant immunization programmes in some African countries (Burnett et al., 2011). 
The vaccine is given in two or three serial doses, usually introduced at 6 weeks or 3 
months, and repeat doses given at 6 months and 9 months, depending on the national 
immunization programme of each country (Burnett et al., 2011). Studies have shown 
that Hepatitis B vaccination may provide long term protection in more than 90% of 
healthy people (Shepard et al., 2006). However, some studies have stated that 
vaccine-induced immunity acquired at this early life, as measured by anti-HB levels, 
may have declined around ages 30-40 years and above, especially among vaccinees 
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who are immunocompromised (Shepard et al., 2006).  As such, when babies who 
received Hepatitis B vaccine attain this age group (≥30 years), they may be 
susceptible to HBV if booster dozes of the vaccine are not given. Follow-up studies 
have further confirmed that most vaccinees (at 10 or more years post-vaccination) 
may develop a rapid rise in anti-HB when booster dozes of Hepatitis B vaccine are 
given (Shepard et al., 2006). Moreover, another important factor is that most of 
today’s global adults were born before Hepatitis B vaccine was introduced and 
implemented (Byass, 2014). Thus, an effective intervention, which gives hope for a 
reduction in liver disease in the near future, is to administer booster doses of 
Hepatitis B vaccine to all adults (Byass, 2014). As well as boosting immunity of 
those who have been vaccinated, this can also ensure some adults are given their first 
doses of the vaccines. However, a South African study suggested that the proportion 
of an adult population in an African setting that is fully vaccinated may be low, as 
the coverage among health care workers, which should be presumably high, was only 
19.9% (Burnett et al., 2011).  Based on the 2010 IHME GBD estimates, there were 
about 19.1 million DALYs and 752 thousand deaths from liver cancer worldwide in 
2010 (Lozano et al., 2012, Murray et al., 2012). In sub-Saharan Africa however, 
IHME estimated that DALYs from liver cancer due to hepatitis B infection increased 
from 491,400 in 1990 to 656,100 in 2010 (33.5% increase), while deaths increased 
by 38.8% from 15,200 to 21,100 over the same period, respectively (see Table 4.4 
for details) (Murray et al., 2012, Lozano et al., 2012).  
High prevalence of Schistosoma Haematobium parasite (which causes bladder 
infection- Schistosomiasis) is thought to be the link to the relatively higher incidence 
of bladder cancer among men in Africa, especially in resource-poor riverine 
communities (Fedewa et al., 2009). The highest incidence and mortality globally was 
reported in Northern Africa, especially in Egypt with an incidence rate of about 
37.1/100,000py in the 2000s (Heyns and van der Merwe, 2008). Some western 
African countries (Mali and Niger) also have higher incidences compared to other 
parts of Africa (Heyns and van der Merwe, 2008). This study reported an estimate of 
5.8 per 100,000py among men, which is fairly comparable with the GLOBOCAN 
2002 and 2008 estimates at 4.5 and 6.7 per 100,000py, respectively (Ferlay et al., 
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2010, Parkin et al., 2005) (Table 4.3). From the 2010 IHME GBD estimates, there 
were about 3.0 million DALYs and 170 thousand deaths from bladder cancer 
worldwide in 2010 (Lozano et al., 2012, Murray et al., 2012). In sub-Saharan Africa 
however, IHME estimated that DALYs from bladder cancer increased from 96,700 
in 1990 to 125,600 in 2010 (30% increase), while deaths increased by 31.6% from 
3,800 to 5,000 over the same period, respectively (see Table 4.4 for details) (Murray 
et al., 2012, Lozano et al., 2012).  
In the 1990 GLOBOCAN study, the incidence rate of ovarian cancer ranged between 
2.0 and 4.7 per 100,000py across the main African regions (Parkin et al., 2003, 
Parkin et al., 1999). In 2002 and 2008, GLOBOCAN reported incidence rates of 4.3 
and 4.2 per 100,000py in Africa, respectively (Table 4.3) (Ferlay et al., 2010, Parkin 
et al., 2005). In this study, the estimated ovarian cancer incidence rate was 
comparable with previous reports at 3.6 per 100,000py. According to the 2010 IHME 
GBD estimates, there were about 4.1 million DALYs and 160 thousand deaths from 
ovarian cancer worldwide in 2010 (Lozano et al., 2012, Murray et al., 2012). For 
reasons already noted above, this can still not be compared to the African population. 
In sub-Saharan Africa however, IHME estimated that DALYs from ovarian cancer 
increased from 93,700 in 1990 to 167,800 in 2010 (79.1% increase), while deaths 
increased by 80% from 3,000 to 5,400 over the same period, respectively (see Table 
4.4 for details) (Murray et al., 2012, Lozano et al., 2012). Meanwhile, some studies 
have shown racial differences in the risk of ovarian cancer, with risk lower among 
women of African descent than observed among white women (Ness et al., 2000). 
This may be partly responsible for the lower incidence rate reported in this study. 
As noted in the introduction, lung cancer is rated the most common cancer globally 
(Ferlay et al., 2010). In this study, a high incidence rate was estimated among men 
(9.3 per 100,000py) compared to a very low rate among women (1.9 per 100,000py). 
This estimate is comparable with the 2008 GLOBOCAN estimate at 8.4 and 2.7 per 
100,000py among men and women respectively (Ferlay et al., 2010) (Table 4.3). 
Generally, the prevalence of lung cancer is lower in many African countries (Ferlay 
et al., 2010).  When compared to global estimates of cancers, the lower incidence 
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rate in Africa may be due to relatively lower smoking rates and lesser exposures to 
industrial and environmental pollution than some other parts of the world (Fadahun 
et al., 2011). The gender difference noted above may still reflect the reported higher 
smoking rates among men compared to women in the Africa region (Jha et al., 2002). 
Meanwhile, according to the 2010 IHME GBD estimates, there were about 32.4 
million DALYs and 1.53 million deaths from lung cancer worldwide in 2010 
(Lozano et al., 2012, Murray et al., 2012). In sub-Saharan Africa however, IHME 
estimated that DALYs from lung cancer increased from 378,300 in 1990 to 529,100 
in 2010 (40% increase), while deaths increased by 41% from 14,300 to 20,100 over 
the same period, respectively (see Table 4.4 for details) (Murray et al., 2012, Lozano 
et al., 2012).  
Colorectal cancer is also increasing in Africa (Dakubo et al., 2010). In this study, the 
pooled estimates of colorectal cancer among men and women were 5.3 and 3.9 per 
100,000py, respectively. This is comparable with the 2002 and 2008 GLOBOCAN 
estimates of colorectal cancers at 5.4 and 6.9 per 100,000py among men, and 4.2 and 
5.0 per 100,000py among women, respectively (Ferlay et al., 2010, Parkin et al., 
2005) (Table 4.3). A 2012 study on sub-Saharan Africa reported an incidence rate of 
4.38 and 3.69 per 100,000py among men and women, respectively (Graham et al., 
2012), which is also comparable with the current estimate. The increasing incidence 
of colorectal cancer in Africa has been linked to a gradual adoption of urban diets 
with high fats and cholesterol content, and a low consumption of fruits, vegetables 
and whole grains (Dakubo et al., 2010). However, in the 2010 IHME GBD estimates, 
there were about 14.4 million DALYs and 710 thousand deaths from colorectal 
cancer worldwide in 2010 (Lozano et al., 2012, Murray et al., 2012). In sub-Saharan 
Africa however, IHME estimated that DALYs from colorectal increased from 
257,800 in 1990 to 483,700 in 2010 (87.6% increase), while deaths increased by 
88.3% from 9,400 to 17,700 over the same period, respectively (see Table 4.4 for 
details) (Murray et al., 2012, Lozano et al., 2012).  
Many studies have reported that the incidence of stomach cancer is high in Africa 
(Ghoshal et al., 2010). From this study, the estimated incidence rates were 5.6 and 
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3.8 per 100,000 among men and women, respectively. This is comparable with the 
2002 and 2008 GLOBOCAN estimates of stomach cancers at 6.2 and 4.7 per 
100,000 among men, and 4.9 and 3.3 among women, respectively (Ferlay et al., 
2010, Parkin et al., 2005)  (Table 4.3). The relatively high incidence rate may be due 
to presence of Helicobacter Pylori infection in many parts of Africa, which is 
indicated in most cases of peptic ulcer disease (Ghoshal et al., 2010). In fact, in some 
Southern African regions, the incidence of stomach cancer has been reported to be as 
high as 98/100,000 due to mix of several population groups and races (Segal et al., 
2001). From the 2010 IHME GBD estimates, there were about 16.4 million DALYs 
and 755 thousand deaths from stomach cancer worldwide in 2010 (Lozano et al., 
2012, Murray et al., 2012). In sub-Saharan Africa however, IHME estimated that 
DALYs from stomach cancer increased from 512,200 in 1990 to 622,400 in 2010 
(21.5% increase), while deaths increased by 27.5% from 18,900 to 24,100 over the 
same period, respectively (see Table 4.4 for details) (Murray et al., 2012, Lozano et 
al., 2012).  
Previous reports have shown that non-Hodgkin lymphoma is rare in Africa with 
incidence rates relatively lower compared to those of European and North American 
countries (Sissolak et al., 2010). From this study, incidence rates of 3.9 and 2.9 per 
100,000 were estimated among men and women, respectively. This is lower 
compared with the 2002 and 2008 GLOBOCAN estimates of stomach cancers at 5.6 
and 6.3 per 100,000 among men, and 3.9 and 4.1 among women, respectively (Ferlay 
et al., 2010, Parkin et al., 2005) (Table 4.3). These lower figures, as explained 
earlier, may further underscore the lack of detailed statistical synthesis and non-
consideration of the age-specific incidence rates (including those of childhood 
cancer, which has high incidence rates of Burkitt’s lymphoma) and rapidly evolving 
population structure in Africa. Available evidence suggests that Burkitt’s lymphoma, 
a variant of NHL and monoclonal B-cell lymphoma, which accounts for about 25-
50% of childhood cancers in eastern, southern and western African regions, may be 
responsible for an increasing trend in the incidence of NHL (Lewis et al., 2012). This 
has been linked to an infection with the Epstein Barr Virus (EBV), which causes the 
oncogenic feature (deregulation of the C-MYC oncogene) responsible for the 
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lymphoma (Lewis et al., 2012). Global studies rated NHL as the fifth commonest 
cancer in Africa, this is still subject to more detailed disease burden estimation 
(Ferlay et al., 2010). According to the 2010 IHME GBD estimates, there were about 
5.9 million DALYs and 210 thousand deaths from NHL worldwide in 2010 (Lozano 
et al., 2012, Murray et al., 2012). In sub-Saharan Africa however, IHME estimated 
that DALYs from NHL increased from 444,000 in 1990 to 694,000 in 2010 (56.3% 
increase), while deaths increased by 64.5% from 9,300 to 15,300 over the same 
period, respectively (see Table 4.4 for details) (Murray et al., 2012, Lozano et al., 
2012).  
Study limitations 
Generally, this study attempted to provide sex-specific incidence rates of leading 
cancers in Africa, and comparing these with reported global estimates, towards 
appreciating the variations in reported estimates, and informing various stakeholders 
on the problems arising from lack of detailed cancer registration in Africa. However, 
this study could have been constrained by a number of factors. While the retained 
studies spread across various parts of Africa, only 27 population-based registries 
were represented. Most of these cancer registries are restricted to specific locations in 
the respective countries, and do not all cover national populations. It is therefore 
difficult to say that the registry reports were representative of the total population of 
the country where the registry is based. In addition, this study mainly included very 
few registries from rural areas where more people generally reside in Africa and they 
typically reported lower cancer incidence rates, compared to the urban registries that 
reported higher incidence rates; this may thus potentially affects our estimates with 
an under-estimation of cancer burden in rural areas and an over-estimation in urban 
areas. Moreover, not all studies reported basis of cancer diagnosis, it was therefore 
based on evidences of epidemiological rigours and clinical case ascertainment 
(active/ passive case finding) that some studies were included. Another limitation, 
which actually resulted in the lack of modelling and estimation of number of specific 
cancer cases, was that many studies only gave overall crude incidence rates, and did 
not report any age-specific incidence rates.  
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For all the pooled cancer prevalence rates, I
2
 ranged between 89.0-99.1%. This 
implies that there is very high heterogeneity across selected studies; and at p<0.0001, 
the heterogeneity is statistically significant. There is therefore strong evidence 
against the null hypothesis that studies are evaluating the same effect. For a 
combination of studies with such high heterogeneity, it may also not be appropriate 
to pool a summary effect. However, as reported earlier, there is very low research 
output in Africa, and the few studies have not been conducted under strict 
international guidelines, so heterogeneities can be expected. In addition, restricting 
my analysis to studies that have the same study design, same sampling frame and 
same case definition is almost impossible. Lastly, I cannot say with all certainty how 
closely representative these estimates were of the larger African population. However, 
this study provides ample evidence on the need for more detailed cancer data 
collation and registration across many African settings towards ensuring a true 
burden of cancer is reflected. 
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Public Health response to Cancer in Africa 
i. Perceptions on cancers in Africa 
Perceptions on cancers among Africans are affected by a wide range of socio-cultural 
behaviours, including inherent beliefs and norms (Parkin, 1994).  
Healthcare-seeking behaviour: A survey in Lagos, Nigeria, showed that 81.7% of 
cervical cancer patients had never heard of the disease prior to diagnosis, 98% 
believed that the cancer was not serious and could be cured, 50% thought the 
symptoms were due to irregular menses or a sexually transmitted infection, while 
only 9% knew the disease was cervical cancer and could have bad prognosis 
(Anorlu, 2008). Moreover, many African women with cervical and breast cancers 
present late to health facilities because their husbands have not allowed them to do so 
early enough (Anorlu, 2008). This further highlights the gender inequity plaguing 
many indigenous African communities (Parkin et al., 2008). It is also important to 
note that some inherent traditional practices have put many African women at risk of 
cancers, as early marriage and high parity are quite predominant (Sitas et al., 2008). 
Health service delivery: The behavioural challenge facing the delivery of health 
services may also be related to stigmatization and discrimination (Lingwood et al., 
2008). Many a time, in the course of receiving care and treatment, cancer patients in 
Africa have been subjected to varying degrees of stigmatization, especially from 
health workers (Sitas et al., 2008), and this further reduces the patronage of standard 
health services. In fact, when care is finally sought, many of these cancer patients 
prefer to be taken to traditional healers, where they believe their illnesses are kept 
secret and the services rendered are thought to be comparatively cheaper. They only 
present to standard health facilities when the cancer is just too advanced for any 
curative treatment (Sitas et al., 2008) 
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ii. Challenges affecting established architecture for cancer care in Africa 
Governance and Policies: As noted above, tobacco smoking is increasing in many 
African countries due to lack of regulatory policies on its sales and use (Otañez et al., 
2009). In fact, due to the support many tobacco companies give to African 
governments, they have been able to manoeuvre policymakers in favour of tobacco 
sales and use (Saloojee and Dagli, 2000, Otañez et al., 2009). Experts have 
clamoured for better public awareness on the need for increased taxation on tobacco 
products, with money derived diverted into useful health promotion measures 
(Groenewald et al., 2007b). In addition, many African countries do not offer patient-
friendly policies related to taxes on cancer medications and screening technology, 
and as such, some chemotherapy drugs have been found to cost about 1000% more 
than the costs in United Kingdom and other parts of Europe (Lingwood et al., 2008). 
Due to this high taxation and the associated high cost of cancer treatment, the 
African Organization for Research and Training in Cancer (AORTIC) is now 
fronting continent-wide lobbying to convince African governments to cut taxes on 
drugs, including those on medical equipment (African Organization for Research and 
Training in Cancer, 2013).  
Health programmes and service delivery: Recent studies show that some African 
countries are beginning to step-up efforts to address cancers by convening awareness 
campaigns programmes on cancers and its risk factors (Sitas et al., 2008). In 
addition, screening programmes for cervical cancer, breast cancer and Burkitt’s 
lymphoma have been established in some countries (Morris, 2003, Albrecht, 2011). 
However, the major challenge lies in the sustainability, as ongoing programmes have 
been aborted abruptly in many cases (Lingwood et al., 2008). Palliative care 
programmes do exist in some settings, but not well equipped to offer pain relieving 
medications and overall well-being of cancer patient (Jemal et al., 2012, Harding et 
al., 2013, Grant et al., 2011). Cancer treatment is gradually improving in Africa, but 
cancer screening and detection, especially in rural areas still remain an important 
public health issue (Kingham et al., 2013). The Oxford Declaration calls for African 
governments to work with international partners and NGOs to implement effective 
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cancer screening programmes using appropriate medical technology (Oxford 
Declaration, 2009). 
Training and health workforce: Training programmes specific for cancer 
management are rare in Africa (African Organization for Research and Training in 
Cancer, 2013, Adebamowo and Akarolo-Anthony, 2009). This is one of the major 
challenges that has resulted in the high mortalities from cancers in Africa, as many 
medical practitioners do not have the requisite expertise to manage cancers, 
especially in rural Africa (Jemal et al., 2012). As highlighted above, health workers 
are still not enough to meet the increasing demand from many diseases, including 
cancers, in Africa (Parkin et al., 2008). Reports show that only 3% of the world 
health workers currently live and work in sub-Saharan Africa (de-Graft Aikins et al., 
2010a). In recent times, there has been an increase influx of medical practitioners to 
high income countries due to poor welfare and condition of services (Mungal-Singh, 
2011). 
Health system funding: Generally, the health care systems of many African countries 
are poorly equipped, despite accounting for a greater fraction of the global cancer 
burden (Lingwood et al., 2008). From the 2009 Oxford Declaration, it was clearly 
evident that many African governments do not recognize the growing cancer 
epidemics in the continent, and as such many health systems have not been 
adequately equipped to address this (Oxford Declaration, 2009). Budget allocation 
for cancers by many African governments is low, as this is rarely considered a 
priority due to the high burden from HIV/AIDS, tuberculosis and malaria (Boyle et 
al., 2008). In the wake of cost-effective measures for cancer control, including 
vaccination against infectious causes, donor funding (from international 
organizations and non-governmental organizations) for cancer control has been 
greatly advocated (Adebamowo and Akarolo-Anthony, 2009).
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iii. Opportunities for improvement 
Lingwood et al. noted that to establish a comprehensive cancer care programme in 
Africa, an integrated effort of clinicians, oncologists, epidemiologists and public 
health experts within an effective health system is paramount, as these are 
opportunities that can prompt effective control, detection and management of cancer 
in the region (Lingwood et al., 2008). These are discussed further under this section. 
Screening, Diagnosis and Treatment: The WHO has championed the screening and 
early detection of cancers globally, especially in developing countries where the 
burden of cancers is highest (World Health Organization, 2013a). Research findings 
show that one third of cancers are preventable and/ or treatable in developing 
countries if detected early, thus making the presence of an effective screening and 
diagnosis system across countries a vital component in cancer management (Cazap, 
2012). However, this is rarely the case in Africa, as resources are far too limited to be 
diverted to cancer diagnosis in the face of other health challenges (Parkin et al., 
2008). For example, Albrecht reported lack of cancer screening programmes in 
Africa, citing that 80% of South African women have never had a pap smear, which 
is a reflection of the lack of a national cytology plan in many African countries 
(Albrecht, 2011, Cronjé and Beyer, 2007). Cronje et al reported that in some African 
countries, minimal screening infrastructure does exist (Cronjé and Beyer, 2007); 
however, due to lack of trained health staff, active cancer screening has been poor 
and even decreasing in some settings (Lingwood et al., 2008). 
Generally, cancer management involve any or a combination of chemotherapy, 
surgery and radiotherapy (Kingham et al., 2013). Chemotherapy has been proven to 
be effective in treating many cancers, usually indicated for cancers that have spread 
to other body parts (Cazap, 2012). However, its use in Africa is subject to availability 
and the ability of patients to pay (Kingham et al., 2013). Reports show that only 5% 
of cancer patients undergo chemotherapy in Africa (Lingwood et al., 2008). Surgery 
is indicated for cancers at early stages, as the tumour is usually localized and easy to 
remove, with chemotherapy or radiotherapy mainly serving as adjuvant therapies 
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(Kingham et al., 2013). The challenge in many African settings is that many medical 
practitioners lack the expertise to perform surgeries, thus post-surgery prognosis is 
usually poor (Lingwood et al., 2008). There is also challenge from lack of effective 
analgesics and follow-up after surgery (discussed further under palliative care) 
(Boyle et al., 2008, O’Brien et al., 2013). In sub-Saharan Africa, radiotherapy has 
been shown to improve surgical outcomes for cancers including breast and colorectal 
cancer (Barton et al., 2006). However, oncologist have reported that the use of 
radiotherapy is limited owing to lack of adequate medical infrastructure, specialty 
centres, radiologists and technical expertise in many African regions (Boyle et al., 
2008). In 2013, research findings show that only 23 countries in Africa offer 
radiotherapy, with external beam radiotherapy the most widely used (Abdel-Wahab 
et al., 2013). Other types of radiotherapy that are rarely used in Africa include 
brachytherapy, which is highly indicated for cervical cancers (Kingham et al., 2013). 
Most advancement in cancer treatments in Africa have been based on new and 
effective vaccines (Boyle et al., 2008). As noted earlier, the coverage of HBV 
vaccine among infants in Africa is increasing, but current reports show that the 
percentage of adult population that is fully vaccinated may be low (World Health 
Organization, 2014c). For HPV vaccine, the coverage is generally low with only 6 
countries in Africa currently identified to have met the GAVI Alliance requirements 
for supporting the introduction of HPV vaccine (Perlman et al., 2014). Vaccinations 
are important in the management of cancers in Africa due to the high prevalence of 
cancers with infectious aetiologies (Parkin, 2006b). Assessing current vaccination 
programmes, monitoring vaccine effectiveness, and ensuring sustainable and 
affordable vaccination with active community participation are believed to be vital to 
successful treatment of cancers (Kingham et al., 2013). 
Palliative care: Palliative care has attracted lots of interest globally and has been 
adjudged by the WHO as an important component of the cancer care pathway 
(Morris, 2003, Harding et al., 2013, World Health Assembly, 2005). Research 
findings have shown that about 80% of cancer cases are detected late in Africa 
(Wakabi, 2007); hence chemotherapy, radiotherapy and surgical treatments may not 
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really suffice. Thus, towards ensuring an improved management of cancer, 
particularly in Africa, palliative care is imperative and is now believed to be a 
practical and humane solution to Africa’s cancer burden  (Wakabi, 2007, Harding et 
al., 2013, Stjernswärd et al., 2007). Some palliative care initiatives have been created 
across Africa, including the African Palliative Care Association (APCA), which 
works with many African health care providers to relieve the pains and improve 
overall wellbeing of people at advanced stages of cancers and other terminal illnesses 
(O’Brien et al., 2013, Harding et al., 2013); however, reports have shown that these 
initiatives have been limited by the unavailability and unaffordability of effective 
pain-relieving medications (O’Brien et al., 2013). According to a 2004 survey, only 
five African countries have cancer palliative care programmes and/ or allow the 
dispensing of oral morphine (Harding et al., 2013, Wright et al., 2008), with this 
increasing to 28 out 57 African countries in 2010 (Grant et al., 2011). It was further 
observed that with strong political will, increased funding, capacity building and 
establishment of improved treatment facilities, sustainable palliative care 
programmes may be established in Africa (Grant et al., 2011), as this was the case in 
Uganda, which is presumably the only country in the world where nurses are allowed 
to prescribe morphine (Morris, 2003). 
Research and technical training: Experts have clamoured for more rigorous research 
that will inform better care of cancer patients in Africa (Morhason-Bello et al., 
2013). A bottom-up approach is thought to be helpful especially from detailed vital 
statistics and cancer registration at rural hospital levels, which can then be synergized 
with larger population-based cancer registries in urban centres (Parkin, 2006a). With 
this, appropriate estimation of the burden can be expected, which can then help in 
policy planning and practices for cancer management in Africa. Importantly, studies 
can be more effective if they tackle problems that address native health needs, which 
can be transferable to other comparable health systems in Africa (Adebamowo and 
Akarolo-Anthony, 2009). Improved technology should be advocated for, especially 
for cancer detection and screening, standard radiotherapy machines and other related 
medical equipment. Finally, health workers should adequately familiarize themselves 
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with technological advancements in cancer management, and the training of health 
workers on current management of cancer patients and/ or based on disseminated 
research findings should be greatly encouraged. 
Cancer registration: According to Parkin et al., incidence data on cancers are better 
sourced jointly from hospital-based and population-based cancer registries, as this 
will allow new cancer cases to be sourced from within hospitals and outwit hospital 
(Parkin, 2006a). According to the WHO, many African countries still do not have a 
functional cancer registration system (World Health Organization, 2013a). The few 
cancer registries in these regions only cover the urban cities and do not really spread 
to the rural areas (Awadelkarim et al., 2010). In fact, only 5 cancer registries from 5 
African countries contributed to the first volume of “Cancer Incidence in Five 
Continents” (Whelan and Ferlay, 1992, Valsecchi and Steliarova-Foucher, 2008). It 
is estimated that in 1990, only 5% of African countries were covered by functional 
cancer registries, with this increasing to about 20% in 2008 (Ferlay et al., 2010). The 
WHO further reported that cancer registration globally has progressed haphazardly 
over the last two decades as most countries do not have an official policy to support 
cancer registration (World Health Organization, 2013a). Moreover,  resource 
allocation for cancer registration is low in many developing countries as this is 
perceived a luxury amidst other challenging health issues (Valsecchi and Steliarova-
Foucher, 2008). 
Meanwhile, vital registration systems are also important sources of mortality data on 
cancers (Parkin, 2001). In fact, this is regarded a reliable source of mortality data 
when deaths are certified by a medical practitioner, with reported causes of death 
conforming to the uniform coding of the International Classification of Diseases 
(ICD) (Parkin, 2006a). Despite about 42% global vital registration coverage as at 
1990, the current coverage in Africa has been reported to be incomplete and 
implausibly low (Parkin, 2001). 
Cancer contributes hugely to the public health burden in Africa. Yet, due to data 
gaps, the exact burden is still far from known. With continued urbanization, 
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population growth and increasing life expectancies in Africa, the burden of cancer is 
still expected to increase. The response from the government of many African 
nations still remains a huge concern. There is need for urgent re-prioritization of 
health programmes in Africa towards improving research and training, screening, 
diagnosis and treatment, cancer registration and data handling, and the overall 
management of cancer in the region.  
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4.4 CHRONIC RESPIRATORY DISEASES 
4.4.1 Chronic Obstructive Pulmonary Disease (COPD) 
Emanating evidences from the literature search suggest there may be on-going efforts 
to estimate the prevalence of COPD in Africa (and or sub-Saharan Africa) by other 
researchers, among which the BOLD initiative is particularly a leading research 
group (Burney, 2011). This study, however, to my best knowledge, provides the first 
systematic continent-wide estimates of COPD prevalence in Africa. The results show 
an internal consistency and homogeneity among spirometry-based data set, which 
was further supported by a significant association between patient’s age and COPD 
prevalence in the spirometry-based data set, as observed across many studies (Chan 
et al., 2012, Mufunda et al., 2006a, Silva-Matos and Beran, 2012a, Lopez Varela et 
al., 2010). Moreover, the analysis points out statistically significant differences 
between spirometry and non-spirometry data.  
One major population based COPD survey conducted in Africa was the 2006 BOLD 
study, which was actually conducted across 12 sites globally. The study reported a 
global COPD prevalence of 10.1% (male 11.8%; female 8.5%) using GOLD criteria 
(Buist et al., 2007). The study did not quote overall estimates for Africa, as South 
Africa the only study site in Africa. However, among men and women aged ≥40 
years in South Africa, the study reported a COPD prevalence of 22.2% and 16.7%, 
respectively (Buist et al., 2007). This estimate seems high and it is very unlikely to 
be representative of the rest of the African population.  
In other studies conducted among community-based population samples, a 
spirometric prevalence of 13.6% was estimated in Malawi in 2001 and 9.2% in 
Algeria in 2009 (Fullerton et al., 2011, Khelafi et al., 2011). Other studies conducted 
in Africa were mainly non-spirometric with relatively low prevalence rates reported, 
asides from studies in occupational settings which had higher prevalence rates, 
possibly due to repeated exposure to risk factors in these settings. For example, 
Nigeria recorded a prevalence of 5.6% and 1.7% in 2009 and 1999 respectively, and 
South Africa recorded a prevalence of 2.6% in 2004 (Desalu, 2011, Ehrlich et al., 
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2004, Khelafi et al., 2011). These studies, albeit, are the major population-based 
studies on COPD conducted in Africa, with none of these reporting a systematic 
continent-wide COPD prevalence estimate. 
In the current study, the reported mean and median prevalence rates from all study 
populations were higher for the spirometric studies compared to non-spirometric 
(other) studies (Table 3.31), which thus supports previous reports on the under-
estimation of COPD from non-spirometric studies (Buist et al., 2007). Although, the 
gender based differences for both spirometric and non-spirometric studies were not 
statistically significant, spirometry studies recorded higher COPD prevalence rates 
(mean and median) among men, which has been observed across many population 
based surveys (Buist et al., 2007). 
Meanwhile, from the 2010 Institute for Health Metrics and Evaluation (IHME) 
global burden of disease estimates, chronic respiratory diseases overall burden have 
been decreasing globally, responsible for about 4.7% of global disability adjusted life 
years (DALYs) in 2010 (Murray et al., 2012). Their analysis further revealed the 
DALYs and deaths for COPD decreased between 1990 and 2010 by 2.0% and 6.4% 
respectively (DALYs decreased from 78.3 to 76.7 million, and deaths from 3.1 to 2.9 
million) (Lozano et al., 2012, Murray et al., 2012). These are global estimates which 
are based on complex modelling, and that these may not necessarily reflect the 
COPD prevalence in many parts of Africa for several reasons, including (but not 
limited to) contextual, socio-economic, demographic and ethnic differences across 
many regions of the world. Moreover, concerns have been raised about the choice of 
data and modelling methods used in the GBD 2010, estimates should therefore be 
treated with caution until they are individually confirmed (Fan and Lam, 2012, 
Whiteford et al., 2013).  In sub-Saharan Africa however, IHME estimated that 
DALYs from COPD increased from 4.8 million in 1990 to 5.7 million in 2010 
(18.8% increase), while deaths decreased by 1% from 70 thousand to 69.3 thousand 
over the same period, respectively (Murray et al., 2012, Lozano et al., 2012).  
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COPD and smoking 
Across retained studies, four studies reported COPD risks among current smokers 
(Buist et al., 2007, Desalu, 2011, Musafiri et al., 2011b, Ayo-Yusuf et al., 2008). 
Based on these studies, it was observed that the prevalence of smoking was high in 
some study populations, and with odds of having COPD among current smokers 
estimated at 6.37 (Nigeria), 3.22 (Rwanda), and 1.15 and 2.84 (South Africa) (Buist 
et al., 2007, Desalu, 2011, Musafiri et al., 2011b, Ayo-Yusuf et al., 2008) (Table 
4.5). Conclusions drawn from this must be interpreted with caution, as this study is 
not a comprehensive review of smoking prevalence in Africa, moreover,  there were 
only four studies reporting COPD risks among current smokers (Buist et al., 2007, 
Desalu, 2011, Musafiri et al., 2011b, Ayo-Yusuf et al., 2008).  











Odds ratio of COPD among current 
smokers (95% CI) 
Ayo-Yusuf et al. 
(33) 
Mixed 4464 3.2 7.3 2.84 (1.60, 5.04)† 
Buist, A.S. et al. 
(23) 
Mixed 847 23.8 30.0* 1.15 (1.00, 1.32)** 
Desalu OO (24) Rural  391 5.6 2.6 6.37  (2.12, 19.4) 
Ehrlich, R.I. et al. 
(26) 
Mixed 13468 2.6 21.7 - 
Gathuru, I.M. et al. 
(28) 
Urban 270 9.5 10.8 - 
Musafiri, S. et al. 
(30) 
Mixed 1824 4.5 16.7 3.22 (1.53, 4.31) 
†odds ratio in women, *20 pack years, **10 pack years 
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However, some authors have warned that Africa is on the verge of a smoking 
epidemic due to a rapidly spreading tobacco market in the region, and this could be 
contributing to the rising burden of COPD in the continent (Jagoe et al., 2002). For 
example, in 1995, Jha and colleagues reported an increasing prevalence of smoking 
in Africa with an overall prevalence estimated at 18% (Jha et al., 2002). Between 
1996 and 2005, a systematic review of studies conducted among persons aged 15 
years or more, across 14 countries in sub-Saharan Africa (SSA), reported smoking 
prevalence ranging from 6% to 24%, with the prevalence significantly higher among 
young smokers (aged 18-25 years) (Townsend et al., 2006). In 2006, a demographic 
health survey, which was also conducted across 14 countries in SSA, further 
supported this increasing smoking prevalence in Africa, with reported smoking 
prevalence ranging from 8% to 27% (Pampel, 2008). Moreover, some other research 
findings have shown that COPD prevalence in many parts of the world increases 
along with the increasing number of cigarette packs per year, with findings in some 
African population groups suggesting these populations could be more prone to the 
health risks from tobacco smoke than people living in other parts of the world (van 
Gemert et al., 2011, Buist et al., 2007, Chatila et al., 2004). 
Study limitations 
This study aimed to provide an evidence-based and data-driven prevalence estimate 
of COPD in Africa, however, the current low research output and the major gaps in 
data availability from many countries have greatly limited the analysis. It is therefore 
understandable there could be uncertainties surrounding the estimates of the 
prevalence of COPD, such as variations in population structures, diagnoses, sampling 
methods, and effects of other health determinants (beyond the age of patients).  
First, the number of retained studies was very low. Only 8 African countries were 
represented, and over 50% of data-points originated from South Africa and Nigeria. 
The results may therefore tend to reflect more the COPD burden in these two 
countries. In addition, given that these two are relatively wealthy countries in African 
terms, this may limit their generalizability to other African countries. Second, the 
overall sample size (at 24,747) was relatively small, with a mean and median sample 
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size per study of 1,767 and 416, respectively. Indeed, I cannot say with all certainty 
how closely representative these estimates were of the larger African population. Third, 
there were significant variations in diagnostic criteria and survey methodologies 
across studies. Although, most retained studies were population-based cross-
sectional studies, however, due to the very limited population-based evidence in 
Africa, and due to the published reports that occupational COPD contributes 
significantly to the global burden of COPD (Boschetto et al., 2006), studies 
conducted in occupational settings were also retained. Inclusion of these 
occupational studies may potentially the analysis, as this is strictly within a 
population where subjects have been exposed over time to COPD risks. Additionally, 
there were only 13 studies retained in total, with only 5 based on spirometry. Due to 
these few studies retained and significant heterogeneity between studies, no pooled 
prevalence rate was estimated (COPD cases were mainly based on median and inter-
quartile range from the studies). This therefore limited the overall analysis of the 
study, thus making interpretations very difficult. Finally, data on age- and sex-
specific prevalence, including corresponding data on urban-rural settings were not 
always provided across all studies, despite these data being of vital importance to 
perform further comparisons and reach conclusions about the prevalence of COPD in 
specific age groups or settings.  
Public health response to COPD in Africa 
The relative neglect by the governments of many African nations has posed a major 
obstacle to the fight against the growing burden of COPD in Africa (van Gemert et 
al., 2011). COPD is thought to be a rather complex disease, usually self-inflicted, 
irreversible, and difficult to treat (Barnes, 2007, Bousquet et al., 2010), thus, many 
African governments have not set up awareness campaigns and preventive 
programmes that can help address the disease (Chan-Yeung et al., 2004).  
The challenges arising from unchecked urbanization in many African countries, with 
no policies and or legislation to protect citizens from adverse effects, such as 
increase tobacco sales and use, and air pollution from industrial effluents, smoke and 
smog, have also contributed to the growing burden of COPD (van Gemert et al., 
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2011). For example, a study showed that less than 10% of the population in 
developing countries, especially in Africa, is fully protected by any form of tobacco-
demand reduction measures (Barnes, 2007). As noted above, instituting effective 
tobacco control measures is even more difficult because tobacco companies, which 
sometimes may be important drivers of some African economies, are using several 
tactics to resist regulation against its products (Otañez et al., 2009). In the global 
market, these companies stress the importance of tobacco to the economy of the 
countries that grow it, fund political parties, lobby and influence policies on tobacco 
products, prevent anti-smoking adverts and campaigns, and buy off researchers and 
experts to create controversies on established facts on smoking (Otañez et al., 2009, 
Saloojee and Dagli, 2000).  
Research findings have further shown that the risk of developing COPD from 
exposure to biomass fuels is comparable to the risk from tobacco smoking (Ait-
Khaled et al., 2001, Kiraz et al., 2003). This is particularly significant in Africa, as 
about 90% of rural dwellers still rely on unprocessed biomass fuel for domestic 
cooking and heating, a situation that has been made worse due to inadequate health 
awareness and intervention programmes reaching these settings (Desalu et al., 2010). 
In fact, emerging evidence now suggest that due to erratic power supply and high 
costs of cooking gas in many African nations, the use of charcoal and firewood is 
gradually increasing among many urban dwellers, as this is now considered a cheap 
alternative for domestic cooking (Musafiri et al., 2011a).  
On the interventions for COPD in LMIC, research evidences suggest that an 
improved biomass stove and cooking environment remain the most cost-effective 
intervention for reducing the prevalence COPD in sub-Saharan Africa (van Gemert et 
al., 2011). There are established reports that health sector reform programmes 
targeted at COPD and other chronic diseases in many African countries have not 
been very effective (Abdool-Gaffar et al., 2011, Aisanov et al., 2012). The Global 
Alliance against chronic Respiratory Diseases (GARD), an initiative of the WHO, 
recommends that a framework for chronic respiratory diseases surveillance should 
involve monitoring the exposures, outcomes and health system capacity response, 
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and technically supporting appropriate interventions as the need may be required 
(Bousquet et al., 2010). However, according to WHO African Regional Office, 
GARD functions in Africa, but insufficient government support at many country 
levels often leads to non-implementation of programmes (WHO Regional Office for 
Africa, 2006, van Gemert et al., 2011). In addition, while appreciable health reforms 
and intervention programmes have been conducted in some parts of Africa, 
adherence to these programmes at a community and individual level is low (Musafiri 
et al., 2011a). For example, biomass stove intervention programmes in some areas 
have not been effective; reports show there are a wide range of national, regional, 
community and individual reasons why people may not adhere to the intervention 
programmes (Stanciole et al., 2012). This further underscores the importance of 
understanding cultural backgrounds and social systems in an African setting towards 
improving acceptability of many interventions (Musafiri et al., 2011a, Stanciole et 
al., 2012). 
The delayed health care seeking behaviour in many African populations has also 
affected the management of COPD (van Gemert et al., 2011). For example, in a 
study of 298 patients attending respiratory clinics in rural South Africa, the observed 
median total delay to health facility was about 10 weeks, despite many being at 
severe stages of disease (Pronyk et al., 2001). This has been linked to high cost of 
health care, illiteracy and inherent cultural beliefs, with all these resulting in 
increased patronage of traditional (herbal) healers (Chan-Yeung et al., 2004). 
Patients often present back at health centres with complications from improper 
management given by the traditional healers (Ait-Khaled et al., 2001). In health 
service delivery, studies have reported that many health workers are ill-equipped in 
diagnosing COPD, making the under-diagnosis of COPD a problem confronting 
many African nations (Martins et al., 2009). Moreover, it is believed that the under-
recognition of COPD in African countries may be because patients present late and, 
even after presentation to health services, diagnoses are typically delayed until the 
disease is relatively advanced (Martins et al., 2009, Menezes et al., 2004). Research 
findings have shown that lack of (use of) spirometers poses a very important 
practical challenge in rural settings with the main reasons being due to unavailability, 
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improper usage, and low awareness of their importance (Mehrotra et al., 2009). The 
unavailability and unaffordability of drugs have also affected health service delivery 
(van Gemert et al., 2011). Many countries provide free tuberculosis and HIV 
treatments, while essential drugs for COPD and other CRDs, such as inhaled 
beclomethasone, are either unavailable or unaffordable (Ait-Khaled et al., 2007a). 
This unavailability of drugs may reflect lack of funds but may also be partly due to 
available limited funds being used inappropriately for expensive drugs that have no 
proven value in the management of COPD (van Gemert et al., 2011). The relatively 
low income status in Africa is also contributory to the overall burden of COPD in 
Africa, especially at the family and individual levels. According to clinicians, poor 
living conditions, such as overcrowded homes, poor domestic cooking environment, 
and poorly ventilated houses, may worsen COPD; and due to the low income status, 
patients may still lack the financial resources to seek proper treatment (Poyser et al., 
2002). Personal healthcare expenses in Africa are mostly out-of-pocket; there are no 
standard health insurance schemes as found in high-income settings (Stanciole et al., 
2012). 
The low level of published research on COPD and other CRDs has posed a major 
challenge to policymakers and many stakeholders (de-Graft Aikins et al., 2010b), as 
there are not yet enough evidence-based findings that can contribute to informed 
policy making to tackle this disease burden (Mehrotra et al., 2009). The limited 
amount of published research in Africa may be partly due to challenges in 
conducting studies that would fully adhere to internationally agreed case definitions 
(Martins et al., 2009). For example, many studies now use post-bronchodilatory 
spirometry as a gold standard (Buist et al., 2007); whereas others state that using 
post-brochodilator estimates may result in a 5-50% reduction in prevalence 
compared to pre-bronchodilator values (Lopez Varela et al., 2010). It has been 
suggested that the low research output reflects the poor recent availability of research 
funding for COPD by funding agencies, which in turn reflects their lack of priority 
given to COPD (Mehrotra et al., 2009, Abdool-Gaffar et al., 2011). The research 
priorities of many African governments still focus on communicable diseases, 
notably HIV/AIDS, tuberculosis and malaria (de-Graft Aikins et al., 2010a). In 
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addition, the influence of the tobacco industry, which financially supports many 
governments in Africa, may also have negatively affected research output in the field 
(van Gemert et al., 2011, Sitas et al., 2004, Adejuwon, 2009).  
With the few published studies only available from some countries in Africa, the 
problems of data availability on COPD still persists. However, it is evident from the 
few studies that the burden of COPD in Africa is significant. With continued 
urbanization, rapid ageing and lack of corresponding measures to check the effects 
on the population, the burden of COPD will continue to grow and it is set to become 
one of the major public health problems in Africa.  
There is need for more research on COPD prevalence, incidence, sequelae and 
mortality, along with well-designed trials, to identify how to effectively reduce risks 
from exposure to biomass fuels and tobacco smoking. With improved awareness of 
this problem, policy makers and governments of many African nations should give 
more attention to NCDs such as COPD, fund relevant research to improve evidence 
for decision making, and thus make informed decisions on preventive and treatment 
strategy options, and so help counter the rising disease burden over the next decade. 
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4.4.2 Asthma 
This study, to the best of my knowledge, provides the first systematic, data-derived 
and continent-wide estimates of asthma prevalence in Africa. The modelling was 
based on published epidemiological data on “current wheeze” prevalence, which has 
relatively higher sensitivity and specificity (Burney et al., 1989, IUATLD, 2011), 
and also shows a significant association between age and asthma prevalence (Murray 
et al., 2012).   
As noted earlier, based on the 2010 IHME GBD estimates, the overall burden of 
chronic respiratory diseases have been decreasing globally, responsible for about 
4.7% of global disability adjusted life years (DALYs) in 2010, with asthma 
accounting for about one-fifth of this (Murray et al., 2012). However, the IHME 
reported that DALYs from asthma increased by 4.6% (from 21.5 to 22.5 million) 
between 1990 and 2010, while deaths decreased by 9.1% (from 0.38 to 0.34 million) 
over the same period globally (Lozano et al., 2012, Murray et al., 2012). It may be 
inappropriate to compare these estimates with the current estimates, as these are 
global estimates and have very different contexts from Africa. Concerns have been 
raised about the application of non-user friendly analytical methods, heavy statistical 
modelling, and difficulties in assessing the design methodologies and metrics used 
(Fan and Lam, 2012, Whiteford et al., 2013).  In sub-Saharan Africa however, IHME 
estimated that DALYs from asthma increased from 3.2 million in 1990 to 4.0 million 
in 2010 (25% increase), while deaths decreased by 1.8% from 39.8 thousand to 39.1 
thousand over the same period, respectively (Murray et al., 2012, Lozano et al., 
2012).  
In Africa however, the ISAAC study group, which mainly conducted 
epidemiological studies on asthma, reported increasing prevalence rates of asthma 
across many study settings in Africa (Ait-Khaled et al., 2007b). For example, the 
prevalence of “current wheeze” (wheeze at rest-12 month) among children aged 13-
14 years old in South Africa increased from 16.1% to 20.3% between 1995 and 2002 
respectively; Nigeria (West Africa) recorded an increase from 10.9% to 13.0%, 
Ethiopia (Horn of Africa) reported an increase from 6.2% to 9.1%, and Kenya (East 
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Africa) increased from 13.9% to 18.0% (Ait-Khaled et al., 2007b, Zar et al., 2007). 
The current pooled crude prevalence rates also reflect this, with a prevalence of 
current wheeze (wheeze at rest- 12 month) at 13.5% and cumulative prevalence of 
asthma at 9.5% (Table 3.40). Furthermore, in keeping with findings from many 
studies, the pooled crude prevalence rates were consistently higher in urban than 
rural settings (Table 3.39), suggesting the effects of increasing urbanization on 
asthma prevalence in Africa (Odhiambo et al., 1998).  
From the modelling, a prevalence of 7.0% was estimated for asthma in Africa in 
2010 among people under the age of 45 years, equivalent to about 30 million people, 
with children <15 years accounting for 51% of those affected. However, in the 
modelling, the R
2
 was just about 2%. This is very low, and may reflect the challenges 
with the conduct of asthma research in an African population. First, the model was 
based on the symptom ‘wheeze at rest’. Even with this symptomatic definition, 
authors still complained it was difficult to distinctly classify people as having 
asthma. In addition, the symptoms of asthma has been said to overlap with COPD 
and respiratory allergies. However, as noted in preceding sections, a low R
2
 may not 
mean the model is not well-fitted (Oles et al., 2012). The argument is that R
2
 may not 
indicate whether a model is adequate, and in such instances a good model may 
present with a low R
2
 and a poor model may have a high R
2 
(Higgins et al., 2009).  
Many have also reported that R
2 
is more appropriate for linear regression (Oles et al., 
2012, Higgins et al., 2009). A detailed discussion on R
2
 has been included earlier 
under hypertension discussion. Meanwhile, the model showed an increasing asthma 
prevalence from early childhood (3.2%) up till age 15 years (9.6%), where a gradual 
decrease in prevalence declining to 1% at 45 years. This model shows a prevalence 
trend that has been reported in some studies, as early childhood has been reported as 
a stage when asthma is most prevalent in many settings (Zar et al., 2007). However, 
the inability of the model to appropriately account for  urbanization, atopic 
sensitizations, pollution, second hand smoke in children, among other determinants 
of asthma, are important factors for consideration. As noted, it is important not only 
to look at the R
2
 and how well the model fits the data, but also to closely if this is a 
reasonable prediction in a scientific context (Cameron and Windmeijer, 1995). 
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To the best of my knowledge, there are no direct comparable estimates of the 
prevalence of asthma in Africa; however, public health experts have reported that 
increasing tobacco smoking without appropriate legislation and implementation of 
relevant health promotional measures in Africa may be responsible for the increase 
in asthma and other chronic respiratory diseases’ burden in the region (Odhiambo et 
al., 1998). Passive smoking among children is a confirmed risk for asthma in this age 
group (Odhiambo et al., 1998), and could possibly account for the higher cases of 
asthma among children <15 years reported in the current study. In addition, the 
Global Burden of Asthma Report (GBAR) reported an increasing trend of asthma 
globally (Braman, 2006). GBAR estimated over 235 million asthma cases 
worldwide, and about 50 million people living with asthma in Africa in 2004, with 
the highest prevalence (8.1%) recorded in South Africa (Braman, 2006). The authors 
argue that this increasing trend is expected due to rise in atopic sensitizations, 
allergic conditions, and changing patterns of environmental triggers (associated with 
environmental smoking exposure in children, population growth and urbanization) in 
Africa over the last two decades (Braman, 2006). These factors may therefore be 
indicative of the current reported high estimates in Africa. 
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Study limitations 
While the aim of this study was to provide an improved prevalence estimate of 
asthma in Africa by carefully selecting high quality studies and applying simple 
analytical tools, there are however factors that could have affected the analysis. 
Variations in population settings, diagnostic criteria, sampling strategies, and effects 
of other health determinants (beyond age of patients) are factors that need be 
considered.  First, as noted in the methods single age (usually mean age) was mostly 
employed in the modelling. None of the selected studies reported age specific 
estimates, as the studies were mainly in the children and adolescents. In fact, 
working on a data with 5-year age specific estimates in children would have made 
the modelling more representative of all included study populations. This could have 
therefore been a limitation in this study. 
For the pooled asthma prevalence, I
2
 was 99.2%. This implies that there is very high 
heterogeneity across selected studies; and at p<0.0001, this is statistically significant. 
There is therefore strong evidence against the null hypothesis that studies are 
evaluating the same effect. For a combination of studies with such high 
heterogeneity, it may also not be appropriate to pool a summary effect. However, as 
reported earlier, there is very low research output in Africa, and the few studies have 
not been conducted under strict international guidelines, so heterogeneities can be 
expected. In addition, restricting my analysis to studies that have the same study 
design, same sampling frame and same case definition is almost impossible.  
The variation in diagnostic criteria was observed across many study settings, with 
criteria based on asthma symptoms and ISAAC scores frequently used. This could 
have reflected in the reported high estimates of asthma in Africa, as there are 
evidences suggesting the ISAAC studies could have over-estimated the prevalence of 
asthma in Africa, as most study centres were mainly urban; and with ISAAC studies 
conducted mainly in the age range 13-14 years, it may still not be representative of 
all age-groups and the overall population (IUATLD, 2011, Patel et al., 2008). Still on 
the ISAAC studies, two ISAAC studies (ISAAC I and III) (Ait-Khaled et al., 2007b, 
Zar et al., 2007), included in the analysis were conducted across many countries in 
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Africa and provided about 50% of the total 64 data points in this study. Second, 
while many studies were cross-sectional population-based, studies conducted in 
occupational settings were also included, as contained in the quality criteria and 
grading. This is in view of reports revealing that occupational asthma contribute 
significantly to the global burden of chronic respiratory diseases (Mengesha and 
Bekele, 1998, Hnizdo et al., 2001). As these studies reported high prevalence rates, I 
understand these could have increased the current estimates, too. Third, despite 
included studies spreading across most parts of Africa (24 countries in total), there 
are still many countries in Africa that are not included in the review. This reflects 
data gaps in the continent, and thus the generalizability of these estimates for Africa 
may need to be cautiously interpreted. In addition, the total sample size of 187904 
(from all studies) may not be a representative sample of the general African 
population as there were younger age groups.  Indeed, I cannot say with all certainty 
how closely representative these estimates were of the larger African population. 
Finally, data on age- and sex-specific prevalence, including corresponding data on 
urban-rural settings, which are vital comparative indices in any study, were not 
always provided across many studies. 
Public health response to asthma in Africa 
It is important to note that chronic respiratory disease burden, including asthma have 
continued to increase in Africa due to lack of appropriate response from the 
governments of many African countries (Ait-Khaled et al., 2001). The national 
emphasis on asthma and relevant health messages have been sub-optimal, leading, in 
sequence, to poor awareness of the burden, low prioritization, inadequate staffing 
and resources, and very low budget allocation. In fact, budget allocation in many 
African countries mainly targets infectious diseases; funds have been greatly biased 
towards HIV/AIDS, malaria and tuberculosis, as these are the main government 
priorities (Bahadori et al., 2010, Beaglehole, 2011). The GBAR authors reported that 
poor government allocation of funds for asthma remain an important factor 
responsible for limited access to asthma medications, emergency health care and 
other related health services in Africa (Braman, 2006).  In addition, with tobacco 
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companies still supporting many African governments, tobacco products’ sales have 
increased, and government funds have remained unavailable for research on asthma, 
as researches aimed at improving management of asthma may be against tobacco 
sales and consumption (Musafiri et al., 2011a). This has greatly resulted in increased 
smoking (without a counter legislation) and a growing burden of asthma, especially 
among children in Africa over the last two decades (van Gemert et al., 2011). For 
example, Mackay et al. reported that a comprehensive smoke free-legislation was 
important to achieving reduction in the incidence of asthma among people without 
occupational exposure to environmental tobacco smoke. Following the 
implementation of this legislation in Scotland, a reduction of 18.2% per year was 
observed in asthma hospital admissions in Scotland among children <15 years in 
2009 compared to a mean increase of admission of 5.2% per year before 
implementation of the legislation in 2006 (Mackay et al., 2010) 
The diagnosis and treatment of asthma still remains a major challenge in Africa 
(Martins et al., 2009). Distinguishing asthma from other obstructive airway diseases 
has posed a clinical challenge to clinicians (Bousquet et al., 2010). Epidemiological 
data have shown that while asthma presents in episodes, usually among non-smokers 
and onset before 40 years, chronic obstructive pulmonary disease (COPD) is 
associated with smokers, people aged 40 years and above, with symptoms being 
persistent and progressive (Bousquet et al., 2010, IUATLD, 2011). In practice, 
asthmatics who smoke may have non-reversible airflow limitation, and some COPD 
patients may be non-smokers having reversible airflow limitation (Jindal et al., 
2006). In addition, many African countries have no standard protocols for the 
diagnosis and management of asthma (Musafiri et al., 2011a); where these are 
available, guidelines are rarely implemented, and for the few implemented 
guidelines, treatment often do not reach the rural population that are mostly affected 
(Ait-Khaled et al., 2007a). In fact, inaccessibility to healthcare services in many rural 
and resource-poor African settings often gives traditional healers undue significance 
in the management of many chronic diseases (Musafiri et al., 2011a). The non-
availability and unaffordability of inhaled steroids, and the relative non-adherence to 
these medications (when available) have also had large negative impact on the 
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success of the response to asthma in Africa. Studies have shown that about 50% of 
people adhere to prescribed medications (Ait-Khaled et al., 2007a, Salama et al., 
2010). Reasons for non-adherence include side-effects, dosing frequencies, and lack 
of patient education on their illness, need for treatment and how to take medications 
(World Health Organization, 2012). There are also inherent socio-cultural 
misconceptions and individual values that need to be understood and addressed 
toward improving the acceptance and use of asthma medications (Zaraket et al., 
2011), with continual public awareness and education being advocated, especially 
among parents of children with asthma (Zaraket et al., 2011, van Gemert et al., 
2011). 
Asthma is an important and increasing public health problem in Africa which 
receives inadequate priority and attention. With increasing urbanization, population 
ageing and adoption of western lifestyles in many African settings, these trends are 
set to continue in the near future. There is need to identify and prioritize feasible 
strategies that can be adopted to promote the implementation of effective 
interventions that will address this increasing burden in Africa. There is a need for 
African national governments to also consider effects of associated risk factors in 
public health policy planning on this topic with a focus on reducing environmental 
triggers, placing restrictions on tobacco adverts, and appropriately educating 
healthcare personnel and the public on the management of the disease and the 
preventive measures. 
One vital point from the findings and discussions is the growing burden of NCDs in 
Africa, yet, I still cannot say with all certainty how representative my estimates are 
of the African population. A poor response from the government of many African 
nations has also not helped in addressing this burden. Other challenges include (but 
not limited to) those associated with diagnosis of these diseases, inadequate health 
workforce, poor funding of the health system, and low socio-economic status. On the 
conduct of this research, the lack of data on many NCDs was a major limitation. And 
in cases where data exist, they are often incomplete and unreliable, making the 
estimation of the disease burden almost impossible.
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In this thesis, I attempted to review available evidence on four major NCDs in Africa 
towards providing close population representative continent-wide estimate of the 
prevalence and/or incidence of these diseases in Africa. Let me point out here that I 
still cannot say with all certainty how representative these estimates are of the 
African population. In this concluding chapter, I will summarise my overall 
observations and discuss recommendations based on my findings. 
5.1 Summary of Observations  
The prevalence and/or incidence of some NCDs reported in this thesis were 
comparable with some of the WHO estimates on NCDs for Africa (Table 5.1). There 
were however some few differences, which a number of factors could have 
accounted for.  As noted in the introduction, top among these is the fact that some of 
the WHO GBD estimates on Africa have been based on an extrapolation and over-
modelling of the very limited data on NCDs in Africa (King and Bertino, 2008). 
Additionally, some authors have possibly derived their estimates by modelling from 
other non-African countries and imputing these into a template for  African countries 
(Fan and Lam, 2012). This was also reported by the former Health Metrics Network, 
which stated that many of the global and regional estimates of disease burden were 
based on advanced statistical modelling rather than through a detailed analysis of 
empirical data (World Health Organization, 2014a). In addition, most of these 
estimates were driven by the needs of the donors rather than that of the population 
the research was primarily conducted (World Health Organization, 2014a). For 
effective policy response, these estimates may need to be carefully interpreted, 
especially with regards to population representativeness.  
Meanwhile, some estimates in this thesis were relatively higher than some of those reported 
in other world regions. For example, in comparison to other regions of the WHO, the 
incidence of cervical cancer in Africa reported in this thesis was the highest, and the 
prevalence of hypertension was the second highest (Table 5.1). This observation may be 
vital to the high burden of NCDs in Africa noted by previous reports, and may thus point to 
the need for African nations to address NCDs more keenly. 
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One major observation is the dearth of data on NCDs across Africa. According to the 
UN, there are 54 fully recognized sovereign states (countries) in Africa (United 
Nations, 2014). Excluding the searches on hypertension and diabetes, which 
relatively had higher number of studies, most data from other NCDs reviewed came 
from less than 50% of all African countries.  For example, studies on stroke were 
conducted in 10 African countries, cancer in 20 countries, COPD in 8 countries, and 
asthma in 24 countries (Table 5.2). This dearth in data has been noted generally 
among public health experts (Alwan et al., 2010). As discussed earlier, Holmes and 
colleagues reported that up till 2009, there were 14 publications on stroke in Africa, 
accounting 0.06 publications per million people with stroke in Africa, and this only 
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representing 0.6% of the total publications on stroke in the United States (Holmes et 
al., 2010). Publications on diabetes in Africa were 84 for the same period, accounting 
for 7 publications per million people with diabetes in Africa, and this represents 8% 
of the total publications on diabetes in the United States (Holmes et al., 2010).  
Table 5.2. Number of studies retained and African countries involved 
NCD Studies retained Countries of selection 
Hypertension 92 31  
Stroke 19 10  
Diabetes 48 28  
Cancer 39 20  
COPD 13 8  
Asthma 45 24  
 
An analysis of retained studies according to their respective study periods revealed 
that most studies were conducted between 2000 and 2013. The main exceptions were 
observed in the stroke and cancer reviews, where most retained studies involved 
collation and analysis of data from stroke and cancer registries over longer study 
periods (Table 5.3). Nonetheless, this observation generally shows a gradual increase 
in NCD research in Africa. It could also show that the relative poor public health 
response to these diseases in the continent may be due to the observed low level of 
research in the preceding years. 
Table 5.3. Number of retained studies by study period 
NCD 1980-89 1990-99 2000-13 
Hypertension 5 13 74 
Stroke 7 3 9 
Diabetes 4 13 31 
Cancer 7 17 15 
COPD 0 4 9 
Asthma 1 20 24 
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A major observation on the lack of data was revealed from the review on COPD. 
Following the literature search, there were only 5 spirometry-based studies on COPD 
retained. It is appalling that despite previous studies reporting that COPD is among 
the leading causes of deaths globally and the burden in many African countries is 
rising (Buist et al., 2007, Musafiri et al., 2011a, Mehrotra et al., 2009), it has yet to 
generate interest among African researchers. In fact, the policy response to COPD in 
many African countries has been affected by this gap.  
Another factor that could have affected the research output in Africa could be 
challenges associated with case ascertainment, disease measurement and study 
designs. For all the NCDs reviewed, excluding hypertension, this was a major 
limitation. Epidemiologists, clinicians and health workers find it difficult to diagnose 
some medical conditions. International diagnostic guidelines, which can be of 
assistance, are hardly adhered to, especially due to lack of proper training and 
medical equipment (Martins et al., 2009). The relatively high number of studies on 
hypertension may be due to the ease of conducting basic blood pressure 
measurement, as reports show that this is among the simplest medical investigation 
carried out by an average health worker in many African settings (Addo et al., 2007). 
The role of international advocacy on certain NCDs, the global recognition NCDs 
attract, and interests from potential funding organizations may have also resulted in 
the dearth of data on NCDs in Africa. Prior to the UN 2011 high level meeting on 
NCDs, researchers have mainly focussed on infectious diseases. The reason 
obviously due to the better recognition infectious diseases receives globally and the 
funding it attracts. As noted in the introduction, a review of World Health Assembly 
(WHA) resolution from 1948 to 2013 revealed that of the total 484 resolutions made 
by WHA, 368 (76.0%) were on infectious diseases, 99 (20.5%) on NCDs and 17 
(3.5%) on both (World Health Organization, 2014e, World Health Organization, 
2014d). However, this trend is gradually changing, as experts believe the awareness 
on NCDs has improved, and about 50% projected increase in NCDs research may be 
expected from 2015 to 2025, as compared to what was observed before 2010 
(Horton, 2013). 
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Meanwhile, the distribution by African sub-regions across retained studies suggests 
the level of NCD research in western Africa is more than in other parts of Africa 
(Table 5.4). This is particularly important with regards to the estimate provided in 
this study. The estimates may reflect more the burden of NCDs in this African 
region, and its generalizability to other parts of the African continent may need to be 
carefully interpreted. 
Table 5.4. Number of retained studies by African sub-regions 
NCD Central East North South West  Horn of Africa 
(excluding 
Ethiopia) 
Hypertension 7 21 12 15 43 1 
Stroke 0 3 7 4 5 0 
Diabetes 4 9 7 12 6 0 
Cancer 3 5 11 11 9 0 
COPD 1 1 3 5 3 0 
Asthma 2 8 5 12 18 0 
 
The relative lack of studies from the Central African region and the horn of Africa 
(excluding Ethiopia) was another observation. This obviously reflects very low level 
of research in this region, particularly in the Central African Republic, Equatorial 
Guinea, and Sao Tome and Principe in central Africa; and Djibouti, Somali and 
Eritrea in the horn of Africa (Tables 5.4 and 5.5). One factor that could be affecting 
the conduct of research in these regions may be due to political instability in some of 
these countries (Dalal et al., 2011). For example, Central African Republic, Somali 
and Eritrea have all witnessed major civil unrests in the last 10-20 years. This may 
not be applicable to countries like Niger, Sao Tome and Principe, Botswana and 
Lesotho, which have experienced relatively smooth political transition in the last 10 
years. No doubt, these countries might be having some other issues, including, but 
not limited to poor socioeconomic status, educational system, and health system, 
respectively. This observation may therefore point to understanding and addressing 
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the mechanisms needed to strengthen research capacities more keenly in countries 
generally undergoing some difficult circumstances. 
Table 5.5. Distribution of countries without studies 
African region Countries without studies 
Central Central African Republic, Equatorial Guinea, Sao 
Tome and Principe, Burundi*, Chad†, Gabon† 
East Comoros, Djibouti, Somali, Eritrea*, Seychelles† 
North Libya† 
South Lesotho, Botswana, Swaziland* 
West Niger, Mauritania, Cape Verde*, Mali† 
†one study, *two studies 
Inequity in the conduct of research and availability of data on NCDs was another 
major point observed. While most studies were conducted in urban big cities, or 
generally in a mixed population settings, the coverage of rural populations was 
remarkably low. Hypertension studies had a fair coverage among rural dwellers, with 
47 rural studies from a total of 92 studies. However, the coverage in other reviews 
was relatively low. Stroke had 4 rural studies out of 19, diabetes had 18 rural studies 
out of 48, COPD had 2 rural studies out of 13, and asthma had 3 rural studies out of 
45, while cancer had no data from any registry covering mainly rural dwellers (Table 
5.6).  
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Table 5.6. Number of retained studies based on study design and settings 
NCD Total number of 
studies 
Number of studies 
based on original 
epidemiological 
surveys 
Number of studies 
based on health 
service records 
Number of studies 
conducted in rural 
settings 
Hypertension 92 92 - 47 
Stroke 19 14 5 4 
Diabetes 48 48 - 18 
Cancer 39 3 36 - 
COPD 13 13 - 2 
Asthma 45 45 - 3 
 
The distribution of studies appears to reveal a geographical pattern characterized by 
small clusters of well-researched urban areas surrounded by large under-researched 
rural areas. While African is experiencing the fastest rate of urbanization worldwide, 
records show that two-thirds of the African population still reside and work in rural 
areas (United Nations, 2014). This thus potentially infers that estimates provided by 
many researchers on the burden of disease in Africa may be mainly representative of 
the relatively smaller urban areas in the continent, while the rural areas which bear 
the larger burden of disease may not be well-represented. This equity in research has 
been noted in a previous study by Rudan and colleagues (Rudan et al., 2005). The 
WHO believes investing in national health information system with effective data 
management strengthened from the grassroots may help address this gap (World 
Health Organization, 2014a). 
Across all studies, with the exception of the cancer and stroke review, data 
originating from health service records were predominantly absent. Data were mainly 
extracted from original epidemiological surveys of NCDs (Table 5.6). In fact, 
emerging evidence now suggest that some routine health service records may provide 
better information necessary for the estimation of disease burden than some 
epidemiological surveys, particularly when there is active registration, monitoring 
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and evaluation of these records (World Health Organization, 2014b). However, 
population-based studies have been the hall-mark of many systematic reviews. 
Estimates are mainly based on deliberate efforts by researchers to ascertain the 
burden of disease in an area, with very little or no contribution from routine health 
service records. The implication is that conclusions may be biased, especially when 
study designs, case definitions and selection criteria do not follow standard protocols. 
Besides, and just as noted above, their conclusions may be tailored along the interests 
of the funders of such studies, and may therefore not necessarily provide results that 
can inform effective public health response. While it is understandable that some 
national health records and results of some national surveys may actually exist in 
Africa, the fact that they are not publicly available may still further imply that health 
management information system are functioning sub-optimally or even non-existent 
across many African countries. 
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5.2 Recommendations 
Based on my findings in this thesis, I have observed that:  
i.  the prevalence and/or incidence of the reviewed four major NCDs is 
relatively high in Africa;  
ii. there is low level of research on these NCDs, with research output gradually 
increasing over the last 10 years;  
iii. health service records, which could have been an alternative source of data on 
NCDs, are virtually non-existent or not publicly available; and 
iv. these three above may have contributed to the dearth of data on NCDs at 
country level, lack of effective policy response to NCDs, and a continued 
increased in the overall burden of NCDs across Africa.  
Hence, what are the feasible options that can effectively address these challenges at 
various country levels and in the African region at large? 
Improvement in country level data through the establishment of a national health 
management information system may be an important and desirable starting point. 
However, considering organizational, technical and financial feasibility, this may be 
difficult to achieve in many African countries. A feasible strategy may be for each 
African country to adopt a policy that allows the selection of some regional health 
centres as special health management information centres, with each centre covering 
a population that is representative of a particular region in the country. Existing 
structures in these centres may be strengthened, so that data collation, recording, 
analysis and management may conform to international standards. Health 
management information specialists may also be assigned to these centres, who can 
train other health workers on the process of keeping up-to-date health data. 
Essentially, governments need to create adequate awareness among health workers in 
these centres and the general public to ensure a smooth conversion. The training of 
health workers on keeping timely, correct and complete record of health data may 
further help in sustaining the scheme.  Data from these special centres can be 
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regularly updated and modelled to be reflective of the total country population. Both 
crude and modelled data can then be incorporated into a national database, and made 
available to health researchers. There may be need to request technical assistance 
from the WHO, and also partner with relevant international agencies like the 
INDEPTH Network, which have been a vital source of comprehensive, longitudinal 
population data that are generally unavailable in many parts of Africa (Evans and 
AbouZahr, 2008, Byass et al., 2014). This could further assist in developing this 
database and ensure better dissemination of data locally and internationally. This 
may possibly be a long-term solution to the non-availability of data in many African 
countries. 
One other option is a regular conduct of national surveys on NCDs across various 
country levels in Africa. National surveys on NCDs are currently being carried out in 
some African countries, but there are concerns on the quality of these surveys and the 
long periods existing between surveys (Holmes et al., 2010). Essentially, existing 
national protocols need to be improved, and adhered to international standards, like 
the WHO STEPwise approach to surveillance (STEPS), which is currently being 
employed in many countries (Bonita et al., 2013, Hakim et al., 2005). For specific 
diseases, some surveys already conducted internationally with proven successes that 
can be adopted by African countries include: the European Community Respiratory 
Health Survey in Adults (ECRHS) for chronic respiratory diseases, the Burden of 
Obstructive lung Disease (BOLD) survey for COPD, the International Study of 
Asthma and Allergies in Childhood (ISAAC)  for asthma, the Epidemiological Trial 
of Hypertension in North Africa (ETHNA) survey for hypertension, and the 
International Stroke (INTERSTROKE) survey for stroke, among many others. 
Moreover, under the national survey schemes, periodic calls may be made to health 
experts within country to conduct original population-based (cohort or cross-
sectional) or hospital-based studies on NCDs, across areas where there are limited 
data on NCDs. Holmes and colleagues already noted that there is need for more 
longitudinal population-based studies on NCDs in Africa to help in better estimation 
of disease burden (Holmes et al., 2010). This may also help address inequity in the 
geographical distribution of research, and all population groups within a country may 
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be well-represented. Rudan and colleagues noted that special attention must be given 
to study designs during epidemiological surveys in many under-resourced settings, as 
this has affected the collation of data on disease incidence (Rudan et al., 2005). Thus, 
with agreed international standards in design, case definitions, diagnostic criteria and 
outcome measures, bias and under-reporting may well be avoided. 
Another complementary strategy that can improve the response to NCDs in Africa 
may be for countries to identify existing research centres (or units) focussing 
specifically on any NCD within the country. Government can then invest in these 
health centres to improve research outputs and other activities carried out by these 
research units. Focussed strategies on capacity building within the research units may 
also be needed, as this can help with improvement in organizational structures, 
training, performing investigations, and other mechanisms that can promote the 
conduct of research (Amuyunzu-Nyamongo, 2010).  
Within countries, there may be need for a leadership in the health sector devoid of 
ethnic, religious or political bias. This ensures that the observed gaps and challenges 
are addressed where and when needed. In addition, a good leadership can help in 
establishing an effective monitoring, evaluation and surveillance system, where the 
conduct of research, disease notification, and data collation and registration can be 
well addressed. This may further help in the sustainability of these strategies. 
Population-based interventions targeted at major risk factors of NCDs (tobacco, 
alcohol, physical inactivity and unhealthy diets) may actually be the needed response 
in most African countries. However, based on an understanding of the problems 
highlighted in preceding sections, the needed health information that can inform 
undertaking these interventions are lacking. However, evidence shows that these 
interventions may be carried out successfully in a population (Asaria et al., 2007). 
They are cost-effective, culturally acceptable, and most people including those 
already suffering from one form of NCD may benefit from it (Asaria et al., 2007). 
Based on reports, increasing taxes on tobacco and alcohol products are some of the 
cheapest and most effective interventions for NCDs, and can in fact generate more 
public funds (Otañez et al., 2009). In many African countries however, achieving this 
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may be difficult politically due to strong lobbying from companies producing these 
products, who, in many instances also support the government financially (Alwan et 
al., 2010). There may be need for strong leadership and high level international 
partnerships to overcome these difficulties. In addition, experts have advocated for 
the non-inclusion of industries marketing unhealthy commodities including tobacco, 
alcohol, and ultra-processed foods, in the formulation of national policy (Boutayeb, 
2006, McCarthy et al., 2010). 
Largely, all these interventions need adequate funding to be successful on the long 
term. It has been reported the lack of funds in African countries have affected the 
sustainability of many interventions for NCDs (Holmes et al., 2010). This is even 
more marked due to frequent shifts in leadership, political instability and civil unrest 
(Rudan et al., 2005). As observed in this thesis, a thorough understanding of how to 
successfully conduct research in difficult circumstances may be needed in most 
African settings. 
In conclusion, I have attempted to give a continent-wide prevalence and/or incidence 
of major NCDs in Africa. My findings suggest these are relatively high in Africa. 
However, I still cannot say with all certainty how exact these are in many African 
countries. There is need for more investment in NCDs research across Africa, 
especially on mortality, risk factors and other determinants of NCDs in the region. I 
hope the findings of this thesis will prompt a comprehensive policy response on 
NCDs across all country level in Africa. 
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APPENDIX 1. Search terms employed on other databases 
Appendix 1a. Search terms for studies on hypertension in Africa 
(EMBASE) 
# Search terms 
1 africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or 
central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or 
sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or 
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or 
benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or 
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2 exp vital statistics/ or exp incidence/ 
3 (incidence* or prevalence* or morbidity or mortality).tw. 
4 (disease adj3 burden).tw. 
5 exp "cost of illness"/ 
6 exp quality-adjusted life years/ 
7 QALY.tw. 
8 Disability adjusted life years.mp. 
9 (initial adj2 burden).tw. 
10 exp risk factors/ 
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 cardiovascular diseases/ or heart diseases/ or exp hypertension/ or peripheral vascular diseases/ 
13 Hypertensive heart disease.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
14 12 or 13  
15 1 and 11 and 14 
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Appendix 1b.  Search terms for studies on hypertension in Africa 
(Global Health) 
# Search terms 
1 africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or 
central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or 
gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or 
sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or 
mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or 
benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or 
liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2 exp vital statistics/ or exp incidence/ 
3 (incidence* or prevalence* or morbidity or mortality).tw. 
4 (disease adj3 burden).tw. 
5 exp "cost of illness"/ 
6 exp quality-adjusted life years/ 
7 QALY.tw. 
8 Disability adjusted life years.mp. 
9 (initial adj2 burden).tw. 
10 exp risk factors/ 
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 exp hypertension/ or blood pressure, high/ or high blood pressure/ or hipertensao/ or hypertension arterial/ 
or exp cardiovascular diseases/ or heart diseases/ or / or peripheral vascular diseases/ 
13 Hypertensive heart disease.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
14 12 or 13  
15 1 and 11 and 14 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ 
or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or 
senegal/ or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
stroke/ or brain infarction/ or brain stem infarctions/ or cerebral infarction/ or stroke, lacunar/ 
13  
cerebrovascular accident [Used For] accident, cerebrovascular, acute focal cerebral, vasculopathy, 
apoplectic stroke, apoplexia, apoplexy, blood flow disturbance, brain, brain accident, brain attack, 
brain blood flow disturbance, brain insult, brain insultus, brain ischemic attack, brain vascular 
accident, cerebral apoplexia, cerebral insult, cerebral stroke, cerebral vascular accident, cerebral 
vascular insufficiency, cerebro vascular accident, cerebrovascular arrest or failure or insufficiency 
or insult or trauma, cerebrum vascular accident, cryptogenic stroke, CVA, ischaemic seizure, 
ischemic cerebral attack, ischemic seizure, stroke 
14  




12 or 13 or 14 or 15 
17  
1 and 11 and 16 
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Appendix 1d. Search terms for studies on stroke in Africa (Global 
Health) 
# Search terms 
1  
africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
stroke/ or brain infarction/ or brain stem infarctions/ or cerebral infarction/ or stroke, lacunar/ broader 
terms derrame cerebral 
13  
cerebrovascular accident/ or intracranial haemorrhage/ or hemorrhagic stroke/ or subarachnoid 
hemorrhage 
14  
cerebrovascular disorders [used for] disturbios cerebrovasculares, trastornos cerebrovasculares, 




12 or 13 or 14 or 15 
17  
1 and 11 and 16 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp diabetes mellitus/ or glucose metabolism disorders/ or disorders of carbohydrate metabolism/ or 
pancreas islet disease/ or diabetes mellitus, type 1/ or  diabetes mellitus, type 2/ or  diabetes, 
gestational/ or  diabetic ketoacidosis/ or  prediabetic state/ or  glycosuria/ or  hyperglycemia/ or  
glucose intolerance/ 
13  
1 and 11 and 12 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp diabetes/ or endocrine diseases/ or  glucose metabolism disorders/ or exp diabetes mellitus/ or 
exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/ or exp diabetes, gestational/ or exp 
diabetic ketoacidosis/ or exp prediabetic state/ or exp glycosuria/ or exp hyperglycemia/ or exp 
glucose intolerance/ 
13  
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Appendix 1g. Search terms for studies on cancer in Africa (EMBASE) 
# Searches 
1  
africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or central 
african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or gabon/ or 
africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or sudan/ or 
tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or mozambique/ or 
namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or 
cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or 
niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp neoplasms/ or physical disease by etiology and pathogenesis/ or tumour/ exp leukemia/ or exp lymphoma, 
non-hodgkin/ or exp burkitt lymphoma/ or exp sarcoma/ or exp sarcoma, kaposi/ or exp breast neoplasms/ or exp 
breast neoplasms, male/ or exp carcinoma, ductal, breast/ or exp "hereditary breast and ovarian cancer syndrome"/ 
or exp inflammatory breast neoplasms/ or exp gastrointestinal neoplasms/ or exp esophageal neoplasms/ or exp 
intestinal neoplasms/ or exp colorectal neoplasms/ or exp adenomatous polyposis coli/ or exp colonic neoplasms/ 
or exp sigmoid neoplasms/ or exp colorectal neoplasms, hereditary nonpolyposis/ or exp rectal neoplasms/ or exp 
anus neoplasms/ or exp ileal neoplasms/ or exp jejunal neoplasms/ or exp stomach neoplasms/ or exp liver 
neoplasms/ or exp adenoma, liver cell/ or exp carcinoma, hepatocellular/ or exp lung neoplasms/ or exp bronchial 
neoplasms/ or exp carcinoma, bronchogenic/ or exp carcinoma, non-small-cell lung/ or exp small cell lung 
carcinoma/ or exp pleural neoplasms/ or exp pleural effusion, malignant/ or exp solitary fibrous tumor, pleural/ or 
exp tracheal neoplasms/ or exp uterine neoplasms/ or exp uterine cervical neoplasms/ or exp prostatic neoplasms/ 
or exp kidney neoplasms/ or exp urinary bladder neoplasms/ 
13  
1 and 11 and 12 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ or central 
african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or gabon/ or 
africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or sudan/ or 
tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or mozambique/ or 
namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina faso/ or 
cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or 
niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp neoplasms/ or cancer (disease)/ or cancers/ or neoplasias/ or neoplasmas/ or tumours/ exp leukemia/ or exp 
lymphoma, non-hodgkin/ or exp burkitt lymphoma/ or exp sarcoma/ or exp sarcoma, kaposi/ or exp breast 
neoplasms/ or exp breast neoplasms, male/ or exp carcinoma, ductal, breast/ or exp "hereditary breast and ovarian 
cancer syndrome"/ or exp inflammatory breast neoplasms/ or exp gastrointestinal neoplasms/ or exp esophageal 
neoplasms/ or exp intestinal neoplasms/ or exp colorectal neoplasms/ or exp adenomatous polyposis coli/ or exp 
colonic neoplasms/ or exp sigmoid neoplasms/ or exp colorectal neoplasms, hereditary nonpolyposis/ or exp rectal 
neoplasms/ or exp anus neoplasms/ or exp ileal neoplasms/ or exp jejunal neoplasms/ or exp stomach neoplasms/ 
or exp liver neoplasms/ or exp adenoma, liver cell/ or exp carcinoma, hepatocellular/ or exp lung neoplasms/ or 
exp bronchial neoplasms/ or exp carcinoma, bronchogenic/ or exp carcinoma, non-small-cell lung/ or exp small 
cell lung carcinoma/ or exp pleural neoplasms/ or exp pleural effusion, malignant/ or exp solitary fibrous tumor, 
pleural/ or exp tracheal neoplasms/ or exp uterine neoplasms/ or exp uterine cervical neoplasms/ or exp prostatic 
neoplasms/ or exp kidney neoplasms/ or exp urinary bladder neoplasms/ 
13  
1 and 11 and 12 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  




chronic obstructive lung disease/ or lung disease/ or obstructive airway disease/ or chronic 
obstructive lung disorder/ or chronic obstructive pulmonary disease/ or chronic obstructive 
respiratory disease 
15  
12 or 13 or 14 
16  
1 and 11 and 15 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  






exp chronic obstructive pulmonary disease/ or bronchitis, chronic/ or exp pulmonary emphysema/ or 
respiratory disease 
15  
12 or 13 or 14 
16  
1 and 11 and 15 
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp asthma/ or wheezing/ or obstructive airway disease/ or respiratory tract allergy/ or allergic 
asthma/ or aspirin exacerbated respiratory disease/ or asthmatic state/ or exercise induced asthma/ or 
nocturnal asthma/ or occupational asthma 
13  
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africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or africa, central/ or cameroon/ 
or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial 
guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or 
rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or 
lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or 
zimbabwe/ or africa, western/ or benin/ or burkina faso/ or cape verde/ or cote d'ivoire/ or gambia/ or 
ghana/ or guinea/ or guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ 
or sierra leone/ or togo/ 
2  
exp vital statistics/ or exp incidence/ 
3  
(incidence* or prevalence* or morbidity or mortality).tw. 
4  
(disease adj3 burden).tw. 
5  
exp "cost of illness"/ 
6  




Disability adjusted life years.mp. 
9  
(initial adj2 burden).tw. 
10  
exp risk factors/ 
11  
2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12  
exp asthma/ or asma/ or respiratory diseases/ or bronchial asthma/ or atopy/ or immediate 
hypersensitivity/ or wheezing 
13  
1 and 11 and 12 
 
Estimating the Prevalence of NCDs in Africa 
 
Appendices  382 
APPENDIX 2. All data points employed in hypertension modelling 























6 Sudan Ahmed 1990 1988-89 urban 35 38 510 7.5       
14 Senegal Astagneau 1992 1989-90 urban 31.45 516 2300 22.5 246 1041 23.6 271 1259 21.5 
22 Nigeria Bunker et al. 1992 1987-88 urban 36.35 174 559 31.1 150 438 34 20 121 17 
28 Cameroon Cruickshank et al. 
2001 












40 Liberia Giles et al. 1994 1991-92 rural 54.5 449 3588 12.5       
46 Egypt Ibrahim et al. 1995 1991-93 mixed 45.6 1771 6733 26.3 860 3348 25.7 911 3385 26.9 
62 DR Congo M'Buyamba-
Kabangu 
1983-84 urban 42.5 71 424 16.7 42 190 22.1 29 234 12.4 
83 South 
Africa 
Steyn et al. 1986 1982 mixed 59 407 976 41.691086
1 
223 490 45.6 183 486 37.75 
84 South 
Africa 
Steyn et al. 1996 1990 mixed 40.5 212 986 21.517241
4 
85 442 19.2 127 544 23.4 
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YEAR 2000 
16 Guinea Balde et al. 2006 2003 mixed 62 483 1537 31.4       
19 Tunisia Ben Romdhane et 
al. 2005 
2002-03 mixed 54.5 814 1837 44.3 291 752 38.7 523 1084 48.2 
20 Tanzania Bovet et al. 2002 1998-99 urban 54.5 2683 9254 28.991020
1 
978 3609 27.1 1705 5645 30.2 
23 Ghana Burket 2006 2003 rural 53 94 287 32.8       
25 Ghana Cappuccio et al. 
2004 
2001 mixed 54.7 291 1013 28.7 115 385 29.9 176 628 28 
27 Nigeria Cooper et al. 1997 Nigeria 
1995 
mixed 49.5 364 2509 14.5 172 1171 14.7 191 1338 14.3 




mixed 49.5 478 2828 16.9 240 1357 17.7 240 1471 16.3 
33 Tanzania Edwards et al. 
2000 
1996 Ilala rural 39.95 224 767 29.204693
6 
99 330 30 125 437 28.6 




54.5 295 928 31.788793
1 
129 401 32.2 166 527 31.5 






39 Tunisia Ghannem & 
HadjFredj 
1995 urban 54.5 277 957 28.9 87 290 30 190 667 28.4 
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51 Ghana Koopman et al. 
2012 
2002-10 rural 66 223 924 24.162337
7 
123 480 25.7 100 444 22.5 
52 Tunisia Laouani Kechrid et 
al. 2004 
2002-03 mixed 69 416 600 69.3       
59 Madagascar Mauny et al. 2003 1996-97 urban 32.75 178 773 23.3 90 360 24.9 88 413 21.7 
63 Egypt Mohammed et al. 
2000 
1999-00 rural 42.5 538 1927 27.9       
67 Guinea N'Gouin-Claih  et 
al. 2003 
2001 rural 45.5 85 188 45.2       
74 Nigeria Oladapo et al. 
2010 
2002-05 rural 42.1 415 2000 20.8 184 873 21.1 231 1127 20.5 
85 South 
Africa 
Steyn et al. 2004 1996 peri-
urban 
42 264 974 27.135112
9 
137 428 31.9 128 546 23.4 
89 Morocco Tazi et al. 2003 2000 mixed 51 713 1802 39.6 281 755 37.2 432 1047 41.3 
91 South 
Africa 
Thorogood et al. 
2007 
2002 rural 59.5 131 402 32.6       
95 Gambia van der Sande et 
al. 2000 
1998-99 mixed 43.7 992 5389 18.4       
YEAR 2010 
1 Nigeria Abegunde & 
Owoaje 2013 
2010-11 mixed 71.1 219 630 34.761904
8 
      
2 Ghana Addo  et al. 2006 2004-05 rural 42.4 92 362 25.4 26 107 24.1 66 255 25.9 
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41.5 248 1004 25.2 136 550 24.7 112 454 24.7 




7 Nigeria Ahaneku et al. 
2011 
2010-11 rural 57.3 97 218 44.5 34 69 49.3 63 149 42.3 
8 South 
Africa 
Alberts et al. 2005 2004-05 rural 59.5 579 2062 28.062609
1 
122 499 24.5 456 1563 29.2 
9 Nigeria Alikor et al. 2013 2012-13 rural 41.3 101 500 20.2 32 156 20.5 69 344 20.1 
10 Tunisia Allal-Elasmi. 2012 2004-05 mixed 44.6 843 2712 31.073893
8 
307 1228 25 536 1484 36.1 
11 Nigeria Amira et al. 2012 2006-10 urban 41.9 456 1368 33 276 720 38.3 180 648 27.8 
12 Nigeria Amole et al. 2011 2008 mixed 48.7 202 400 50.5 93 179 52 109 221 49.3 
13 Ethiopia Araya Giday & 
Tadesse 2011 
2008 mixed 36.08 97 979 9.9       
15 Ethiopia Awoke et al. 2012 2012 urban 51.4 192 679 28.3 84 323 26 108 356 30.3 
17 Togo Baragou et al. 
2012 
2009-10 urban 39 532 2000 26.6 243 945 25.7 289 1055 27.6 
18 Tunisia Ben Romdhane et 
al. 2012 
2004-05 mixed 49.6 2428 8007 30.6 920 3417 27.3 1508 4590 33.1 
Estimating the Prevalence of NCDs in Africa 
 
Appendices  386 
21 Seychelles Bovet et al. 2006 2004 mixed 44.5 397 1255 31.6 241 628 38.4 155 627 24.8 
24 Angola Capingana et al. 
2013 
2009-10 urban 44.5 278 615 45.2 136 294 46.3 142 321 44.2 
26 Ghana Cook-Huynh et al . 
2012 
2006-07 rural 53.5 114 326 35 35 94 37.2 79 232 34.1 
29 Mozambiqu
e 
Damasceno et al. 
2009 
2005 mixed 54.5 1020 3081 33.1 457 1281 35.7 562 1800 31.2 




38.4 94 406 23 40 163 25 53 243 22 




42.2 86 535 16 34 216 16 52 319 16 




42.8 145 542 27 93 328 28 52 213 24 








32 Chad Dionadji et al. 
2010 




34 Nigeria Ejim et al. 2011 2005-06 rural 59.8 398 858 46.4 124 247 50.2 274 611 44.8 
35 Nigeria Ekanem et al. 2013 2012 semi 
urban 
31.7 201 442 47 129 228 30.1 72 214 16.8 
36 Nigeria Ekwunife et al. 
2010 
2009 mixed 34.9 160 756 21.1       
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41 Zambia Goma et al. 2011 2009-10 urban 57 658 1928 34.8 337 634 38 419 1288 33.3 
42 Algeria Hamida et al. 2013 2010 rural 58.5 365 722 50.2 123 238 51.3 240 484 49.7 
43 Tunisia Hammami et al. 
2011 
2008-09 rural 72.3 311 598 52 91 202 45 220 396 55.5 




45.3 563 2678 21       




40.9 426 2111 20.2       




36.8 199 1046 19       




36.9 555 1733 32       
45 Benin Houinato et al. 
2012 
2008 mixed 42.7 1912 6853 27.9       
47 Nigeria Isezuo et al.2011 2009-10 mixed 38.9 194 782 24.8 106 409 25.9 88 373 23.6 




31.35 377 2559 20.8       
50 DR Congo Katchunga et al. 
2011 
2009-10 mixed 54.5 281 699 40.2       
53 Algeria Latifa & Kaouel 
2007 
2004-05 urban 54.5 263 805 32.7 98 399 24.5 165 406 40.6 
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55 South 
Africa 
Malaza et a.l 2012 2010 rural 54.5 3090 11786 26.2 728 3500 20.8 2362 8286 28.5 
56 Senegal Macia et al. 2012 2009 urban 69.5 327 500 65.4 168 263 63.9 159 237 67.1 
57 Uganda Maher et al. 2011 2008-09 rural 32.75 1489 6678 22.3 602 2719 22.5 887 3959 22.6 
58 Kenya Mathenge et al. 
2010 
2007-08 mixed 69.5 2191 4376 50.1       
60 Uganda Mayega et al. 2012 2011 rural 42.5 340 1656 20.5 167 805 20.7 173 851 20.4 
61 Nigeria Mbah et al. 2013 2011-12 semi-
urban 
50 65 200 32.5       
64 Malawi Msyamboza et al. 
2012 
2009 mixed 45.5 1237 3727 33.2 438 1187 36.9 759 2540 29.9 
65 Eritea Mufunda et al. 
2006 
2004 mixed 39.5 376 2352 16 196 1160 16.88 181 1182 15.28 
66 Uganda Musinguzi & 
Nuwaha 2013 
2012 mixed 35.15 997 4563 21.8 362 1623 22.3 635 2940 21.7 
68 Burkina 
Faso 
Niakara et al. 2007 2004 urban 54.5 839 2087 40.2       
69 Ethiopia Nshisso et al. 2012 2009 urban 50.5 413 2153 19.1 286 1298 22 127 855 14.9 




139 400 34.8       
71 Nigeria Ogah et al. 2013 2011-12 mixed 41.7 931 2928 31.8 479 1430 33.5 474 1553 30.5 
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72 Nigeria Oghagbon et al. 
2008 
2006-07 urban 50.5 76 281 27.1 60 211 28.4 16 70 22.9 
76 Nigeria Omorogiuwa et al. 
2009 
2007-08 urban 41.6 396 1200 33 137 488 28.1 259 712 36.4 
77 Nigeria Omuemu et al. 
2007 





2008 mixed 65 2842 3840 77.3 1159 1638 74.4 1683 2202 79.6 
79 Angola Pires et al. 2013 2011 mixed 41.5 337 1464 23 158 598 26.4 171 866 19.8 




50.5 60 400 15 30 160 18.8 30 240 12.5 
88 Algeria Temmar et al. 2007 peri-
urban 




90 Ethiopia Tesfaye et al. 2009 2006 urban 49.5 982 3273 30.010540
8 
440 1398 31.5 542 1875 28.9 
92 Ethiopia Tran et al. 2011 2009-
2010 
urban 42.9 343 1935 17.749457
4 
234 1171 20 109 764 14.3 
93 Nigeria Ulasi et al. 2010 2007-08 mixed 40.8 478 1458 32.8       
94 Nigeria Ulasi et al. 2011 2009-10 mixed 38.02 290 688 42.2 164 354 46.3 126 334 37.7 
96 Kenya van de Vijver et al. 
2013 
2009-09 urban 48.5 638 5190 12.3 355 2794 12.7 288 2396 12 
97 Uganda Wamala et al. 2009 2006 rural 42 252 842 30.4 102 441 25.4 150 401 34 
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98 Ghana Williams et al. 
2013 
2012 rural 53.84 190 425 44.7       
100 Togo Yayehd et al. 2013 2011 urban 40.8 734 2002 36.7 314 907 34.6 420 1095 38.4 
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APPENDIX 3. All data points employed in stroke modelling 
Study 
Id 

























1 Connor et al. 2004 2001-02 all 15+  103 42378 243 37 20042 185 66 22336 296 
15-24 2 15358 13       
25-34 6 10315 58       
35-44 8 6855 117       
45-54 21 4340 484       
55-64 19 2497 761       
65-74 22 1925 1143       
75-84 22 901 2442       
85+ 3 187 1604       
3 Cossi et al. 2012 2008-09 all 15+   70 15155 460 38 6293 610 32 8862 360 
15-44 4 12580 30 3 5300 60 1 7279 10 
45-54 17 1212 1400 9 443 2030 8 769 1040 
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55-64 19 799 2380 9 309 2910 10 490 2040 
65-74 18 348 5170 10 159 6290 8 189 4230 
75-84 10 134 7460 6 50 12000 4 84 7410 
85+ 2 30 6670 1 9 11100 1 21 4760 
5 Danesi et al. 2007 2005-06 all 0+  15 13127 114 11 7295 151 4 5832 69 
35-44 1 1802 56 1 999 100 0 803 0 
45-54 3 1219 246 3 704 426 0 515 0 
55-64 4 492 813 1 284 357 3 211 1421 
65-74 3 203 1478 2 120 1667 1 83 1205 
75-84 3 66 4545 3 46 6522 0 20 0 
85+ 1 21 4761 1 8 12500 0 13 0 
7 Dewhurst et al. 2013 2009-10 70+  51 2232 2300  976   1256  
8 El Tallawy et al. 2013 2009-12 all 20+  130 19848 655 85 9916 860 48 9932 480 
20-39 3 11664 26       
40-59 49 6077 806       
60+ 78 2107 3702       
12 
 
Farghaly et al. 2013a (El 
Tallawy 2010) 
2005-09 all 0+ 351 62583 560 196 32165 610 155 30418 510 
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Farghaly et al. 2013b (El 
Tallawy 2010) 
2005-09 all 0+ 257 44600 580 142 22908 620 115 21692 530 
Farghaly et al. 2013c (El 
Tallawy 2010) 
2005-09 all 0+ 94 17983 520 54 9257 580 40 8726 460 
  20-39 18 20334 90       
40-59 114 11545 990       




Kandil et al. 2006a 1992-93 all 0+ 127 25000 508 65  520 62  490 
Kandil et al. 2006b 1992-93 all 0+ 35 8464 410 20  460 15  470 
Kandil et al. 2006c 1992-93 all 0+ 61 11228 540 29  510 32  570 
  20-39 17 6629 260       
40-59 56 4017 1390       
60+ 52 1688 3080       
16 Khedr et al. 2013 
 
2010 0+ 57 5920 963 36 3066 1174 21 2854 736 
17 Attia Romdhane et al. 1993 
 
1985 0+ 15 34874 42       
18 Osuntokun et al. 1987 1982 0+ 11 18954 58       
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Danesi et al. 2013 2007 all 0+  189 750000 25.2 118 417000 28.3 71 333000 21.3 
25-34 9 148560 6.1 5 83400 6 4 65160 6.1 
35-44 22 102860 21.4 15 57127 28.8 7 45733 15.3 
45-54 36 69750 51.6 24 40446 59.4 12 29304 40.95 
55-64 54 28610 188.7 36 16262 221.4 18 12348 145.8 
65-74 50 11343 440.8 22 6680 329.3 28 4663 600.5 
75-84 14 3501 399.9 12 2502 479.6 2 999 200.2 




El Tallawy et al. 2013 2012 all 20+  36 19848 181 21 9916 212 15 9932 150 
40-59 16 6077 263       





Walker et al. 2010a 2006 all 0+  453 159814 94.5 235 71916.3 106.7 10 87897.7 76.7 
0-44 34 60216.7 9 17 21948.06 8 17 39132.21 9.9 
45-54 32 38600.72 82.9 20 21905.81 91.3 12 15810.28 75.9 
55-64 55 26712 205.9 30 12484.39 240.3 25 14068.66 177.7 
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65-74 116 20415.35 568.2 66 9776.329 675.1 50 10636.03 470.1 
75-84 139 9981.33 1392.6 70 4175.365 1676.5 69 5996.35 1150.7 








Walker et al. 2010b 2006 all 0+  183 56517 107.9 92 25432.65 115.2 91 31084.35 99.7 
0-44 30 35977.15 20.1 14 11141.5 19.5 16 20470.07 20.8 
45-54 27 11344.54 238 17 9900.99 171.7 20 6172.84 324 
55-64 33 5709.343 578 17 2930.024 580.2 16 2784.061 574.7 
65-74 55 2399.965 2291.7 23 887.1403 2592.6 22 1154.977 1904.8 
75-84 32 840.0053 3809.5 18 431.9965 4166.7 14 400.4004 3496.5 
85+ 6 246.0025 2439 3 140.9973 2127.7 3 101.9992 2941.2 
12 Farghaly et al. 2013a 2007 52.5 156 62583 250 86 32165 270 70 30418 230 
Farghaly et al. 2013b 2007 48.9 114 44600 260 63 22908 280 51 21692 240 







Osuntokun et al. 1979 1975 all 0+ 318 1223077 26 229 538461.5 25 89 684615.4 13 
20-29 8 800000 1 5 500000 1 3 300000 1 
30-39 26 236363.6 11 18 150000 12 8 100000 8 
40-49 70 104477.6 67 54 60000 90 16 40000 40 
50-59 80 39603.96 202 55 22000 250 25 17857.14 140 
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60-69 87 19772.73 440 60 11111.11 540 27 9310.345 290 
70-79 32 6956.522 460 28 3589.744 780 4 3076.923 130 







Kandil et al. 2006a 1993 all 0+ 39 25000 180 21 21000 100 18 21176.47 85 
Kandil et al. 2006b 1993  11 8464 150 7 7777.778 90 4 7547.17 53 
Kandil et al. 2006c 1993  20 11228 210 9 9278.351 97 11 9243.697 119 
  20-39 6 5774 104       
40-59 12 3073 390       
60+ 19 1302 1460       
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APPENDIX 4. All data points employed in diabetes modelling 
Study ID Country Study 
period 






















1 Ghana 2001 Diabetes 44.3 300 3462 6.4 145 1309 11 155 2153 7.2 
1 Ghana 2001 IGT 44.3 502 3462 10.7 178 1309 13.6 324 2153 15 
1 Ghana 2001 IFG 44.3 289 3462 6 143 1309 10.9 146 2153 6.8 
2 Tanzania 1997 ALL 54.5          
2 Tanzania 1997 Diabetes 54.5 47 1698 2.8 24 733 3.3 23 965 2.4 
2 Tanzania 1997 IFG 54.5 50 1698 2.9 18 733 2.5 32 965 3.3 
   RURAL           
2 Tanzania 1997 Diabetes 54.5 12 928 1.3 6 401 1.5 6 527 1.1 
2 Tanzania 1997 IFG 54.5 13 928 1.4 5 401 1.2 8 527 1.5 
   URBAN           
2 Tanzania 1997 Diabetes 54.5 35 770 4.5 18 332 5.3 17 438 4 
2 Tanzania 1997 IFG 54.5 37 770 4.8 13 332 4 24 438 5.4 
3 Guinea 2003 ALL 49.4          
3 Guinea 2003 Diabetes 49.4 94 1537 6.1 45 730 6.2 49 807 6.1 
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3 Guinea 2003 IFG 49.4 206 1537 13.4       
   RURAL           
3 Guinea 2003 Diabetes 49.4 26 651 4       
3 Guinea 2003 IFG 49.4 91 886 10.3       
   URBAN           
3 Guinea 2003 Diabetes 49.4 68 886 7.7       
3 Guinea 2003 IFG 49.4 115 651 17.7       
4 Sierra Leone 1996 Diabetes (All) 35.7 6 501 1.2 5 247 2 1 254 0.4 
4 Sierra Leone 1996 Diabetes (rural) 35.7 0 256 0       
4 Sierra Leone 1996 Diabetes (urban) 35.7 6 245 2.4       
5 South Africa 1993 Diabetes 73.8 51 200 28.7 22 96 25.7 29 104 30.3 
5 South Africa 1993 IGT 73.8 24 200 15 17 96 23.7 7 104 9.8 
6 Kenya 2008 ALL 38.6          
6 Kenya 2008 Diabetes 38.6 61 1459 4.2 27 615 4.5 34 844 4.2 
6 Kenya 2008 IFG 38.6 175 1459 12 37 615 6.1 110 844 13.1 
   RURAL           
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6 Kenya 2008 Diabetes 38.6 26 1180 2.2       
6 Kenya 2008 IFG 38.6 101 1180 8.6       
   URBAN           
6 Kenya 2008 Diabetes 38.6 34 279 12.2       
6 Kenya 2008 IFG 38.6 37 279 13.2       
7 Ghana 2007  (Rural) Diabetes 52 25 326 7.7       
8 Senegal 2009 (Urban) Diabetes 57 107 600 17.8 43 307 14 64 293 21.8 
9 Mauritania 1985 Diabetes 34.6 14 744 1.88 4 307 1.3 10 437 2.29 
10 Cameroon 2011 (Urban) Diabetes 43.7 307 2120 14.4 218 1591 13.7 89 529 17 
11 Sudan 1995 ALL 59.5          
11 Sudan 1995 Diabetes 59.5 44 1284 3.4 16 461 3.5 28 823 3.4 
11 Sudan 1995 IFG 59.5 37 1284 2.9 10 461 2.2 27 823 3.3 
   RURAL           
11 Sudan 1995 Diabetes 59.5 12 458 2.62       
11 Sudan 1995 IFG 59.5 10 458 2.18       
   URBAN           
11 Sudan 1995 Diabetes 59.5 32 826 3.87       
Estimating the Prevalence of NCDs in Africa 
 
Appendices  400 
11 Sudan 1995 IFG 59.5 27 826 3.27       
12 Nigeria 1988 Diabetes   40 2800 1.43 75 1727 4.3 15 1073 1.4 
13 South Africa 1992 (Urban) Diabetes 57 102 563 18.1       
13 South Africa 1992 IFG 57 25 563 4.4       
13 South Africa 1992 IGT 57 86 563 15.3       
14 Morocco 2010 Diabetes (type 
1&2) 
54.48 234 610 38.6       
               
15 Angola 2009 (Rural) Diabetes 54.3 12 421 2.8 4 124 3.2 8 297 2.7 
15 Angola 2009 IGT 54.3 34 421 8.1 7 124 5.6 27 297 9.1 
               
16 Nigeria 1995 Diabetes 60.8 8 500 1.6 3 205 1.4 5 295 1.9 
               
17 Seychelles 2005 Diabetes 45.2 144 1255 11.5 62 568 11 82 687 12.1 
17 Seychelles 2005 IFG 45.2 304 1255 24.2 172 568 30.4 123 687 18 
17 Seychelles 2005 IGT 45.2 130 1255 10.4 63 568 11.2 67 687 9.6 
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18 South Africa 2007 Diabetes 46 42 552 7.6 8 155 5.2 34 397 8.6 
18 South Africa 2007 IFG 46 35 552 6.3 7 155 4.5 28 397 7.1 
19 Zimbabwe 2005 Diabetes 59.7 115 3081 3.7 32 770 4.2 83 2311 3.4 
               
20 Egypt 1994 Diabetes (All) 59.7 429 4620 9.3       
20 Egypt 1994 Diabetes (Rural) 59.7 79 1619 4.9       
20 Egypt 1994 Diabetes (Urban) 59.7 350 3001 11.7       
21 South Africa 1990 Diabetes 56 46 717 6.3 14 214 6.5 32 503 6.4 
21 South Africa 1990 IGT 56 43 717 5.9 13 214 6 30 503 5.9 
22 Uganda 2009 (Rural) Diabetes 48 23 5719 0.4 10 2307 0.4 13 3412 0.4 
22 Uganda 2009 IGT 48 172 5719 3 74 2307 3.2 98 3412 2.9 
   ALL           
23 Cameroon 1995 Diabetes 49 18 1767 1.02 7 750 0.9 11 1017 1.1 
23 Cameroon 1995 IGT 49 46 1767 2.6 25 750 3.3 21 1017 2.1 
   RURAL           
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23 Cameroon 1995 Diabetes 49 5 719 0.7 3 292 0.9 2 427 0.5 
23 Cameroon 1995 IGT 49 16 719 2.2 17 292 5.8 9 427 2.2 
   URBAN           
23 Cameroon 1995 Diabetes 49 13 1048 1.2 4 458 0.8 9 590 1.6 
23 Cameroon 1995 IGT 49 20 1048 1.9 8 458 1.8 12 590 2 
               
24 Tanzania 1987 (Rural) Diabetes 37 53 6087 0.87 29 2627 1.1 24 3460 0.68 
24 Tanzania 1987 IGT 37 468 6087 0.8 192 2627 6.9 276 3460 7.7 
25 South Africa 2003 (Rural) Diabetes 46.9 46 999 4.6 9 200 4.5 37 799 4.6 
25 South Africa 2003 IGT 46.9 64 999 6.4 13 200 6.5 51 799 6.4 
25 South Africa 2003 IFG 46.9 16 999 1.6 9 200 4.5 7 799 0.9 
26 Tanzania 2007 (Urban) Diabetes 59.7 13 209 6       
27 Zambia 2007 (Urban) Diabetes 59.7 75 1478 5.1 21 495 4.2 54 983 5.5 
28 Ethiopia 2010 Diabetes 57 140 2153 6.5 83 1298 6.4 57 855 6.6 
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28 Ethiopia 2010 IGT 57 465 2153 21.6 288 1298 22.2 187 855 21.8 
29 Nigeria 2000 Diabetes 48.9 34 502 6.8 21 273 7.7 13 299 5.7 
30 Nigeria 2011 (Urban) Diabetes 49 14 301 4.7 6 112 2 8 189 2.7 
30 Nigeria 2011 IFG 49 10 301 3.3 5 112 1.65 5 189 1.65 
               
31 Nigeria 2005 (Rural) Diabetes 42.1 49 2000 2.5 18 873 2.1 31 1127 2.8 
32 Nigeria 1995 (Urban) Diabetes 40.8 7 849 0.8 4 487 0.82 3 362 0.83 
32 Nigeria 1995 IGT 40.8 19 849 2.2 11 487 2.26 8 362 2.21 
33 Congo DR 2005 Diabetes 46 2600 9770 10       
33 Congo DR 2005 IFG 46 1030 9770 8.3       
33 Congo DR 2005 IGT 46 670 9770 26.6       
34 Tunisia 1987 Diabetes (All) 57 168 5613 2.99 87 2381 3.65 81 3232 2.51 
   Diabetes (Rural)  24 1787 1.34 18 792 2.3 6 995 0.6 
   Diabetes (Urban)  144 3826 3.76 69 1589 4.3 75 2237 3.4 
35 South Africa 2009 (Urban) Diabetes 43.3 160 1071 14.9 64 509 12.6 96 562 17.1 
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35 South Africa 2009 IGT 43.3 125 1071 11.7 60 509 11.8 65 562 11.6 
35 South Africa 2009 IFG 43.3 14 1071 1.3 8 509 1.6 6 562 1.1 
   ALL           
36 Mozambique 2005 Diabetes 44.5 82 2343 3.5 23 942 2.5 59 1401 4.2 
36 Mozambique 2005 IFG 44.5 58 2343 2.5 18 942 1.9 40 1401 2.9 
   RURAL           
36 Mozambique 2005 Diabetes 44.5 19 1125 1.7 5 442 2.4 14 683 1.2 
36 Mozambique 2005 IFG 44.5 28 1125 2.5 2 442 2.3 26 683 2.6 
   URBAN           
36 Mozambique 2005 Diabetes 44.5 63 1218 5.2 18 500 5.5 45 718 4.9 
36 Mozambique 2005 IFG 44.5 30 1218 2.5 16 500 3.2 14 718 2 
   1987           
37 Mauritius 1987 Diabetes 43.1 696 4991 12.8 334 2339 13 362 2652 12.6 
37 Mauritius 1987 IGT 43.1 823 4991 16.1 308 2339 12.7 515 2652 19.1 
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37 Mauritius 1987 IFG 43.1 192 4991 3.8 120 2339 5.1 72 2652 2.6 
   1992           
37 Mauritius 1992 Diabetes 45.2 1213 6463 15.2 577 2986 15.5 636 3477 15 
37 Mauritius 1992 IGT 45.2 1003 6463 14.3 389 2986 12 614 3477 16.3 
37 Mauritius 1992 IFG 45.2 399 6463 5.9 255 2986 8.2 144 3477 3.9 
   1998           
37 Mauritius 1998 Diabetes 48.6 1317 5392 17.9 602 2392 18.3 715 3000 17.6 
37 Mauritius 1998 IGT 48.6 831 5392 14 316 2392 11.2 515 3000 16.2 
37 Mauritius 1998 IFG 48.6 241 5392 4.3 137 2392 6.2 104 3000 2.9 
38 Morocco 2000 Diabetes (All) 57 151 1802 8.4 65 755 8.6 86 1047 8.2 
38 Morocco 2000 Diabetes (Rural) 57 54 950 5.6       
38 Morocco 2000 Diabetes (Urban) 57 97 852 11.3       
39 Ghana 2010 Diabetes 55 23 597 3.85 10 288 3.5 13 309 4.2 
40 Tanzania 1983 Diabetes (All) 57 50 3145 1.6             
   Diabetes (Rural)  5 1003 0.5       
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   Diabetes (Urban)  45 2142 1.9       
41 Nigeria 2007 (Urban) Diabetes 59.4 4 199 2       
41 Nigeria 2007 IFG 59.4 5 199 2.5       
42 Chad 2004 (Rural )Diabetes 59.4 29 412 7.4 8 222 2.8 19 190 9 
43 Benin 2011 (Urban) Diabetes 59.4 77 1673 4.6 28 534 4.7 49 1039 4.5 
43 Benin 2011 IFG 59.4 58 1673 3.5       
44 Sudan 1997 Diabetes 59.4 60 724 8.3 28 282 9.9 32 442 7.5 
44 Sudan 1997 IFG 59.4 57 724 7.9 16 282 4.1 41 442 9.7 
45 South Africa 2000 (Urban) Diabetes 67 9 374 2.45 4 170 2.4 5 204 2.5 
45 South Africa 2000 IFG 67 10 374 2.7 6 170 3.4 4 204 1.5 
46 Mali 1987 Diabetes 59.4 69 7472 0.92       
47 Tunisia 2001 Diabetes (All) 42.5 49 692 7.2 21 318 6.6 28 374 7.5 
47 Tunisia 2001 Diabetes (Rural) 42.5 9 281 3.25 3 150 2 6 131 4.5 
47 Tunisia 2001 DiabEtes (Urban) 42.5 40 411 9.8 18 199 9.2 22 212 10.4 
48 Tunisia 1981 Diabetes   223 9712 2.3             
49 Libya 2000 (Urban) Diabetes 57 122 868 14.1 51 314 16.3 71 554 13 
49 Libya 2000 IGT 57 74 868 8.5 27 314 8.6 47 554 8.5 
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50 Algeria 2000 Diabetes 47 119 1457 8.2       
50 Algeria 2000 IGT 47 103 1457 7.1       
51 Nigeria 1995 Diabetes 62 7 247 2.8       
52 Algeria 2006 Diabetes (All) 59.5 1087 7656 14.2 501 2455 20.4 586 5201 10.7 
52 Algeria 2006 Diabetes (Rural) 59.5 214 1660 12.9       
52 Algeria 2006 Diabtes (Urban) 59.5 873 5996 15.3       
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APPENDIX 5. All data points employed in asthma modelling 






















wheeze @ rest (12mth) 
1 Ait-Khaled et al. 2007 Algeria 2003 13.5 367 4312 8.7       
1 Ait-Khaled et al. 2007 Cameroon 2003 13.5 169 3066 5.7       
1 Ait-Khaled et al. 2007 Congo Braz 2003 13.5 201 1010 19.9       
1 Ait-Khaled et al. 2007 Cote d'ivoire 2003 13.5 645 3312 19.3       
1 Ait-Khaled et al. 2007 Gabon 2003 13.5 324 3166 10.2       
1 Ait-Khaled et al. 2007 Morocco 2003 13.5 285 1769 16       
1 Ait-Khaled et al. 2007 DR Congo 2003 13.5 221 2950 7.5       
1 Ait-Khaled et al. 2007 Guinea 2003 13.5 578 3138 18.6       
1 Ait-Khaled et al. 2007 Sudan 2003 13.5 361 2909 12.5       
1 Ait-Khaled et al. 2007 Togo 2003 13.5 520 3095 16.8       
1 Ait-Khaled et al. 2007 Tunisia 2003 13.5 944 6115 15.4       
1 Ait-Khaled et al. 2007 Ethiopia 2003 13.5 290 3142 9.1       
1 Ait-Khaled et al. 2007 Kenya 2003 13.5 543 3036 18       
1 Ait-Khaled et al. 2007 Nigeria 2003 13.5 408 3122 13       
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1 Ait-Khaled et al. 2007 South Africa 2003 13.5 1025 5037 20.3 396 2025 19.6 626 2994 20.9 
2 Zar et al. 2007 Ethiopia 1995 13.5 371 5978 6.2       
2 Zar et al. 2007 Kenya 1995 13.5 871 6267 13.9       
2 Zar et al. 2007 Nigeria 1995 13.5 327 3057 10.7       
2 Zar et al. 2007 South Africa 1995 13.5 832 5178 16.1 324 2088 15.5 505 3073 16.4 
12 Esamai & Anabwani 2002 Kenya 2001 13.5 449 3258 13.8       
15 Dagoye at al. 2004 Ethiopia 2003 3 246 7155 3.4 137 3532 3 109 3623 3.9 
17 Ehrlich et al. 1995 South Africa 1994 10.5 509 1899 26.8       
18 Ehrlich et al. 2005 South Africa 1996 29 2253 13826 16.3 817 5671 14.4 1436 8155 17.6 
20 Erharbor et al. 2006 Nigeria 2005 25 81 903 9       
22 Khaldi et al. 2005 Tunisia 2004 13.5 442 3350 13.2       
23 Koffi et al. 2000 Cote d'ivoire 1998 13.5 475 3045 15.6       
27*+ Falade et al. 2004 Nigeria 1995 6.5 87 1704 5.1 50 797 6.3 37 907 4.1 
28*+ Faniran et al. 1999 Nigeria 1998 9.5 58 566 10.2             
29 Georgy et al. 2006 Egypt 2005 13 379 2570 14.7             
30 Hailu et al. 2003 Ethiopia 1997 13.5 545 3365 16.2       
40 Nyembue et al. 2012 DR Congo 2010 44 217 1412 15.4       
44 Wichmann et al. 2007 South Africa 2005 13.5 742 3926 18.9       
47 Nriagu et al. 1999 South Africa 1998 35.5 253 1060 23.9       
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49 Odhiambo et al. 1998 Kenya 1993 10.8 54 568 9.5 34 282 12.1 20 286 7 
50 Poyser et al. 2002 South Africa 2000 13.5 750 4688 16       
51 Walraven et al. 2001 Gambia 1997 29.5 196 5399 3.63 64 2149 3 126 3074 4.1 
9 Desalu et al. 2009 Nigeria 2006 32 103 810 12.7       
25 Mavale-Manuel et al. 2006 Mozambique 2005 13.5 215 1614 13.3       
Asthma ever (not used in modelling, only included for comparisons) 
2 Zar et al. 2007 Ethiopia 1995 13.5 149 5978 2.5       
2 Zar et al. 2007 Kenya 1995 13.5 702 6267 11.2       
2 Zar et al. 2007 Nigeria 1995 13.5 562 3057 18.4       
2 Zar et al. 2007 South Afr 1995 13.5 678 5178 13.1 292 2088 14 396 3073 12.8 
3* Aguwa et al. 2007 Nigeria 2006 45 38 591 6.5             
5 Bennis et al. 1992 Morocco 1991 10.5 50 1464 3.4             
7 Bezzaoucha 1992 Algeria 1991 18 159 4677 3.42       
8 Benarab-Boucherit et al. 2011 Algeria 2010 11 19 286 6.7       
9 Desalu et al. 2009 Nigeria 2006 32 123 810 15.2 82 385 21.2 41 425 9.6 
10 Ehrlich et al. 1998 South Africa 1997 9 1036 1955 53       
11 Esamai & Anabwani 1996 Kenya 1995 13.5 175 3018 5.8       
12 Esamai & Anabwani 2002 Kenya 2001 13.5 410 3258 12.6       
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17 Ehrlich et al. 1995 South Africa 1994 12 205 1905 10.8       
18 Ehrlich et al. 2005 South Africa 1996 29 525 13826 3.8 212 5671 3.7 313 8155 3.8 
19 Nafti et al. 2009 Algeria 2008 14.1 236 10015 3.45       
19 Nafti et al. 2009 Morocco 2008 14.5 310 10051 3.89       
19 Nafti et al. 2009 Tunisia 2008 13.8 326 10284 3.53       
20 Erharbor et al. 2006 Nigeria 2005 25 127 903 14.1 49 469 10.4 78 434 17.9 
24* Laraqui Hosni et al. 2002 Morocco 2001 37 29 353 8.2       
26 Miningou et al. 2002 Burkina Faso 1998 39.5 78 808 9.6       
27*+ Falade et al. 2004 Nigeria 1995 6.5 52 1704 3.1 32 797 4 20 907 2.2 
28*+ Faniran et al. 1999 Nigeria 1998 9.5 34 566 6       
29 Georgy et al. 2006 Egypt 2005 13 246 2609 26.5       
30 Hailu et al. 2003 Ethiopia 1997 13.5 74 3365 2.2       
34 Mengesha & Bekele 1998 Ethiopia 1997 39 69 422 16.3       
35 Miszkurka et al. 2012 Burkina Faso 2001 36 559 4822 11.6       
36 de Almeida et al. 2001 Cape Verde 1993 8 41 588 7       
37 Mustapha et al. 2011 Nigeria 2004 10.5 76 1397 5.4       
39 Musafiri et al. 2011 Rwanda 2009 38.3 163 1920 8.9       
41 Roudaut et al. 1992 Cote d'Ivoire 1990 13 263 2433 10.8       
45 Wolff et al. 2012 Madagascar 2010 10.5 111 1236 9       
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47 Nriagu et al. 1999 South Africa 1998 35.5 119 1060 11.2       
49 Odhiambo et al. 1998 Kenya 1993 10.8 25 1172 2.1 14 571 2.5 11 601 1.8 
50 Poyser et al. 2002 South Africa 2000 13.5 626 4706 13.3       
51 Walraven et al. 2001 Gambia 1997 32 101 5399 1.87       
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